Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Habitual
Severe factor X deficiency in pregnancy: case report and review of the literature.
Abortion, Habitual
The fgl2 prothrombinase/fibroleukin gene is required for lipopolysaccharide-triggered abortions and for normal mouse reproduction.
Abortion, Septic
Connective tissue disease associated with sclerodermoid features, early abortion, and circulating anticoagulant.
Abortion, Spontaneous
Activated partial thromboplastin time is a predictive parameter for further miscarriages in cases of recurrent fetal loss.
Abortion, Spontaneous
Activation of the novel prothrombinase, fg12, as a basis for the pregnancy complications spontaneous abortion and pre-eclampsia.
Abortion, Spontaneous
Anticardiolipin antibodies in pathogenesis of infertility.
Abortion, Spontaneous
Antiphospholipid and other autoantibodies in a cohort of habitual aborters and healthy multiparous women in Jamaica.
Abortion, Spontaneous
Antiphospholipid antibody syndrome: an unusual cause of stroke in a 22-year-old female.
Abortion, Spontaneous
Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids.
Abortion, Spontaneous
Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus.
Abortion, Spontaneous
Hypercoagulability. Should every patient with venous thrombosis be tested?
Abortion, Spontaneous
LPS-induced occult loss in mice requires FGL2.
Abortion, Spontaneous
Pregnancy outcome in recurrent aborters is not influenced by Chlamydia IgA and/or G.
Abortion, Spontaneous
Primary antiphospholipid syndrome presenting as thrombotic microangiopathy: Successful treatment with steroids, plasma exchange and anticoagulants.
Abortion, Spontaneous
Sjögren's syndrome and pregnancy.
Abortion, Spontaneous
The emerging role of immunoregulation of fibrinogen-related procoagulant Fgl2 in the success or spontaneous abortion of early pregnancy in mice and humans.
Abortion, Spontaneous
The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population.
Abortion, Spontaneous
The same immunoregulatory molecules contribute to successful pregnancy and transplantation.
Abortion, Spontaneous
[Antiphospholipid antibodies in systemic lupus erythematosus: study of a caseload of 120 patients]
Abruptio Placentae
A rapid test for abruptio placentae: evaluation of a D-dimer latex agglutination slide test.
Abruptio Placentae
Activation of thromboplastin in a case of abruptio placentae with hypofibrinogenemia.
Abruptio Placentae
Disseminated intravascular coagulation.
Abruptio Placentae
New approach to the risk variables for administration of fibrinogen in patients with postpartum hemorrhage by using cluster analysis.
Abscess
Abscess in bilateral ovarian haematomas in a girl with factor X deficiency, necessitating oopherectomy.
Abscess
The omentoplasty: a neglected ally in gynecologic surgery.
Abscess
Use of preprocedural tests by interventional radiologists.
Acidosis
Acidosis and coagulopathy: the differential effects on fibrinogen synthesis and breakdown in pigs.
Acidosis
Cytoreductive surgery and continuous hyperthermic peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis: hemodynamic, metabolic, and anesthetic considerations.
Acidosis
Diagnostic evaluation of risk for bleeding in cardiac surgery with extracorporeal circulation.
Acidosis
Disseminated intravascular coagulation.
Acidosis
Effects of emergency treatment mode of damage-control orthopedics in pelvic fracture complicated with multiple fractures.
Acidosis
Evaluation of tris-hydroxymethylaminomethane on reversing coagulation abnormalities caused by acidosis in pigs.
Acidosis
Factors associated with the increased bleeding in the postoperative period of cardiac surgery: A cohort study.
Acidosis
Neuroleptic Malignant Syndrome Associated With Metoclopramide Use in a Boy: Case Report and Review of the Literature.
Acidosis
Polytrauma Defined by the New Berlin Definition: A Validation Test Based on Propensity-Score Matching Approach.
Acidosis
Pulmonary tractotomy as an abbreviated thoracotomy technique.
Acidosis
Rodenticide Poisoning: Critical Appraisal of Patients at a Tertiary Care Center.
Acidosis
Thromboelastometry-guided hemostatic therapy for hemorrhagic shock in the postoperative period of vascular surgery: a case report.
Acidosis
[Dengue infection with fatal ending]
Acidosis
[Strategy of the metabolic acidosis correction and indices of coagulation profile in patients with severe traumatic shock].
Acidosis, Lactic
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.
Acquired Immunodeficiency Syndrome
Acquired circulating anticoagulants in children with acquired immunodeficiency syndrome.
Acquired Immunodeficiency Syndrome
Common variable immune deficiency syndrome associated with lupus anticoagulant.
Acquired Immunodeficiency Syndrome
Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.
Acquired Immunodeficiency Syndrome
Lupus anticoagulant associated with specific inhibition of factor VII in a patient with AIDS.
Acquired Immunodeficiency Syndrome
Lupus anticoagulant in the acquired immunodeficiency syndrome.
Acquired Immunodeficiency Syndrome
PLASMA prothrombin, serum prothrombin and thromboplastin generation tests; aids in study of defects in coagulation. No. 1.
Acquired Immunodeficiency Syndrome
THE THROMBOPLASTIN generation test; aids in the study of coagulation defects. II.
Acquired Immunodeficiency Syndrome
Update on the Clot Waveform Analysis.
Activated Protein C Resistance
A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
Activated Protein C Resistance
A chromogenic assay for activated protein C resistance.
Activated Protein C Resistance
A comparison of glass and plastic blood collection tubes for routine and specialized coagulation assays: a comprehensive study.
Activated Protein C Resistance
A gene-centric analysis of activated partial thromboplastin time and activated protein C resistance using the HumanCVD focused genotyping array.
Activated Protein C Resistance
A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
Activated Protein C Resistance
A rare case of unprovoked venous thromboembolism manifestation in a young patient with antithrombin Type IIB deficiency combined with inferior vena cava anomaly from Lithuania.
Activated Protein C Resistance
Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism.
Activated Protein C Resistance
Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy.
Activated Protein C Resistance
Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
Activated Protein C Resistance
Activated protein C resistance associated with lupus anticoagulants is a high risk in acute mesenteric venous thrombosis.
Activated Protein C Resistance
Activated Protein C Resistance in Behçet's Disease.
Activated Protein C Resistance
Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome.
Activated Protein C Resistance
Activated protein C resistance--a major risk factor for thrombosis.
Activated Protein C Resistance
Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.
Activated Protein C Resistance
Activated protein C resistance: prevalence and implications in peripheral vascular disease.
Activated Protein C Resistance
Activated protein C resistance: the influence of ABO-blood group, gender and age.
Activated Protein C Resistance
Activated-protein-C resistance in cancer patients.
Activated Protein C Resistance
Alteration of haemostasis in non-metastatic gastric cancer.
Activated Protein C Resistance
APC resistance during the normal menstrual cycle.
Activated Protein C Resistance
Are women with polycystic ovary syndrome resistant to activated protein C?
Activated Protein C Resistance
Association between adverse pregnancy outcomes and maternal factor V G1691A (Leiden) and prothrombin G20210A genotypes in women with a history of recurrent idiopathic miscarriages.
Activated Protein C Resistance
Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation.
Activated Protein C Resistance
Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population.
Activated Protein C Resistance
Coagulation factor V gene 1691G>A polymorphism as an indicator for risk and prognosis of lower extremity deep venous thrombosis in Chinese Han population.
Activated Protein C Resistance
Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables.
Activated Protein C Resistance
Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C.
Activated Protein C Resistance
Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay.
Activated Protein C Resistance
Discrimination between normal wildtype and carriers of coagulation factor V Leiden mutation by the activated protein C resistance test in the presence of factor V deficient plasma.
Activated Protein C Resistance
Early cerebral sinovenous thrombosis in a child with acute lymphoblastic leukemia carrying the prothrombin G20210A variant: a case report and review of the literature.
Activated Protein C Resistance
Effect of Freezing Plasma at -20°C for 2 Weeks on Prothrombin Time, Activated Partial Thromboplastin Time, Dilute Russell Viper Venom Time, Activated Protein C Resistance, and d-Dimer Levels.
Activated Protein C Resistance
Effect of oral contraceptives on the anticoagulant activity of protein S in plasma.
Activated Protein C Resistance
Effects of hormone replacement on hemostasis in spontaneous menopause.
Activated Protein C Resistance
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
Activated Protein C Resistance
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Activated Protein C Resistance
Elevated prothrombin and activated protein C resistance in patients with thoracic aortic atheroma.
Activated Protein C Resistance
Genetic determinants of hemostasis phenotypes in Spanish families.
Activated Protein C Resistance
Hemostasis during normal pregnancy and puerperium.
Activated Protein C Resistance
Hemostatic alterations in patients with acute, unilateral vestibular paresis.
Activated Protein C Resistance
High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C.
Activated Protein C Resistance
Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
Activated Protein C Resistance
Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations.
Activated Protein C Resistance
Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance.
Activated Protein C Resistance
Is elevated level of soluble endothelial protein C receptor a new risk factor for retinal vein occlusion?
Activated Protein C Resistance
Lack of association between inherited thrombophilic risk factors and idiopathic sudden sensorineural hearing loss in Italian patients.
Activated Protein C Resistance
Low prevalence of the factor V Leiden among patients with ischemic stroke.
Activated Protein C Resistance
Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system.
Activated Protein C Resistance
Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
Activated Protein C Resistance
Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease.
Activated Protein C Resistance
Normalization of haemoglobin concentration with recombinant erythropoietin has minimal effect on blood haemostasis.
Activated Protein C Resistance
Physical activity and hemostatic and inflammatory variables in elderly men.
Activated Protein C Resistance
Prevalence and patient profile in activated protein C resistance.
Activated Protein C Resistance
Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease.
Activated Protein C Resistance
Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays.
Activated Protein C Resistance
Quality standards for sample collection in coagulation testing.
Activated Protein C Resistance
Resistance to activated protein C in thalassaemic patients: an underlying cause of thrombosis.
Activated Protein C Resistance
Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer.
Activated Protein C Resistance
Resistance to activated protein C: a major cause of inherited thrombophilia.
Activated Protein C Resistance
Role of protein S and tissue factor pathway inhibitor in the development of activated protein C resistance early in pregnancy in women with a history of preeclampsia.
Activated Protein C Resistance
Screening for thrombophilia: a laboratory perspective.
Activated Protein C Resistance
Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis.
Activated Protein C Resistance
Shortened activated partial thromboplastin time, a hemostatic marker for hypercoagulable state during acute coronary event.
Activated Protein C Resistance
Snake Venoms in Diagnostic Hemostasis and Thrombosis.
Activated Protein C Resistance
The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.
Activated Protein C Resistance
The carbohydrate moiety of factor V modulates inactivation by activated protein C.
Activated Protein C Resistance
The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
Activated Protein C Resistance
The effect of dabigatran on select specialty coagulation assays.
Activated Protein C Resistance
Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade.
Activated Protein C Resistance
[A case report of syphilitic uveitis and deafness.]
Activated Protein C Resistance
[Hematological changes and related gene mutation of post-severe acute respiratory syndrome patients with osteonecrosis]
Acute Coronary Syndrome
A new regimen for heparin use in acute coronary syndromes.
Acute Coronary Syndrome
A rare case of fondaparinux-induced major bleeding in postmenopausal woman prescribed for non-ST segment elevation Ml.
Acute Coronary Syndrome
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin.
Acute Coronary Syndrome
Acute coronary syndromes: oral factor Xa inhibitors in acute coronary syndromes.
Acute Coronary Syndrome
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
Acute Coronary Syndrome
Apixaban in Acute Coronary Syndromes.
Acute Coronary Syndrome
Apixaban with antiplatelet therapy after acute coronary syndrome.
Acute Coronary Syndrome
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
Acute Coronary Syndrome
Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: A nested case-control study.
Acute Coronary Syndrome
Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants.
Acute Coronary Syndrome
Clinical and experimental experience with factor Xa inhibitors.
Acute Coronary Syndrome
Clinical pharmacology of direct and indirect factor Xa inhibitors.
Acute Coronary Syndrome
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
Acute Coronary Syndrome
Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome: meta-analysis of randomized trials.
Acute Coronary Syndrome
Drug evaluation: the directly activated Factor Xa inhibitor otamixaban.
Acute Coronary Syndrome
Dual pathway therapy in acute coronary syndrome.
Acute Coronary Syndrome
Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.
Acute Coronary Syndrome
Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
Acute Coronary Syndrome
Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis.
Acute Coronary Syndrome
Enantiomeric characterization and structure elucidation of Otamixaban.
Acute Coronary Syndrome
Establishing a new target range for unfractionated heparin for acute coronary syndromes.
Acute Coronary Syndrome
Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.
Acute Coronary Syndrome
Factor X inhibitors.
Acute Coronary Syndrome
Factor Xa inactivation in acute coronary syndrome.
Acute Coronary Syndrome
Factor Xa inhibitors for acute coronary syndromes.
Acute Coronary Syndrome
Factor Xa Inhibitors in Acute Coronary Syndromes and Venous Thromboembolism.
Acute Coronary Syndrome
Factor Xa inhibitors in acute coronary syndromes: moving from mythology to reality.
Acute Coronary Syndrome
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.
Acute Coronary Syndrome
Fondaparinux in the management of patients with ST-elevation acute myocardial infarction.
Acute Coronary Syndrome
Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
Acute Coronary Syndrome
Heparin dosing and therapeutic activated partial thromboplastin times (aPTT) in acute coronary syndrome (ACS).
Acute Coronary Syndrome
High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes.
Acute Coronary Syndrome
High-Risk Non-ST Elevation Acute Coronary Syndrome Outcomes in Patients Treated with Unfractionated Heparin Monitored Using Anti-Xa Concentrations Versus Activated Partial Thromboplastin Time.
Acute Coronary Syndrome
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.
Acute Coronary Syndrome
Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Acute Coronary Syndrome
Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction.
Acute Coronary Syndrome
Intravenous Thrombolysis for Acute Ischemic Stroke in a Patient Receiving Rivaroxaban.
Acute Coronary Syndrome
Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.
Acute Coronary Syndrome
Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
Acute Coronary Syndrome
Monitoring the anticoagulant effect after a massive rivaroxaban overdose.
Acute Coronary Syndrome
Myocardial infarctions and other acute coronary syndromes in rare congenital bleeding disorders: a critical analysis of all reported cases.
Acute Coronary Syndrome
New anticoagulants.
Acute Coronary Syndrome
Novel anticoagulant therapy: principle and practice.
Acute Coronary Syndrome
Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes.
Acute Coronary Syndrome
Phase 2 study of TAK-442, an oral factor Xa inhibitor, in patients following acute coronary syndrome.
Acute Coronary Syndrome
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
Acute Coronary Syndrome
Promise of factor Xa inhibition in acute coronary syndromes.
Acute Coronary Syndrome
Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium.
Acute Coronary Syndrome
Random Forests Are Able to Identify Differences in Clotting Dynamics from Kinetic Models of Thrombin Generation.
Acute Coronary Syndrome
Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial.
Acute Coronary Syndrome
Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
Acute Coronary Syndrome
Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
Acute Coronary Syndrome
Rivaroxaban in acute coronary syndromes--is it prime time?
Acute Coronary Syndrome
Rivaroxaban in patients with a recent acute coronary syndrome.
Acute Coronary Syndrome
Rivaroxaban in the contemporary treatment of acute coronary syndromes.
Acute Coronary Syndrome
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Acute Coronary Syndrome
Rivaroxaban: A New Treatment Paradigm in the Setting of Vascular Protection?
Acute Coronary Syndrome
Role of oral factor Xa inhibitors after acute coronary syndrome.
Acute Coronary Syndrome
Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban.
Acute Coronary Syndrome
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.
Acute Coronary Syndrome
SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: A pilot study.
Acute Coronary Syndrome
Spotlight on fondaparinux sodium in acute coronary syndromes.
Acute Coronary Syndrome
TAK-442, a Direct Factor Xa Inhibitor, Inhibits Monocyte Chemoattractant Protein 1 Production in Endothelial Cells via Involvement of Protease-Activated Receptor 1.
Acute Coronary Syndrome
The 'chest pain kit' study: A 'pill in the pocket' concept to improve the pre-hospital therapy of acute coronary syndrome.
Acute Coronary Syndrome
The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin-dependent factor Xa inhibition without an increase in the bleeding risk in the rabbit.
Acute Coronary Syndrome
The ATLAS ACS 2-TIMI 51 Trial and the Burden of Missing Data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
Acute Coronary Syndrome
The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb.
Acute Coronary Syndrome
The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.
Acute Coronary Syndrome
The ineffectiveness of a non-weight based heparin regimen in achieving therapeutic activated partial thromboplastin time (aPTT) in acute coronary syndrome.
Acute Coronary Syndrome
The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes.
Acute Coronary Syndrome
What did we learn from new oral anticoagulant treatment?
Acute Coronary Syndrome
[New oral anticoagulants: recommendations, precautions and perspectives for use].
Acute Kidney Injury
Acute respiratory failure in adult patients with dengue virus infection.
Acute Kidney Injury
Apixaban and Rivaroxaban Anti-Xa Level Monitoring Versus Standard Monitoring in Hospitalized Patients With Acute Kidney Injury.
Acute Kidney Injury
Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions.
Acute Kidney Injury
Clinical assessment and pathophysiology of Bothrops venom-related acute kidney injury: a scoping review.
Acute Kidney Injury
Early Postoperative Acute Kidney Injury Among Pediatric Liver Transplant Recipients.
Acute Kidney Injury
The epidemiology of acute kidney injury in critically ill patients in the Gansu Province: The EACG study.
Acute Kidney Injury
Thromboelastometry-guided hemostatic therapy for hemorrhagic shock in the postoperative period of vascular surgery: a case report.
Acute Kidney Injury
Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion.
Acute Kidney Injury
[Combined predictive value of the risk factors influencing the short-term prognosis of sepsis].
Acute Kidney Injury
[The effect of AN69 ST membrane on filter lifetime in continuous renal replacement therapy without anticoagulation in patients with high risk of bleeding].
Acute Lung Injury
Coagulation and inflammation in acute lung injury.
Acute Lung Injury
Direct factor Xa inhibition attenuates acute lung injury progression via modulation of the PAR-2/NF-?B signaling pathway.
Acute Lung Injury
Multivariate regression modeling for the prediction of inflammation, systemic pressure, and end-organ function in severe sepsis.
Adenocarcinoma
Fatal hemoperitoneum after fine-needle aspiration of a liver metastasis.
Adenocarcinoma
Fc Receptor is Involved in Nk Cell Functional Anergy Induced by Miapaca2 Tumor Cell Line.
Adenocarcinoma
[Clinical and Imaging Features of Acute Cerebral Infarction ?in Non-small Cell Lung Cancer Patients with Trousseau Syndrome].
Adenoma
[Mixed corticomedullary tumor]
Adenomyosis
[Changes of coagulation function in patients with adenomyosis and its clinical significance].
Adenoviridae Infections
Adrenal gland infection by serotype 5 adenovirus requires coagulation factors.
Adrenocortical Hyperfunction
Evaluation of coagulation status in dogs with naturally occurring canine hyperadrenocorticism.
Afibrinogenemia
An instructive case of presumed brown snake (Pseudonaja spp.) envenoming.
Afibrinogenemia
Asphyxia by Drowning Induces Massive Bleeding Due To Hyperfibrinolytic Disseminated Intravascular Coagulation.
Afibrinogenemia
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Afibrinogenemia
Clinical audit of inherited bleeding disorders in a developing country.
Afibrinogenemia
Congenital afibrinogenemia in Hasan Sadikin Hospital.
Afibrinogenemia
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Afibrinogenemia
Studies on the role of adhesive proteins in maintaining pregnancy.
Afibrinogenemia
The activated partial thromboplastin time may not reveal even severe fibrinogen deficiency.
Afibrinogenemia
Treatment of afibrinogenemia in a chihuahua.
Afibrinogenemia
[Inherited Afibrinogenemia Caused by Compound Heterozygous Mutations in the Beta beta-Chain of Fibrinogen.]
Afibrinogenemia
[Studies on the presence of active thrombokinase in the amniotic fluid; a contribution to the etiology of afibrinogenemia during labor.]
Agammaglobulinemia
Case Report: An Adult Patient With Deficiency of Adenosine Deaminase 2 Resembled Unilateral Frosted Branch Angiitis.
Agammaglobulinemia
Follow-up of renal transplant recipients after acute COVID-19-A prospective cohort single-center study.
Alopecia
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Alopecia
Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience.
Alopecia
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.
alpha 1-Antitrypsin Deficiency
[Thrombokinase inhibitors and alpha 1-antitrypsin deficiency in liver cirrhosis as a cause for hemorrhage in ascites shunt]
Alzheimer Disease
Proteolysis of Alzheimer's disease beta-amyloid precursor protein by factor Xa.
Amyloidosis
A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against factor X.
Amyloidosis
A Case Report of Acquired Factor X Deficiency in a Patient With Multiple Myeloma.
Amyloidosis
A Rare Cause of Coagulopathy in a Patient with Rapidly Progressive Renal Failure.
Amyloidosis
A reproducible model for the study of factor X kinetics in AA amyloidosis.
Amyloidosis
Acquired factor X deficiency and amyloidosis treated with melphalan and prednisone.
Amyloidosis
Acquired factor X deficiency and amyloidosis.
Amyloidosis
Acquired factor X deficiency associated with atypical AL-amyloidosis.
Amyloidosis
Acquired factor X deficiency in a patient with amyloidosis.
Amyloidosis
Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis.
Amyloidosis
Acquired factor x deficiency in light chain amyloidosis: a report of 2 korean cases.
Amyloidosis
Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease.
Amyloidosis
Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
Amyloidosis
Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis.
Amyloidosis
Acquired factor X deficiency in systemic amyloidosis.
Amyloidosis
Acquired factor X deficiency in systemic amyloidosis: management of two cases.
Amyloidosis
Acquired factor X deficiency. Altered plasma antithrombin activity and association with amyloidosis.
Amyloidosis
Acquired isolated factor X deficiency associated with systemic amyloidosis. Case report and review of literature.
Amyloidosis
Acquired-transient factor X deficiency in a teenager with extensive burns.
Amyloidosis
Amyloidosis and factor X deficiency.
Amyloidosis
AMYLOIDOSIS ASSOCIATED WITH FACTOR X (STUART) DEFICIENCY; CASE REPORT.
Amyloidosis
Amyloidosis with factor X deficiency.
Amyloidosis
An acquired, calcium-dependent, factor X inhibitor.
Amyloidosis
Atraumatic splenic rupture in amyloidosis.
Amyloidosis
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.
Amyloidosis
Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients.
Amyloidosis
Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency.
Amyloidosis
Cardiac Amyloidosis Presenting with Pre-Excitation Syndrome, Heart Failure, and Severe Factor X Deficiency as Part of Systemic Amyloid Light-Chain (AL) Amyloidosis - A Fatal Combination.
Amyloidosis
Coagulation and fibrinolysis abnormalities in familial amyloid polyneuropathy.
Amyloidosis
Direct Factor X sequestration by systemic amyloid light-chain amyloidosis.
Amyloidosis
Evidence of both von Willebrand factor deposition and factor V deposition onto AL amyloid as the cause of a severe bleeding diathesis.
Amyloidosis
Factor X and its deficiency states.
Amyloidosis
Factor X deficiency and systemic amyloidosis.
Amyloidosis
Factor X Deficiency Caused by Nonsecretory Myeloma Successfully Corrected with Bortezomib: A Case Report and Review of the Literature.
Amyloidosis
Factor X deficiency in systemic amyloidosis.
Amyloidosis
Factor X deficiency.
Amyloidosis
Hemostatic abnormalities in multiple myeloma and related disorders.
Amyloidosis
Heterogeneity of hereditary and acquired factor X deficiencies by combined immunochemical and functional analyses.
Amyloidosis
Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency.
Amyloidosis
Importance of pharmacokinetic studies in the management of acquired factor X deficiency.
Amyloidosis
Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis.
Amyloidosis
Isolated factor X deficiency in amyloidosis. Case report and review of the literature.
Amyloidosis
Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis.
Amyloidosis
Lupus anticoagulant associated with transient severe factor X deficiency: a report of two patients presenting with major bleeding complications.
Amyloidosis
Massive Upper and Lower GI Bleed from Simultaneous Primary (AL) Amyloidosis of the Stomach and Transverse Colon in a Patient with Multiple Myeloma.
Amyloidosis
Mechanism of factor X deficiency in systemic amyloidosis.
Amyloidosis
Normalization of plasma factor X levels in amyloidosis after plasma exchange.
Amyloidosis
Poor recovery and short survival of infused factor X in a case of acquired factor X deficiency and amyloidosis.
Amyloidosis
Presurgical plasma exchange is ineffective in correcting amyloid associated factor X deficiency.
Amyloidosis
Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency.
Amyloidosis
Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency.
Amyloidosis
Recurrent, isolated factor X deficiency in myeloma: repeated normalization of factor X levels after cytostatic chemotherapy followed by late treatment failure associated with the development of systemic amyloidosis.
Amyloidosis
Refractory hematuria from amyloidosis successfully treated by splenectomy.
Amyloidosis
Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy.
Amyloidosis
Resolution of acquired factor X deficiency with amyloidosis secondary to plasma cell dyscrasia.
Amyloidosis
Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding.
Amyloidosis
Spontaneous major bleeding in acquired factor X deficiency secondary to AL-amyloidosis.
Amyloidosis
Spontaneous resolution of acquired factor X deficiency in amyloidosis.
Amyloidosis
Spontaneous spinal epidural hematoma in a patient with acquired Factor X deficiency secondary to systemic amyloid light-chain amyloidosis.
Amyloidosis
Successful perioperative use of prothrombin complex concentrate in the treatment of acquired factor X deficiency in the setting of systemic light-chain (AL) amyloidosis.
Amyloidosis
Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
Amyloidosis
Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X.
Amyloidosis
Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients.
Amyloidosis
Systemic amyloidosis associated with factor X deficiency.
Amyloidosis
Systemic amyloidosis associated with micro-angiopathic haemolytic anaemia and factor X (Stuart factor) deficiency.
Amyloidosis
The 13-year bleed: Exuberant amyloid angiopathies, angiodysplasias, and acquired coagulopathies of the gut.
Amyloidosis
The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
Amyloidosis
Treatment of amyloidosis associated factor X deficiency.
Amyloidosis
Use of prothrombin complex concentrate for prophylaxis of bleeding in acquired factor X deficiency associated with light-chain amyloidosis.
Amyloidosis
Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis.
Amyloidosis
[A case of primary hepatic amyloidosis with factor X deficiency.]
Amyloidosis
[A case of retroperitoneal hemorrhage due to multiple myeloma complicated with factor X deficiency and amyloidosis]
Amyloidosis
[A deficiency of blood coagulation factor X in a female patient with primary generalized amyloidosis]
Amyloidosis
[Acquired deficit in factor X associated with amyloidosis. One case (author's transl)]
Amyloidosis
[Acquired factor X deficiency associated with A.L.type amyloidosis. A case report]
Amyloidosis
[Acquired isolated factor X deficiency in generalized amyloidosis]
Amyloidosis
[Decreased Quick percentage, acquired factor X deficiency, hemarthrosis and ecchymosis: amyloidosis]
Amyloidosis
[Factor X deficiency in amyloidosis (author's transl)]
Amyloidosis
[Factor X deficiency in systemic amyloidosis. Presentation of a case]
Amyloidosis
[Systemic light chain amyloidosis with acquired factor X deficiency: a case report].
Amyloidosis, Familial
[Familial amyloidosis of AL type and factor X deficiency. The valve of long-term colchicine administration]
Anaphylaxis
An unusual cause of spontaneous bleeding in the intensive care unit - mastocytosis: a case report.
Anemia
A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia.
Anemia
A pilot study of the effect of rivaroxaban in sickle cell anemia.
Anemia
A Retrospective Analysis of the Clinical and Epidemiological Characteristics of COVID-19 Patients in Henan Provincial People's Hospital, Zhengzhou, China.
Anemia
Acquired factor VIII deficiency presenting with compartment syndrome.
Anemia
Acquired hemophilia A developing cerebral infarction 36 days after the frequent administration of bypass hemostatic agents.
Anemia
Acquired Hemophilia A in a Patient with Essential Thrombocythemia.
Anemia
Acquired von Willebrand's syndrome caused by primary hypothyroidism in a 5-year-old girl.
Anemia
Acquired Von Willebrand's Syndrome in Systemic Lupus Erythematosus.
Anemia
Activated coagulation times in normal cats and dogs using MAX-ACT tubes.
Anemia
Adenoviral pneumonia in children.
Anemia
Bleeding manifestations in males with von Willebrand disease.
Anemia
Blood cells diseases and thrombosis.
Anemia
Clinical Assessment of Postoperative Anemia Associated with Edoxaban in Patients Undergoing Total Knee Arthroplasty Compared to Fondaparinux.
Anemia
Connective tissue disease associated with sclerodermoid features, early abortion, and circulating anticoagulant.
Anemia
Crimean-Congo hemorrhagic fever.
Anemia
Dabigatran overdose: case report of laboratory coagulation parameters and hemodialysis of an 85-year-old man.
Anemia
Deficiency of the contact phase of intrinsic coagulation in a horse.
Anemia
Diffuse hemangiomatosis, coagulopathy and microangiopathic hemolytic anemia.
Anemia
Erythema multiforme major and disseminated intravascular coagulation in a dog following application of a d-limonene-based insecticidal dip.
Anemia
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
Anemia
Experimental Sarcocystis suicanis infections: disease in growing pigs.
Anemia
Factor X Deficiency: A Rare Cause of Puberty Menorrhagia.
Anemia
Hematologic manifestation of childhood celiac disease.
Anemia
Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder.
Anemia
Immunologic reactions associated with anemia, thrombocytopenia, and coagulopathy in experimental African trypanosomiasis.
Anemia
Lupus anticoagulant-like activity observed in a dimeric lambda protein produced by myeloma cells.
Anemia
Malignant histiocytosis in a cat.
Anemia
Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review.
Anemia
Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience.
Anemia
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Anemia
Pharmaceutical Approval Update.
Anemia
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Anemia
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.
Anemia
Preoperative laboratory testing of children undergoing elective surgery.
Anemia
Prevalence of retinopathy in patients with anemia or thrombocytopenia.
Anemia
Primary pulmonary hypertension. Its association with microangiopathic hemolytic anemia and thrombocytopenia.
Anemia
Prognostic indicators for canine monocytic ehrlichiosis.
Anemia
Renal hemorrhage caused by acquired inhibitors to coagulation factors VIII and V in a hemodialysis patient.
Anemia
Severe adenovirus infection in children.
Anemia
Splenic infarction, warm autoimmune hemolytic anemia and antiphospholipid antibodies in a patient with infectious mononucleosis.
Anemia
Spontaneous hemoperitoneum in cats: 65 cases (1994-2006).
Anemia
Spontaneous Retrobulbar Hemorrhage in a Previously Healthy Infant.
Anemia
The clinical impact of edoxaban for the patients with postoperative anemia after total hip arthroplasty.
Anemia
The hemostatic effect of packed red cell transfusion in patients with anemia.
Anemia
Thromboelastometry-guided hemostatic therapy for hemorrhagic shock in the postoperative period of vascular surgery: a case report.
Anemia
Unusual metastatic behavior and clinicopathologic findings in eight cats with cutaneous or visceral hemangiosarcoma.
Anemia
Unusual Presentation of Diffuse Large B-Cell Lymphoma With Splenic Infarcts.
Anemia
Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?
Anemia
Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?
Anemia
[Abdominal inflammatory pseudotumor (plasma cell granuloma) with anemia and hypergammaglobulinemia]
Anemia
[An uncommon cause of severe soft tissue bleeding during phenprocoumon treatment.]
Anemia
[Changes of coagulation function in patients with adenomyosis and its clinical significance].
Anemia
[Clinical evaluation of three elderly cases with acquired hemophilia A].
Anemia
[Crimean-Congo hemorrhagic fever]
Anemia
[Effective immunosuppresive therapies including steroid pulse treatment for intramuscular hematoma in iliopsoas in acquired hemophilia]
Anemia
[Perioperative management of a patient with systemic lupus erythematosus, myasthenia gravis, and pemphigus foliaceous]
Anemia
[Significance of blood tests prior to adenoidectomy]
Anemia
[Successful total gastrectomy of gastric cancer in a congenital factor V deficient patient]
Anemia, Aplastic
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
Anemia, Hemolytic
Complement in Secondary Thrombotic Microangiopathy.
Anemia, Hemolytic
Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic anemia.
Anemia, Hemolytic
Impaired and exhausted platelets in modified generalized Shwartzman reaction: an analogue of hemolytic uremic syndrome associated with endotoxemia.
Anemia, Hemolytic
Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies.
Anemia, Hemolytic
Systemic amyloidosis associated with micro-angiopathic haemolytic anaemia and factor X (Stuart factor) deficiency.
Anemia, Hemolytic
Zinc toxicosis in a dog secondary to prolonged zinc oxide ingestion.
Anemia, Hemolytic
[Catastrophic antiphospholipid syndrome and rituximab: a new report]
Anemia, Hemolytic
[Hemostatic disorders as a complication of autoimmune hemolytic anemia in dogs]
Anemia, Hemolytic
[Treatment of fulminant falciparum malaria with erythrapheresis]
Anemia, Iron-Deficiency
A bleeding disorder (von Willebrand's disease) in a Himalayan cat.
Anemia, Iron-Deficiency
Celiac disease with diffuse cutaneous vitamin K-deficiency bleeding.
Anemia, Iron-Deficiency
Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review.
Anemia, Sickle Cell
A pilot study of the effect of rivaroxaban in sickle cell anemia.
Anemia, Sickle Cell
Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.
Anemia, Sickle Cell
Plasma levels of some blood coagulation parameters in Nigerian homozygous sickle cell patients (HbSS) in steady state.
Anemia, Sickle Cell
Prolongation of the prothrombin time and activated partial thromboplastin time in children with sickle cell disease.
Anemia, Sickle Cell
SICKLE CELL DISEASE. A SERUM DEFECT IN THE THROMBOPLASTIN GENERATION TEST.
Aneurysm
Active aneurysm thrombosis after Kawasaki disease in an adult: Insight into anticoagulation therapy.
Aneurysm
Coagulopathy induced by aortoiliac aneurysms.
Aneurysm
Low-Dose versus Therapeutic Range Intravenous Unfractionated Heparin Prophylaxis in the Treatment of Patients with Severe Aneurysmal Subarachnoid Hemorrhage After Aneurysm Occlusion.
Aneurysm
Presurgical plasma exchange is ineffective in correcting amyloid associated factor X deficiency.
Aneurysm
Primary fibrinolysis during supraceliac aortic clamping.
Aneurysm
Thrombosis of Large Aneurysm Induced by Flow-Diverter Stent and Dissolved by Direct Factor Xa Inhibitor.
Aneurysm, Dissecting
Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin.
Aneurysm, Ruptured
Recent risk factors for open surgical mortality in patients with ruptured abdominal aortic aneurysm.
Angina Pectoris
Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis.
Angina, Stable
The effect of different nitrate preparations on plasma heparin concentrations and the activated partial thromboplastin time.
Angina, Unstable
A rare case of fondaparinux-induced major bleeding in postmenopausal woman prescribed for non-ST segment elevation Ml.
Angina, Unstable
Antithrombin-III plasma activity during and after prolonged use of heparin in unstable angina.
Angina, Unstable
Assessment of the drug interaction between intravenous nitroglycerin and heparin.
Angina, Unstable
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Angina, Unstable
Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
Angina, Unstable
Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
Angina, Unstable
Intracoronary recombinant tissue-type plasminogen activator in unstable angina: a pilot angiographic study.
Angina, Unstable
Low molecular weight heparin in acute stroke.
Angina, Unstable
Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.
Angina, Unstable
Spotlight on fondaparinux sodium in acute coronary syndromes.
Angina, Unstable
The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention.
Angina, Unstable
Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris.
Angina, Unstable
ZK-807834. Berlex.
Angiodysplasia
Gastrointestinal angiodysplasia: a possible component of von Willebrand's disease.
Angiodysplasia
The 13-year bleed: Exuberant amyloid angiopathies, angiodysplasias, and acquired coagulopathies of the gut.
Angioedema
Shortened Activated Partial Thromboplastin Time May Help in Diagnosing Hereditary and Acquired Angioedema.
Anisocoria
The sequential trauma score - a new instrument for the sequential mortality prediction in major trauma.
Antiphospholipid Syndrome
A Diagnostic Solution for Lupus Anticoagulant Testing in Patients Taking Direct Oral FXa Inhibitors Using DOAC Filter.
Antiphospholipid Syndrome
A patient with pleuritic chest pain and abnormal blood clotting tests.
Antiphospholipid Syndrome
Activated protein C resistance: molecular mechanisms.
Antiphospholipid Syndrome
An increase of blood anti-beta2-glycoprotein I antibody in Japanese encephalitis associated with cerebral ischemia.
Antiphospholipid Syndrome
Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin.
Antiphospholipid Syndrome
Antiphospholipid antibody syndrome: an unusual cause of stroke in a 22-year-old female.
Antiphospholipid Syndrome
Antiphospholipid syndrome and factor V Leiden. Three cases with recurrent venous thrombosis.
Antiphospholipid Syndrome
Antiphospholipid syndrome and thrombosis.
Antiphospholipid Syndrome
Antiphospholipid syndrome presenting as intracardiac thrombus with pulmonary embolism.
Antiphospholipid Syndrome
Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.
Antiphospholipid Syndrome
Association of lupus anticoagulant and anticardiolipin antibodies with thrombosis in patients with systemic lupus erythematosus, primary antiphospholipid syndrome and other disorders.
Antiphospholipid Syndrome
Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
Antiphospholipid Syndrome
Dilute Russell viper venom time interpretation and clinical correlation: A two-year retrospective institutional review.
Antiphospholipid Syndrome
Etanercept and venous thromboembolism: a case series.
Antiphospholipid Syndrome
Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: a longitudinal cohort study.
Antiphospholipid Syndrome
Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: additional information.
Antiphospholipid Syndrome
Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome.
Antiphospholipid Syndrome
FcRn augments induction of tissue factor activity by IgG-containing immune complexes.
Antiphospholipid Syndrome
Heparin monitoring in acute thrombosis associated with antiphospholipid antibody syndrome.
Antiphospholipid Syndrome
Identification of anti-prothrombin antibodies in the anti-phospholipid syndrome that display the prothrombinase activity.
Antiphospholipid Syndrome
Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies.
Antiphospholipid Syndrome
Lupus erythematosus with antiphospholipid syndrome and erythema multiforme-like lesions.
Antiphospholipid Syndrome
Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time.
Antiphospholipid Syndrome
Monitoring anticoagulant therapy with vitamin K antagonists in patients with antiphospholipid syndrome.
Antiphospholipid Syndrome
Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin.
Antiphospholipid Syndrome
Perioperative anticoagulation management in antiphospholipid syndrome.
Antiphospholipid Syndrome
Prolonged activated partial thromboplastin time in patients with antiphospholipid antibody syndrome.
Antiphospholipid Syndrome
Pulmonary embolism, thrombocytopenia, and antiphospholipid syndrome.
Antiphospholipid Syndrome
Pyoderma gangrenosum and extensive caval thrombosis associated with the antiphospholipid syndrome--a case report.
Antiphospholipid Syndrome
Rowell's syndrome and associated antiphospholipid syndrome.
Antiphospholipid Syndrome
Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome.
Antiphospholipid Syndrome
Secondary severe factor X deficiency associated with antiphospholipid syndrome.
Antiphospholipid Syndrome
Successful delivery in a pregnant woman with lupus anticoagulant positive systemic lupus erythematosus treated with double filtration plasmapheresis.
Antiphospholipid Syndrome
Successful Peritoneal Dialysis Catheter Placement in a New End-Stage Renal Disease Patient with Combined Antiphospholipid Syndrome and Factor XI Deficiency.
Antiphospholipid Syndrome
The activated seven lupus anticoagulant assay detects clinically significant antibodies.
Antiphospholipid Syndrome
The anaesthetist and the antiphospholipid syndrome.
Antiphospholipid Syndrome
Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome.
Antiphospholipid Syndrome
Transient lupus anticoagulant: an unusual cause of bruising in children.
Antiphospholipid Syndrome
Vascular disease in the antiphospholipid syndrome: a comparison with the patient population with atherosclerosis.
Antiphospholipid Syndrome
Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant.
Antiphospholipid Syndrome
[Diagnosis of secondary antiphospholipid syndrome in children by means of screening tests]
Antiphospholipid Syndrome
[Effectiveness and safety of selective and non - selective factor Xa inhibitors in antiphospholipid syndrome and systemic lupus erythematosus: anti - Xa - activity range].
Antiphospholipid Syndrome
[Splenic vein thrombosis with pancytopenia and fever: antiphospholipid antibody syndrome]
Antithrombin III Deficiency
Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome.
Antithrombin III Deficiency
An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
Antithrombin III Deficiency
Measurement of markers of activated coagulation in antithrombin III deficient subjects.
Antithrombin III Deficiency
[Reasons for fresh frozen plasma transfusion in a general hospital]
Aortic Aneurysm
Coagulopathy induced by aortoiliac aneurysms.
Aortic Aneurysm
Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
Aortic Aneurysm, Abdominal
Factor Xa inhibition by Rivaroxaban modified mitochondrial-associated proteins in human abdominal aortic aneurysms.
Aortic Aneurysm, Abdominal
Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation.
Aortic Aneurysm, Abdominal
FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms.
Aortic Coarctation
Attributable fraction for cardiac malformations.
Aortic Valve Stenosis
Oral Anticoagulation Therapy and Progression of Calcific Aortic Valve Stenosis: Factor Xa versus Factor IIa Inhibition?
Appendicitis
Alterations of the preoperative coagulation profile in patients with acute appendicitis.
Appendicitis
[Unsuspected prolonged activated partial thromboplastin time in emergency surgery. Diagnostic and therapeutic guide]
Arrhythmias, Cardiac
The role of hypothermia in the management of severe brain injury: a meta-analysis.
Arterial Occlusive Diseases
[Hemorheologic and blood coagulation studies in 94 patients with chronic obstructive peripheral arterial disease]
Arteriosclerosis Obliterans
Accelerated thromboplastin generation in acute arterial occulusion complicating arteriosclerosis obliterans.
Arteriovenous Fistula
A case of a severe factor XI deficiency in patient undergoing hemodialysis without the use of heparin.
Arteriovenous Fistula
[Acquired factor XI inhibitor and chronic lymphocytic leukemia.]
Arteriovenous Malformations
Acquired hemophilia A that required surgical hemostasis of hematomas occupying oral cavity: a case report.
Arthralgia
Alkhumra (Alkhurma) virus outbreak in Najran, Saudi Arabia: Epidemiological, clinical, and Laboratory characteristics.
Arthritis
Activated partial thromboplastin time sensitivity to lupus anticoagulant in a patient with transient arthritis and lupus anticoagulant-hypoprothrombinemia syndrome.
Arthritis
Altered regulation of in-vivo coagulation in orthopedic patients prior to knee or hip replacement surgery.
Arthritis
Effects on leukocyte function by arthroplasty. Thromboplastin activity and oxygen-derived free radicals studied in rheumatoid arthritis and arthrosis.
Arthritis
Leech thrombin inhibitors.
Arthritis
The prothrombinase activity of FGL2 contributes to the pathogenesis of experimental arthritis.
Arthritis
[Acquired pseudohemophilia caused by an anticoagulant factor inhibiting the formation of thromboplastin during chronic evolutive polyarthritis.]
Arthritis
[Hemorrhagic diathesis due to anticoagulant inhibiting the formation or action of thromboplastin; concerning a personal case observed during chronic evolutive polyarthritis.]
Arthritis, Gouty
The inflammatory process in acute gouty arthritis. II. The presence of Hageman factor and plasma thromboplastin antecedent in synovial fluid.
Arthritis, Rheumatoid
Apixaban exhibits anti-arthritic effects by inhibiting activated factor X-mediated JAK2/STAT3 and MAPK phosphorylation pathways.
Arthritis, Rheumatoid
Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Arthritis, Rheumatoid
Effects of intravenous high doses of ketoprofen on blood clotting, bleeding time and platelet aggregation in man.
Arthritis, Rheumatoid
Effects on leukocyte function by arthroplasty. Thromboplastin activity and oxygen-derived free radicals studied in rheumatoid arthritis and arthrosis.
Arthritis, Rheumatoid
Factor VIII inhibitors. Laboratory diagnosis of inhibitors.
Arthritis, Rheumatoid
Macrophages synthesize factor X and secrete factor X/Xa-containing prothrombinase activity into the surrounding medium.
Arthritis, Rheumatoid
Microparticles as biomarkers in autoimmunity: from dust bin to center stage.
Arthus Reaction
TLT-1-CONTROLS EARLY THROMBUS FORMATION AND STABILITY BY FACILITATING AIIBB3 OUTSIDE-IN SIGNALING IN MICE.
Ascorbic Acid Deficiency
Effect of ascorbic acid deficiency on plasma prothrombin time and partial thromboplastin time in guinea pigs.
Aspergillosis
[Blood coagulation in domestic deep-seated mycoses]
Asthma
Coagulation factor Xa modulates airway remodeling in a murine model of asthma.
Asthma
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
Asthma
The Coagulant Factor Xa Induces Protease-Activated Receptor-1 and Annexin A2-Dependent Airway Smooth Muscle Cytokine Production and Cell Proliferation.
Asthma
[Changes in platelet function, activated partial thromboplastin time and plasminogen activator inhibitor in patients with bronchial asthma after prednisone treatment]
Atherosclerosis
Activated partial thromboplastin time and risk of future venous thromboembolism.
Atherosclerosis
Anticoagulant properties of the anti-inflammatory cytokine IL-10 in a factor Xa-activated human monocyte model.
Atherosclerosis
Antithrombin III and factor Xa inhibitor in atherosclerosis.
Atherosclerosis
Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators.
Atherosclerosis
Clinical significance of increased thromboplastin activity on the monocyte surface--a brief review.
Atherosclerosis
Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis.
Atherosclerosis
Effects of vitamin K2 (menatetrenone) on atherosclerosis and blood coagulation in hypercholesterolemic rabbits.
Atherosclerosis
Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?
Atherosclerosis
Peripheral vascular disease in patients with systemic lupus erythematosus.
Atherosclerosis
Pleiotropic actions of factor Xa inhibition in cardiovascular prevention - mechanistic insights and implications for anti-thrombotic treatment.
Atherosclerosis
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
Atherosclerosis
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
Atherosclerosis
Protease-Activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice.
Atherosclerosis
Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial.
Atherosclerosis
Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease.
Atherosclerosis
Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction.
Atherosclerosis
Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.
Atherosclerosis
Sulphur: the vulnerable factor X in atherosclerosis.
Atherosclerosis
Targeting Coagulation Factor Xa Promotes Regression of Advanced Atherosclerosis in Apolipoprotein-E Deficient Mice.
Atherosclerosis
Targeting factor Xa and thrombin: impact on coagulation and beyond.
Atherosclerosis
Tissue factor-driven thrombin generation and inflammation in atherosclerosis.
Atherosclerosis
Two Cu(II) coordination polymers: Heterogeneous catalytic Knoevenagel condensation reaction and treatment activity on atherosclerosis via regulating the expression of the COX-2 in vascular endothelial cells.
Atherosclerosis
[Experimental cholesterin atherosclerosis in the rabbit: action of a duodenal heparinoid. III. Modifications in the factors of hemocoagulation, plasmin and plasminogen, and in the thromboplastin and fibrinolytic activity of the aortic wall.]
Atherosclerosis
[Immunohistochemical characteristics of thromboplastin and beta-lipoproteins of the human aorta in atherosclerosis]
Atrial Fibrillation
A cost-analysis model for anticoagulant treatment in the hospital setting.
Atrial Fibrillation
A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
Atrial Fibrillation
A novel coagulation parameter monitoring bleeding tendency of Chinese nonvalvular atrial fibrillation patients prescribing dabigatran etexilate.
Atrial Fibrillation
A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).
Atrial Fibrillation
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Atrial Fibrillation
A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.
Atrial Fibrillation
ABO Blood Type and Response of Activated Partial Thromboplastin Time to Dabigatran in Nonvalvular Atrial Fibrillation Patients.
Atrial Fibrillation
Accidental Rivaroxaban Intoxication in a Boy: Some Lessons in Managing New Oral Anticoagulants in Children.
Atrial Fibrillation
Activated Factor X Signaling Pathway via Protease-Activated Receptor 2 Is a Novel Therapeutic Target for Preventing Atrial Fibrillation.
Atrial Fibrillation
Acute management of bleeding in patients on novel oral anticoagulants.
Atrial Fibrillation
An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation.
Atrial Fibrillation
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation.
Atrial Fibrillation
An Inhibitor of Activated Blood Coagulation Factor X Shows Anti-Endothelial Senescence and Anti-Atherosclerotic Effects.
Atrial Fibrillation
An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
Atrial Fibrillation
An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.
Atrial Fibrillation
Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
Atrial Fibrillation
Angiotensin II promotes the anticoagulant effects of rivaroxaban via angiotensin type 2 receptor signaling in mice.
Atrial Fibrillation
Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation.
Atrial Fibrillation
Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study.
Atrial Fibrillation
Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Atrial Fibrillation
Anticoagulation in atrial fibrillation with factor X deficiency-A management dilemma.
Atrial Fibrillation
Anticoagulation in atrial fibrillation.
Atrial Fibrillation
Anticoagulation-related intracranial hemorrhages.
Atrial Fibrillation
Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Atrial Fibrillation
Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions.
Atrial Fibrillation
Apixaban and atrial fibrillation: no clear advantage.
Atrial Fibrillation
Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries.
Atrial Fibrillation
Apixaban for periprocedural anticoagulation during catheter ablation of atrial fibrillation: a systematic review and meta-analysis of 1691 patients.
Atrial Fibrillation
Apixaban to prevent stroke in patients with atrial fibrillation: a review.
Atrial Fibrillation
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
Atrial Fibrillation
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
Atrial Fibrillation
Apixaban: A New Factor Xa Inhibitor for Stroke Prevention in Patients with Atrial Fibrillation.
Atrial Fibrillation
Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
Atrial Fibrillation
Assessing Safety of Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors and Vitamin K Antagonists in Patients with Atrial Fibrillation: A Nation-Wide Propensity Score Matched Cohort from Sweden.
Atrial Fibrillation
Association between activated partial thromboplastin time, age and bleeding events in NVAF patients receiving dabigatran.
Atrial Fibrillation
Association between Coagulation Function and Cerebral Microbleeds in Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease.
Atrial Fibrillation
Atrial fibrillation in 2011: Stroke prevention in AF.
Atrial Fibrillation
Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute.
Atrial Fibrillation
Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants.
Atrial Fibrillation
Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
Atrial Fibrillation
Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
Atrial Fibrillation
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects.
Atrial Fibrillation
Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
Atrial Fibrillation
Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
Atrial Fibrillation
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
Atrial Fibrillation
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Atrial Fibrillation
Characteristics, Management, and Outcomes of Patients with Atrial Fibrillation Experiencing a Major Bleeding Event While on Rivaroxaban.
Atrial Fibrillation
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.
Atrial Fibrillation
Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
Atrial Fibrillation
Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation.
Atrial Fibrillation
Clinical management of rivaroxaban-treated patients.
Atrial Fibrillation
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Atrial Fibrillation
Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy.
Atrial Fibrillation
Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.
Atrial Fibrillation
Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation - patient considerations.
Atrial Fibrillation
Clopidogrel hydrogen sulphate for atrial fibrillation.
Atrial Fibrillation
Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran.
Atrial Fibrillation
Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue.
Atrial Fibrillation
Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.
Atrial Fibrillation
Comparative analysis and meta-analysis of major clinical trials with oral factor Xa inhibitors versus warfarin in atrial fibrillation.
Atrial Fibrillation
Comparative effectiveness of oral anticoagulants in everyday practice.
Atrial Fibrillation
Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review.
Atrial Fibrillation
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Atrial Fibrillation
Comparative efficacy and safety of the non-vitamin k antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Atrial Fibrillation
Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism.
Atrial Fibrillation
Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
Atrial Fibrillation
Comparing Safety and Efficacy of Dabigatran and Factor Xa Inhibitors for Stroke Prevention in Hemophiliacs with Non-Valvular Atrial Fibrillation.
Atrial Fibrillation
Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
Atrial Fibrillation
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
Atrial Fibrillation
Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation.
Atrial Fibrillation
Controversies: Stroke Prevention in Chronic Kidney Disease.
Atrial Fibrillation
Correction to: Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Atrial Fibrillation
Cost-Effective Medicines for Stroke Prophylaxis in Patients with Atrial Fibrillation.
Atrial Fibrillation
Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective.
Atrial Fibrillation
Cost-Effectiveness of High-Dose Edoxaban Compared to Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients.
Atrial Fibrillation
Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Atrial Fibrillation
Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.
Atrial Fibrillation
Critique of Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation trial.
Atrial Fibrillation
Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
Atrial Fibrillation
Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time.
Atrial Fibrillation
Defining nonvalvular atrial fibrillation: A quest for clarification.
Atrial Fibrillation
Delayed Vesicular Urticarial Dermatosis Due to Apixaban.
Atrial Fibrillation
Design and baseline characteristics of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
Atrial Fibrillation
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
Atrial Fibrillation
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Atrial Fibrillation
Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial.
Atrial Fibrillation
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Atrial Fibrillation
Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Atrial Fibrillation
Direct Factor Xa Inhibitors for Long-term Stroke Prevention in Atrial Fibrillation: Could the Lower Dose Fit All?
Atrial Fibrillation
Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding.
Atrial Fibrillation
Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing.
Atrial Fibrillation
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Atrial Fibrillation
Direct oral factor Xa inhibitors for the prevention of non-central nervous systemic embolism patients with non-valvular atrial fibrillation - a systematic review and meta-analysis.
Atrial Fibrillation
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Atrial Fibrillation
Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?
Atrial Fibrillation
Drug-drug interaction studies of cardiovascular drugs involving p-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor xa inhibitor.
Atrial Fibrillation
Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
Atrial Fibrillation
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48.
Atrial Fibrillation
Edoxaban in patients with atrial fibrillation.
Atrial Fibrillation
Edoxaban suppresses the progression of atrial fibrosis and atrial fibrillation in a canine congestive heart failure model.
Atrial Fibrillation
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Atrial Fibrillation
Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Atrial Fibrillation
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
Atrial Fibrillation
Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial.
Atrial Fibrillation
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Atrial Fibrillation
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation
Atrial Fibrillation
Edoxaban: a new oral direct factor xa inhibitor.
Atrial Fibrillation
Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-Valvular Atrial Fibrillation and Venous Thromboembolism.
Atrial Fibrillation
Edoxaban: a review in nonvalvular atrial fibrillation.
Atrial Fibrillation
Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial.
Atrial Fibrillation
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.
Atrial Fibrillation
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Atrial Fibrillation
Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.
Atrial Fibrillation
Effectiveness and Safety of Factor Xa Inhibitors in Patients with Atrial Fibrillation.
Atrial Fibrillation
Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
Atrial Fibrillation
Efficacy and Safety of Direct Factor Xa Inhibitors Versus Warfarin in Prevention of Primary and Secondary Ischemic Strokes in Non-Valvular Atrial Fibrillation: A Literature Review.
Atrial Fibrillation
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
Atrial Fibrillation
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.
Atrial Fibrillation
Efficacy and safety of oral direct factor Xa inhibitors versus warfarin in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.
Atrial Fibrillation
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Atrial Fibrillation
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Atrial Fibrillation
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
Atrial Fibrillation
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).
Atrial Fibrillation
Efficacy of direct factor Xa inhibitors compared to warfarin in preventing stroke in adults with non-valvular atrial fibrillation: a systematic review protocol.
Atrial Fibrillation
Emerging antithrombotic agents: what does the intensivist need to know?
Atrial Fibrillation
ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation.
Atrial Fibrillation
Evaluation of Extended-Interval Dabigatran Dosing in Older Patients With Non-Valvular Atrial Fibrillation.
Atrial Fibrillation
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Atrial Fibrillation
Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.
Atrial Fibrillation
Factor Xa inhibition by rivaroxaban regulates fibrogenesis in human atrial fibroblasts with modulation of nitric oxide synthesis and calcium homeostasis.
Atrial Fibrillation
Factor Xa Inhibitor Suppresses the Release of Phosphorylated HSP27 from Collagen-Stimulated Human Platelets: Inhibition of HSP27 Phosphorylation via p44/p42 MAP Kinase.
Atrial Fibrillation
Factor Xa Inhibitor, Rivaroxaban, Regulates the Burden of Atrial Fibrillation and Ventricular Premature Captures.
Atrial Fibrillation
Factor Xa inhibitors differently modulate electrical activities in pulmonary veins and the sinoatrial node.
Atrial Fibrillation
Factor Xa inhibitors in patients with continuous-flow left ventricular assist devices.
Atrial Fibrillation
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
Atrial Fibrillation
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolismin patients with atrial fibrillation.
Atrial Fibrillation
Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation.
Atrial Fibrillation
Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation.
Atrial Fibrillation
Factors That Determine the Prothrombin Time in Patients With Atrial Fibrillation Receiving Rivaroxaban.
Atrial Fibrillation
Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.
Atrial Fibrillation
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.
Atrial Fibrillation
Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).
Atrial Fibrillation
Hemopericardium with subsequent cardiac tamponade secondary to rivaroxaban treatment: a case report.
Atrial Fibrillation
Hemopericardium with tamponade following rivaroxaban administration and its attenuation by CYP3A4 inhibitors.
Atrial Fibrillation
Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment.
Atrial Fibrillation
Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
Atrial Fibrillation
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
Atrial Fibrillation
Imaging of Hemorrhagic Stroke.
Atrial Fibrillation
Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation.
Atrial Fibrillation
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Atrial Fibrillation
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.
Atrial Fibrillation
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Atrial Fibrillation
Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
Atrial Fibrillation
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Atrial Fibrillation
Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors.
Atrial Fibrillation
Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes.
Atrial Fibrillation
Insights into atrial fibrillation.
Atrial Fibrillation
Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Atrial Fibrillation
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
Atrial Fibrillation
Intracranial hemorrhage in patient treated with rivaroxaban.
Atrial Fibrillation
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.
Atrial Fibrillation
Intravenous Thrombolysis for Acute Ischemic Stroke in a Patient Receiving Rivaroxaban.
Atrial Fibrillation
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
Atrial Fibrillation
Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation.
Atrial Fibrillation
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.
Atrial Fibrillation
Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts".
Atrial Fibrillation
Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulants.
Atrial Fibrillation
Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis.
Atrial Fibrillation
Management of Periprocedural and Early Pericardial Effusions with Tamponade Following Ablation of Atrial Fibrillation with Uninterrupted Factor Xa Inhibitors: A Case Series.
Atrial Fibrillation
Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks.
Atrial Fibrillation
Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation.
Atrial Fibrillation
Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.
Atrial Fibrillation
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
Atrial Fibrillation
Monitoring and reversal strategies for new oral anticoagulants.
Atrial Fibrillation
Monitoring the roles of prothrombin activation fragment 1 and 2 (F1?+?2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.
Atrial Fibrillation
More light at the end of the tunnel - apixaban in atrial fibrillation.
Atrial Fibrillation
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban.
Atrial Fibrillation
New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials.
Atrial Fibrillation
New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery.
Atrial Fibrillation
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
Atrial Fibrillation
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Atrial Fibrillation
Novel anticoagulant therapy: principle and practice.
Atrial Fibrillation
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Atrial Fibrillation
Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban.
Atrial Fibrillation
Off-label use of reduced dose direct oral factor Xa-inhibitors in subjects with atrial fibrillation: a review of clinical evidence.
Atrial Fibrillation
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
Atrial Fibrillation
Optimising stroke prevention in non-valvular atrial fibrillation.
Atrial Fibrillation
Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis.
Atrial Fibrillation
Oral anticoagulants. New oral anticoagulants for atrial fibrillation: the factor Xa inhibitors rivaroxaban and apixaban.
Atrial Fibrillation
Oral anticoagulation and vitamin K deficiency.
Atrial Fibrillation
Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation.
Atrial Fibrillation
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Atrial Fibrillation
Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease.
Atrial Fibrillation
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Atrial Fibrillation
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Atrial Fibrillation
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Atrial Fibrillation
Paroxysmal atrial fibrillation during acute myocardial infarction associated with subclinical hyperthyroidism, severe three vessels coronary artery disease and elevation of prostate-specific antigen after TURP.
Atrial Fibrillation
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
Atrial Fibrillation
Perinephric Hematoma Induced by Factor Xa Inhibitor in a Patient with a Vascular Renal Mass.
Atrial Fibrillation
Periprocedural management of rivaroxaban-treated patients.
Atrial Fibrillation
Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects.
Atrial Fibrillation
Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination.
Atrial Fibrillation
Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination.
Atrial Fibrillation
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Atrial Fibrillation
Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm.
Atrial Fibrillation
Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor.
Atrial Fibrillation
Platelet aggregation in direct oral factor Xa inhibitors-treated patients with atrial fibrillation: a pilot study.
Atrial Fibrillation
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Atrial Fibrillation
Population Pharmacokinetic-Pharmacodynamic Modeling Analysis of Intrinsic FXa and Bleeding From Edoxaban Treatment.
Atrial Fibrillation
Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation.
Atrial Fibrillation
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
Atrial Fibrillation
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Atrial Fibrillation
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.
Atrial Fibrillation
Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.
Atrial Fibrillation
Preclinical and clinical data for factor Xa and "universal" reversal agents.
Atrial Fibrillation
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
Atrial Fibrillation
Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice.
Atrial Fibrillation
Promise of factor Xa inhibition in atrial fibrillation.
Atrial Fibrillation
Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis.
Atrial Fibrillation
Quick reference guide to apixaban.
Atrial Fibrillation
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Atrial Fibrillation
Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis.
Atrial Fibrillation
Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation.
Atrial Fibrillation
Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.
Atrial Fibrillation
Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry.
Atrial Fibrillation
Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
Atrial Fibrillation
Rectus Sheath Hematoma Associated with Apixaban.
Atrial Fibrillation
Reduced Smoke-like Echo and Resolved Thrombus in the Left Atrium with Rivaroxaban Therapy in an Acute Cardioembolic Stroke Patient.
Atrial Fibrillation
Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.
Atrial Fibrillation
Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
Atrial Fibrillation
Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation.
Atrial Fibrillation
Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy.
Atrial Fibrillation
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Atrial Fibrillation
Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH.
Atrial Fibrillation
Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts".
Atrial Fibrillation
Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7).
Atrial Fibrillation
Retroperitoneal haematoma in a postoperative ALIF patient taking rivaroxaban for atrial fibrillation.
Atrial Fibrillation
Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies.
Atrial Fibrillation
Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal.
Atrial Fibrillation
Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran.
Atrial Fibrillation
Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial.
Atrial Fibrillation
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.
Atrial Fibrillation
Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer.
Atrial Fibrillation
Rivaroxaban in atrial fibrillation.
Atrial Fibrillation
Rivaroxaban in patients with ischaemic chronic cardiomyopathy and obstructive peripheral arterial disease: rationale for treatment and results.
Atrial Fibrillation
Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1.
Atrial Fibrillation
RIVAroxaban TWICE daily for lysis of thrombus in the left atrial appendage in patients with non-valvular atrial fibrillation: the RIVA-TWICE study.
Atrial Fibrillation
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
Atrial Fibrillation
Rivaroxaban: a review of its use in acute coronary syndromes.
Atrial Fibrillation
Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Atrial Fibrillation
ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation.
Atrial Fibrillation
Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban.
Atrial Fibrillation
Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
Atrial Fibrillation
Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
Atrial Fibrillation
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.
Atrial Fibrillation
Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation.
Atrial Fibrillation
Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.
Atrial Fibrillation
Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation.
Atrial Fibrillation
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
Atrial Fibrillation
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.
Atrial Fibrillation
Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban.
Atrial Fibrillation
Spontaneous Hemopericardium in a Patient Receiving Apixaban Therapy: First Case Report.
Atrial Fibrillation
Spontaneous rectus sheath hematoma during rivaroxaban therapy.
Atrial Fibrillation
Spontaneous rectus sheath hematoma in a patient treated with apixaban.
Atrial Fibrillation
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Atrial Fibrillation
Stroke Prevention in Atrial Fibrillation - Outcomes and Future Directions.
Atrial Fibrillation
Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.
Atrial Fibrillation
Sudden Loss of Vision: An Insight into Rivaroxaban.
Atrial Fibrillation
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
Atrial Fibrillation
The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure.
Atrial Fibrillation
The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
Atrial Fibrillation
The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
Atrial Fibrillation
The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis.
Atrial Fibrillation
The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Atrial Fibrillation
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
Atrial Fibrillation
The pharmacology of novel oral anticoagulants.
Atrial Fibrillation
The Potential Role of Edoxaban in Stroke Prevention Guidelines.
Atrial Fibrillation
The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes.
Atrial Fibrillation
Therapeutic Plasma Exchange for Urgent Rivaroxaban Reversal.
Atrial Fibrillation
Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke.
Atrial Fibrillation
Transitions of care in anticoagulated patients.
Atrial Fibrillation
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
Atrial Fibrillation
Update on Pharmacologic Approaches To Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
Atrial Fibrillation
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
Atrial Fibrillation
Use of rivaroxaban in patients with stroke.
Atrial Fibrillation
Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
Atrial Fibrillation
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.
Atrial Fibrillation
Vitamin K antagonists. Ready to be replaced?
Atrial Fibrillation
What did we learn from new oral anticoagulant treatment?
Atrial Fibrillation
[Anticoagulant therapy for chronic cardiac diseases. Atrial fibrillation, valvular heart disease, congestive heart failure].
Atrial Fibrillation
[Characteristics and clinical use of rivaroxaban for the treatment of atrial fibrillation and venous thromboembolism].
Atrial Fibrillation
[Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation].
Atrial Fibrillation
[Dabigatran, a New Oral Anticoagulant.]
Atrial Fibrillation
[Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
Atrial Fibrillation
[Effect of low-dosage intravenous nitrate therapy on the anticoagulant effect of heparin]
Atrial Fibrillation
[Evidence of novel oral anticoagulants (NOAC)].
Atrial Fibrillation
[Factor Xa inhibitor (rivaroxaban and drugs under investigation)].
Atrial Fibrillation
[New anticoagulant drugs for atrial fibrillation. Feasibility and necessity of monitoring].
Atrial Fibrillation
[New oral anticoagulants for the prevention of stroke : Open questions in geriatric patients].
Atrial Fibrillation
[New oral anticoagulants: recommendations, precautions and perspectives for use].
Atrial Fibrillation
[Novel oral anticoagulants (NOAC)].
Atrial Fibrillation
[Occurrence of acquired factor V inhibitor during antibiotic therapy for a surgical wound infection].
Atrial Fibrillation
[Perioperative management and therapy of bleeding complications].
Atrial Fibrillation
[Pharmacology of the new oral anticoagulants].
Atrial Fibrillation
[Preventing cerebrovascular accidents during atrial fibrillation]
Atrial Fibrillation
[Prevention of stroke in nonvalvular atrial fibrillation. Oral direct factor Xa inhibitor apixaban: positive experiences in general medical practice].
Atrial Fibrillation
[Risk factors analysis of acute respiratory distress syndrome in intensive care unit traumatic patients].
Atrial Fibrillation
[Rivaroxaban use in prevention of stroke in patients with non-valvular atrial fibrillation in clinical practice, results of observational studies and our experience].
Atrial Fibrillation
[Rivaroxaban-resistant right ventricular thrombus, successfully treated with vitamin K antagonist in a patient with dilated cardiomyopathy].
Atrial Fibrillation
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
Atypical Hemolytic Uremic Syndrome
A case of atypical hemolytic uremic syndrome due to anti-factor H antibody in a patient presenting with a factor XII deficiency identified two novel mutations.
Autoimmune Diseases
Characterization and acute phase modulation of canine apolipoprotein H (beta 2-glycoprotein I).
Autoimmune Diseases
Cutaneous histopathologic findings in 'antiphospholipid syndrome'. Correlation with disease, including human immunodeficiency virus disease.
Autoimmune Diseases
Immunological analogy between allograft rejection, recurrent abortion and pre-eclampsia - the same basic mechanism?
Autoimmune Diseases
[GFHT proposals for management of discordance between the International normalized ratio measured in the laboratory and by self-testing].
Avitaminosis
[Blood coagulation in C avitaminosis. Part II. The change in the prothrombin and thrombotropin concentration and causes of decreased thromboplastin activity of the blood in C avitaminosis in guinea pigs.]
Azotemia
A recalcitrant, erythematous, desquamating disorder associated with toxin-producing staphylococci in patients with AIDS.
Azotemia
Acquired hemophilia complicated by cardiorenal syndrome type 3.
Azotemia
Acute intrinsic renal failure and blood coagulation disorders after a snakebite in a dog.
Azotemia
Acute renal failure as a complication of acquired hemophilia due to autoantibody to factor VIII.
Azotemia
Erythema multiforme major and disseminated intravascular coagulation in a dog following application of a d-limonene-based insecticidal dip.
Azotemia
The successful treatment of multiple organ dysfunction syndrome and severe hypernatremia, secondary to joint supplement toxicity in a dog.
Azotemia
[Heatstroke in dogs in southern Germany. A retrospective study over a 5.5-year period].
Azotemia
[Indications for liver transplantation in severe amanita phalloides mushroom poisoning]
Bacteremia
Prolonged partial thromboplastin times in children with fever and petechiae without bacteremia or sepsis.
Bacterial Infections
Acute respiratory failure in adult patients with dengue virus infection.
Bacterial Infections
Assessment of aPTT-based clot waveform analysis for the detection of haemostatic changes in different types of infections.
Bacterial Infections
Chest radiographic presentation in patients with dengue hemorrhagic Fever.
Bacterial Infections
Cytochemical determination of intracellular polymorphonuclear leukocyte elastase content in patients with severe bacterial infection and septicaemia correlated with coagulation parameters.
Bacterial Infections
Endogenous heparin-like activity detected by anti-Xa assay in infected cirrhotic and non-cirrhotic patients.
Bacterial Infections
Perioperative management and postoperative outcome of patients undergoing cytoreduction surgery with hyperthermic intraperitoneal chemotherapy.
Bacterial Infections
Procalcitonin and Other Common Biomarkers Do Not Reliably Identify Patients at Risk for Bacterial Infection After Congenital Heart Surgery.
Bacterial Infections
Procalcitonin, C-reactive protein, neutrophil gelatinase-associated lipocalin, resistin and the APTT waveform for the early diagnosis of serious bacterial infection and prediction of outcome in critically ill children.
Bernard-Soulier Syndrome
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Bernard-Soulier Syndrome
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
Bernard-Soulier Syndrome
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Bernard-Soulier Syndrome
Platelet prothrombin converting activity in hereditary disorders of platelet function.
Bernard-Soulier Syndrome
The spectrum of bleeding disorders in women with menorrhagia: a report from Western India.
beta-Thalassemia
Demonstration of kallikrein-like protease activity in nonactivated plasma of patients with Cooley's anemia.
beta-Thalassemia
Intracranial hemorrhage and circulating coagulation inhibitor in beta-thalassemia major.
beta-Thalassemia
Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes.
beta-Thalassemia
Thalassemia major - on the verge of bleeding or thrombosis?
Bile Duct Neoplasms
Management of postoperative hemorrhage associated with factor VIII inhibitor: report of a case.
Blood Coagulation Disorders
An evaluation of the partial thromboplastin time in the detection of blood coagulation disorders.
Blood Coagulation Disorders
Analysis of the activated partial thromboplastin time test using mathematical modeling.
Blood Coagulation Disorders
Should We Postpone Elective Cardiovascular Procedures and Percutaneous Coronary Interventions During the COVID-19 Pandemic?
Blood Coagulation Disorders
[Blood coagulation disorder in a 7-year-old child with a partial factor X or Stuart-Prower factor deficiency]
Blood Coagulation Disorders
[Congenital blood coagulation disorder caused by abnormal factor X]
Blood Coagulation Disorders
[Suggestions and propositions to resolve some issues for standardization of prothrombin time and activated partial thromboplastin time]
Blood Coagulation Disorders, Inherited
A rare cause of intracranial hemorrhage: factor X deficiency.
Blood Coagulation Disorders, Inherited
A rare inherited coagulation disorder: combined homozygous factor VII and factor X deficiency.
Blood Coagulation Disorders, Inherited
A recurrent Gly43Asp substitution in coagulation Factor X rigidifies its catalytic pocket and impairs catalytic activity and intracellular trafficking.
Blood Coagulation Disorders, Inherited
Factor X and its deficiency states.
Blood Coagulation Disorders, Inherited
Factor X deficiency in North Pakistan.
Blood Coagulation Disorders, Inherited
Factor X deficiency--a rare disorder.
Blood Coagulation Disorders, Inherited
Factor X deficiency.
Blood Coagulation Disorders, Inherited
Factor XI deficiency and obstetrical anesthesia.
Blood Coagulation Disorders, Inherited
Membranoproliferative glomerulonephritis and a rare bleeding disorder: factor X deficiency.
Blood Coagulation Disorders, Inherited
Routine preoperative coagulation screening detects a rare bleeding disorder.
Blood Coagulation Disorders, Inherited
Severe Factor X Deficiency Presenting as Febrile Seizure in an Infant.
Blood Coagulation Disorders, Inherited
The role of primary prophylactic factor replacement therapy in children with severe factor X deficiency.
Blood Coagulation Disorders, Inherited
[Factor X deficiency and pregnancy]
Blood Platelet Disorders
Functional and morphological studies on blood platelets in a thrombasthenic horse.
Bluetongue
Experimentally induced bluetongue virus infection in white-tailed deer: coagulation, clinical pathologic, and gross pathologic changes.
Bone Diseases, Metabolic
Effect of antithrombotic drugs on bone health.
Borna Disease
Autogenous translational regulation of the Borna disease virus negative control factor X from polycistronic mRNA using host RNA helicases.
Borna Disease
Polymerase read-through at the first transcription termination site contributes to regulation of borna disease virus gene expression.
Bradycardia
Acute Q fever in southern Taiwan: atypical manifestations of hyperbilirubinemia and prolonged fever.
Brain Contusion
Emergent surgical evacuation of traumatic intracranial hematoma in patients with preoperative thrombocytopenia: surgical risk and early outcome.
Brain Diseases
Poor prediction of blood transfusion requirements in adult liver transplantations from preoperative variables.
Brain Diseases
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
Brain Diseases
Pretransplant status and patient survival following liver transplantation.
Brain Diseases
[Predictive value of changes in the hemostasis system in patients with ischemic brain diseases]
Brain Edema
Edema from intracerebral hemorrhage: the role of thrombin.
Brain Injuries
Disseminated intravascular coagulation as a complication of ventricular catheter placement. Case report.
Brain Injuries
Disturbances of the coagulatory system in patients with severe cerebral trauma. I.
Brain Injuries
Impaired fibrinolysis and traumatic brain injury in mice.
Brain Injuries
Machine Learning Without Borders? An Adaptable Tool to Optimize Mortality Prediction in Diverse Clinical Settings.
Brain Injuries
Prognostic value of coagulation tests for in-hospital mortality in patients with traumatic brain injury.
Brain Injuries
[Secondary blood coagulation disturbances after severe head injuries (author's transl)]
Brain Injuries, Traumatic
Impaired fibrinolysis and traumatic brain injury in mice.
Brain Injuries, Traumatic
Predictors of 30-Day Mortality in Traumatic Brain-Injured Patients after Primary Decompressive Craniectomy.
Brain Injuries, Traumatic
Trauma Early Mortality Prediction Tool (TEMPT) for assessing 28-day mortality.
Brain Injuries, Traumatic
[Study on the difference of blood coagulation function in patients with traumatic brain injury in plain and plateau area].
Brain Ischemia
An increase of anticardiolipin antibody in association with stroke and chronic chemical exposure.
Brain Ischemia
Coagulation factor Xa activates thrombin in ischemic neural tissue.
Brain Ischemia
Human umbilical cord blood-derived CD34+ cells cause attenuation of multiorgan dysfunction during experimental heatstroke.
Brain Ischemia
Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation.
Brain Ischemia
Use of rivaroxaban in patients with stroke.
Breast Neoplasms
Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients.
Breast Neoplasms
Coagulation factor VII is regulated by androgen receptor in breast cancer.
Breast Neoplasms
Effects on blood coagulation of adjuvant CNF (cyclophosphamide, novantrone, 5-fluorouracil) chemotherapy in stage II breast cancer patients.
Breast Neoplasms
Interaction of human tumor cells with human platelets and the coagulation system.
Breast Neoplasms
Mechanism of the high coagulation state of breast cancer tissue factor.
Breast Neoplasms
PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology.
Breast Neoplasms
Project for the National Program of Early Diagnosis of Endometrial Cancer Part I.
Breast Neoplasms
Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa.
Breast Neoplasms
Systemic Delivery of a Novel Liver-Detargeted Oncolytic Adenovirus Causes Reduced Liver Toxicity but Maintains the Antitumor Response in a Breast Cancer Bone Metastasis Model.
Breast Neoplasms
The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Bronchiectasis
São paulo lung transplantation waiting list: patient characteristics and predictors of death.
Brown-Sequard Syndrome
Rivaroxaban-induced acute cervical spine epidural hematoma: Report of a case and review.
Budd-Chiari Syndrome
Primary sclerosing cholangitis in the presence of a lupus anticoagulant.
Budd-Chiari Syndrome
Spectrum of hemostatic derangements, in Budd-Chiari syndrome.
CADASIL
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy with severe factor XII deficiency.
Calciphylaxis
Direct oral anticoagulant medications in calciphylaxis.
Carcinogenesis
Ovarian cancer, the coagulation pathway, and inflammation.
Carcinogenesis
Somatic and germline mutations in the pathogenesis of pituitary adenomas.
Carcinogenesis
[Expression of RAD51 and MAX in pancreatic cancer rats.]
Carcinoma
A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?
Carcinoma
Acquired factor X deficiency and disseminated intravascular coagulation in a case of metastasizing carcinoma of the stomach and its course under chemotherapy.
Carcinoma
Acquired Hemophilia in an Elderly Patient with Carcinoma of the Ampulla of Vater.
Carcinoma
Binding of annexin V to a human ovarian carcinoma cell line (OC-2008). Contrasting effects on cell surface factor VIIa/tissue factor activity and prothrombinase activity.
Carcinoma
Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa.
Carcinoma
Binding of human factors X and Xa to HepG2 and J82 human tumor cell lines. Evidence that factor Xa binds to tumor cells independent of factor Va.
Carcinoma
Cellular localization of activated factor X by Xa-specific probes.
Carcinoma
Coagulation/fibrinolysis balance and lung cancer.
Carcinoma
Correlation of haemostatic abnormalities with tumour stage and characteristics in dogs with mammary carcinoma.
Carcinoma
Evidence for a warfarin-sensitive serum factor that participates in factor X activation by Lewis lung tumor cells.
Carcinoma
Factor IXi-antithrombin (IXiAT) and thrombin-antithrombin (TAT) complexes in lung cancer patients.
Carcinoma
Factor VIIa/tissue factor-catalyzed activation of factors IX and X on a cell surface and in suspension: a kinetic study.
Carcinoma
gamma-Glutamyl carboxylase activity in experimental tumor tissues: a biochemical basis for vitamin K dependence of cancer procoagulant.
Carcinoma
Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine.
Carcinoma
Identification of a thrombin receptor with factor Xa receptor and tissue factor in human pancreatic carcinoma cells.
Carcinoma
Inhibition of recombinant human blood coagulation factor VIIa amidolytic and proteolytic activity by zinc ions.
Carcinoma
Loss of metastatic and primary tumor factor X activator capabilities by Lewis lung carcinoma cells cultured in vitamin K-dependent protein deficient serum.
Carcinoma
Mechanism of the high coagulation state of breast cancer tissue factor.
Carcinoma
Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues.
Carcinoma
Preoperative D-dimers as an independent prognostic marker in cervical carcinoma.
Carcinoma
Prognostic significance of blood coagulation tests in carcinoma of the lung and colon.
Carcinoma
Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions.
Carcinoma
Serum proteomics analysis of feline mammary carcinoma based on label-free and PRM techniques.
Carcinoma
Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics.
Carcinoma
The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma.
Carcinoma
The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor.
Carcinoma
The influence of thymus factor X (TFX) and of anti-TFX globulin on the growth of Lewis lung carcinoma in mice.
Carcinoma
The inhibition of human factor VIIa-tissue factor by antithrombin III-heparin is enhanced by factor X on a human bladder carcinoma cell line.
Carcinoma
Tumor volume estimation by the percentage carcinoma method in uterine cervix carcinoma.
Carcinoma
[Clinical and Imaging Features of Acute Cerebral Infarction ?in Non-small Cell Lung Cancer Patients with Trousseau Syndrome].
Carcinoma
[Disseminated intravascular coagulation and hyperfibrinolysis in dogs with metastasizing mammary carcinoma]
Carcinoma
[Establishment and characterization of a human squamous cell carcinoma cell line LK-52 which produce direct activator of coagulant factor X]
Carcinoma
[Prolonged activated partial thromboplastin time (aPTT): not always indicative of increased risk of bleeding]
Carcinoma, Ductal
Mechanism of the high coagulation state of breast cancer tissue factor.
Carcinoma, Hepatocellular
Binding of human factors X and Xa to HepG2 and J82 human tumor cell lines. Evidence that factor Xa binds to tumor cells independent of factor Va.
Carcinoma, Hepatocellular
Characterisation of a prothrombinase activator on the hepatoma derived cell-line, PLC/PRF/5.
Carcinoma, Hepatocellular
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Carcinoma, Hepatocellular
Human hepatoma cells secrete single chain factor X, prothrombin, and antithrombin III.
Carcinoma, Hepatocellular
Improved survival of patients presenting with acute variceal bleeding. Prognostic indicators of short- and long-term mortality.
Carcinoma, Hepatocellular
Interaction of thrombin and factor Xa with bovine vascular endothelial cells, smooth muscle cells and rat hepatoma cells.
Carcinoma, Hepatocellular
Liver-enriched transcription factor HNF-4 and ubiquitous factor NF-Y are critical for expression of blood coagulation factor X.
Carcinoma, Hepatocellular
Quantitative study on thromboplastin in various strains of Yoshida ascites hepatoma cells of rat.
Carcinoma, Hepatocellular
Rat factor X is synthesized as a single chain precursor inducible by prothrombin fragments.
Carcinoma, Hepatocellular
Receptor-mediated endocytosis of coagulation factor Xa requires cell surface-bound tissue factor pathway inhibitor.
Carcinoma, Hepatocellular
Steady state levels of factor X mRNA in liver and Hep G2 cells.
Carcinoma, Hepatocellular
The influence of insulin, beta-estradiol, dexamethasone and thyroid hormone on the secretion of coagulant and anticoagulant proteins by HepG2 cells.
Carcinoma, Hepatocellular
Tissue factor pathway inhibitor and protease nexin-1 are major factor Xa binding proteins on the HepG2 cell surface.
Carcinoma, Large Cell
[Clinical and Imaging Features of Acute Cerebral Infarction ?in Non-small Cell Lung Cancer Patients with Trousseau Syndrome].
Carcinoma, Lewis Lung
Loss of metastatic and primary tumor factor X activator capabilities by Lewis lung carcinoma cells cultured in vitamin K-dependent protein deficient serum.
Carcinoma, Lewis Lung
The influence of thymus factor X (TFX) and of anti-TFX globulin on the growth of Lewis lung carcinoma in mice.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of blood coagulation tests in carcinoma of the lung and colon.
Carcinoma, Ovarian Epithelial
Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.
Carcinoma, Renal Cell
Cellular localization of activated factor X by Xa-specific probes.
Carcinoma, Renal Cell
[Contribution to the aetiology of "reversible hepatic dysfunction" (Stauffer's syndrome) associated with renal tumours]
Carcinoma, Small Cell
Cellular localization of activated factor X by Xa-specific probes.
Carcinoma, Small Cell
Prognostic significance of blood coagulation tests in carcinoma of the lung and colon.
Carcinoma, Squamous Cell
Preoperative D-dimers as an independent prognostic marker in cervical carcinoma.
Carcinoma, Squamous Cell
[Clinical and Imaging Features of Acute Cerebral Infarction ?in Non-small Cell Lung Cancer Patients with Trousseau Syndrome].
Carcinoma, Squamous Cell
[Establishment and characterization of a human squamous cell carcinoma cell line LK-52 which produce direct activator of coagulant factor X]
Carcinoma, Transitional Cell
A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?
Cardiac Tamponade
Clinical experience of idarucizumab use in cases of cardiac tamponade under uninterrupted anticoagulation of dabigatran during catheter ablation of atrial fibrillation.
Cardiac Tamponade
Inherited Moderate Factor X Deficiency Presenting as Cardiac Tamponade.
Cardiomegaly
Cardiac Expression of Factor X Mediates Cardiac Hypertrophy and Fibrosis in Pressure Overload.
Cardiomyopathies
Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction.
Cardiomyopathy, Hypertrophic
Homozygous factor X deficiency associated with familial hypercholesterolemia, mitral valve prolapse, and hypertrophic cardiomyopathy.
Cardiovascular Diseases
Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy.
Cardiovascular Diseases
Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.
Cardiovascular Diseases
Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.
Cardiovascular Diseases
Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, Ixodes scapularis: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex.
Cardiovascular Diseases
Leech thrombin inhibitors.
Cardiovascular Diseases
Metabolism-based synthesis, biologic evaluation and SARs analysis of O-methylated analogs of quercetin as thrombin inhibitors.
Cardiovascular Diseases
Novel inhibitors of factor X for use in cardiovascular diseases.
Cardiovascular Diseases
Preventive Effects of Aspirin on Cardiovascular Complications in Prostate Cancer Cases after Endocrinotherapy.
Cardiovascular Diseases
Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression.
Cardiovascular Diseases
Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.
Cardiovascular Diseases
Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis.
Cardiovascular Diseases
The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review.
Cardiovascular Diseases
Thromboembolic risk factors in patients undergoing kidney transplant: implication of abnormally short activated partial thromboplastin time.
Cardiovascular Diseases
Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences.
Cardiovascular Diseases
[Roles of coagulation pathway and factor Xa in chronic kidney disease (CKD)].
Carotid Artery Diseases
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis.
Carotid Artery Injuries
A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice.
Carotid Artery Injuries
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Carotid Artery Thrombosis
Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis.
Carotid Artery Thrombosis
Antiplatelet and antithrombotic activities of Korean Red Ginseng.
Carotid Artery Thrombosis
Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.
Carotid Artery Thrombosis
Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis.
Carotid Artery Thrombosis
Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis.
Carotid Artery Thrombosis
Lactadherin blocks thrombosis and hemostasis in vivo: correlation with platelet phosphatidylserine exposure.
Carotid Artery Thrombosis
Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.
Carotid Artery Thrombosis
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Carotid Artery Thrombosis
Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.
Carotid Stenosis
Dipyridamole decreases protease-activated receptor and annexin-v binding on platelets of post stroke patients with aspirin nonresponsiveness.
Carotid Stenosis
Effects of asymptomatic abdominal aortic aneurysm on the soluble coagulation system, platelet count and platelet activation.
Cataract
Circulating anticoagulant in CREST syndrome.
Cataract
Preoperative prediction of hyphemas.
Catheter-Related Infections
Internal jugular versus subclavian vein catheterization for central venous catheterization in orthotopic liver transplantation.
Cellulitis
Apparent cellulitis with a prolonged APTT. Activated partial thromboplastin time.
Cellulitis
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.
Cerebral Hemorrhage
Clinical Characteristics and Outcomes Associated With Oral Anticoagulant Use Among Patients Hospitalized With Intracerebral Hemorrhage.
Cerebral Hemorrhage
Comparison of the effect of edoxaban, a direct factor Xa inhibitor, with a direct thrombin inhibitor, melagatran, and heparin on intracerebral hemorrhage induced by collagenase in rats.
Cerebral Hemorrhage
Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data.
Cerebral Hemorrhage
Evidence for Andexanet Alpha in Reversing Intracerebral Hemorrhage due to Factor Xa Inhibitors?
Cerebral Hemorrhage
Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation.
Cerebral Hemorrhage
Intracerebral hemorrhage in stroke patients anticoagulated with heparin.
Cerebral Hemorrhage
Preclinical Pharmacokinetics, Pharmacodynamics, Tissue Distribution, and Interspecies Scaling of Recombinant Human Coagulation Factor Xa(I16L).
Cerebral Hemorrhage
Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding.
Cerebral Hemorrhage
Sensitivity and specificity of fluid-blood levels for coagulopathy in acute intracerebral hematomas.
Cerebral Hemorrhage
Unusual Initial Manifestation of Acquired Hemophilia A: A Normal Activated Partial Thromboplastin Time, Intramuscular Hematoma and Cerebral Hemorrhage.
Cerebral Hemorrhage
Vitamin K deficiency in newborns: a case report in alpha-1-antitrypsin deficiency and a review of factors predisposing to hemorrhage.
Cerebral Hemorrhage
[Factor Xa Inhibitor for the Treatment of Cerebral Venous Thrombosis with Intracerebral Hemorrhage during Anticoagulation Therapy:A Case Report].
Cerebral Infarction
Antiphospholipid antibodies and stroke in the young--a study of three cases.
Cerebral Infarction
Coagulation Assay and Stroke Severity upon Admission of Patients with Cardioembolic Cerebral Infarction during Direct Oral Anticoagulant Use.
Cerebral Infarction
Correlations of acute myocardial infarction complicated by cerebral infarction with insulin resistance, adiponectin and HMGB1.
Cerebral Infarction
Dynamic change of coagulation and anticoagulation markers of patients with acute cerebral infarction during intravenous urokinase thrombolysis.
Cerebral Infarction
Evaluation of the Efficacy and Safety of Direct Oral Anticoagulants in Japanese Patients-Analysis of Pharmaceuticals and Medical Devices Agency Data.
Cerebral Infarction
Factor V inhibitor associated with Sjögren's syndrome.
Cerebral Infarction
Hematologic abnormalities occur in both cortical and lacunar infarction.
Cerebral Infarction
[Clinical and Imaging Features of Acute Cerebral Infarction ?in Non-small Cell Lung Cancer Patients with Trousseau Syndrome].
Cerebral Palsy
Clotting parameters and thromboelastography in children with neuromuscular and idiopathic scoliosis undergoing posterior spinal fusion.
Cerebrospinal Fluid Leak
[Effect of long-term and short-term mild hypothermia in severe traumatic brain injury: a comparative study].
Cerebrovascular Disorders
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
Cerebrovascular Disorders
IgG and IgM anticardiolipin antibodies in patients with lupus with anticardiolipin antibody associated clinical syndromes.
Cholangiocarcinoma
Activated partial thromboplastin time abnormality in patients with cholangiocarcinoma.
Cholangiocarcinoma
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Cholangitis, Sclerosing
Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography.
Choledocholithiasis
Safety of immediate endoscopic sphincterotomy in acute suppurative cholangitis caused by choledocholithiasis.
Cholestasis
Hypofibrinogenemia induced by tigecycline: a potentially life-threatening coagulation disorder.
Cholestasis
Pulsus alternans in a critically ill dog hospitalized for xylitol toxicity.
Cholestasis
Quantitative aspects of the parenchyma-stroma relationship in experimentally induced cholestasis.
Cholestasis
Reversibility of cholestatic changes following experimental common bile duct obstruction: fact or fantasy?
Ciliopathies
Fine tuning of RFX/DAF-19-regulated target gene expression through binding to multiple sites in Caenorhabditis elegans.
Ciliopathies
RFX7 is required for the formation of cilia in the neural tube.
coagulation factor ixa deficiency
A Candidate Activation Pathway for Coagulation Factor VII.
coagulation factor ixa deficiency
Five novel point mutations: two causing haemophilia B and three causing factor X deficiency.
coagulation factor ixa deficiency
Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
coagulation factor ixa deficiency
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
coagulation factor viia deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
coagulation factor viia deficiency
A NlaIII polymorphism within the human factor VII gene.
coagulation factor viia deficiency
A novel factor X mutation Cys81 by Arg and a reported factor VII polymorphism Arg353 replaced by Gln co-occured in a patient.
coagulation factor viia deficiency
An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.
coagulation factor viia deficiency
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
coagulation factor viia deficiency
Another patient with a congenital hemorrhagic disorder intermediate between factor X and factor VII deficiency.
coagulation factor viia deficiency
Asymptomatic factor VII deficiency: gene analysis and structure-function relationships.
coagulation factor viia deficiency
Clinical audit of inherited bleeding disorders in a developing country.
coagulation factor viia deficiency
Combined factor VII/protein C deficiency results in intrauterine coagulopathy in mice.
coagulation factor viia deficiency
Combined mild PTC (plasma thromboplastin component) and factor VII deficiencies.
coagulation factor viia deficiency
Congenital combined defects of factor VII: a critical review.
coagulation factor viia deficiency
Determinants of coagulation activation in humans.
coagulation factor viia deficiency
Determinants of plasma factor VIIa levels in humans.
coagulation factor viia deficiency
Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds.
coagulation factor viia deficiency
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
coagulation factor viia deficiency
Factor VII deficiency detected in pregnancy: a case report.
coagulation factor viia deficiency
Factor VII deficiency with intracranial hemorrhage: a case report.
coagulation factor viia deficiency
Factor VII Deficiency: A Rare Case Report.
coagulation factor viia deficiency
Fatal intracranial hemorrhage in a newborn with factor VII deficiency.
coagulation factor viia deficiency
Haemoperitoneum associated with ovulation in women with bleeding disorders: the case for conservative management and the role of the contraceptive pill.
coagulation factor viia deficiency
Hereditary factor VII deficiency in two siblings: two different clinical presentation.
coagulation factor viia deficiency
Homozygous FVII deficiencies with different reactivity towards tissue thromboplastins of different origin.
coagulation factor viia deficiency
Inherited bleeding disorders in Indian women with menorrhagia.
coagulation factor viia deficiency
Inherited bleeding disorders in the Eastern Province of Saudi Arabia.
coagulation factor viia deficiency
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
coagulation factor viia deficiency
Models of blood coagulation.
coagulation factor viia deficiency
Multiple intracranial hemorrhages at the time of a transiently prolonged activated partial thromboplastin time in an infant with congenital factor VII deficiency.
coagulation factor viia deficiency
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
coagulation factor viia deficiency
Paracetamol poisoning unmasking factor VII deficiency.
coagulation factor viia deficiency
Rare inherited coagulation disorders in India.
coagulation factor viia deficiency
Sensitivity of different thromboplastin reagents to factor VII deficiency in the blood of beagle dogs.
coagulation factor viia deficiency
Spectrum of factor X gene mutations in Iranian patients with congenital factor X deficiency.
coagulation factor viia deficiency
Synergistic effect of factor VII gene polymorphisms causing mild factor VII deficiency in a case of severe factor X deficiency.
coagulation factor viia deficiency
The K-test (trypsin clotting time) in coumarin treated patients and in congenital deficiencies and abnormalities of the prothrombin complex.
coagulation factor viia deficiency
[A new case of homozygous congenital factor VII deficiency. Associated factor X deficiency in some members of the family]
coagulation factor viia deficiency
[Congenital factor VII deficiency: about two family cases].
coagulation factor viia deficiency
[Significant decrease in factor VII activity by tissue thromboplastin derived from rabbit brain in a patient with congenital factor VII deficiency (FVII Padua)].
coagulation factor viia deficiency
[The change and significance of coagulation activity in bleomycin-induced lung fibrosis in rats]
coagulation factor xa deficiency
"I have been refused to be treated by three dentists": Barriers to patient care.
coagulation factor xa deficiency
A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against factor X.
coagulation factor xa deficiency
A case of factor X deficiency in a Chihuahua dog.
coagulation factor xa deficiency
A Case Report of Acquired Factor X Deficiency in a Patient With Multiple Myeloma.
coagulation factor xa deficiency
A Compound Heterozygosis of Two Novel Mutations Causes Factor X Deficiency in a Chinese Pedigree.
coagulation factor xa deficiency
A family with factor X deficiency from Argentina: a compound heterozygosis because of the combination of a new mutation (Gln138Arg) with an already known one (Glu350Lys).
coagulation factor xa deficiency
A family with hereditary factor X deficiency with a point mutation Gla32 to Gln in the Gla domain (factor X Tokyo).
coagulation factor xa deficiency
A functional factor X deficiency.
coagulation factor xa deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
coagulation factor xa deficiency
A new family with classical factor X deficiency as demonstrated by electroimmunoassay.
coagulation factor xa deficiency
A NlaIII polymorphism within the human factor VII gene.
coagulation factor xa deficiency
A novel factor X gene mutation Val (GTC) 384Ala (GCC) in a Chinese family resulting in congenital factor X deficiency.
coagulation factor xa deficiency
A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?
coagulation factor xa deficiency
A possible new thromboplastin deficiency occurring in five siblings.
coagulation factor xa deficiency
A Rare Cause of Coagulopathy in a Patient with Rapidly Progressive Renal Failure.
coagulation factor xa deficiency
A rare cause of intracranial hemorrhage: factor X deficiency.
coagulation factor xa deficiency
A Rare Cause of Isolated Prothrombin Time Prolongation: Congenital Factor X Deficiency.
coagulation factor xa deficiency
A rare inherited coagulation disorder: combined homozygous factor VII and factor X deficiency.
coagulation factor xa deficiency
A rare presentation of homozygous factor X deficiency in a pregnant patient: A case report and review of the literature.
coagulation factor xa deficiency
A tongue resection in macroglossia due to primary amyloidosis.
coagulation factor xa deficiency
A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X.
coagulation factor xa deficiency
Abscess in bilateral ovarian haematomas in a girl with factor X deficiency, necessitating oopherectomy.
coagulation factor xa deficiency
Acquired and transient factor X deficiency associated with sodium valproate treatment.
coagulation factor xa deficiency
Acquired circulating anticoagulants in systemic collagen disease; auto-immune thromboplastin deficiency.
coagulation factor xa deficiency
Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome.
coagulation factor xa deficiency
Acquired factor X deficiency and amyloidosis treated with melphalan and prednisone.
coagulation factor xa deficiency
Acquired factor X deficiency and amyloidosis.
coagulation factor xa deficiency
Acquired factor X deficiency and disseminated intravascular coagulation in a case of metastasizing carcinoma of the stomach and its course under chemotherapy.
coagulation factor xa deficiency
Acquired factor X deficiency associated with atypical AL-amyloidosis.
coagulation factor xa deficiency
Acquired factor X deficiency associated with systematized amyloidosis--a report of a case.
coagulation factor xa deficiency
Acquired factor X deficiency developed four years after autologous transplantation in a patient with multiple myeloma associated with systemic AL amyloidosis.
coagulation factor xa deficiency
Acquired factor X deficiency in a Negro boy.
coagulation factor xa deficiency
Acquired factor X deficiency in a patient with amyloidosis.
coagulation factor xa deficiency
Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis.
coagulation factor xa deficiency
Acquired factor x deficiency in light chain amyloidosis: a report of 2 korean cases.
coagulation factor xa deficiency
Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease.
coagulation factor xa deficiency
Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
coagulation factor xa deficiency
Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis.
coagulation factor xa deficiency
Acquired factor X deficiency in systemic amyloidosis.
coagulation factor xa deficiency
Acquired factor X deficiency in systemic amyloidosis: management of two cases.
coagulation factor xa deficiency
Acquired factor X deficiency with associated defects in platelet aggregation. A response to corticosteroid therapy.
coagulation factor xa deficiency
Acquired factor X deficiency. Altered plasma antithrombin activity and association with amyloidosis.
coagulation factor xa deficiency
Acquired factor X deficiency: an experience with multiple tooth extraction.
coagulation factor xa deficiency
Acquired isolated factor X deficiency associated with systemic amyloidosis. Case report and review of literature.
coagulation factor xa deficiency
Acquired selective factor X deficiency in acute nonlymphocytic leukemia.
coagulation factor xa deficiency
Acquired, non-amyloid related factor X deficiency: review of the literature.
coagulation factor xa deficiency
Acquired, transient factor X (Stuart factor) deficiency in patient with mycoplasma pneumonial infection.
coagulation factor xa deficiency
Acquired-transient factor X deficiency associated with anticardiolipin antibodies in a child with extensive burns.
coagulation factor xa deficiency
Acquired-transient factor X deficiency in a teenager with extensive burns.
coagulation factor xa deficiency
Advances in treatment of bleeding disorders.
coagulation factor xa deficiency
Amyloidosis and factor X deficiency.
coagulation factor xa deficiency
Amyloidosis with factor X deficiency.
coagulation factor xa deficiency
An analysis of 8 cases of factor X deficiency.
coagulation factor xa deficiency
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
coagulation factor xa deficiency
Angiodysplasia of upper gastrointestinal tract with coagulopathy.
coagulation factor xa deficiency
Antenatally diagnosed subdural haemorrhage in congenital factor X deficiency.
coagulation factor xa deficiency
Antibody-induced acute factor X deficiency: clinical manifestations and properties of the antibody.
coagulation factor xa deficiency
Atraumatic splenic rupture in amyloidosis.
coagulation factor xa deficiency
Autoimmune Coagulation Factor X Deficiency as a Rare Acquired Hemorrhagic Disorder: A Literature Review.
coagulation factor xa deficiency
Autologous bone marrow transplantation and factor XII, factor VII, and protein C deficiencies. Report of a new association and its possible relationship to endothelial cell injury.
coagulation factor xa deficiency
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.
coagulation factor xa deficiency
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
coagulation factor xa deficiency
Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies.
coagulation factor xa deficiency
Bilateral periorbital ecchymoses. An often missed sign of amyloid purpura.
coagulation factor xa deficiency
Bleeding manifestations in 100 patients with amyloidosis.
coagulation factor xa deficiency
Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice.
coagulation factor xa deficiency
Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.
coagulation factor xa deficiency
Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency.
coagulation factor xa deficiency
Candida vertebra osteomyelitis in a girl with factor X deficiency.
coagulation factor xa deficiency
Cardiac Amyloidosis Presenting with Pre-Excitation Syndrome, Heart Failure, and Severe Factor X Deficiency as Part of Systemic Amyloid Light-Chain (AL) Amyloidosis - A Fatal Combination.
coagulation factor xa deficiency
Characterization of amyloid deposits and P component from a patient with factor X deficiency reveals proteins derived from a lambda VI light chain.
coagulation factor xa deficiency
Chronic peritoneal dialysis in a patient with primary amyloidosis, renal failure, and factor X deficiency.
coagulation factor xa deficiency
Circumcision in Patients with Congenital Factor X Deficiency.
coagulation factor xa deficiency
Classical factor X deficiency. Report of a further case.
coagulation factor xa deficiency
Clinical analysis of six cases of multiple myeloma first presenting with coagulopathy.
coagulation factor xa deficiency
Clinical audit of inherited bleeding disorders in a developing country.
coagulation factor xa deficiency
Coagulation and fibrinolysis abnormalities in familial amyloid polyneuropathy.
coagulation factor xa deficiency
Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid.
coagulation factor xa deficiency
Coincidence of acquired factor-X deficiency and disseminated intravascular coagulation in patients with acute nonlymphoblastic leukemia.
coagulation factor xa deficiency
Complete remission in a bleeding patient with idiopathic autoimmune factor X deficiency caused by non-neutralizing anti-factor X autoantibody.
coagulation factor xa deficiency
Complex history of the discovery and characterization of congenital factor X deficiency.
coagulation factor xa deficiency
Congenital bleeding disorders of the vitamin K-dependent clotting factors.
coagulation factor xa deficiency
Congenital coagulation factor X deficiency: Genetic analysis of five patients and functional characterization of mutant factor X proteins.
coagulation factor xa deficiency
Congenital coagulopathies and pregnancy: report of four pregnancies in a factor X-deficient woman.
coagulation factor xa deficiency
Congenital factor X deficiencies with a defect only or predominantly in the extrinsic or in the intrinsic system: a critical evaluation.
coagulation factor xa deficiency
Congenital factor X deficiency and incomplete transverse paralysis.
coagulation factor xa deficiency
Congenital factor X deficiency in Japan.
coagulation factor xa deficiency
Congenital Factor X deficiency in women: A systematic review of the literature.
coagulation factor xa deficiency
Congenital factor X deficiency of coagulation revealed by epistaxis.
coagulation factor xa deficiency
Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients.
coagulation factor xa deficiency
Congenital haemorrhagic condition similar but not identical to factor X deficiency. A haemorrhagic state due to an abnormal factor X?
coagulation factor xa deficiency
Corpus luteum hemorrhage: rare complication of congenital and acquired coagulation abnormalities.
coagulation factor xa deficiency
Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency.
coagulation factor xa deficiency
Danazol therapy in factor X deficiency.
coagulation factor xa deficiency
Danazol therapy in factor X deficiency: more questions than answers.
coagulation factor xa deficiency
Dental management of a patient with factor X deficiency.
coagulation factor xa deficiency
Diagnosis and treatment of inherited factor X deficiency.
coagulation factor xa deficiency
Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency.
coagulation factor xa deficiency
Diagnostic Error of a Patient with Combined Inherited Factor VII and Factor X Deficiency due to Accidental Ingestion of a Diphacinone Rodenticide.
coagulation factor xa deficiency
Different genotypes are responsible for the normal Russell viper venom assays seen in some cases of congenital factor X deficiency.
coagulation factor xa deficiency
Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe Factor X deficiency in Iran.
coagulation factor xa deficiency
Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency.
coagulation factor xa deficiency
Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency.
coagulation factor xa deficiency
Ethnic Differences in Coagulation Factor Abnormalities After the Fontan Procedure.
coagulation factor xa deficiency
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
coagulation factor xa deficiency
Evidence of both von Willebrand factor deposition and factor V deposition onto AL amyloid as the cause of a severe bleeding diathesis.
coagulation factor xa deficiency
Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery.
coagulation factor xa deficiency
Factor VII and factor X deficiency in a child with a chromosome 13q duplication and deletion.
coagulation factor xa deficiency
Factor X and its deficiency states.
coagulation factor xa deficiency
Factor X assays using chromogenic substrate S-2222.
coagulation factor xa deficiency
Factor X deficiency and hemophilia A : occurrence of two different coagulation defects in a family.
coagulation factor xa deficiency
Factor X deficiency and intracranial bleeding: who is at risk?
coagulation factor xa deficiency
Factor X deficiency and pregnancy: case report and counselling.
coagulation factor xa deficiency
Factor X deficiency and pregnancy: preconception counselling and therapeutic options.
coagulation factor xa deficiency
Factor X deficiency and systemic amyloidosis.
coagulation factor xa deficiency
Factor X deficiency associated with compound heterozygosity involving a novel missense mutation at codon 38 from Val (GTC) to Leu (CTC) in exon 2.
coagulation factor xa deficiency
Factor X Deficiency Caused by Nonsecretory Myeloma Successfully Corrected with Bortezomib: A Case Report and Review of the Literature.
coagulation factor xa deficiency
Factor X deficiency due to a compound heterozygosis between a new mutation (Gla72Asp) in exon 2 and an already known one (Gly154Arg) in exon 5: Factor X Mar del Plata 1).
coagulation factor xa deficiency
Factor X deficiency during treatment of relapsed acute myeloid leukaemia with amsacrine.
coagulation factor xa deficiency
Factor X deficiency in a cat.
coagulation factor xa deficiency
Factor X deficiency in a Jack Russell terrier.
coagulation factor xa deficiency
Factor X deficiency in North Pakistan.
coagulation factor xa deficiency
Factor X deficiency in primary amyloidosis.
coagulation factor xa deficiency
Factor X deficiency in primary amyloidosis: resolution after splenectomy.
coagulation factor xa deficiency
Factor X deficiency in systemic amyloidosis.
coagulation factor xa deficiency
Factor X deficiency in the neonatal period.
coagulation factor xa deficiency
Factor X Deficiency Management for Elective Cesarean Delivery in a Pregnant Patient.
coagulation factor xa deficiency
Factor X deficiency presenting as a pseudotumor. Case report.
coagulation factor xa deficiency
Factor X deficiency presenting with bilateral chronic subdural hematoma.
coagulation factor xa deficiency
Factor X Deficiency with Heterozygous Mutations of Novel p.G435S and Known p.G244R in a Patient Presenting with Severe Umbilical Hemorrhage.
coagulation factor xa deficiency
Factor X deficiency--a rare disorder.
coagulation factor xa deficiency
Factor X deficiency.
coagulation factor xa deficiency
Factor X Deficiency: A Rare Cause of Puberty Menorrhagia.
coagulation factor xa deficiency
Factor X deficiency: An uncommon presentation of AL amyloidosis.
coagulation factor xa deficiency
Factor X deficiency: an unusual cause for spontaneous intracranial bleeding.
coagulation factor xa deficiency
Factor x deficiency: an unusual cause of spontaneous intracranial bleeding.
coagulation factor xa deficiency
Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene.
coagulation factor xa deficiency
Factor X Frankfurt I: molecular and functional characterization of a hereditary factor X deficiency (Gla+25 to Lys).
coagulation factor xa deficiency
Factor X inhibitor: a fulminant presentation and fatal course of a rare syndrome in a 59-year-old male.
coagulation factor xa deficiency
Factor X level in coumarin treated patients and in factor X deficiency as assayed with different techniques.
coagulation factor xa deficiency
Factor X Nagoya 1 and Nagoya 2: a CRM- factor X deficiency and a dysfunctional CRM+ factor X deficiency characterized by substitution of Arg306 by Cys and of Gly366 by Ser, respectively.
coagulation factor xa deficiency
Factor XDebrecen: Gly204Arg mutation in factor X causes the synthesis of a non-secretable protein and severe factor X deficiency.
coagulation factor xa deficiency
Factors X Nice I and II: two novel missense mutations (Met-40Val and Pro304Ser) in patient with coagulation factor X deficiency.
coagulation factor xa deficiency
Femur fracture in a woman with severe factor X deficiency - an experience using factor X concentrate in surgery.
coagulation factor xa deficiency
Five novel point mutations: two causing haemophilia B and three causing factor X deficiency.
coagulation factor xa deficiency
Frequencies of mild factor V, VII and X deficiencies in a Japanese population.
coagulation factor xa deficiency
Frequency of inherited bleeding disorders in women with menorrhagia.
coagulation factor xa deficiency
Frequency of the p.Gly262Asp mutation in congenital Factor X deficiency.
coagulation factor xa deficiency
Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID-19-A common clinical feature between a rare disorder and a new, common infection.
coagulation factor xa deficiency
Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency.
coagulation factor xa deficiency
Genetic analysis of a compound heterozygous patient with congenital factor X deficiency and regular replacement therapy with a prothrombin complex concentrate.
coagulation factor xa deficiency
Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lankan ancestry: in vitro expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X.
coagulation factor xa deficiency
Genotype analysis and identification of novel mutations in a multicentre cohort of patients with hereditary factor X deficiency.
coagulation factor xa deficiency
Genotyping of five Pakistani patients with severe inherited factor X deficiency: identification of two novel mutations.
coagulation factor xa deficiency
Haemoperitoneum associated with ovulation in women with bleeding disorders: the case for conservative management and the role of the contraceptive pill.
coagulation factor xa deficiency
Hemorrhage because of amyloid-related factor x deficiency after insertion of tenckhoff catheter.
coagulation factor xa deficiency
Hemorrhagic diathesis caused by factor X deficiency in a child with thymic cyst.
coagulation factor xa deficiency
Hemostatic abnormalities in multiple myeloma and related disorders.
coagulation factor xa deficiency
Hereditary coagulation factor X deficiency--a clinico-haematological profile of 5 cases from Varanasi.
coagulation factor xa deficiency
Hereditary coagulation factor X deficiency.
coagulation factor xa deficiency
Heterogeneity of hereditary and acquired factor X deficiencies by combined immunochemical and functional analyses.
coagulation factor xa deficiency
Homozygous factor X deficiency associated with familial hypercholesterolemia, mitral valve prolapse, and hypertrophic cardiomyopathy.
coagulation factor xa deficiency
Human coagulation factor X deficiency caused by a mutant signal peptide that blocks cleavage by signal peptidase but not targeting and translocation to the endoplasmic reticulum.
coagulation factor xa deficiency
Identification of a novel factor X deletion in combination with a missense mutation in the gene - Genotype-phenotype correlation in a girl with severe factor X deficiency.
coagulation factor xa deficiency
Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency.
coagulation factor xa deficiency
Impact of Rare Bleeding Disorders during Pregnancy on Maternal and Fetal Outcomes: Review of 29 Pregnancies at a Single Center.
coagulation factor xa deficiency
Importance of pharmacokinetic studies in the management of acquired factor X deficiency.
coagulation factor xa deficiency
Influence of glass and anticoagulant concentration on improvement of factor X deficiency tests.
coagulation factor xa deficiency
Inherited bleeding disorders in Indian women with menorrhagia.
coagulation factor xa deficiency
Inherited bleeding disorders in the Eastern Province of Saudi Arabia.
coagulation factor xa deficiency
Inherited factor X deficiency in two brothers.
coagulation factor xa deficiency
Inherited factor X deficiency: molecular genetics and pathophysiology.
coagulation factor xa deficiency
Inherited factor X deficiency: presentation of a case with etiologic and treatment considerations.
coagulation factor xa deficiency
Inherited Moderate Factor X Deficiency Presenting as Cardiac Tamponade.
coagulation factor xa deficiency
Intracerebral haemorrhage in an adult due to transient factor X deficiency.
coagulation factor xa deficiency
Intracranial haemorrhage in patients with congenital haemostatic defects.
coagulation factor xa deficiency
Intracranial Hemorrhage as the First Manifestation of Severe Congenital Factor X Deficiency in a 20-Month-Old Male: Case Report and Review of the Literature.
coagulation factor xa deficiency
Isolated factor X deficiency in amyloidosis. Case report and review of the literature.
coagulation factor xa deficiency
Kinetic analysis of the clotting system in the presence of heparin and depolymerized heparin.
coagulation factor xa deficiency
Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis.
coagulation factor xa deficiency
Life-threatening bleeding tendency provoked by an acquired isolated factor X deficiency associated with respiratory infection.
coagulation factor xa deficiency
Liver transplantation for haemophiliacs with hepatitis C cirrhosis.
coagulation factor xa deficiency
Lupus anticoagulant associated with transient severe factor X deficiency: a report of two patients presenting with major bleeding complications.
coagulation factor xa deficiency
Management of Factor X Deficiency for Vaginal Delivery in a Parturient: A Case Report.
coagulation factor xa deficiency
Massive Upper and Lower GI Bleed from Simultaneous Primary (AL) Amyloidosis of the Stomach and Transverse Colon in a Patient with Multiple Myeloma.
coagulation factor xa deficiency
Mechanism of factor X deficiency in systemic amyloidosis.
coagulation factor xa deficiency
Membranoproliferative glomerulonephritis and a rare bleeding disorder: factor X deficiency.
coagulation factor xa deficiency
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
coagulation factor xa deficiency
Mode of inheritance of factor X deficiency.
coagulation factor xa deficiency
Modulation of severity of clinical bleeding by co-inherited thrombophilia is also true for severe factor X deficiency.
coagulation factor xa deficiency
Molecular analysis of patients with severe congenital factor X deficiency: First report from north and northwest of Iran.
coagulation factor xa deficiency
Molecular analysis of the genotype-phenotype relationship in factor X deficiency.
coagulation factor xa deficiency
Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glu102Lys) in the second EGF-like domain.
coagulation factor xa deficiency
Molecular basis of factor X deficiency cases from India.
coagulation factor xa deficiency
Molecular characterization of factor X deficiency associated with borderline plasma factor X level.
coagulation factor xa deficiency
Molecular characterization of human factor XSan Antonio.
coagulation factor xa deficiency
Molecular characterization of two novel mutations causing factor X deficiency in a Chinese pedigree.
coagulation factor xa deficiency
Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg").
coagulation factor xa deficiency
Molecular dynamics characterization of five pathogenic Factor X mutants associated with decreased catalytic activity.
coagulation factor xa deficiency
Molecular genetic analysis of factor X deficiency: gene deletion and germline mosaicism.
coagulation factor xa deficiency
Near fatal spontaneous intraperitoneal bleeding: A rare manifestation in a congenital factor X deficiency carrier.
coagulation factor xa deficiency
Neonatal congenital Factor X deficiency.
coagulation factor xa deficiency
Neonatal congenital factor X deficiency.
coagulation factor xa deficiency
Neonatal onset of congenital factor X deficiency: a description of two novel mutations with 6-year follow-up.
coagulation factor xa deficiency
NORETHYNODREL IN THE TREATMENT OF FACTOR X DEFICIENCY.
coagulation factor xa deficiency
Normalization of plasma factor X levels in amyloidosis after plasma exchange.
coagulation factor xa deficiency
Novel factor X deficiency. Normal partial thromboplastin time and associated spindle cell thymoma.
coagulation factor xa deficiency
Occurrence and management of severe bleeding episodes in patients with hereditary factor X deficiency.
coagulation factor xa deficiency
One missense mutation in the factor X gene causing factor X deficiency--factor X Kanazawa.
coagulation factor xa deficiency
Partial gene deletion in a family with factor X deficiency.
coagulation factor xa deficiency
Pharmacokinetics and prophylactic use of FEIBA(®) in a child with severe congenital factor X deficiency and recurrent spontaneous intracranial haemorrhage: a case report.
coagulation factor xa deficiency
Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency.
coagulation factor xa deficiency
Phenotype and genotype report on homozygous and heterozygous patients with congenital factor X deficiency.
coagulation factor xa deficiency
PheWAS uncovers a pathological role of coagulation Factor X during Acinetobacter baumannii infection.
coagulation factor xa deficiency
Plasma exchange in a case of severe factor X deficiency in pregnancy: critical review of the literature.
coagulation factor xa deficiency
Plasma-derived factor X concentrate compassionate use for hereditary factor X deficiency: Long-term safety and efficacy in a retrospective data-collection study.
coagulation factor xa deficiency
Platelet aggregation and adhesiveness in classical factor X deficiency and in the abnormal factor X (factor X Friuli) coagulation disorder.
coagulation factor xa deficiency
Poor recovery and short survival of infused factor X in a case of acquired factor X deficiency and amyloidosis.
coagulation factor xa deficiency
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
coagulation factor xa deficiency
Posttraumatic lipoma in a patient with congenital factor X deficiency.
coagulation factor xa deficiency
Pregnancy in a patient with severe factor X deficiency.
coagulation factor xa deficiency
Prenatal diagnosis of factor X deficiency using a combination of direct mutation detection and linkage analysis with an intragenic single nucleotide polymorphism.
coagulation factor xa deficiency
Presurgical plasma exchange is ineffective in correcting amyloid associated factor X deficiency.
coagulation factor xa deficiency
Prevalence of bleeding manifestations in 128 heterozygotes for Factor X deficiency, mainly for FX Friuli, matched vs 128 unaffected family members, during a long sequential observation period (23.5 years).
coagulation factor xa deficiency
Prevention of recurrent intracranial hemorrhage in a factor X-deficient infant.
coagulation factor xa deficiency
Primary amyloidosis with severe nephrotic syndrome and acquired factor X deficiency.
coagulation factor xa deficiency
Progressive systemic sclerosis with the nephrotic syndrome and acquired factor X deficiency.
coagulation factor xa deficiency
Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency.
coagulation factor xa deficiency
Prophylactic treatment of bleeding episodes in children <12 years with moderate to severe hereditary factor X deficiency (FXD): Efficacy and safety of a high-purity plasma-derived factor X (pdFX) concentrate.
coagulation factor xa deficiency
Prophylactic treatment of severe factor X deficiency with prothrombin complex concentrate.
coagulation factor xa deficiency
Prophylaxis in rare coagulation disorders -- factor X deficiency.
coagulation factor xa deficiency
Prophylaxis with prothrombin complex concentrate in four children with severe congenital factor X deficiency.
coagulation factor xa deficiency
Prothrombin in factor X deficiency.
coagulation factor xa deficiency
Rare case of combined factor V and factor X deficiency in pregnancy: presenting as secondary postpartum haemorrhage in first pregnancy and successful outcome in second pregnancy.
coagulation factor xa deficiency
Rare inherited coagulation disorders in India.
coagulation factor xa deficiency
Rare post-operative complications in a previously undiagnosed Congenital Factor X deficiency patient.
coagulation factor xa deficiency
Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency.
coagulation factor xa deficiency
Recurrent ovarian haemorrhage in a girl with congenital factor X deficiency.
coagulation factor xa deficiency
Recurrent, isolated factor X deficiency in myeloma: repeated normalization of factor X levels after cytostatic chemotherapy followed by late treatment failure associated with the development of systemic amyloidosis.
coagulation factor xa deficiency
Replacement therapy for congenital Factor X deficiency.
coagulation factor xa deficiency
Report on a disease-adapted treatment in a patient with severe factor X deficiency resulting from a homozygous factor X gene mutation.
coagulation factor xa deficiency
Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy.
coagulation factor xa deficiency
Resolution of acquired factor X deficiency with amyloidosis secondary to plasma cell dyscrasia.
coagulation factor xa deficiency
Resolution of factor X deficiency in primary amyloidosis following splenectomy.
coagulation factor xa deficiency
Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding.
coagulation factor xa deficiency
Retroperitoneal amyloidosis, factor IX and X deficiency,and gastrointestinal bleeding.
coagulation factor xa deficiency
Routine preoperative coagulation screening detects a rare bleeding disorder.
coagulation factor xa deficiency
Secondary severe factor X deficiency associated with antiphospholipid syndrome.
coagulation factor xa deficiency
Severe congenital factor X deficiency in 5-month-old child.
coagulation factor xa deficiency
Severe congenital factor X deficiency with intracranial bleeding in two siblings.
coagulation factor xa deficiency
Severe congenital factor X deficiency with intracranial haemorrhage.
coagulation factor xa deficiency
Severe factor X deficiency and successful pregnancy.
coagulation factor xa deficiency
Severe factor X deficiency due to a homozygous mutation (Cys364Arg) that disrupts a disulphide bond in the catalytic domain.
coagulation factor xa deficiency
Severe factor X deficiency in a pair of siblings: clinical presentation, phenotypic and genotypic features, prenatal diagnosis and treatment.
coagulation factor xa deficiency
Severe factor X deficiency in a twin pregnancy.
coagulation factor xa deficiency
Severe factor X deficiency in pregnancy: case report and review of the literature.
coagulation factor xa deficiency
Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry.
coagulation factor xa deficiency
Severe Factor X Deficiency Presenting as Febrile Seizure in an Infant.
coagulation factor xa deficiency
Severe factor X deficiency treated with heparin-added prothrombin complex concentrate.
coagulation factor xa deficiency
Six novel missense mutations causing factor X deficiency and application of thrombin generation test.
coagulation factor xa deficiency
Six novel mutations including triple heterozygosity for Phe31Ser, 514delT and 516T-->G factor X gene mutations are responsible for congenital factor X deficiency in patients of Nepali and Indian origin.
coagulation factor xa deficiency
Spectrum of factor X gene mutations in Iranian patients with congenital factor X deficiency.
coagulation factor xa deficiency
Splenectomy in an uraemic patient with acquired factor X deficiency due to AL amyloidosis.
coagulation factor xa deficiency
Splenectomy in plasma cell dyscrasias: a review of the clinical practice.
coagulation factor xa deficiency
Spontaneous epidural hematoma following a shunt in an infant with congenital factor X deficiency. Case report and literature review.
coagulation factor xa deficiency
Spontaneous major bleeding in acquired factor X deficiency secondary to AL-amyloidosis.
coagulation factor xa deficiency
Spontaneous perinephric hematoma due to acquired factor X deficiency in AL amyloidosis.
coagulation factor xa deficiency
Spontaneous resolution of acquired factor X deficiency in amyloidosis.
coagulation factor xa deficiency
Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis.
coagulation factor xa deficiency
Spontaneous rupture of the spleen in AL amyloidosis.
coagulation factor xa deficiency
Spontaneous spinal epidural hematoma in a patient with acquired Factor X deficiency secondary to systemic amyloid light-chain amyloidosis.
coagulation factor xa deficiency
Staged Surgical Palliation for HLHS in a Girl with Severe Factor X Deficiency.
coagulation factor xa deficiency
Steroid hormone-responsive secondary factor X deficiency.
coagulation factor xa deficiency
Subclinical factor X deficiency may increase hemorrhage in women undergoing cesarean section.
coagulation factor xa deficiency
Subgaleal hemorrhage in a neonate with factor X deficiency following a non-traumatic cesarean section.
coagulation factor xa deficiency
Successful liver transplantation for a child with life-threatening recurrent bleeding episodes due to congenital factor X deficiency: a case report.
coagulation factor xa deficiency
Successful perioperative management of factor X deficiency associated with primary amyloidosis.
coagulation factor xa deficiency
Successful perioperative use of prothrombin complex concentrate in the treatment of acquired factor X deficiency in the setting of systemic light-chain (AL) amyloidosis.
coagulation factor xa deficiency
Successful pregnancy in a woman with severe factor X deficiency.
coagulation factor xa deficiency
Successful treatment of a noninhibitory antibody-mediated acquired factor X deficiency in a patient with marginal-zone lymphoma.
coagulation factor xa deficiency
Successful treatment of an acquired haemorrhagic diathesis due to factor X deficiency with chemotherapy.
coagulation factor xa deficiency
Successful Treatment of Life-threatening Bleeding Caused by Acquired Factor X Deficiency Associated with Respiratory Infection.
coagulation factor xa deficiency
Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
coagulation factor xa deficiency
Successful treatment of transient acquired factor X deficiency by plasmapheresis with concomitant intravenous immunoglobulin and steroid therapy.
coagulation factor xa deficiency
Successful Use of Four Factor-Prothrombin Complex Concentrate for Congenital Factor X Deficiency in the Setting of Neurosurgery.
coagulation factor xa deficiency
Surgical excision of a pseudotumour under the coverage of the plasma-derived factor X concentrate in a patient with severe factor X deficiency: A case report.
coagulation factor xa deficiency
Surgical treatment for a paraplegic patient induced by congenital factor X deficiency.
coagulation factor xa deficiency
Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X.
coagulation factor xa deficiency
Synergistic effect of factor VII gene polymorphisms causing mild factor VII deficiency in a case of severe factor X deficiency.
coagulation factor xa deficiency
Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients.
coagulation factor xa deficiency
Systemic amyloidosis associated with factor X deficiency.
coagulation factor xa deficiency
The 13-year bleed: Exuberant amyloid angiopathies, angiodysplasias, and acquired coagulopathies of the gut.
coagulation factor xa deficiency
The Clinical Findings and Prophylactic Treatment in Children with Factor X Deficiency.
coagulation factor xa deficiency
The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency.
coagulation factor xa deficiency
The impact of Glu102Lys on the factor X function in a patient with a doubly homozygous factor X deficiency (Gla14Lys and Glu102Lys).
coagulation factor xa deficiency
THE INHERITANCE OF STUART DISEASE: INVESTIGATION OF A FAMILY WITH FACTOR X DEFICIENCY.
coagulation factor xa deficiency
The K-test (trypsin clotting time) in coumarin treated patients and in congenital deficiencies and abnormalities of the prothrombin complex.
coagulation factor xa deficiency
The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
coagulation factor xa deficiency
The perils of inhibiting deficient factors.
coagulation factor xa deficiency
The role of primary prophylactic factor replacement therapy in children with severe factor X deficiency.
coagulation factor xa deficiency
Therapeutic approaches to factor X deficiency with emphasis on the use of a new clotting-factor concentrate (Konyne).
coagulation factor xa deficiency
Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy.
coagulation factor xa deficiency
Transient acquired factor X deficiency associated with pneumonia.
coagulation factor xa deficiency
Transient acquired factor X deficiency: report of the use of activated clotting concentrate to control a life-threatening hemorrhage.
coagulation factor xa deficiency
Transient selective factor X deficiency in a severely burned child.
coagulation factor xa deficiency
Transient, selective factor X deficiency and acute liver failure following chest infection treated with erythromycin BP.
coagulation factor xa deficiency
Treatment of amyloidosis associated factor X deficiency.
coagulation factor xa deficiency
Two episodes of hemoperitoneum from luteal cysts rupture in a patient with congenital factor X deficiency.
coagulation factor xa deficiency
Two novel factor X gene mutations in a Chinese family with factor X deficiency.
coagulation factor xa deficiency
Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
coagulation factor xa deficiency
Use of a High-Purity Factor X Concentrate in Turkish Subjects with Hereditary Factor X Deficiency: Post Hoc Cohort Subanalysis of a Phase 3 Study.
coagulation factor xa deficiency
Use of plasma-derived factor X concentrate in neonates and infants with congenital factor X deficiency.
coagulation factor xa deficiency
Use of prothrombin complex concentrate for prophylaxis of bleeding in acquired factor X deficiency associated with light-chain amyloidosis.
coagulation factor xa deficiency
Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis.
coagulation factor xa deficiency
["NON-CORRECTABLE" THROMBOPLASTIN DEFICIENCY AND HEMORRHAGIC MANIFESTATIONS IN THROMBOPENIC HEMOBLASTOSIS.]
coagulation factor xa deficiency
[3 families with a congenital factor X deficiency, one of them with an associated factor XII deficiency]
coagulation factor xa deficiency
[A case of double valve substitution in a female patient carrier of a factor X deficiency]
coagulation factor xa deficiency
[A case of factor X deficiency (author's transl)]
coagulation factor xa deficiency
[A case of primary hepatic amyloidosis with factor X deficiency.]
coagulation factor xa deficiency
[A case of retroperitoneal hemorrhage due to multiple myeloma complicated with factor X deficiency and amyloidosis]
coagulation factor xa deficiency
[A new case of homozygous congenital factor VII deficiency. Associated factor X deficiency in some members of the family]
coagulation factor xa deficiency
[A new family with factor X deficiency]
coagulation factor xa deficiency
[A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review]
coagulation factor xa deficiency
[Acquired coagulation factor X deficiency: three cases report and literature review].
coagulation factor xa deficiency
[Acquired factor X deficiency associated with A.L.type amyloidosis. A case report]
coagulation factor xa deficiency
[Acquired factor X deficiency in a case of monoclonal gammopathy]
coagulation factor xa deficiency
[ACQUIRED FACTOR X DEFICIENCY IN A PATIENT WITH PRIMARY AMYLOIDOSIS. INJECTION OF A B.S.C. FRACTION.]
coagulation factor xa deficiency
[Acquired factor X deficiency in a patient with primary amyloidosis. Injection of a coagulating fraction (C.S.B)]
coagulation factor xa deficiency
[Acquired factor X deficiency in primary amyloidosis]
coagulation factor xa deficiency
[ACQUIRED HEMORRHAGIC DIATHESIS CAUSED BY ISOLATED FACTOR X DEFICIENCY.]
coagulation factor xa deficiency
[Acquired isolated factor X deficiency in generalized amyloidosis]
coagulation factor xa deficiency
[Analysis of seven cases of multiple myeloma with initial manifestation of bleeding].
coagulation factor xa deficiency
[Blood clotting in an infant with factor X deficiency]
coagulation factor xa deficiency
[Case of congenital Stuart factor deficiency in a 22-month-old child]
coagulation factor xa deficiency
[Case of hemorrhagic diathesis following prothrombase deficiency.]
coagulation factor xa deficiency
[Case of severe hemorrhagic disease due to combined antihemophilic globulin deficiency and plasma thromboplastin deficiency.]
coagulation factor xa deficiency
[Cerebromeningeal hemorrhages and their sequelae in congenital deficiencies of plasma hemostasis factors. Apropos of a case of Stuart factor deficiency with early cerebromengeal hemorrhage leading to hydrocephalus with considerable psychomotor retardation]
coagulation factor xa deficiency
[Clinical and coagulation studies in 3 cases of congenital factor X deficiency and review of reported cases in Japan (author's transl)]
coagulation factor xa deficiency
[Clotting factor X deficiency resulted from an T 58-->G mutation within exon 1 of human factor X gene]
coagulation factor xa deficiency
[Combined 2d-type TAR syndrome, factor X deficiency, immune deficiency and mitral valve prolapse]
coagulation factor xa deficiency
[Congenital and familial Stuart factor deficiency. Apropos of 2 personal cases considered congenital hypoconvertinemia.]
coagulation factor xa deficiency
[Congenital blood coagulation factor X deficiency. Successful result of the use prothrombin concentrated complex in the control of ++cesarean section hemorrhage in 2 pregnancies]
coagulation factor xa deficiency
[Congenital factor X deficiency showing cross-reacting material negative (CRM-)]
coagulation factor xa deficiency
[Congenital factor X deficiency, the Prower-Stuart deficiency]
coagulation factor xa deficiency
[Congenital factor X deficiency. Case report and review of literature]
coagulation factor xa deficiency
[CONGENITAL STUART FACTOR DEFICIENCY. UNCOMPLICATED DELIVERY FOLLOWING INJECTION OF CSB FRACTION.]
coagulation factor xa deficiency
[Congenital stuart factor deficiency: 4 cases]
coagulation factor xa deficiency
[Decreased Quick percentage, acquired factor X deficiency, hemarthrosis and ecchymosis: amyloidosis]
coagulation factor xa deficiency
[Differential diagnosis of congenital Stuart factor deficiency.]
coagulation factor xa deficiency
[Extensive subcutaneous hemorrhage complicating primary amyloidosis]
coagulation factor xa deficiency
[Factor X deficiency and pregnancy]
coagulation factor xa deficiency
[Factor X deficiency and systemic amylosis]
coagulation factor xa deficiency
[Factor X deficiency associated with multiple myeloma.]
coagulation factor xa deficiency
[Factor X deficiency in amyloidosis (author's transl)]
coagulation factor xa deficiency
[Factor X deficiency in systemic amyloidosis. Presentation of a case]
coagulation factor xa deficiency
[Factors VII, VIII, IX, and X: molecular genetics and gene diagnosis]
coagulation factor xa deficiency
[Familial amyloidosis of AL type and factor X deficiency. The valve of long-term colchicine administration]
coagulation factor xa deficiency
[Familial hemorrhagic diathesis caused by factor X deficiency]
coagulation factor xa deficiency
[Gene analysis of a combined inherited factor VII and factor X deficiency pedigree].
coagulation factor xa deficiency
[Hemarthrosis disclosing factor X deficiency in primary amyloidosis]
coagulation factor xa deficiency
[Hemorrhage of delivery and during the sequelae of labor caused by Stuart factor deficiency.]
coagulation factor xa deficiency
[Hemorrhagic syndrome due to isolated Stuart factor deficiency during Kahler's disease with amylosis]
coagulation factor xa deficiency
[Homozygous missense mutation p.Val298Met of F10 gene causing hereditary coagulation factor X deficiency in a Chinese pedigree].
coagulation factor xa deficiency
[How can factor X deficiency in nephropathy explained?]
coagulation factor xa deficiency
[Inherited coagulation factor X deficiency caused by two novel mutations in factor X gene.]
coagulation factor xa deficiency
[Isolated factor X deficiency in chronic myelomonocytic leukemia: Report of one case].
coagulation factor xa deficiency
[New form of pseudohemophilia following prothrombinase deficiency.]
coagulation factor xa deficiency
[Primary amyloidosis associated to severe factor X deficiency]
coagulation factor xa deficiency
[Primary pseudotumoral pulmonary amyloidosis with Pierre-Marie syndrome]
coagulation factor xa deficiency
[Probably inherited factor X deficiency. Report of a case (author's transl)]
coagulation factor xa deficiency
[Recurrence of Waldenström macroglobulinemia accompanied by factor X deficiency].
coagulation factor xa deficiency
[Successful long-term management of ovarian bleeding and menorrhagia with prothrombin complex concentrate in a patient with congenital factor X deficiency].
coagulation factor xa deficiency
[Systemic light chain amyloidosis with acquired factor X deficiency: a case report].
coagulation factor xa deficiency
[The change and significance of coagulation activity in bleomycin-induced lung fibrosis in rats]
coagulation factor xia deficiency
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
coagulation factor xia deficiency
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
coagulation factor xia deficiency
Definition of the population at risk of bleeding due to factor XI deficiency in Ashkenazic Jews and the value of activated partial thromboplastin time in its detection.
coagulation factor xia deficiency
Factor XI deficiency in an Ashkenazi Jewish child, causing severe postoperative hemorrhage.
coagulation factor xia deficiency
Factor XI deficiency in Kerry Blue Terriers.
coagulation factor xia deficiency
Factor XI deficiency-related spontaneous primary intraventricular hemorrhage.
coagulation factor xia deficiency
Factor XI deficiency: detection and management during urological surgery.
coagulation factor xia deficiency
Factor XI deficiency: implications for management of patients undergoing aesthetic surgery.
coagulation factor xia deficiency
Failure of Routine Coagulation Screening Tests to Detect Heterozygous State of Bovine Factor XI Deficiency.
coagulation factor xia deficiency
Identification of factor XI deficiency in Holstein-Friesian cattle in Britain.
coagulation factor xia deficiency
Intraneural hematoma after nerve stimulation-guided femoral block in a patient with factor XI deficiency: case report.
coagulation factor xia deficiency
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
coagulation factor xia deficiency
Normal aPTT in children with mild factor XI deficiency.
coagulation factor xia deficiency
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
coagulation factor xia deficiency
Perioperative management of factor XI deficiency in a patient undergoing hip arthroplasty.
coagulation factor xia deficiency
Preoperative screening for coagulopathy using prothrombin time and partial thromboplastin time in patients requiring primary cranial vault remodeling.
coagulation factor xia deficiency
Successful Peritoneal Dialysis Catheter Placement in a New End-Stage Renal Disease Patient with Combined Antiphospholipid Syndrome and Factor XI Deficiency.
coagulation factor xia deficiency
The activated partial thromboplastin time and factor XI deficiency.
coagulation factor xia deficiency
The factor of factor XI deficiency in thyroid neoplasia.
coagulation factor xia deficiency
The rare inherited coagulation disorders.
coagulation factor xia deficiency
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
coagulation factor xia deficiency
[Thrombocyte dysfunction in children with albinism]
coagulation factor xiia deficiency
A female hemophilia A combined with hereditary coagulation factor XII deficiency: a case report.
coagulation factor xiia deficiency
Additional factor XII (Hageman factor) deficiency in hemophilia A and in von Willebrand syndrome.
coagulation factor xiia deficiency
Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis.
coagulation factor xiia deficiency
Factor XII (Hageman Factor) Deficiency: a rare harbinger of life threatening complications.
coagulation factor xiia deficiency
Factor XII deficiency and pregnancy.
coagulation factor xiia deficiency
Feline factor XII (Hageman) deficiency.
coagulation factor xiia deficiency
Implications for cardiac surgery in patients with factor XII deficiency.
coagulation factor xiia deficiency
Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients.
coagulation factor xiia deficiency
Inherited bleeding disorders in Indian women with menorrhagia.
coagulation factor xiia deficiency
Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects.
coagulation factor xiia deficiency
Periodic painful purpura: Fact or factitious?
coagulation factor xiia deficiency
Prolonged activated partial thromboplastin time secondary to factor XII deficiency in two surgical patients.
coagulation factor xiia deficiency
Rosai-Dorfman disease with factor XII deficiency.
coagulation factor xiia deficiency
[3 families with a congenital factor X deficiency, one of them with an associated factor XII deficiency]
coagulation factor xiia deficiency
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
coagulation factor xiia deficiency
[Successes and failures of the activated partial thromboplastin time in the preoperative evaluation]
Coinfection
Clinical and Laboratory Characteristics of Dengue-Orientia tsutsugamushi co-Infection from a Tertiary Care Center in South India.
Colic
Clinical relevance of monocyte procoagulant activity in horses with colic.
Colic
Hemostatic abnormalities in equine colic.
Colic
The coagulation system in horses with colic.
Colitis
Free colonic perforation without dilatation in ulcerative colitis.
Colitis
Rivaroxaban Induces Mucosal Healing in a Rat Model of Trinitrobenzene Sulfonic Acid-Induced Colitis.
Colitis
Thromboelastography in healthy horses and horses with inflammatory gastrointestinal disorders and suspected coagulopathies.
Colitis, Ulcerative
Effect of low molecular weight heparin rectal suppository on experimental ulcerative colitis in mice.
Colitis, Ulcerative
Efficacy of oral colon-specific delivery capsule of low-molecular-weight heparin on ulcerative colitis.
Colitis, Ulcerative
Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
Collagen Diseases
Acquired circulating anticoagulants in systemic collagen disease; auto-immune thromboplastin deficiency.
Collagen Diseases
Immunologic abnormalities associated with primary anetoderma.
Colonic Neoplasms
Co-localization of Protein Z, Protein Z-Dependent protease inhibitor and coagulation factor X in human colon cancer tissue: implications for coagulation regulation on tumor cells.
Colonic Neoplasms
Coagulation Factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation.
Colonic Neoplasms
Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation.
Colonic Neoplasms
Successful resection of sigmoid colon cancer in a patient with factor XI deficiency.
Colorectal Neoplasms
Factor X-activating activity in patients with colorectal carcinoma.
Colorectal Neoplasms
Prediction of Poor Outcomes in Patients with Colorectal Cancer: Elevated Preoperative Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT).
Colorectal Neoplasms
Project for the National Program of Early Diagnosis of Endometrial Cancer Part I.
Colorectal Neoplasms
Tumor cell generation of thrombin via functional prothrombinase assembly.
Colorectal Neoplasms
[Prolonged prophylaxis of thromboembolic disease in patients with colorectal surgical resections for malignancy]
Colorectal Neoplasms, Hereditary Nonpolyposis
Project for the National Program of Early Diagnosis of Endometrial Cancer Part I.
Coma
A new prognostic scoring system for meningococcal septic shock in children. Comparison with three other scoring systems.
Coma
A Newly Established Severity Scoring System in Predicting the Prognosis of Patients with Severe Fever with Thrombocytopenia Syndrome.
Coma
An explainable machine learning algorithm for risk factor analysis of in-hospital mortality in sepsis survivors with ICU readmission.
Coma
Association of Platelets and White Blood Cells Subtypes with Trauma Patients' Mortality Outcome in the Intensive Care Unit.
Coma
Clinical characteristics and risk factors of male exertional heatstroke in patients with myocardial injury: an over 10-year retrospective cohort study.
Coma
Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery.
Coma
Coronavirus disease 2019 (COVID-19) can predispose young to Intracerebral hemorrhage: a retrospective observational study.
Coma
Development and internal validation of the multivariable CIPHER (Collaborative Integrated Pregnancy High-dependency Estimate of Risk) clinical risk prediction model.
Coma
Development and validation of the revised injury severity classification score for severely injured patients.
Coma
Early coagulopathy and metabolic acidosis predict transfusion of packed red blood cells in pediatric trauma patients.
Coma
Early coagulopathy is an independent predictor of mortality in children after severe trauma.
Coma
Early hemorrhagic progression of traumatic brain contusions: frequency, correlation with coagulation disorders, and patient outcome: a prospective study.
Coma
Expanding traumatic intracerebral contusion/hematoma.
Coma
FDP/fibrinogen ratio reflects the requirement of packed red blood cell transfusion in patients with blunt trauma.
Coma
Fibrinolytic markers and neurologic outcome in traumatic brain injury.
Coma
Gastrointestinal failure score in children with traumatic brain injury.
Coma
Glasgow Coma Scale predicts coagulopathy in pediatric trauma patients.
Coma
Hematological factors predicting mortality in patients with traumatic epidural or subdural hematoma undergoing emergency surgical evacuation: A retrospective cohort study.
Coma
Hypernatremia and Coagulopathy May or May Not Be Useful Clinical Biomarkers in Dogs with Head Trauma: A Retrospective Study.
Coma
In vivo diagnosis of massive hepatic infarction by computed tomography.
Coma
Intracranial Hemorrhages Related with Warfarin Use and Comparison of Warfarin and Acetylsalicylic Acid.
Coma
Massive blood transfusion and outcome in 1062 polytrauma patients: a prospective study based on the Trauma Registry of the German Trauma Society.
Coma
Model for predicting the injury severity score.
Coma
Multivariate regression modeling for the prediction of inflammation, systemic pressure, and end-organ function in severe sepsis.
Coma
PIRO concept: staging of sepsis.
Coma
Polytrauma Defined by the New Berlin Definition: A Validation Test Based on Propensity-Score Matching Approach.
Coma
Potential applicability of recombinant factor VIIa for intracerebral hemorrhage.
Coma
The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial.
Coma
The exploration of risk factors of concurrent bacteraemia in patients critically ill with severe dengue.
Coma
The influence of hemocoagulation disorders on the development of posttraumatic cerebral infarction and outcome in patients with moderate or severe head trauma.
Coma
The influence of hemocoagulative disorders on the outcome of children with head injury.
Coma
Validating the incidence of coagulopathy and disseminated intravascular coagulation in patients with traumatic brain injury ? analysis of 242 cases.
Coma
[A new warning scoring system establishment for prediction of sepsis in patients with trauma in intensive care unit].
Coma
[Effect of long-term and short-term mild hypothermia in severe traumatic brain injury: a comparative study].
Coma
[Risk factors analysis of acute respiratory distress syndrome in intensive care unit traumatic patients].
Communicable Diseases
Clinical trials of deep vein thrombosis prophylaxis in medical patients.
Communicable Diseases
[Blood coagulation studies in children. VIII. Thromboplastin formation in various infectious diseases in childhood.]
Compartment Syndromes
Enoxaparin-induced bleeding resulting in compartment syndrome of the thigh: A case report.
Compartment Syndromes
The Compartment Syndrome Associated with Deep Vein Thrombosis due to Rattlesnake Bite: A Case Report.
complement factor d deficiency
Deletion of plasma thromboplastin factor D deficiency.
Confusion
Severe Fever with Thrombocytopenia Syndrome in South Korea, 2013-2015.
Congenital Abnormalities
Identification of factor XI deficiency in Holstein-Friesian cattle in Britain.
Congenital Disorders of Glycosylation
Coagulation abnormalities in the carbohydrate-deficient glycoprotein syndrome: case report and review of the literature.
Connective Tissue Diseases
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients.
Connective Tissue Diseases
Superior mesenteric vein thrombosis presented transient false positivity for lupus anticoagulant under heparin treatment.
Connective Tissue Diseases
The clinical significance of a shortened activated partial thromboplastin time in patients with connective tissue disease.
Coronary Artery Disease
Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
Coronary Artery Disease
Association of Platelets and White Blood Cells Subtypes with Trauma Patients' Mortality Outcome in the Intensive Care Unit.
Coronary Artery Disease
Coronary Artery Disease Presentation and Its Association with Shortened Activated Partial Thromboplastin Time.
Coronary Artery Disease
Correlation between the aPTT and clinical events in acute coronary syndromes treated with unfractionated heparin.
Coronary Artery Disease
Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.
Coronary Artery Disease
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48.
Coronary Artery Disease
Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.
Coronary Artery Disease
Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.
Coronary Artery Disease
Genetic associations for activated partial thromboplastin time and prothrombin time, their gene expression profiles, and risk of coronary artery disease.
Coronary Artery Disease
Haemostatic function in coronary artery disease (CAD).
Coronary Artery Disease
Protease-Activated Receptor-2 Plays a Critical Role in Vascular Inflammation and Atherosclerosis in Apolipoprotein E-Deficient Mice.
Coronary Artery Disease
Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression.
Coronary Artery Disease
Risk Factors for Major Amputation in Diabetic Foot Ulcer Patients.
Coronary Artery Disease
Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease.
Coronary Artery Disease
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Coronary Artery Disease
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
Coronary Artery Disease
Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
Coronary Artery Disease
SR-90107 (Sanofi-Synthélabo).
Coronary Artery Disease
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Coronary Artery Disease
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
Coronary Artery Disease
YM-150, a Factor Xa inhibitor for the prevention of venous thromboembolism and coronary artery disease.
Coronary Disease
Analysis of influencing factors related to elevated serum troponin I level for COVID-19 patients in Yichang, China.
Coronary Disease
Analysis of Risk Factors in Endoscopic Retrograde Cholangiopancreatography-Related Immediate and Delayed Hemorrhage.
Coronary Disease
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
Coronary Disease
[ASPECTS OF BLOOD COAGULATION IN CORONARY HEART DISEASE. HEMATIC THROMBOPLASTIN.]
Coronary Stenosis
Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
Coronary Thrombosis
Acute myocardial infarction and antiphospholipid antibody syndrome: a systematic review.
Coronary Thrombosis
Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis.
Coronary Thrombosis
Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model.
Coronavirus Infections
Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.
Cough
A novel risk score to predict cardiovascular complications in patients with coronavirus disease 2019 (COVID-19): A retrospective, multicenter, observational study.
Cough
Acute respiratory failure in adult patients with dengue virus infection.
Cough
Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children.
Cough
The clinical differences between dengue and scrub typhus with acute respiratory failure in southern Taiwan.
COVID-19
A Case Series of Thromboelastography-Guided Anticoagulation in COVID-19 Patients with Inherited and Acquired Hypercoagulable States.
COVID-19
Characteristics of laboratory indexes in COVID-19 patients with non-severe symptoms in Hefei City, China: diagnostic value in organ injuries.
COVID-19
Clinical characteristics and outcome of influenza virus infection among adults hospitalized with severe COVID-19: a retrospective cohort study from Wuhan, China.
COVID-19
Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach.
COVID-19
Coagulation Panel in Patients with SARS-CoV2 Infection (COVID-19).
COVID-19
Coagulopathy in COVID-19.
COVID-19
Comparative analysis of clinical features of SARS-CoV-2 and adenovirus infection among children.
COVID-19
Comparison of clinical features on admission between coronavirus disease 2019 and influenza a among children: a retrospective study in China.
COVID-19
COVID-19 and acute coagulopathy in pregnancy.
COVID-19
COVID-19 and coagulation dysfunction in adults: A systematic review and meta-analysis.
COVID-19
COVID-19 and Hematology-What Do We Know So Far?
COVID-19
COVID-19 and its implications for thrombosis and anticoagulation.
COVID-19
COVID-19 versus HIT hypercoagulability.
COVID-19
Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.
COVID-19
D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis.
COVID-19
Decreased CRRT Filter Lifespan in COVID-19 ICU Patients.
COVID-19
Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy.
COVID-19
FXa cleaves the SARS-CoV-2 spike protein and blocks cell entry to protect against infection with inferior effects in B.1.1.7 variant.
COVID-19
Hemostatic abnormalities in COVID-19: A guided review.
COVID-19
Hemostatic Changes in Patients with COVID-19: A Meta-Analysis with Meta-Regressions.
COVID-19
Higher admission activated partial thromboplastin time, neutrophil-lymphocyte ratio, serum sodium, and anticoagulant use predict in-hospital COVID-19 mortality in people with Diabetes: Findings from Two University Hospitals in the U.K.
COVID-19
Management of therapeutic unfractionated heparin in COVID-19 patients: A retrospective cohort study.
COVID-19
Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO.
COVID-19
Myocarditis in athletes after COVID-19 infection: The heart is not the only place to screen.
COVID-19
Phlegmasia cerulea dolens superimposed on disseminated intravascular coagulation in COVID-19.
COVID-19
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases.
COVID-19
Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.
COVID-19
Pragmatic Recommendations for the Management of Anticoagulation and Venous Thrombotic Disease for Hospitalized Patients with COVID-19 in Low- and Middle-Income Countries.
COVID-19
Prognostic Factors in COVID-19 Patients With New Neurological Manifestations: A Retrospective Cohort Study in a Romanian Neurology Department.
COVID-19
Prognostic Value of Fibrinogen among COVID-19 Patients Admitted to an Emergency Department: An Italian Cohort Study.
COVID-19
Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19.
COVID-19
Routine Hematological Parameters May Be Predictors of COVID-19 Severity.
COVID-19
Severe COVID-19 has a distinct phenotype from bacterial sepsis: a retrospective cohort study in deceased patients.
COVID-19
The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents.
COVID-19
The values of coagulation function in COVID-19 patients.
COVID-19
Thrombotic Complications in Patients with COVID-19: Pathophysiological Mechanisms, Diagnosis, and Treatment.
COVID-19
Thyroid dysfunction may be associated with poor outcomes in patients with COVID-19.
COVID-19
Unclear Issues Regarding COVID-19.
COVID-19
Venous thromboembolic events in patients with COVID-19: a systematic review and meta-analysis.
COVID-19
Viscoelastic Tests in the Evaluation of Haemostasis Disturbances in SARS-CoV2 Infection.
Craniocerebral Trauma
A retrospective and prospective study of cerebral tissue pulmonary embolism in severe head trauma.
Craniocerebral Trauma
Blunt brain injury activates the coagulation process.
Craniocerebral Trauma
Development and validation of the revised injury severity classification score for severely injured patients.
Craniocerebral Trauma
Effect of hypothermia on serum electrolyte, inflammation, coagulation, and nutritional parameters in patients with severe traumatic brain injury.
Craniocerebral Trauma
Glasgow Coma Scale predicts coagulopathy in pediatric trauma patients.
Craniocerebral Trauma
Haemostatic Abnormalities in Patients with Closed Head Injuries and their role in Predicting Early Mortality.
Craniocerebral Trauma
Hemophilia presenting with intracranial hemorrhage. An approach to the infant with intracranial bleeding and coagulopathy.
Craniocerebral Trauma
Hemostatic abnormalities in patients with closed head injuries and their role in predicting early mortality.
Craniocerebral Trauma
Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study.
Craniocerebral Trauma
Role of coagulopathy in patients with head trauma.
Craniocerebral Trauma
The incidence and significance of hemostatic abnormalities in patients with head injuries.
Craniocerebral Trauma
The influence of hemocoagulative disorders on the outcome of children with head injury.
Craniopharyngioma
Preoperative and intraoperative predictors of deep venous thrombosis in adult patients undergoing craniotomy for brain tumors: A Chinese single-center, retrospective study.
Craniosynostoses
Elevated prothrombin time on routine preoperative laboratory results in a healthy infant undergoing craniosynostosis repair: Diagnosis and perioperative management of congenital factor VII deficiency.
Crohn Disease
Hemostasis in Crohn's disease: low factor XIII levels in active disease.
Crohn Disease
Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
Cross Infection
The Significance of Prolonged and Saddleback Fever in Hospitalised Adult Dengue.
Cryptococcosis
Cryptococcosis in patients with liver cirrhosis: Death risk factors and predictive value of prognostic models.
Cryptococcosis
Disseminated intravascular coagulation associated with disseminated cryptococcosis in a patient with acquired immunodeficiency syndrome.
Cystic Fibrosis
Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin.
Cystic Fibrosis
Crystal Structure of Isoform CBd of the Basic Phospholipase A2 Subunit of Crotoxin: Description of the Structural Framework of CB for Interaction with Protein Targets.
Cystic Fibrosis
Exclusion of human chromosome 13q34 as the site of the cystic fibrosis mutation.
Cystitis
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Cysts
Cause of hematic cysts of the orbit: increased fibrinolysis and immunohistologic expression of tissue plasminogen activator.
Cysts
Corpus luteum hemorrhage: rare complication of congenital and acquired coagulation abnormalities.
Cysts
Two episodes of hemoperitoneum from luteal cysts rupture in a patient with congenital factor X deficiency.
Dehydration
The use of protein-DNA, chromatin immunoprecipitation, and transcriptome arrays to describe transcriptional circuits in the dehydrated male rat hypothalamus.
Dehydration
[Clinical characteristics and outcomes of cerebral venous sinus thrombosis during pregnancy and puerperium].
Dehydration
[Effects of dehydration and infusion of blood substitutes on the hemostasis system in an experiment with 21-hour bed rest]
Dementia
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Dementia
Treatment with the direct oral anticoagulants (DOACs) apixaban and rivaroxaban associated with significant worsening of behavioural and psychological symptoms of dementia (BPSD).
Dengue
Acute kidney injury in dengue virus infection.
Dengue
Acute respiratory failure in adult patients with dengue virus infection.
Dengue
Assessment of aPTT-based clot waveform analysis for the detection of haemostatic changes in different types of infections.
Dengue
Clinical and Laboratory Characteristics of Dengue-Orientia tsutsugamushi co-Infection from a Tertiary Care Center in South India.
Dengue
Coagulation abnormalities in Dengue fever infection: A systematic review and meta-analysis.
Dengue
Coagulation abnormalities in dengue hemorrhagic Fever: serial investigations in 167 Vietnamese children with Dengue shock syndrome.
Dengue
Determinants of mortality and prolonged hospital stay among dengue patients attending tertiary care hospital: a cross-sectional retrospective analysis.
Dengue
Expression of NF-kB and COX-2 in Young Versus Older Patients with Sporadic Colorectal Cancer.
Dengue
Prothrombin time and partial thromboplastin time as a predictor of bleeding in patients with dengue hemorrhagic fever.
Dengue
Risk factors associated with development of dengue haemorrhagic fever or dengue shock syndrome in adults in Hospital Tengku Ampuan Afzan Kuantan.
Dengue
The clinical differences between dengue and scrub typhus with acute respiratory failure in southern Taiwan.
Dengue
The exploration of risk factors of concurrent bacteraemia in patients critically ill with severe dengue.
Dengue
Trajectories of hepatic and coagulation dysfunctions related to a rapidly fatal outcome among hospitalized patients with dengue fever in Tainan, 2015.
Dermatitis
Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
Diabetes Complications
Evaluation of Coagulation Profile in Children with Type 1 Diabetes Mellitus Using Rotational Thromboelastometry.
Diabetes Mellitus
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Diabetes Mellitus
Association of activated partial thromboplastin time and fibrinogen level in patients with type II diabetes mellitus.
Diabetes Mellitus
Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy.
Diabetes Mellitus
Coronavirus disease 2019 (COVID-19) can predispose young to Intracerebral hemorrhage: a retrospective observational study.
Diabetes Mellitus
Deep Venous Thrombosis Recurrence and Its Predictors at Selected Tertiary Hospitals in Ethiopia: A Prospective Cohort Study.
Diabetes Mellitus
Determination of risk factors affecting the in-hospital prognosis of patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention.
Diabetes Mellitus
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Diabetes Mellitus
Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values.
Diabetes Mellitus
Does von Willebrand Factor Have an Effect on the Occurrence of the Diabetic Complications?
Diabetes Mellitus
Factor VII hyperactivity in chronic dialysis patients.
Diabetes Mellitus
Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients.
Diabetes Mellitus
Prognosis of spontaneous intracerebral hemorrhage in hemodialysis patients.
Diabetes Mellitus
Prothrombin time, activated partial thromboplastin time and platelet counts of type II diabetes mellitus: a comparative study.
Diabetes Mellitus
Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus.
Diabetes Mellitus
Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.
Diabetes Mellitus
Shortened Activated Partial Thromboplastin Time and Increased Superoxide Dismutase Levels Are Associated with Type 2 Diabetes Mellitus.
Diabetes Mellitus
The role of hyperglycaemia-induced alterations of antithrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus.
Diabetes Mellitus
The tissue thromboplastin inhibition test in diabetics without cerebro-cardiovascular diseases.
Diabetes Mellitus
The use of dielectric blood coagulometry in the evaluation of coagulability in patients with peripheral arterial disease.
Diabetes Mellitus
[Hemostatic studies in decompensated diabetes mellitus]
Diabetes Mellitus, Type 1
Enhanced anticoagulant response to activated protein C in patients with IDDM.
Diabetes Mellitus, Type 1
Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy.
Diabetes Mellitus, Type 1
Platelet prothrombinase activity, a final pathway platelet procoagulant activity, is overexpressed in type 1 diabetes: no relationship with mean platelet volume or background retinopathy.
Diabetes Mellitus, Type 2
Association of coagulation profile with microvascular complications and glycemic control in type 2 diabetes mellitus - a study at a tertiary care center in Delhi.
Diabetes Mellitus, Type 2
Expression and significance of fgl2 prothrombinase in cardiac microvascular endothelial cells of rats with type 2 diabetes.
Diabetes Mellitus, Type 2
Novel Risk Factors and the Prediction of Type 2 Diabetes in the Atherosclerosis Risk in Communities (ARIC) Study.
Diabetes Mellitus, Type 2
Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.
Diabetes Mellitus, Type 2
Shortened Activated Partial Thromboplastin Time and Increased Superoxide Dismutase Levels Are Associated with Type 2 Diabetes Mellitus.
Diabetic Foot
Clinical Characteristics, Treatment, and Prognosis of Diabetic Foot Disease in Macao and Beijing: A Retrospective Study.
Diabetic Nephropathies
Coagulation Factor Xa and Protease-Activated Receptor 2 as Novel Therapeutic Targets for Diabetic Nephropathy.
Diabetic Nephropathies
Protease-activated receptor 2 protects against VEGF inhibitor-induced glomerular endothelial and podocyte injury.
Diabetic Nephropathies
Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice.
Diabetic Nephropathies
[Roles of coagulation pathway and factor Xa in chronic kidney disease (CKD)].
Diabetic Retinopathy
VEGF: From Discovery to Therapy: The Champalimaud Award Lecture.
Diphtheria
Biologically active interleukin 2-ricin A chain fusion proteins may require intracellular proteolytic cleavage to exhibit a cytotoxic effect.
Disseminated Intravascular Coagulation
6,7-Dihydroxy-3-phenylcoumarin inhibits thromboplastin induced disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
A comparative study of the disease in cattle caused by Theileria parva or T. lawrencei: II. Hematology, clinical chemistry, coagulation studies and complement.
Disseminated Intravascular Coagulation
A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor induced disseminated intravascular coagulation in rats.
Disseminated Intravascular Coagulation
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.
Disseminated Intravascular Coagulation
ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats.
Disseminated Intravascular Coagulation
Acquired factor X deficiency and disseminated intravascular coagulation in a case of metastasizing carcinoma of the stomach and its course under chemotherapy.
Disseminated Intravascular Coagulation
Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders.
Disseminated Intravascular Coagulation
Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha 1-antitrypsin and alpha 2-macroglobulin, in patients with disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Acute Promyelocytic Leukemia-Associated Thrombosis.
Disseminated Intravascular Coagulation
Acute renal failure after snakebite: a report of four cases.
Disseminated Intravascular Coagulation
Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWf:AgII) Levels.
Disseminated Intravascular Coagulation
Amplified anticoagulant activity of tissue factor-targeted thrombomodulin: in-vivo validation of a tissue factor-neutralizing antibody fused to soluble thrombomodulin.
Disseminated Intravascular Coagulation
Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin.
Disseminated Intravascular Coagulation
Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin.
Disseminated Intravascular Coagulation
Beneficial effect of JTV-803, a new synthetic inhibitor of activated factor X, against both lipopolysaccharide-induced and tissue factor-induced disseminated intravascular coagulation in rat models.
Disseminated Intravascular Coagulation
Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia.
Disseminated Intravascular Coagulation
Clinical significance of increased thromboplastin activity on the monocyte surface--a brief review.
Disseminated Intravascular Coagulation
Coagulopathy in the nephrotic syndrome.
Disseminated Intravascular Coagulation
Diagnostic efficacy of activated partial thromboplastin time waveform and procalcitonin analysis in pediatric meningococcal sepsis.
Disseminated Intravascular Coagulation
Diagnostic efficacy of six plasma proteins in evaluating consumptive coagulopathies. Use of receiver operating characteristic curves to compare antithrombin III, plasminogen, alpha 2-plasmin inhibitor, fibronectin, prothrombin, and protein C.
Disseminated Intravascular Coagulation
DIC Score: Statistical Relationship with PT, APTT, and Simplified Scoring Systems with Combinations of PT and APTT.
Disseminated Intravascular Coagulation
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Disseminated Intravascular Coagulation
Discreplasminin, a plasmin inhibitor isolated from Tityus discrepans scorpion venom.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation caused by moojenactivase, a procoagulant snake venom metalloprotease.
Disseminated Intravascular Coagulation
Disseminated intravascular coagulation in post-dysenteric haemolytic uraemic syndrome.
Disseminated Intravascular Coagulation
Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis.
Disseminated Intravascular Coagulation
Effect of a selective PAF antagonist SM-10661 ((+/-)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one HCl) on experimental disseminated intravascular coagulation (DIC).
Disseminated Intravascular Coagulation
Effect of FR128998, a novel PAF receptor antagonist, on endotoxin-induced disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Effect of NOS Inhibitors and Anticoagulants on Nitric Oxide Production in a Tissue-factor Induced Rat DIC Model.
Disseminated Intravascular Coagulation
Effects of a highly selective synthetic inhibitor of plasma kallikrein on disseminated intravascular coagulation in rats.
Disseminated Intravascular Coagulation
Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats.
Disseminated Intravascular Coagulation
Effects of intravascular clotting on the activation of the complement system: The role of the platelet.
Disseminated Intravascular Coagulation
Effects of intravenous infusion of human prostate tissue substances in dogs.
Disseminated Intravascular Coagulation
Effects of prolonged poisoning by Russell's viper venom on blood coagulation, platelets and fibrinolysis.
Disseminated Intravascular Coagulation
Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock.
Disseminated Intravascular Coagulation
Extracorporeal CO2-removal with a heparin coated artificial lung.
Disseminated Intravascular Coagulation
Fibrin degradation products in renal diseases.
Disseminated Intravascular Coagulation
Frequency of abnormal biphasic aPTT clot waveforms in patients with underlying disorders associated with disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis.
Disseminated Intravascular Coagulation
Haemostatic Abnormalities in Patients with Closed Head Injuries and their role in Predicting Early Mortality.
Disseminated Intravascular Coagulation
Hemorrhagic, Hemostatic, and Thromboelastometric Disorders in 35 Dogs with a Clinical Diagnosis of Leptospirosis: A Prospective Study.
Disseminated Intravascular Coagulation
Hemostatic abnormalities in dogs with hemangiosarcoma.
Disseminated Intravascular Coagulation
Hemostatic abnormalities in patients with closed head injuries and their role in predicting early mortality.
Disseminated Intravascular Coagulation
Hemostatic disorders in cats: a retrospective study and review of the literature.
Disseminated Intravascular Coagulation
Hirudin in disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Increased plasma levels of tissue factor pathway inhibitor-activated factor X complex in patients with disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis.
Disseminated Intravascular Coagulation
Induction of disseminated intravascular coagulation in the factor XII-deficient fowl. Morphological effects of liquoid, bacterial endotoxin and tissue thromboplastin in the normal and anticoagulated fowl.
Disseminated Intravascular Coagulation
Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats.
Disseminated Intravascular Coagulation
Involvement of the heparanase procoagulant domain in bleeding and wound healing.
Disseminated Intravascular Coagulation
Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis.
Disseminated Intravascular Coagulation
Measurement of tissue factor messenger RNA levels in leukocytes from patients in hypercoagulable state caused by several underlying diseases.
Disseminated Intravascular Coagulation
Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target?
Disseminated Intravascular Coagulation
Mononuclear phagocyte thromboplastin, bacterial counts and endotoxin levels in experimental endogenous gram-negative sepsis.
Disseminated Intravascular Coagulation
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Disseminated Intravascular Coagulation
Normal prothrombinase activity, increased systemic thrombin activity, and lower antithrombin levels in patients with disseminated intravascular coagulation at an early phase of trauma: comparison with acute coagulopathy of trauma-shock.
Disseminated Intravascular Coagulation
Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Oral Route Driven Acute Trypanosoma cruzi Infection Unravels an IL-6 Dependent Hemostatic Derangement.
Disseminated Intravascular Coagulation
Outcome and risk factors of patients with acute fatty liver of pregnancy: a multicentre retrospective study.
Disseminated Intravascular Coagulation
Pathogenesis of thrombocytopenia in cyanotic congenital heart disease.
Disseminated Intravascular Coagulation
Pig kidney transplantation in baboons: anti-Gal(alpha)1-3Gal IgM alone is associated with acute humoral xenograft rejection and disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988.
Disseminated Intravascular Coagulation
Post-traumatic thrombotic microangiopathy following pelvic fracture treated with transcatheter arterial embolization: a case report.
Disseminated Intravascular Coagulation
Postoperative bleeding in a patient with normal screening coagulation tests.
Disseminated Intravascular Coagulation
Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass.
Disseminated Intravascular Coagulation
Prognostic significance of abnormal hematological parameters in severe traumatic brain injury requiring decompressive craniectomy.
Disseminated Intravascular Coagulation
Progression of plasma D-dimer concentration and coagulopathies during hospitalization in horses with colic.
Disseminated Intravascular Coagulation
Prolonged prothrombin time and partial thromboplastin time in disseminated intravascular coagulation not due to deficiency of factors V and VIII.
Disseminated Intravascular Coagulation
Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats.
Disseminated Intravascular Coagulation
Retinal detachment in association with preeclampsia and abruptio placentae.
Disseminated Intravascular Coagulation
Serotonin Syndrome, Disseminated Intravascular Coagulation, and Hepatitis After a Single Ingestion of MDMA in an Asian Woman.
Disseminated Intravascular Coagulation
Severe coagulopathy in Merrem's hump-nosed pit viper (Hypnale hypnale) envenoming unresponsive to fresh frozen plasma: A case report.
Disseminated Intravascular Coagulation
Snakebite doesn't cause disseminated intravascular coagulation: coagulopathy and thrombotic microangiopathy in snake envenoming.
Disseminated Intravascular Coagulation
Sporadic cases of Legionnaires' disease: the expanding clinical spectrum.
Disseminated Intravascular Coagulation
Studies of Factors V and VIII:C in an animal model of disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome successfully treated with cyclosporin A.
Disseminated Intravascular Coagulation
Successful treatment of uterine torsion in a cat with severe metabolic and haemostatic complications.
Disseminated Intravascular Coagulation
The glycosaminoglycan of recombinant human soluble thrombomodulin affects antithrombotic activity in a rat model of tissue factor-induced disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
The incidence and significance of hemostatic abnormalities in patients with head injuries.
Disseminated Intravascular Coagulation
The pathophysiologic role of fat in dysbaric osteonecrosis.
Disseminated Intravascular Coagulation
The production and availability of tissue thromboplastin in cellular populations of whole blood exposed to various concentrations of endotoxin. An assay for detection of endotoxin.
Disseminated Intravascular Coagulation
The role of cellular cooperation in thromboplastin synthesis.
Disseminated Intravascular Coagulation
The role of the E2F1 transcription factor in the innate immune response to systemic LPS.
Disseminated Intravascular Coagulation
The value of variables of disseminated intravascular coagulation in the diagnosis of adult respiratory distress syndrome.
Disseminated Intravascular Coagulation
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.
Disseminated Intravascular Coagulation
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice.
Disseminated Intravascular Coagulation
Tissue thromboplastin induced reversible DIC and heparin-enhanced inhibitors in dogs.
Disseminated Intravascular Coagulation
Transmittance waveform of routine coagulation tests is a sensitive and specific method for diagnosing non-overt disseminated intravascular coagulation.
Disseminated Intravascular Coagulation
Treatment of adult patients with sepsis-induced coagulopathy and purpura fulminans using a plasma-derived protein C concentrate (Ceprotin).
Disseminated Intravascular Coagulation
Unclear Issues Regarding COVID-19.
Disseminated Intravascular Coagulation
Unusual metastatic behavior and clinicopathologic findings in eight cats with cutaneous or visceral hemangiosarcoma.
Disseminated Intravascular Coagulation
Update on hemostasis: neurosurgery.
Disseminated Intravascular Coagulation
Update on the Clot Waveform Analysis.
Disseminated Intravascular Coagulation
Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies.
Disseminated Intravascular Coagulation
Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit.
Disseminated Intravascular Coagulation
Vascular liver calcification in infants. A case report with some pathogenetic considerations.
Disseminated Intravascular Coagulation
[Diagnostic therapeutic problems of defibrination syndrome in shock, sepsis, and neonatal hypoxia (author's transl)]
Disseminated Intravascular Coagulation
[Disseminated intravascular coagulation masking neonatal hemophilia]
Disseminated Intravascular Coagulation
[Experimental therapy of disseminated intravascular coagulation by streptokinase administration]
Disseminated Intravascular Coagulation
[Inhibitory effect of heparin in dogs with acute disseminated intravascular coagulation induced by tissue thromboplastin]
Disseminated Intravascular Coagulation
[Prevention of endotoxin-induced disseminated intravascular coagulation, and inhibition of endotoxin-induced release of thromboplastin activity from leukocytes by a protease-inhibitor, urinastatin]
Disseminated Intravascular Coagulation
[Proceedings: Consumption coagulopathy in the newborn infant caused by inwashing of tissue thromboplastin]
Disseminated Intravascular Coagulation
[Purpura fulminans in the newborn. Report of two cases successfully treated with heparin and antithrombin III]
Disseminated Intravascular Coagulation
[Reasons for fresh frozen plasma transfusion in a general hospital]
Disseminated Intravascular Coagulation
[Secondary blood coagulation disturbances after severe head injuries (author's transl)]
Disseminated Intravascular Coagulation
[Significance of fibrinopeptide A as an indicator for coagulative analysis in thrombotic diseases]
Disseminated Intravascular Coagulation
[Use of partial thromboplastin time and thrombin time in the diagnosis of disseminated intravascular coagulation]
Down Syndrome
Attributable fraction for cardiac malformations.
Drug-Related Side Effects and Adverse Reactions
Adverse Drug Reactions and Cutaneous Manifestations Associated With Anticoagulation.
Drug-Related Side Effects and Adverse Reactions
Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic anemia.
Drug-Related Side Effects and Adverse Reactions
The efficacy and safety of low-molecular-weight heparin calcium combined with Xueshuantong injections in the treatment of elderly acute deep venous thrombosis patients.
Duodenal Ulcer
Mononuclear phagocyte thromboplastin and endotoxin in patients with secondary bacterial peritonitis.
Dyslipidemias
Selected Blood Inflammatory and Metabolic Parameters Predicted Successive Bilateral Sudden Sensorineural Hearing Loss.
Dyspnea
Acute respiratory failure in adult patients with dengue virus infection.
Dyspnea
Pulmonary hemorrhage after intracoronary stent placement.
Dyspnea
Surgical treatment of early acute thrombosis of mechanical mitral prosthesis.
Ecchymosis
Acquired factor VIII inhibitor syndrome: A rare cause of hematuria.
Ecchymosis
Acquired hemophilia A in a patient associated with community-acquired pneumonia.
Ecchymosis
Coagulopathy induced by aortoiliac aneurysms.
Ecchymosis
Comparison of curative effect between different anticoagulation regimens in continuous renal replacement therapy after cardiac valve replacement.
Ecchymosis
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
Ecchymosis
Factor VIII inhibitors. Laboratory diagnosis of inhibitors.
Ecchymosis
Neonatal congenital Factor X deficiency.
Ecchymosis
Propylthiouracil-related hemorrhagic diathesis: a case report and review of the literature.
Ecchymosis
Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
Ecchymosis
[Clinical study on the application of covered vacuum sealing drainage technology to the bite of venomous snakes of Trimeresurus stejnegeri in Guangxi].
Ecchymosis
[Decreased Quick percentage, acquired factor X deficiency, hemarthrosis and ecchymosis: amyloidosis]
Ecchymosis
[Refractory kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: clinical analysis of 10 cases].
Eclampsia
Eclampsia II. Clinical significance of laboratory findings.
Ehlers-Danlos Syndrome
Plasma thromboplastin component deficiency in the Ehlers-Danlos syndrome.
Embolic Stroke
Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients.
Embolic Stroke
Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial.
Embolic Stroke
Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design.
Embolic Stroke
Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source.
Embolic Stroke
Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
Embolic Stroke
Embolic Stroke of Undetermined Source: Gateway to a New Stroke Entity?
Embolic Stroke
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial.
Embolic Stroke
Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial.
Embolic Stroke
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.
Embolic Stroke
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
Embolic Stroke
Reduced Smoke-like Echo and Resolved Thrombus in the Left Atrium with Rivaroxaban Therapy in an Acute Cardioembolic Stroke Patient.
Embolic Stroke
Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial.
Embolic Stroke
Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials.
Embolism
A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.
Embolism
Accidental Rivaroxaban Intoxication in a Boy: Some Lessons in Managing New Oral Anticoagulants in Children.
Embolism
Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial.
Embolism
An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
Embolism
Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial.
Embolism
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
Embolism
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
Embolism
Apixaban: A New Factor Xa Inhibitor for Stroke Prevention in Patients with Atrial Fibrillation.
Embolism
Arterial thromboembolism and associated antithrombin III deficiency.
Embolism
Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source.
Embolism
Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
Embolism
Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
Embolism
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
Embolism
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Embolism
Cholesterol Crystal Embolism Induced by Direct Factor Xa inhibitor: A First Case Report.
Embolism
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.
Embolism
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Embolism
Coagulation abnormalities associated with acute Angiostrongylus vasorum infection in dogs.
Embolism
Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation.
Embolism
Correction to: Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Embolism
Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Embolism
Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.
Embolism
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Embolism
Design and baseline characteristics of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
Embolism
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
Embolism
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Embolism
Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing.
Embolism
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Embolism
Direct oral factor Xa inhibitors for the prevention of non-central nervous systemic embolism patients with non-valvular atrial fibrillation - a systematic review and meta-analysis.
Embolism
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Embolism
Disseminated intravascular coagulation.
Embolism
Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis.
Embolism
Drug-drug interaction studies of cardiovascular drugs involving p-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor xa inhibitor.
Embolism
Early anticoagulation after large cerebral embolic infarction: a safety study.
Embolism
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Embolism
EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial.
Embolism
Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Embolism
Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-Valvular Atrial Fibrillation and Venous Thromboembolism.
Embolism
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Embolism
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Embolism
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
Embolism
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).
Embolism
Embolic Stroke of Undetermined Source: Gateway to a New Stroke Entity?
Embolism
Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.
Embolism
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
Embolism
Factors Associated With Major Bleeding Events: Insights From the ROCKET AF Trial (Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Embolism
Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.
Embolism
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial.
Embolism
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial.
Embolism
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
Embolism
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Embolism
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.
Embolism
Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
Embolism
Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation.
Embolism
Indications for antithrombotic therapy after myocardial infarction.
Embolism
Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Embolism
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
Embolism
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.
Embolism
Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts".
Embolism
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.
Embolism
Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks.
Embolism
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Embolism
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
Embolism
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban.
Embolism
New anticoagulants in atrial fibrillation.
Embolism
New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials.
Embolism
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Embolism
Novel oral anticoagulant management issues for the stroke clinician.
Embolism
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Embolism
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
Embolism
Oral anticoagulants for Asian patients with atrial fibrillation.
Embolism
Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease.
Embolism
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Embolism
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Embolism
Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects.
Embolism
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Embolism
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
Embolism
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Embolism
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.
Embolism
Practical management of patients on apixaban: a consensus guide.
Embolism
Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.
Embolism
Preclinical and clinical data for factor Xa and "universal" reversal agents.
Embolism
Preliminary Observations on the Antihypertension Action of Dabigatran Etexilate in Patients With Nonvalvular Atrial Fibrillation: A Prospective Multicenter Single-Arm Interventional Study.
Embolism
Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice.
Embolism
Pulmonary embolism in congenital bleeding disorders: intriguing discrepancies among different clotting factors deficiencies.
Embolism
Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression.
Embolism
Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
Embolism
Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
Embolism
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Embolism
Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban.
Embolism
Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts".
Embolism
Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial.
Embolism
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.
Embolism
Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer.
Embolism
Rivaroxaban in atrial fibrillation.
Embolism
Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study.
Embolism
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
Embolism
Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Embolism
ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation.
Embolism
Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
Embolism
Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.
Embolism
Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
Embolism
Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
Embolism
Safety and efficacy of apixaban in the treatment of atrial fibrillation.
Embolism
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.
Embolism
Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation.
Embolism
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.
Embolism
Spontaneous Arterial Dissection.
Embolism
Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials.
Embolism
Stroke Prevention in Atrial Fibrillation: Impact of Novel Oral Anticoagulants.
Embolism
Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.
Embolism
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
Embolism
The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
Embolism
The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Embolism
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
Embolism
The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy.
Embolism
The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes.
Embolism
Transitions of care in anticoagulated patients.
Embolism
Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.
Embolism
Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Embolism
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
Embolism
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
Embolism
Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
Embolism
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
Embolism
[Anticoagulation with low molecular-weight heparin in patients with prosthetic heart valve replacements]
Embolism
[Clinical treatment and therapy for dissected cervicocerebral artery]
Embolism
[Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
Embolism
[Hemodynamic and respiratory changes during hip and knee arthroplasty. An echocardiographic study]
Embolism
[Pharmacology of the new oral anticoagulants].
Embolism
[Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update].
Embolism, Amniotic Fluid
Disseminated intravascular coagulation.
Embolism, Fat
The pathophysiologic role of fat in dysbaric osteonecrosis.
Encephalitis
Antithrombin activity of an algal polysaccharide.
Encephalomyelitis
Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis.
Encephalopathy, Bovine Spongiform
Antithrombin activity of an algal polysaccharide.
Endocarditis
Changes in hemostasis parameters in nonfatal methicillin-sensitive Staphylococcus aureus bacteremia complicated by endocarditis or thromboembolic events: a prospective gender-age adjusted cohort study.
Endocarditis, Bacterial
Enhancement of generation of monocyte tissue thromboplastin by bacterial phagocytosis: possible pathway for fibrin formation on infected vegetations in bacterial endocarditis.
Endocarditis, Bacterial
The role of bacterial adherence in the pathogenesis of infective endocarditis.
Endometrial Neoplasms
Co-localization of Coagulation Factor X and its Inhibitory System, PZ/ZPI, in Human Endometrial Cancer Tissue.
Endometriosis
Assessment of Coagulation Parameters in Women Affected by Endometriosis: Validation Study and Systematic Review of the Literature.
Endometriosis
Coagulation Status in Women With Endometriosis.
Endometriosis
Noninvasive evaluation of ovarian endometriosis: a single-center experience.
Endometritis
New approach to the risk variables for administration of fibrinogen in patients with postpartum hemorrhage by using cluster analysis.
Endotoxemia
Antithrombin-III treatment limits disseminated intravascular coagulation in endotoxemia.
Endotoxemia
Beneficial effect of cod liver oil in murine endotoxemia.
Endotoxemia
Endotoxemia in horses: protection provided by antiserum to core lipopolysaccharide.
Endotoxemia
Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats.
Endotoxemia
Propofol lowers serum PF4 level and partially corrects hypercoagulopathy in endotoxemic rats.
Endotoxemia
Protection against disseminated intravascular coagulation and death by antithrombin-III in the Escherichia coli endotoxemic rat.
Eosinophilia
Acquired Factor V Inhibitors in a Patient with End-stage Renal Disease.
Eosinophilia
Eosinophilia and first-line coagulation testing.
Epilepsy, Tonic-Clonic
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
Epiretinal Membrane
Activated Blood Coagulation Factor X (FXa) Contributes to the Development of Traumatic PVR Through Promoting RPE Epithelial-Mesenchymal Transition.
Epistaxis
A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against factor X.
Epistaxis
Acquired Hemophilia A: A Potentially Fatal Bleeding Disorder.
Epistaxis
Congenital factor X deficiency of coagulation revealed by epistaxis.
Epistaxis
Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents.
Epistaxis
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
Epistaxis
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
Epistaxis
Hemorrhage in a cat caused by inhibition of factor XI (plasma thromboplastin antecedent).
Epistaxis
In response to Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents.
Epistaxis
Propylthiouracil-related hemorrhagic diathesis: a case report and review of the literature.
Epistaxis
Rare coagulation disorders.
Epistaxis
Regarding epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents.
Epistaxis
Replacement therapy for congenital Factor X deficiency.
Epistaxis
Report of the fifth homozygous patient with factor VII Padua defect.
Epistaxis
Risk factors for epistaxis in patients followed in general practices in Germany.
Epistaxis
Superwarfarin Exposure: An Important Uncommon Cause of Painless Bleeding.
Epistaxis
von Willebrand factor activity and activated partial thromboplastin time as proxy biomarkers for coagulopathies in women with menorrhagia in Zambia: a case-control study.
Epistaxis
[Acquired factor V inhibitors in a polytraumatized patient]
Epistaxis
[Clinical and epidemiological characteristic of dengue]
Epistaxis
[The determination of activated partial thromboplastin time, coagulate time and thrombin time in patients with epistaxis of indeterminate cause]
Epstein-Barr Virus Infections
Transient lupus anticoagulant and prolonged activated partial thromboplastin time secondary to Epstein-Barr virus infection.
Esophageal and Gastric Varices
Survival in alcoholic liver cirrhosis: prognostic value of portal pressure, size of esophageal varices and biochemical data. Comparison with Child classification.
Essential Hypertension
Coagulation and the hypertensive diseases of pregnancy.
Essential Hypertension
Increased sensitivity to thromboplastin synthesis in blood monocytes from pre-eclamptic patients.
Essential Hypertension
Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension.
Exanthema
Diagnostic Pitfalls in a Man with Systemic Lupus Erythematous.
Exanthema
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
Exanthema
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Exanthema
Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
Exanthema
The Significance of Prolonged and Saddleback Fever in Hospitalised Adult Dengue.
Exotropia
Neurological Involvement and Hepatocellular Injury Caused by a Snake With Hematotoxin Envenomation.
Eye Diseases
Platelet coagulant activities in arterial occlusive disease of the eye.
Factor V Deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
Factor V Deficiency
A novel compensating mechanism for homozygous coagulation factor V deficiency suggested by enhanced activated partial thromboplastin time after reconstitution with normal factor V.
Factor V Deficiency
Abnormal formation of the prothrombinase complex: factor V deficiency and related disorders.
Factor V Deficiency
Acquired Factor V Deficiency Associated with CFPM Administration.
Factor V Deficiency
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Factor V Deficiency
Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies.
Factor V Deficiency
Clinical audit of inherited bleeding disorders in a developing country.
Factor V Deficiency
Familial association of hypoplasminogenemia and heterozygous factor V deficiency.
Factor V Deficiency
Intracranial haemorrhage due to factor V deficiency.
Factor V Deficiency
Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis.
Factor V Deficiency
Observations on hemophilia, parahemophilia, and coexistent hemophilia and parahemophilia; alterations in the platelets and the thromboplastin generation test.
Factor V Deficiency
Patients with congenital factor V deficiency have decreased factor Xa binding sites on their platelets.
Factor V Deficiency
Rare inherited coagulation disorders in India.
Factor V Deficiency
Snake Venoms in Diagnostic Hemostasis and Thrombosis.
Factor V Deficiency
Splenectomy and proximal lieno-renal shunt in a factor five deficient patient with extra-hepatic portal vein obstruction.
Factor V Deficiency
Successful Management of Life-threatening Pelvic Hemorrhage From Acquired Factor V Deficiency With immunosuppressive Therapy.
Factor VII Deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
Factor VII Deficiency
A NlaIII polymorphism within the human factor VII gene.
Factor VII Deficiency
An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.
Factor VII Deficiency
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Factor VII Deficiency
Another patient with a congenital hemorrhagic disorder intermediate between factor X and factor VII deficiency.
Factor VII Deficiency
Asymptomatic factor VII deficiency: gene analysis and structure-function relationships.
Factor VII Deficiency
Clinical audit of inherited bleeding disorders in a developing country.
Factor VII Deficiency
Combined mild PTC (plasma thromboplastin component) and factor VII deficiencies.
Factor VII Deficiency
Determinants of coagulation activation in humans.
Factor VII Deficiency
Determinants of plasma factor VIIa levels in humans.
Factor VII Deficiency
Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds.
Factor VII Deficiency
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
Factor VII Deficiency
Factor VII deficiency detected in pregnancy: a case report.
Factor VII Deficiency
Factor VII deficiency with intracranial hemorrhage: a case report.
Factor VII Deficiency
Factor VII Deficiency: A Rare Case Report.
Factor VII Deficiency
Fatal intracranial hemorrhage in a newborn with factor VII deficiency.
Factor VII Deficiency
Haemoperitoneum associated with ovulation in women with bleeding disorders: the case for conservative management and the role of the contraceptive pill.
Factor VII Deficiency
Inherited bleeding disorders in Indian women with menorrhagia.
Factor VII Deficiency
Inherited bleeding disorders in the Eastern Province of Saudi Arabia.
Factor VII Deficiency
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Factor VII Deficiency
Multiple intracranial hemorrhages at the time of a transiently prolonged activated partial thromboplastin time in an infant with congenital factor VII deficiency.
Factor VII Deficiency
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Factor VII Deficiency
Paracetamol poisoning unmasking factor VII deficiency.
Factor VII Deficiency
Rare inherited coagulation disorders in India.
Factor VII Deficiency
Sensitivity of different thromboplastin reagents to factor VII deficiency in the blood of beagle dogs.
Factor VII Deficiency
Spectrum of factor X gene mutations in Iranian patients with congenital factor X deficiency.
Factor VII Deficiency
Synergistic effect of factor VII gene polymorphisms causing mild factor VII deficiency in a case of severe factor X deficiency.
Factor VII Deficiency
The K-test (trypsin clotting time) in coumarin treated patients and in congenital deficiencies and abnormalities of the prothrombin complex.
Factor VII Deficiency
[A new case of homozygous congenital factor VII deficiency. Associated factor X deficiency in some members of the family]
Factor VII Deficiency
[Congenital factor VII deficiency: about two family cases].
Factor VII Deficiency
[Significant decrease in factor VII activity by tissue thromboplastin derived from rabbit brain in a patient with congenital factor VII deficiency (FVII Padua)].
Factor VII Deficiency
[The change and significance of coagulation activity in bleomycin-induced lung fibrosis in rats]
Factor X Deficiency
"I have been refused to be treated by three dentists": Barriers to patient care.
Factor X Deficiency
A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against factor X.
Factor X Deficiency
A case of factor X deficiency in a Chihuahua dog.
Factor X Deficiency
A Case Report of Acquired Factor X Deficiency in a Patient With Multiple Myeloma.
Factor X Deficiency
A Compound Heterozygosis of Two Novel Mutations Causes Factor X Deficiency in a Chinese Pedigree.
Factor X Deficiency
A family with factor X deficiency from Argentina: a compound heterozygosis because of the combination of a new mutation (Gln138Arg) with an already known one (Glu350Lys).
Factor X Deficiency
A family with hereditary factor X deficiency with a point mutation Gla32 to Gln in the Gla domain (factor X Tokyo).
Factor X Deficiency
A functional factor X deficiency.
Factor X Deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
Factor X Deficiency
A new family with classical factor X deficiency as demonstrated by electroimmunoassay.
Factor X Deficiency
A NlaIII polymorphism within the human factor VII gene.
Factor X Deficiency
A novel factor X gene mutation Val (GTC) 384Ala (GCC) in a Chinese family resulting in congenital factor X deficiency.
Factor X Deficiency
A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?
Factor X Deficiency
A Rare Cause of Coagulopathy in a Patient with Rapidly Progressive Renal Failure.
Factor X Deficiency
A rare cause of intracranial hemorrhage: factor X deficiency.
Factor X Deficiency
A Rare Cause of Isolated Prothrombin Time Prolongation: Congenital Factor X Deficiency.
Factor X Deficiency
A rare inherited coagulation disorder: combined homozygous factor VII and factor X deficiency.
Factor X Deficiency
A rare presentation of homozygous factor X deficiency in a pregnant patient: A case report and review of the literature.
Factor X Deficiency
A tongue resection in macroglossia due to primary amyloidosis.
Factor X Deficiency
A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X.
Factor X Deficiency
Abscess in bilateral ovarian haematomas in a girl with factor X deficiency, necessitating oopherectomy.
Factor X Deficiency
Acquired and transient factor X deficiency associated with sodium valproate treatment.
Factor X Deficiency
Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome.
Factor X Deficiency
Acquired factor X deficiency and amyloidosis treated with melphalan and prednisone.
Factor X Deficiency
Acquired factor X deficiency and amyloidosis.
Factor X Deficiency
Acquired factor X deficiency and disseminated intravascular coagulation in a case of metastasizing carcinoma of the stomach and its course under chemotherapy.
Factor X Deficiency
Acquired factor X deficiency associated with atypical AL-amyloidosis.
Factor X Deficiency
Acquired factor X deficiency associated with systematized amyloidosis--a report of a case.
Factor X Deficiency
Acquired factor X deficiency developed four years after autologous transplantation in a patient with multiple myeloma associated with systemic AL amyloidosis.
Factor X Deficiency
Acquired factor X deficiency in a Negro boy.
Factor X Deficiency
Acquired factor X deficiency in a patient with amyloidosis.
Factor X Deficiency
Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis.
Factor X Deficiency
Acquired factor x deficiency in light chain amyloidosis: a report of 2 korean cases.
Factor X Deficiency
Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease.
Factor X Deficiency
Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
Factor X Deficiency
Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis.
Factor X Deficiency
Acquired factor X deficiency in systemic amyloidosis.
Factor X Deficiency
Acquired factor X deficiency in systemic amyloidosis: management of two cases.
Factor X Deficiency
Acquired factor X deficiency with associated defects in platelet aggregation. A response to corticosteroid therapy.
Factor X Deficiency
Acquired factor X deficiency. Altered plasma antithrombin activity and association with amyloidosis.
Factor X Deficiency
Acquired factor X deficiency: an experience with multiple tooth extraction.
Factor X Deficiency
Acquired isolated factor X deficiency associated with systemic amyloidosis. Case report and review of literature.
Factor X Deficiency
Acquired selective factor X deficiency in acute nonlymphocytic leukemia.
Factor X Deficiency
Acquired, non-amyloid related factor X deficiency: review of the literature.
Factor X Deficiency
Acquired, transient factor X (Stuart factor) deficiency in patient with mycoplasma pneumonial infection.
Factor X Deficiency
Acquired-transient factor X deficiency associated with anticardiolipin antibodies in a child with extensive burns.
Factor X Deficiency
Acquired-transient factor X deficiency in a teenager with extensive burns.
Factor X Deficiency
Advances in treatment of bleeding disorders.
Factor X Deficiency
Amyloidosis and factor X deficiency.
Factor X Deficiency
Amyloidosis with factor X deficiency.
Factor X Deficiency
An analysis of 8 cases of factor X deficiency.
Factor X Deficiency
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Factor X Deficiency
Angiodysplasia of upper gastrointestinal tract with coagulopathy.
Factor X Deficiency
Antenatally diagnosed subdural haemorrhage in congenital factor X deficiency.
Factor X Deficiency
Antibody-induced acute factor X deficiency: clinical manifestations and properties of the antibody.
Factor X Deficiency
Atraumatic splenic rupture in amyloidosis.
Factor X Deficiency
Autoimmune Coagulation Factor X Deficiency as a Rare Acquired Hemorrhagic Disorder: A Literature Review.
Factor X Deficiency
Autologous bone marrow transplantation and factor XII, factor VII, and protein C deficiencies. Report of a new association and its possible relationship to endothelial cell injury.
Factor X Deficiency
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.
Factor X Deficiency
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Factor X Deficiency
Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies.
Factor X Deficiency
Bilateral periorbital ecchymoses. An often missed sign of amyloid purpura.
Factor X Deficiency
Bleeding manifestations in 100 patients with amyloidosis.
Factor X Deficiency
Blood coagulation factor X deficiency causes partial embryonic lethality and fatal neonatal bleeding in mice.
Factor X Deficiency
Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.
Factor X Deficiency
Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency.
Factor X Deficiency
Candida vertebra osteomyelitis in a girl with factor X deficiency.
Factor X Deficiency
Cardiac Amyloidosis Presenting with Pre-Excitation Syndrome, Heart Failure, and Severe Factor X Deficiency as Part of Systemic Amyloid Light-Chain (AL) Amyloidosis - A Fatal Combination.
Factor X Deficiency
Characterization of amyloid deposits and P component from a patient with factor X deficiency reveals proteins derived from a lambda VI light chain.
Factor X Deficiency
Chronic peritoneal dialysis in a patient with primary amyloidosis, renal failure, and factor X deficiency.
Factor X Deficiency
Circumcision in Patients with Congenital Factor X Deficiency.
Factor X Deficiency
Classical factor X deficiency. Report of a further case.
Factor X Deficiency
Clinical analysis of six cases of multiple myeloma first presenting with coagulopathy.
Factor X Deficiency
Clinical audit of inherited bleeding disorders in a developing country.
Factor X Deficiency
Coagulation and fibrinolysis abnormalities in familial amyloid polyneuropathy.
Factor X Deficiency
Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid.
Factor X Deficiency
Coincidence of acquired factor-X deficiency and disseminated intravascular coagulation in patients with acute nonlymphoblastic leukemia.
Factor X Deficiency
Complete remission in a bleeding patient with idiopathic autoimmune factor X deficiency caused by non-neutralizing anti-factor X autoantibody.
Factor X Deficiency
Complex history of the discovery and characterization of congenital factor X deficiency.
Factor X Deficiency
Congenital bleeding disorders of the vitamin K-dependent clotting factors.
Factor X Deficiency
Congenital coagulation factor X deficiency: Genetic analysis of five patients and functional characterization of mutant factor X proteins.
Factor X Deficiency
Congenital coagulopathies and pregnancy: report of four pregnancies in a factor X-deficient woman.
Factor X Deficiency
Congenital factor X deficiencies with a defect only or predominantly in the extrinsic or in the intrinsic system: a critical evaluation.
Factor X Deficiency
Congenital factor X deficiency and incomplete transverse paralysis.
Factor X Deficiency
Congenital factor X deficiency in Japan.
Factor X Deficiency
Congenital Factor X deficiency in women: A systematic review of the literature.
Factor X Deficiency
Congenital factor X deficiency of coagulation revealed by epistaxis.
Factor X Deficiency
Congenital factor X deficiency: spectrum of bleeding symptoms in 32 Iranian patients.
Factor X Deficiency
Congenital haemorrhagic condition similar but not identical to factor X deficiency. A haemorrhagic state due to an abnormal factor X?
Factor X Deficiency
Corpus luteum hemorrhage: rare complication of congenital and acquired coagulation abnormalities.
Factor X Deficiency
Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency.
Factor X Deficiency
Danazol therapy in factor X deficiency.
Factor X Deficiency
Danazol therapy in factor X deficiency: more questions than answers.
Factor X Deficiency
Dental management of a patient with factor X deficiency.
Factor X Deficiency
Diagnosis and treatment of inherited factor X deficiency.
Factor X Deficiency
Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency.
Factor X Deficiency
Diagnostic Error of a Patient with Combined Inherited Factor VII and Factor X Deficiency due to Accidental Ingestion of a Diphacinone Rodenticide.
Factor X Deficiency
Different genotypes are responsible for the normal Russell viper venom assays seen in some cases of congenital factor X deficiency.
Factor X Deficiency
Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe Factor X deficiency in Iran.
Factor X Deficiency
Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency.
Factor X Deficiency
Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in women and girls with hereditary factor X deficiency.
Factor X Deficiency
Ethnic Differences in Coagulation Factor Abnormalities After the Fontan Procedure.
Factor X Deficiency
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
Factor X Deficiency
Evidence of both von Willebrand factor deposition and factor V deposition onto AL amyloid as the cause of a severe bleeding diathesis.
Factor X Deficiency
Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery.
Factor X Deficiency
Factor VII and factor X deficiency in a child with a chromosome 13q duplication and deletion.
Factor X Deficiency
Factor X and its deficiency states.
Factor X Deficiency
Factor X assays using chromogenic substrate S-2222.
Factor X Deficiency
Factor X deficiency and hemophilia A : occurrence of two different coagulation defects in a family.
Factor X Deficiency
Factor X deficiency and intracranial bleeding: who is at risk?
Factor X Deficiency
Factor X deficiency and pregnancy: case report and counselling.
Factor X Deficiency
Factor X deficiency and pregnancy: preconception counselling and therapeutic options.
Factor X Deficiency
Factor X deficiency and systemic amyloidosis.
Factor X Deficiency
Factor X deficiency associated with compound heterozygosity involving a novel missense mutation at codon 38 from Val (GTC) to Leu (CTC) in exon 2.
Factor X Deficiency
Factor X Deficiency Caused by Nonsecretory Myeloma Successfully Corrected with Bortezomib: A Case Report and Review of the Literature.
Factor X Deficiency
Factor X deficiency due to a compound heterozygosis between a new mutation (Gla72Asp) in exon 2 and an already known one (Gly154Arg) in exon 5: Factor X Mar del Plata 1).
Factor X Deficiency
Factor X deficiency during treatment of relapsed acute myeloid leukaemia with amsacrine.
Factor X Deficiency
Factor X deficiency in a cat.
Factor X Deficiency
Factor X deficiency in a Jack Russell terrier.
Factor X Deficiency
Factor X deficiency in North Pakistan.
Factor X Deficiency
Factor X deficiency in primary amyloidosis.
Factor X Deficiency
Factor X deficiency in primary amyloidosis: resolution after splenectomy.
Factor X Deficiency
Factor X deficiency in systemic amyloidosis.
Factor X Deficiency
Factor X deficiency in the neonatal period.
Factor X Deficiency
Factor X Deficiency Management for Elective Cesarean Delivery in a Pregnant Patient.
Factor X Deficiency
Factor X deficiency presenting as a pseudotumor. Case report.
Factor X Deficiency
Factor X deficiency presenting with bilateral chronic subdural hematoma.
Factor X Deficiency
Factor X Deficiency with Heterozygous Mutations of Novel p.G435S and Known p.G244R in a Patient Presenting with Severe Umbilical Hemorrhage.
Factor X Deficiency
Factor X deficiency--a rare disorder.
Factor X Deficiency
Factor X deficiency.
Factor X Deficiency
Factor X Deficiency: A Rare Cause of Puberty Menorrhagia.
Factor X Deficiency
Factor X deficiency: An uncommon presentation of AL amyloidosis.
Factor X Deficiency
Factor X deficiency: an unusual cause for spontaneous intracranial bleeding.
Factor X Deficiency
Factor x deficiency: an unusual cause of spontaneous intracranial bleeding.
Factor X Deficiency
Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene.
Factor X Deficiency
Factor X Frankfurt I: molecular and functional characterization of a hereditary factor X deficiency (Gla+25 to Lys).
Factor X Deficiency
Factor X inhibitor: a fulminant presentation and fatal course of a rare syndrome in a 59-year-old male.
Factor X Deficiency
Factor X level in coumarin treated patients and in factor X deficiency as assayed with different techniques.
Factor X Deficiency
Factor X Nagoya 1 and Nagoya 2: a CRM- factor X deficiency and a dysfunctional CRM+ factor X deficiency characterized by substitution of Arg306 by Cys and of Gly366 by Ser, respectively.
Factor X Deficiency
Factor XDebrecen: Gly204Arg mutation in factor X causes the synthesis of a non-secretable protein and severe factor X deficiency.
Factor X Deficiency
Factors X Nice I and II: two novel missense mutations (Met-40Val and Pro304Ser) in patient with coagulation factor X deficiency.
Factor X Deficiency
Femur fracture in a woman with severe factor X deficiency - an experience using factor X concentrate in surgery.
Factor X Deficiency
Five novel point mutations: two causing haemophilia B and three causing factor X deficiency.
Factor X Deficiency
Frequencies of mild factor V, VII and X deficiencies in a Japanese population.
Factor X Deficiency
Frequency of inherited bleeding disorders in women with menorrhagia.
Factor X Deficiency
Frequency of the p.Gly262Asp mutation in congenital Factor X deficiency.
Factor X Deficiency
Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID-19-A common clinical feature between a rare disorder and a new, common infection.
Factor X Deficiency
Gene mutations and three-dimensional structural analysis in 13 families with severe factor X deficiency.
Factor X Deficiency
Genetic analysis of a compound heterozygous patient with congenital factor X deficiency and regular replacement therapy with a prothrombin complex concentrate.
Factor X Deficiency
Genetic analysis of hereditary factor X deficiency in a French patient of Sri Lankan ancestry: in vitro expression study identified Gly366Ser substitution as the molecular basis of the dysfunctional factor X.
Factor X Deficiency
Genotype analysis and identification of novel mutations in a multicentre cohort of patients with hereditary factor X deficiency.
Factor X Deficiency
Genotyping of five Pakistani patients with severe inherited factor X deficiency: identification of two novel mutations.
Factor X Deficiency
Haemoperitoneum associated with ovulation in women with bleeding disorders: the case for conservative management and the role of the contraceptive pill.
Factor X Deficiency
Hemorrhage because of amyloid-related factor x deficiency after insertion of tenckhoff catheter.
Factor X Deficiency
Hemorrhagic diathesis caused by factor X deficiency in a child with thymic cyst.
Factor X Deficiency
Hemostatic abnormalities in multiple myeloma and related disorders.
Factor X Deficiency
Hereditary coagulation factor X deficiency--a clinico-haematological profile of 5 cases from Varanasi.
Factor X Deficiency
Hereditary coagulation factor X deficiency.
Factor X Deficiency
Heterogeneity of hereditary and acquired factor X deficiencies by combined immunochemical and functional analyses.
Factor X Deficiency
Homozygous factor X deficiency associated with familial hypercholesterolemia, mitral valve prolapse, and hypertrophic cardiomyopathy.
Factor X Deficiency
Human coagulation factor X deficiency caused by a mutant signal peptide that blocks cleavage by signal peptidase but not targeting and translocation to the endoplasmic reticulum.
Factor X Deficiency
Identification of a novel factor X deletion in combination with a missense mutation in the gene - Genotype-phenotype correlation in a girl with severe factor X deficiency.
Factor X Deficiency
Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency.
Factor X Deficiency
Impact of Rare Bleeding Disorders during Pregnancy on Maternal and Fetal Outcomes: Review of 29 Pregnancies at a Single Center.
Factor X Deficiency
Importance of pharmacokinetic studies in the management of acquired factor X deficiency.
Factor X Deficiency
Influence of glass and anticoagulant concentration on improvement of factor X deficiency tests.
Factor X Deficiency
Inherited bleeding disorders in Indian women with menorrhagia.
Factor X Deficiency
Inherited bleeding disorders in the Eastern Province of Saudi Arabia.
Factor X Deficiency
Inherited factor X deficiency in two brothers.
Factor X Deficiency
Inherited factor X deficiency: molecular genetics and pathophysiology.
Factor X Deficiency
Inherited factor X deficiency: presentation of a case with etiologic and treatment considerations.
Factor X Deficiency
Inherited Moderate Factor X Deficiency Presenting as Cardiac Tamponade.
Factor X Deficiency
Intracerebral haemorrhage in an adult due to transient factor X deficiency.
Factor X Deficiency
Intracranial haemorrhage in patients with congenital haemostatic defects.
Factor X Deficiency
Intracranial Hemorrhage as the First Manifestation of Severe Congenital Factor X Deficiency in a 20-Month-Old Male: Case Report and Review of the Literature.
Factor X Deficiency
Isolated factor X deficiency in amyloidosis. Case report and review of the literature.
Factor X Deficiency
Kinetic analysis of the clotting system in the presence of heparin and depolymerized heparin.
Factor X Deficiency
Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis.
Factor X Deficiency
Life-threatening bleeding tendency provoked by an acquired isolated factor X deficiency associated with respiratory infection.
Factor X Deficiency
Liver transplantation for haemophiliacs with hepatitis C cirrhosis.
Factor X Deficiency
Lupus anticoagulant associated with transient severe factor X deficiency: a report of two patients presenting with major bleeding complications.
Factor X Deficiency
Management of Factor X Deficiency for Vaginal Delivery in a Parturient: A Case Report.
Factor X Deficiency
Massive Upper and Lower GI Bleed from Simultaneous Primary (AL) Amyloidosis of the Stomach and Transverse Colon in a Patient with Multiple Myeloma.
Factor X Deficiency
Mechanism of factor X deficiency in systemic amyloidosis.
Factor X Deficiency
Membranoproliferative glomerulonephritis and a rare bleeding disorder: factor X deficiency.
Factor X Deficiency
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Factor X Deficiency
Mode of inheritance of factor X deficiency.
Factor X Deficiency
Modulation of severity of clinical bleeding by co-inherited thrombophilia is also true for severe factor X deficiency.
Factor X Deficiency
Molecular analysis of patients with severe congenital factor X deficiency: First report from north and northwest of Iran.
Factor X Deficiency
Molecular analysis of the genotype-phenotype relationship in factor X deficiency.
Factor X Deficiency
Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glu102Lys) in the second EGF-like domain.
Factor X Deficiency
Molecular basis of factor X deficiency cases from India.
Factor X Deficiency
Molecular characterization of factor X deficiency associated with borderline plasma factor X level.
Factor X Deficiency
Molecular characterization of human factor XSan Antonio.
Factor X Deficiency
Molecular characterization of two novel mutations causing factor X deficiency in a Chinese pedigree.
Factor X Deficiency
Molecular defect (Gla+14----Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg").
Factor X Deficiency
Molecular genetic analysis of factor X deficiency: gene deletion and germline mosaicism.
Factor X Deficiency
Near fatal spontaneous intraperitoneal bleeding: A rare manifestation in a congenital factor X deficiency carrier.
Factor X Deficiency
Neonatal congenital Factor X deficiency.
Factor X Deficiency
Neonatal congenital factor X deficiency.
Factor X Deficiency
Neonatal onset of congenital factor X deficiency: a description of two novel mutations with 6-year follow-up.
Factor X Deficiency
NORETHYNODREL IN THE TREATMENT OF FACTOR X DEFICIENCY.
Factor X Deficiency
Normalization of plasma factor X levels in amyloidosis after plasma exchange.
Factor X Deficiency
Novel factor X deficiency. Normal partial thromboplastin time and associated spindle cell thymoma.
Factor X Deficiency
Occurrence and management of severe bleeding episodes in patients with hereditary factor X deficiency.
Factor X Deficiency
One missense mutation in the factor X gene causing factor X deficiency--factor X Kanazawa.
Factor X Deficiency
Partial gene deletion in a family with factor X deficiency.
Factor X Deficiency
Pharmacokinetics and prophylactic use of FEIBA(®) in a child with severe congenital factor X deficiency and recurrent spontaneous intracranial haemorrhage: a case report.
Factor X Deficiency
Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiency.
Factor X Deficiency
Phenotype and genotype report on homozygous and heterozygous patients with congenital factor X deficiency.
Factor X Deficiency
PheWAS uncovers a pathological role of coagulation Factor X during Acinetobacter baumannii infection.
Factor X Deficiency
Plasma exchange in a case of severe factor X deficiency in pregnancy: critical review of the literature.
Factor X Deficiency
Plasma-derived factor X concentrate compassionate use for hereditary factor X deficiency: Long-term safety and efficacy in a retrospective data-collection study.
Factor X Deficiency
Platelet aggregation and adhesiveness in classical factor X deficiency and in the abnormal factor X (factor X Friuli) coagulation disorder.
Factor X Deficiency
Poor recovery and short survival of infused factor X in a case of acquired factor X deficiency and amyloidosis.
Factor X Deficiency
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
Factor X Deficiency
Posttraumatic lipoma in a patient with congenital factor X deficiency.
Factor X Deficiency
Pregnancy in a patient with severe factor X deficiency.
Factor X Deficiency
Prenatal diagnosis of factor X deficiency using a combination of direct mutation detection and linkage analysis with an intragenic single nucleotide polymorphism.
Factor X Deficiency
Presurgical plasma exchange is ineffective in correcting amyloid associated factor X deficiency.
Factor X Deficiency
Prevalence of bleeding manifestations in 128 heterozygotes for Factor X deficiency, mainly for FX Friuli, matched vs 128 unaffected family members, during a long sequential observation period (23.5 years).
Factor X Deficiency
Prevention of recurrent intracranial hemorrhage in a factor X-deficient infant.
Factor X Deficiency
Primary amyloidosis with severe nephrotic syndrome and acquired factor X deficiency.
Factor X Deficiency
Progressive systemic sclerosis with the nephrotic syndrome and acquired factor X deficiency.
Factor X Deficiency
Prolongation of thrombin and reptilase times in patients with amyloidosis and acquired factor X deficiency.
Factor X Deficiency
Prophylactic treatment of bleeding episodes in children <12 years with moderate to severe hereditary factor X deficiency (FXD): Efficacy and safety of a high-purity plasma-derived factor X (pdFX) concentrate.
Factor X Deficiency
Prophylactic treatment of severe factor X deficiency with prothrombin complex concentrate.
Factor X Deficiency
Prophylaxis in rare coagulation disorders -- factor X deficiency.
Factor X Deficiency
Prophylaxis with prothrombin complex concentrate in four children with severe congenital factor X deficiency.
Factor X Deficiency
Prothrombin in factor X deficiency.
Factor X Deficiency
Rare case of combined factor V and factor X deficiency in pregnancy: presenting as secondary postpartum haemorrhage in first pregnancy and successful outcome in second pregnancy.
Factor X Deficiency
Rare inherited coagulation disorders in India.
Factor X Deficiency
Rare post-operative complications in a previously undiagnosed Congenital Factor X deficiency patient.
Factor X Deficiency
Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency.
Factor X Deficiency
Recurrent ovarian haemorrhage in a girl with congenital factor X deficiency.
Factor X Deficiency
Recurrent, isolated factor X deficiency in myeloma: repeated normalization of factor X levels after cytostatic chemotherapy followed by late treatment failure associated with the development of systemic amyloidosis.
Factor X Deficiency
Replacement therapy for congenital Factor X deficiency.
Factor X Deficiency
Report on a disease-adapted treatment in a patient with severe factor X deficiency resulting from a homozygous factor X gene mutation.
Factor X Deficiency
Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisone therapy.
Factor X Deficiency
Resolution of acquired factor X deficiency with amyloidosis secondary to plasma cell dyscrasia.
Factor X Deficiency
Resolution of factor X deficiency in primary amyloidosis following splenectomy.
Factor X Deficiency
Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding.
Factor X Deficiency
Retroperitoneal amyloidosis, factor IX and X deficiency,and gastrointestinal bleeding.
Factor X Deficiency
Routine preoperative coagulation screening detects a rare bleeding disorder.
Factor X Deficiency
Secondary severe factor X deficiency associated with antiphospholipid syndrome.
Factor X Deficiency
Severe congenital factor X deficiency in 5-month-old child.
Factor X Deficiency
Severe congenital factor X deficiency with intracranial bleeding in two siblings.
Factor X Deficiency
Severe congenital factor X deficiency with intracranial haemorrhage.
Factor X Deficiency
Severe factor X deficiency and successful pregnancy.
Factor X Deficiency
Severe factor X deficiency due to a homozygous mutation (Cys364Arg) that disrupts a disulphide bond in the catalytic domain.
Factor X Deficiency
Severe factor X deficiency in a pair of siblings: clinical presentation, phenotypic and genotypic features, prenatal diagnosis and treatment.
Factor X Deficiency
Severe factor X deficiency in a twin pregnancy.
Factor X Deficiency
Severe factor X deficiency in pregnancy: case report and review of the literature.
Factor X Deficiency
Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG-correlation with thrombin generation and thromboelastometry.
Factor X Deficiency
Severe Factor X Deficiency Presenting as Febrile Seizure in an Infant.
Factor X Deficiency
Severe factor X deficiency treated with heparin-added prothrombin complex concentrate.
Factor X Deficiency
Six novel missense mutations causing factor X deficiency and application of thrombin generation test.
Factor X Deficiency
Six novel mutations including triple heterozygosity for Phe31Ser, 514delT and 516T-->G factor X gene mutations are responsible for congenital factor X deficiency in patients of Nepali and Indian origin.
Factor X Deficiency
Spectrum of factor X gene mutations in Iranian patients with congenital factor X deficiency.
Factor X Deficiency
Splenectomy in an uraemic patient with acquired factor X deficiency due to AL amyloidosis.
Factor X Deficiency
Splenectomy in plasma cell dyscrasias: a review of the clinical practice.
Factor X Deficiency
Spontaneous epidural hematoma following a shunt in an infant with congenital factor X deficiency. Case report and literature review.
Factor X Deficiency
Spontaneous major bleeding in acquired factor X deficiency secondary to AL-amyloidosis.
Factor X Deficiency
Spontaneous perinephric hematoma due to acquired factor X deficiency in AL amyloidosis.
Factor X Deficiency
Spontaneous resolution of acquired factor X deficiency in amyloidosis.
Factor X Deficiency
Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis.
Factor X Deficiency
Spontaneous rupture of the spleen in AL amyloidosis.
Factor X Deficiency
Spontaneous spinal epidural hematoma in a patient with acquired Factor X deficiency secondary to systemic amyloid light-chain amyloidosis.
Factor X Deficiency
Staged Surgical Palliation for HLHS in a Girl with Severe Factor X Deficiency.
Factor X Deficiency
Steroid hormone-responsive secondary factor X deficiency.
Factor X Deficiency
Subclinical factor X deficiency may increase hemorrhage in women undergoing cesarean section.
Factor X Deficiency
Subgaleal hemorrhage in a neonate with factor X deficiency following a non-traumatic cesarean section.
Factor X Deficiency
Successful liver transplantation for a child with life-threatening recurrent bleeding episodes due to congenital factor X deficiency: a case report.
Factor X Deficiency
Successful perioperative management of factor X deficiency associated with primary amyloidosis.
Factor X Deficiency
Successful perioperative use of prothrombin complex concentrate in the treatment of acquired factor X deficiency in the setting of systemic light-chain (AL) amyloidosis.
Factor X Deficiency
Successful pregnancy in a woman with severe factor X deficiency.
Factor X Deficiency
Successful treatment of a noninhibitory antibody-mediated acquired factor X deficiency in a patient with marginal-zone lymphoma.
Factor X Deficiency
Successful treatment of an acquired haemorrhagic diathesis due to factor X deficiency with chemotherapy.
Factor X Deficiency
Successful Treatment of Life-threatening Bleeding Caused by Acquired Factor X Deficiency Associated with Respiratory Infection.
Factor X Deficiency
Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
Factor X Deficiency
Successful treatment of transient acquired factor X deficiency by plasmapheresis with concomitant intravenous immunoglobulin and steroid therapy.
Factor X Deficiency
Successful Use of Four Factor-Prothrombin Complex Concentrate for Congenital Factor X Deficiency in the Setting of Neurosurgery.
Factor X Deficiency
Surgical excision of a pseudotumour under the coverage of the plasma-derived factor X concentrate in a patient with severe factor X deficiency: A case report.
Factor X Deficiency
Surgical treatment for a paraplegic patient induced by congenital factor X deficiency.
Factor X Deficiency
Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X.
Factor X Deficiency
Synergistic effect of factor VII gene polymorphisms causing mild factor VII deficiency in a case of severe factor X deficiency.
Factor X Deficiency
Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients.
Factor X Deficiency
Systemic amyloidosis associated with factor X deficiency.
Factor X Deficiency
The 13-year bleed: Exuberant amyloid angiopathies, angiodysplasias, and acquired coagulopathies of the gut.
Factor X Deficiency
The Clinical Findings and Prophylactic Treatment in Children with Factor X Deficiency.
Factor X Deficiency
The clinical significance of the lack of arterial or venous thrombosis in patients with congenital prothrombin or FX deficiency.
Factor X Deficiency
The impact of Glu102Lys on the factor X function in a patient with a doubly homozygous factor X deficiency (Gla14Lys and Glu102Lys).
Factor X Deficiency
THE INHERITANCE OF STUART DISEASE: INVESTIGATION OF A FAMILY WITH FACTOR X DEFICIENCY.
Factor X Deficiency
The K-test (trypsin clotting time) in coumarin treated patients and in congenital deficiencies and abnormalities of the prothrombin complex.
Factor X Deficiency
The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
Factor X Deficiency
The perils of inhibiting deficient factors.
Factor X Deficiency
The role of primary prophylactic factor replacement therapy in children with severe factor X deficiency.
Factor X Deficiency
Therapeutic approaches to factor X deficiency with emphasis on the use of a new clotting-factor concentrate (Konyne).
Factor X Deficiency
Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy.
Factor X Deficiency
Transient acquired factor X deficiency associated with pneumonia.
Factor X Deficiency
Transient acquired factor X deficiency: report of the use of activated clotting concentrate to control a life-threatening hemorrhage.
Factor X Deficiency
Transient selective factor X deficiency in a severely burned child.
Factor X Deficiency
Transient, selective factor X deficiency and acute liver failure following chest infection treated with erythromycin BP.
Factor X Deficiency
Treatment of amyloidosis associated factor X deficiency.
Factor X Deficiency
Two episodes of hemoperitoneum from luteal cysts rupture in a patient with congenital factor X deficiency.
Factor X Deficiency
Two novel factor X gene mutations in a Chinese family with factor X deficiency.
Factor X Deficiency
Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
Factor X Deficiency
Use of a High-Purity Factor X Concentrate in Turkish Subjects with Hereditary Factor X Deficiency: Post Hoc Cohort Subanalysis of a Phase 3 Study.
Factor X Deficiency
Use of plasma-derived factor X concentrate in neonates and infants with congenital factor X deficiency.
Factor X Deficiency
Use of prothrombin complex concentrate for prophylaxis of bleeding in acquired factor X deficiency associated with light-chain amyloidosis.
Factor X Deficiency
Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis.
Factor X Deficiency
[3 families with a congenital factor X deficiency, one of them with an associated factor XII deficiency]
Factor X Deficiency
[A case of double valve substitution in a female patient carrier of a factor X deficiency]
Factor X Deficiency
[A case of factor X deficiency (author's transl)]
Factor X Deficiency
[A case of primary hepatic amyloidosis with factor X deficiency.]
Factor X Deficiency
[A case of retroperitoneal hemorrhage due to multiple myeloma complicated with factor X deficiency and amyloidosis]
Factor X Deficiency
[A new case of homozygous congenital factor VII deficiency. Associated factor X deficiency in some members of the family]
Factor X Deficiency
[A new family with factor X deficiency]
Factor X Deficiency
[A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review]
Factor X Deficiency
[Acquired coagulation factor X deficiency: three cases report and literature review].
Factor X Deficiency
[Acquired factor X deficiency associated with A.L.type amyloidosis. A case report]
Factor X Deficiency
[Acquired factor X deficiency in a case of monoclonal gammopathy]
Factor X Deficiency
[ACQUIRED FACTOR X DEFICIENCY IN A PATIENT WITH PRIMARY AMYLOIDOSIS. INJECTION OF A B.S.C. FRACTION.]
Factor X Deficiency
[Acquired factor X deficiency in a patient with primary amyloidosis. Injection of a coagulating fraction (C.S.B)]
Factor X Deficiency
[Acquired factor X deficiency in primary amyloidosis]
Factor X Deficiency
[ACQUIRED HEMORRHAGIC DIATHESIS CAUSED BY ISOLATED FACTOR X DEFICIENCY.]
Factor X Deficiency
[Acquired isolated factor X deficiency in generalized amyloidosis]
Factor X Deficiency
[Analysis of seven cases of multiple myeloma with initial manifestation of bleeding].
Factor X Deficiency
[Blood clotting in an infant with factor X deficiency]
Factor X Deficiency
[Blood coagulation disorder in a 7-year-old child with a partial factor X or Stuart-Prower factor deficiency]
Factor X Deficiency
[Clinical and coagulation studies in 3 cases of congenital factor X deficiency and review of reported cases in Japan (author's transl)]
Factor X Deficiency
[Clotting factor X deficiency resulted from an T 58-->G mutation within exon 1 of human factor X gene]
Factor X Deficiency
[Combined 2d-type TAR syndrome, factor X deficiency, immune deficiency and mitral valve prolapse]
Factor X Deficiency
[Congenital blood coagulation factor X deficiency. Successful result of the use prothrombin concentrated complex in the control of ++cesarean section hemorrhage in 2 pregnancies]
Factor X Deficiency
[Congenital factor X deficiency showing cross-reacting material negative (CRM-)]
Factor X Deficiency
[Congenital factor X deficiency, the Prower-Stuart deficiency]
Factor X Deficiency
[Congenital factor X deficiency. Case report and review of literature]
Factor X Deficiency
[Decreased Quick percentage, acquired factor X deficiency, hemarthrosis and ecchymosis: amyloidosis]
Factor X Deficiency
[Extensive subcutaneous hemorrhage complicating primary amyloidosis]
Factor X Deficiency
[Factor X deficiency and pregnancy]
Factor X Deficiency
[Factor X deficiency and systemic amylosis]
Factor X Deficiency
[Factor X deficiency associated with multiple myeloma.]
Factor X Deficiency
[Factor X deficiency in amyloidosis (author's transl)]
Factor X Deficiency
[Factor X deficiency in systemic amyloidosis. Presentation of a case]
Factor X Deficiency
[Factors VII, VIII, IX, and X: molecular genetics and gene diagnosis]
Factor X Deficiency
[Familial amyloidosis of AL type and factor X deficiency. The valve of long-term colchicine administration]
Factor X Deficiency
[Familial hemorrhagic diathesis caused by factor X deficiency]
Factor X Deficiency
[Gene analysis of a combined inherited factor VII and factor X deficiency pedigree].
Factor X Deficiency
[Hemarthrosis disclosing factor X deficiency in primary amyloidosis]
Factor X Deficiency
[Homozygous missense mutation p.Val298Met of F10 gene causing hereditary coagulation factor X deficiency in a Chinese pedigree].
Factor X Deficiency
[How can factor X deficiency in nephropathy explained?]
Factor X Deficiency
[Inherited coagulation factor X deficiency caused by two novel mutations in factor X gene.]
Factor X Deficiency
[Isolated factor X deficiency in chronic myelomonocytic leukemia: Report of one case].
Factor X Deficiency
[Primary amyloidosis associated to severe factor X deficiency]
Factor X Deficiency
[Primary pseudotumoral pulmonary amyloidosis with Pierre-Marie syndrome]
Factor X Deficiency
[Probably inherited factor X deficiency. Report of a case (author's transl)]
Factor X Deficiency
[Recurrence of Waldenström macroglobulinemia accompanied by factor X deficiency].
Factor X Deficiency
[Successful long-term management of ovarian bleeding and menorrhagia with prothrombin complex concentrate in a patient with congenital factor X deficiency].
Factor X Deficiency
[Systemic light chain amyloidosis with acquired factor X deficiency: a case report].
Factor X Deficiency
[The change and significance of coagulation activity in bleomycin-induced lung fibrosis in rats]
Factor XI Deficiency
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Factor XI Deficiency
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Factor XI Deficiency
Definition of the population at risk of bleeding due to factor XI deficiency in Ashkenazic Jews and the value of activated partial thromboplastin time in its detection.
Factor XI Deficiency
Factor XI deficiency in an Ashkenazi Jewish child, causing severe postoperative hemorrhage.
Factor XI Deficiency
Factor XI deficiency in Kerry Blue Terriers.
Factor XI Deficiency
Factor XI deficiency-related spontaneous primary intraventricular hemorrhage.
Factor XI Deficiency
Factor XI deficiency: detection and management during urological surgery.
Factor XI Deficiency
Factor XI deficiency: implications for management of patients undergoing aesthetic surgery.
Factor XI Deficiency
Failure of Routine Coagulation Screening Tests to Detect Heterozygous State of Bovine Factor XI Deficiency.
Factor XI Deficiency
Identification of factor XI deficiency in Holstein-Friesian cattle in Britain.
Factor XI Deficiency
Intraneural hematoma after nerve stimulation-guided femoral block in a patient with factor XI deficiency: case report.
Factor XI Deficiency
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Factor XI Deficiency
Normal aPTT in children with mild factor XI deficiency.
Factor XI Deficiency
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Factor XI Deficiency
Perioperative management of factor XI deficiency in a patient undergoing hip arthroplasty.
Factor XI Deficiency
Preoperative screening for coagulopathy using prothrombin time and partial thromboplastin time in patients requiring primary cranial vault remodeling.
Factor XI Deficiency
Successful Peritoneal Dialysis Catheter Placement in a New End-Stage Renal Disease Patient with Combined Antiphospholipid Syndrome and Factor XI Deficiency.
Factor XI Deficiency
The activated partial thromboplastin time and factor XI deficiency.
Factor XI Deficiency
The factor of factor XI deficiency in thyroid neoplasia.
Factor XI Deficiency
The rare inherited coagulation disorders.
Factor XI Deficiency
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
Factor XI Deficiency
[Thrombocyte dysfunction in children with albinism]
Factor XII Deficiency
A female hemophilia A combined with hereditary coagulation factor XII deficiency: a case report.
Factor XII Deficiency
A new family with congenital factor XII deficiency.
Factor XII Deficiency
Additional factor XII (Hageman factor) deficiency in hemophilia A and in von Willebrand syndrome.
Factor XII Deficiency
Deep venous thrombosis and previous myocardial infarction in mild factor XII deficiency: a risk factor for both venous and arterial thrombosis.
Factor XII Deficiency
Factor XII (Hageman Factor) Deficiency: a rare harbinger of life threatening complications.
Factor XII Deficiency
Factor XII deficiency and pregnancy.
Factor XII Deficiency
Feline factor XII (Hageman) deficiency.
Factor XII Deficiency
Implications for cardiac surgery in patients with factor XII deficiency.
Factor XII Deficiency
Influence of factor XII deficiency on activated partial thromboplastin time (aPTT) in critically ill patients.
Factor XII Deficiency
Inherited bleeding disorders in Indian women with menorrhagia.
Factor XII Deficiency
Loss of the largest von Willebrand factor multimers from the plasma of patients with congenital cardiac defects.
Factor XII Deficiency
Periodic painful purpura: Fact or factitious?
Factor XII Deficiency
Prolonged activated partial thromboplastin time secondary to factor XII deficiency in two surgical patients.
Factor XII Deficiency
Rosai-Dorfman disease with factor XII deficiency.
Factor XII Deficiency
[3 families with a congenital factor X deficiency, one of them with an associated factor XII deficiency]
Factor XII Deficiency
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
Factor XII Deficiency
[Successes and failures of the activated partial thromboplastin time in the preoperative evaluation]
Factor XIII Deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
Factor XIII Deficiency
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Factor XIII Deficiency
Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease.
Factor XIII Deficiency
Clinical audit of inherited bleeding disorders in a developing country.
Factor XIII Deficiency
De Novo Precursor B-Lymphoblastic Leukemia/Lymphoma With Double-Hit Gene Rearrangements (MYC/BCL-2) Presented With Spinal Cord Compression and Acquired Factor XIII Deficiency.
Factor XIII Deficiency
Hemorrhagic Shock after Neonatal Circumcision: Severe Congenital Factor XIII Deficiency.
Factor XIII Deficiency
Inherited bleeding disorders in Indian women with menorrhagia.
Factor XIII Deficiency
Intracranial haemorrhage in patients with congenital haemostatic defects.
Factor XIII Deficiency
Lobar Hemorrhage Induced by Acquired Factor XIII Deficiency in a Patient with Cerebral Amyloid Angiopathy.
Factor XIII Deficiency
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Factor XIII Deficiency
Rare bleeding disorders in children: identification and primary care management.
Factor XIII Deficiency
Rare inherited coagulation disorders in India.
Factor XIII Deficiency
The rare inherited coagulation disorders.
Familial Primary Pulmonary Hypertension
The FGL2 prothrombinase contributes to the pathological process of experimental pulmonary hypertension.
Fasciitis, Necrotizing
Contact activation in shock caused by invasive group A Streptococcus pyogenes.
Fasciitis, Necrotizing
Erysipelas and necrotizing fasciitis.
Fatty Liver
Hemostatic alterations in fatty liver disease.
Fetal Death
Antibody to cardiolipin, lupus anticoagulant, and fetal death.
Fetal Death
Autoimmune hepatitis associated with the antiphospholipid syndrome.
Fetal Death
Hypercoagulability. Should every patient with venous thrombosis be tested?
Fetal Death
Outcome and risk factors of patients with acute fatty liver of pregnancy: a multicentre retrospective study.
Fetal Growth Retardation
Impact of Rare Bleeding Disorders during Pregnancy on Maternal and Fetal Outcomes: Review of 29 Pregnancies at a Single Center.
Fetal Resorption
Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin.
Fetal Resorption
Animal models for antiphospholipid syndrome in pregnancy.
Fetal Resorption
Characteristics and pathogenic role of anti-beta2-glycoprotein I single-chain Fv domains: induction of experimental antiphospholipid syndrome.
Fetal Resorption
Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome.
Fetal Resorption
Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice.
Fetal Resorption
Induction of tolerance to experimental anti-phospholipid syndrome (APS) by syngeneic bone marrow cell transplantation.
Fetal Resorption
Oral tolerance to low dose beta 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome.
Fetal Resorption
Oxidized low-density lipoprotein (Ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome (APS).
Fetal Resorption
The pathogenic role of anti-phosphatidylserine antibodies: active immunization with the antibodies leads to the induction of antiphospholipid syndrome.
Fetal Resorption
Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation. The importance of the T cell.
Fibromyalgia
Antibodies against serotonin have no diagnostic relevance in patients with fibromyalgia syndrome.
Fibrosarcoma
The production of a factor X activator by a methylcholanthrene-induced rat fibrosarcoma.
Fibrosarcoma
Thromboplastin release, but not content, correlates with spontaneous metastasis of cancer cells.
Fibrosarcoma
Tumour sublines with different metastatic capacity induce similar blood coagulation changes in the host.
Foot Diseases
Clinical Characteristics, Treatment, and Prognosis of Diabetic Foot Disease in Macao and Beijing: A Retrospective Study.
Foramen Ovale, Patent
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
Gaucher Disease
Coexistence of factor XI (plasma thromboplastin antecedent) deficiency and Gaucher's disease.
Gaucher Disease
[Gaucher's disease type I, anticoagulant factor and pregnancy]
Glaucoma
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Glaucoma
Risk Factors for Decompression Retinopathy After Glaucoma Surgery.
Glioblastoma
Coagulation Factor X Regulated by CASC2c Recruited Macrophages and Induced M2 Polarization in Glioblastoma Multiforme.
Glioblastoma
Corrigendum: Coagulation Factor X Regulated by CASC2c Recruited Macrophages and Induced M2 Polarization in Glioblastoma Multiforme.
Glioblastoma
Routine Blood Tests Do Not Predict Survival in Patients with Glioblastoma-Multivariable Analysis of 497 Patients.
Glioblastoma
Targeting FGL2, a molecular drug target for glioblastoma, with natural compounds through virtual screening method.
Glioma
F10 gene hypomethylation, a putative biomarker for glioma prognosis.
Glioma
Preoperative and intraoperative predictors of deep venous thrombosis in adult patients undergoing craniotomy for brain tumors: A Chinese single-center, retrospective study.
Glomerulonephritis
Effects of membrane plasma exchange on the hemostatic system and on thyroid hormones in critically ill patients.
Glomerulonephritis
Enhanced glomerular procoagulant activity and fibrin deposition in rats with mercuric chloride-induced autoimmune nephritis.
Glomerulonephritis
Further investigations on the significance of a plasma coagulation-accelerating factor in glomerular disease.
Glomerulonephritis
Glomerular coagulation system in renal diseases.
Glomerulonephritis
Hypercoagulation in glomerulonephritis.
Glomerulonephritis
Lipopolysaccharide-triggered acute aggravation of mesangioproliferative glomerulonephritis through activation of coagulation in a high IgA strain of ddY mice.
Glomerulonephritis
Roles of coagulation pathway and factor Xa in rat mesangioproliferative glomerulonephritis.
Glomerulonephritis
Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice.
Glomerulonephritis
[Roles of coagulation pathway and factor Xa in chronic kidney disease (CKD)].
Glomerulonephritis, IGA
Role of coagulation factor Xa and protease-activated receptor 2 in human mesangial cell proliferation.
Glomerulonephritis, Membranoproliferative
Membranoproliferative glomerulonephritis and a rare bleeding disorder: factor X deficiency.
Glucose Intolerance
Comparison of the hypoglycemic and antithrombotic (anticoagulant) actions of whole bovine and camel milk in streptozotocin-induced diabetes mellitus in rats.
Gonorrhea
Contemporary Concepts in Managing Menorrhagia.
Granulosa Cell Tumor
Androgenic adult granulosa cell tumour with prolongation of the activated partial thromboplastin time in a 29 year old woman.
Gray Platelet Syndrome
Platelet prothrombin converting activity in hereditary disorders of platelet function.
Hashimoto Disease
Anti-Factor V inhibitor in patients with autoimmune diseases: case report and literature review.
Hashimoto Disease
Study on an antibody against F1F2 fragment of human factor V in a patient with Hashimoto's disease and bullous pemphigoid.
Head and Neck Neoplasms
Systemic effects of subcutaneous heparin use in otolaryngology patients.
Head Injuries, Closed
Coagulopathy in acute head injury--a study of its role as a prognostic indicator.
Hearing Loss, Sudden
[The correlation analysis of coagulation detection and blood routine parameters of sudden hearing loss].
Heart Arrest
Asphyxia by Drowning Induces Massive Bleeding Due To Hyperfibrinolytic Disseminated Intravascular Coagulation.
Heart Arrest
Development and validation of the revised injury severity classification score for severely injured patients.
Heart Arrest
Microvesicular liver graft steatosis as a risk factor of initial poor function in relation to suboptimal donor parameters.
Heart Arrest
Prolonged Activated Partial Thromboplastin Time after Successful Resuscitation from Cardiac Arrest is Associated with Unfavorable Neurologic Outcome.
Heart Defects, Congenital
Pediatric patients with congenital heart disease: thrombin generation measured by calibrated automated thrombography.
Heart Defects, Congenital
Usefulness of high-concentration calcium chloride solution for correction of activated partial thromboplastin time (APTT) in patients with high-hematocrit value.
Heart Diseases
A novel risk score to predict cardiovascular complications in patients with coronavirus disease 2019 (COVID-19): A retrospective, multicenter, observational study.
Heart Diseases
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Heart Diseases
Clinical experience with argatroban for heparin-induced thrombocytopenia in a large teaching hospital.
Heart Diseases
Experience with heparin dosing at Christchurch Hospital.
Heart Diseases
Risk factors for increased postoperative drainage of calcaneal fractures after open reduction and internal fixation: An observational study.
Heart Diseases
Thromboembolism and resistance to activated protein C in children with underlying cardiac disease.
Heart Failure
Cardiac Amyloidosis Presenting with Pre-Excitation Syndrome, Heart Failure, and Severe Factor X Deficiency as Part of Systemic Amyloid Light-Chain (AL) Amyloidosis - A Fatal Combination.
Heart Failure
Clinical trials of deep vein thrombosis prophylaxis in medical patients.
Heart Failure
Correction to: Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction.
Heart Failure
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Heart Failure
Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction.
Heart Failure
Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients.
Heart Failure
Hemostatic Markers in Congestive Heart Failure Dogs with Mitral Valve Disease.
Heart Failure
Levels of vitamin K-dependent procoagulant and anticoagulant proteins in over-anticoagulated patients.
Heart Failure
Patients' self-evaluation of symptoms, signs and compliance to therapy for heart failure surveillance: A pilot study on identification of worsening heart failure.
Heart Failure
Procoagulant activity of purified protein derivative-stimulated pleural effusion mononuclear cells in tuberculous pleurisy.
Heart Failure
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
Heart Failure
Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
Heart Failure
Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.
Heart Failure
Successful COMPASS, disappointing COMMANDER HF, what have we learned from these two trials?
Heart Failure
The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure.
Heart Failure
Thromboembolic Risk in the Patient with Heart Failure.
Heart Failure
Whole blood hypercoagulability despite anticoagulation during mechanical cardiac assist.
Heart Septal Defects, Atrial
Attributable fraction for cardiac malformations.
Heart Septal Defects, Ventricular
Attributable fraction for cardiac malformations.
HELLP Syndrome
Disseminated intravascular coagulation complicating HELLP syndrome: perioperative management.
Hemangioma
Giant hemangioma of the liver (Kasabach-Merritt syndrome): successful suppression of intravascular coagulation permitting surgical removal.
Hemangioma
Hemangioma of the radius associated with Kasabach-Merritt syndrome: case report and literature review.
Hemangioma
[Peculiar features of the coagulation, fibrinolytic, and anticoagulation systems of blood in the patients presenting with vascular ENT tumours].
Hemangioma
[Refractory kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: clinical analysis of 10 cases].
Hemangiosarcoma
Platelet function in dogs treated for lymphoma and hemangiosarcoma and supplemented with dietary n-3 fatty acids.
Hemarthrosis
Acquired Factor VIII Inhibitors: Three Cases.
Hemarthrosis
Rare coagulation disorders.
Hemarthrosis
Replacement therapy for congenital Factor X deficiency.
Hemarthrosis
[Decreased Quick percentage, acquired factor X deficiency, hemarthrosis and ecchymosis: amyloidosis]
Hemarthrosis
[Hemarthrosis disclosing factor X deficiency in primary amyloidosis]
Hematologic Diseases
Clinical factors and biomarkers predicting outcome in patients with immune-mediated thrombotic thrombocytopenic purpura.
Hematologic Diseases
Viscoelastic testing in oncology patients (including for the diagnosis of fibrinolysis): Review of existing evidence, technology comparison, and clinical utility.
Hematologic Diseases
[Behavior of the Biggs-Douglas thromboplastin generation test in various blood diseases in children.]
Hematologic Diseases
[Hemorrhagic diathesis in patients with malignant neoplasms (author's transl)]
Hematologic Neoplasms
[Correlation of coagulation indicators with inflammatory markers for sepsis in the patients with hematological malignancies].
Hematoma, Subdural
Chronic peritoneal dialysis in a patient with primary amyloidosis, renal failure, and factor X deficiency.
Hematoma, Subdural
Nontraumatic spinal subdural hematoma complicating direct factor Xa inhibitor treatment (rivaroxaban): a challenging management.
Hematoma, Subdural
Oral factor Xa inhibitors and risk of subdural hematoma: COMPASS trial results and meta-analysis.
Hematoma, Subdural
Predictors of 30-Day Mortality in Traumatic Brain-Injured Patients after Primary Decompressive Craniectomy.
Hematoma, Subdural
Spontaneous thoracic spinal subdural hematoma associated with apixaban therapy.
Hematoma, Subdural
[The relationship between coagulation time and bilateral occurrence in chronic subdural hematoma]
Hematoma, Subdural, Chronic
Factor X deficiency presenting with bilateral chronic subdural hematoma.
Hematoma, Subdural, Intracranial
Spontaneous thoracic spinal subdural hematoma associated with apixaban therapy.
Hematuria
A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against factor X.
Hematuria
Acquired Hemophilia A: A Potentially Fatal Bleeding Disorder.
Hematuria
Brodifacoum-Laced Synthetic Marijuana Toxicity: A Fight Against Time.
Hematuria
Convulsive status epilepticus as the initial presentation of superwarfarin poisoning: a case report.
Hematuria
Development of cephradine-induced acquired factor v inhibitors: a case report.
Hematuria
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
Hematuria
Prekallikrein deficiency in a dog.
Hematuria
Rare coagulation disorders.
Hematuria
Renal hemorrhage caused by acquired inhibitors to coagulation factors VIII and V in a hemodialysis patient.
Hematuria
[Crimean-Congo hemorrhagic fever]
Hemoglobinuria
Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria
[Presence of lupus-type anticoagulant, in systemic lupus erythematosus and other clinical entities]
Hemoglobinuria
[Thromboplastin formation characteristics in paroxysmal nocturnal hemoglobinuria]
Hemoglobinuria, Paroxysmal
Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria, Paroxysmal
[Presence of lupus-type anticoagulant, in systemic lupus erythematosus and other clinical entities]
Hemoglobinuria, Paroxysmal
[Thromboplastin formation characteristics in paroxysmal nocturnal hemoglobinuria]
Hemoperitoneum
Corpus luteum hemorrhage: rare complication of congenital and acquired coagulation abnormalities.
Hemoperitoneum
Replacement therapy for congenital Factor X deficiency.
Hemoperitoneum
Two episodes of hemoperitoneum from luteal cysts rupture in a patient with congenital factor X deficiency.
Hemophilia A
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
Hemophilia A
A cell-based model of coagulation and the role of factor VIIa.
Hemophilia A
A diagnosis of mild hemophilia A made by massive intraabdominal bleeding in a 13-year-old boy.
Hemophilia A
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
Hemophilia A
A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A.
Hemophilia A
A perioperative uncontrollable bleeding in an elderly patient with acquired hemophilia A: a case report.
Hemophilia A
A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
Hemophilia A
A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.
Hemophilia A
A Thrombin-Activatable Factor X Variant Corrects Hemostasis in a Mouse Model for Hemophilia A.
Hemophilia A
A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia.
Hemophilia A
A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia.
Hemophilia A
Acquired haemophilia A in a patient with breast cancer and lung carcinoma: a case report and literature review.
Hemophilia A
Acquired Haemophilia A in Association with Influenza A and Urinary Tract Infection.
Hemophilia A
Acquired haemophilia complicated with gastrointestinal bleeding and spontaneous iliopsoas muscle haematoma in a woman with chronic C hepatitis under treatment with pegylated IFN alpha 2a and ribavirin.
Hemophilia A
Acquired haemophilia syndrome: pathophysiology and therapy.
Hemophilia A
Acquired hemophilia A associated with therapeutic cupping.
Hemophilia A
Acquired hemophilia A in women postpartum: clinical manifestations, diagnosis, and treatment.
Hemophilia A
Acquired Hemophilia A.
Hemophilia A
Acquired hemophilia A.
Hemophilia A
Acquired Hemophilia A.
Hemophilia A
Acquired Hemophilia A: A Rare but Potentially Fatal Bleeding Disorder.
Hemophilia A
Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B.
Hemophilia A
Activated partial thromboplastin time. A multicenter evaluation of 11 reagents in the screening of mild haemophilia A.
Hemophilia A
Activated ppsb in the treatment of a patient with haemophilia and antibodies to factor VIII.
Hemophilia A
Acute onset dysphagia associated with an intramural oesophageal haematoma in acquired haemophilia.
Hemophilia A
An Evaluation of Hemostatic Abnormalities in Patients With Hemophilia According to the Activated Partial Thromboplastin Time Waveform.
Hemophilia A
An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.
Hemophilia A
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Hemophilia A
An Unusual Etiology for Elevation of Activated Partial Thromboplastin Time (aPTT) in SLE: Acquired Hemophilia and Lupus Anticoagulant.
Hemophilia A
Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.
Hemophilia A
Barriers to effective diagnosis and management of a bleeding patient with undiagnosed bleeding disorder across multiple specialties: results of a quantitative case-based survey.
Hemophilia A
Bedside measurement of factor VIII:C activity in individuals with hemophilia A.
Hemophilia A
Bioengineered factor Xa as a potential new strategy for hemophilia therapy.
Hemophilia A
Bioengineering factor Xa to treat bleeding.
Hemophilia A
Bone haemophilic pseudotumour of the ulna: A rare complication of haemophilia in a dog.
Hemophilia A
Bullous pemphigoid associated with acquired hemophilia a: a rare association of autoimmune disease.
Hemophilia A
Characteristics and thrombogenicity of factor IX concentrate.
Hemophilia A
Christmas disease: diagnosis and management of a haemorrhagic diathesis following dentofacial trauma.
Hemophilia A
Clinical audit of inherited bleeding disorders in a developing country.
Hemophilia A
Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.
Hemophilia A
Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - Phase I trial.
Hemophilia A
Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.
Hemophilia A
Clotting defect in hemophilia; deficiency in a plasma factor required for thromboplastin liberation from platelets.
Hemophilia A
Combined congenital deficiency of factor V and factor VIII. Report of a further case with some considerations on the hetereditary transmission of this disorder.
Hemophilia A
Combined deficiency of factor V and factor VIII. A report of another case.
Hemophilia A
Comparing Safety and Efficacy of Dabigatran and Factor Xa Inhibitors for Stroke Prevention in Hemophiliacs with Non-Valvular Atrial Fibrillation.
Hemophilia A
Comparison of the behavior of normal factor IX and the factor IX Bm variant Hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources.
Hemophilia A
Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette.
Hemophilia A
Congenital hemophilia A diagnosed with postoperative hemorrhage after thyroidectomy for papillary thyroid carcinoma: a case report.
Hemophilia A
Current laboratory practices in the diagnosis and management of haemophilia: a global assessment.
Hemophilia A
Detailed analysis of anti-emicizumab antibody decreasing drug efficacy, using plasma samples from a patient with hemophilia A.
Hemophilia A
Determination of normal values using an automated coagulation timer for activated coagulation time and its application in dogs with hemophilia.
Hemophilia A
Development of a World Federation of Hemophilia External Quality Assessment Scheme: results of a pilot study.
Hemophilia A
Diagnostic analysis of lupus anticoagulant using clot waveform analysis in activated partial thromboplastin time prolonged cases: A retrospective analysis.
Hemophilia A
Dr Leandro Tocantins's inhibitor theory of hemophilia and factor X: reply.
Hemophilia A
Effect of lipoprotein-associated coagulation inhibitor (LACI) on thromboplastin-induced coagulation of normal and hemophiliac plasmas.
Hemophilia A
Efficacy of therapeutic plasma exchange in a patient with coagulation inhibitors (acquired haemophilia A) - A case report.
Hemophilia A
Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery.
Hemophilia A
Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort.
Hemophilia A
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Hemophilia A
Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A.
Hemophilia A
Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII.
Hemophilia A
Factor VII and haemostasis.
Hemophilia A
Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: Mode of its action.
Hemophilia A
Factor VIII inhibitors. Laboratory diagnosis of inhibitors.
Hemophilia A
Factor X deficiency and hemophilia A : occurrence of two different coagulation defects in a family.
Hemophilia A
FEIBA: mode of action.
Hemophilia A
FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice.
Hemophilia A
Genetic variants of haemophilia B detected by immunoradiometric assay: implications for prenatal diagnosis.
Hemophilia A
Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex.
Hemophilia A
Haemophilia A: molecular insights.
Hemophilia A
Haemophilia B: from molecular diagnosis to gene therapy.
Hemophilia A
Hemophilia and hemophilia-like diseases caused by deficiencies in plasma thromboplastin factors: anti-hemophilic globulin (AHG), plasma thromboplastin component (PTC) and plasma thromboplastin antecedent (PTA).
Hemophilia A
Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor.
Hemophilia A
Hemophilia BM in a female.
Hemophilia A
Hemophilia presenting as recurrent ocular hemorrhage.
Hemophilia A
Hemophilia presenting with intracranial hemorrhage. An approach to the infant with intracranial bleeding and coagulopathy.
Hemophilia A
Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
Hemophilia A
Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia.
Hemophilia A
Identification of a modified coagulation factor X with enhanced activation properties as potential hemostatic agent.
Hemophilia A
Identification of de novo deletion in the factor VIII gene by MLPA technique in two girls with isolated factor VIII deficiency.
Hemophilia A
Identification of patients with congenital hemophilia in a large electronic health record database.
Hemophilia A
Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
Hemophilia A
In vitro detection of mild inhibitors to factor VIII in hemophilia.
Hemophilia A
In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia.
Hemophilia A
Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma.
Hemophilia A
Intracranial haemorrhage in patients with congenital haemostatic defects.
Hemophilia A
Issues with the assay of factor VIII activity in plasma and factor VIII concentrates.
Hemophilia A
Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges.
Hemophilia A
Laboratory diagnosis of hereditary bleeding disorders: external quality assessment.
Hemophilia A
Laboratory performance of haemophilia centres in developing countries: 3 years' experience of the World Federation of Hemophilia External Quality Assessment Scheme.
Hemophilia A
Life-threatening bleeding in a patient with pemphigoid-induced acquired hemophilia A and successfully treated with rituximab and rFVIIa: A case report.
Hemophilia A
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Hemophilia A
Mild Hemophilia A Diagnosed in a 55-year-old Patient after Pancreatoduodenectomy for Carcinoma of the Papilla of Vater.
Hemophilia A
Mild hemophilia A presaged by recurrent postoperative hemorrhagic complications in an elderly patient.
Hemophilia A
Myelofibrosis and acquired hemophilia A: a case report.
Hemophilia A
Next Generation Antibody Therapeutics Using Bispecific Antibody Technology.
Hemophilia A
Normalization of the haemostatic plugs of dogs with haemophilia A (factor VIII deficiency) following the infusion of a combination of factor Xa and phosphatidylcholine/phosphatidylserine vesicles.
Hemophilia A
Novel molecules for the correction of factor Xa generation and phenotype in hemophilia.
Hemophilia A
Observations on hemophilia, parahemophilia, and coexistent hemophilia and parahemophilia; alterations in the platelets and the thromboplastin generation test.
Hemophilia A
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
Hemophilia A
Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate).
Hemophilia A
Parallel use of by-passing agents in haemophilia with inhibitors: a critical review.
Hemophilia A
PARTIAL THROMBOPLASTIN TIME TEST WITH KAOLIN. NORMAL RANGE AND MODIFICATIONS FOR THE DIAGNOSIS OF HAEMOPHILIA AND CHRISTMAS DISEASE.
Hemophilia A
Partial thromboplastin time test with kaolin: diagnosis of haemophilia and Christmas disease without natural reference plasmas.
Hemophilia A
Partial thromboplastin time test--proposed performance guidelines. ICSH Panel on the PTT.
Hemophilia A
Performance guidelines for the partial thromboplastin time test.
Hemophilia A
Pharmacokinetics, distribution, and excretion of (125)I-labeled human plasma-derived-FVIIa and -FX with MC710 (FVIIa/FX mixture) in rats.
Hemophilia A
Plasma thromboplastin component (PTC) deficiency; a new disease resembling hemophilia.
Hemophilia A
PLASMA THROMBOPLASTIN GENERATION BLOCKING ANTICOAGULANT IN HEMOPHILIA. CLINICOPATHOLOGIC STUDY OF A REFRACTORY CASE.
Hemophilia A
Problems involved in grading the severity of hemophilia by test results.
Hemophilia A
Prohemostatic Activity of Factor X in Combination With Activated Factor VII in Dilutional Coagulopathy.
Hemophilia A
Prolonged Activated Partial Thromboplastin Time: Difficulties in Discriminating Coexistent Factor VIII Inhibitor and Lupus Anticoagulant.
Hemophilia A
Rapid decrease in high titer of factor VIII inhibitors upon immunosuppressive treatment in severe postpartum acquired hemophilia A.
Hemophilia A
Recombinant Factor VIIa.
Hemophilia A
Retrospective analysis of 1,226 Chinese patients with haemophilia in a single medical centre.
Hemophilia A
Reversible acylation of factor Xa as a potential therapy for hemophilia.
Hemophilia A
Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies: comment.
Hemophilia A
Screening and diagnosis of coagulation disorders.
Hemophilia A
Simultaneous deep venous thrombosis and acquired factor VIII inhibitor.
Hemophilia A
Spectrum of factor X gene mutations in Iranian patients with congenital factor X deficiency.
Hemophilia A
Structure and function of factor IX: defects in haemophilia B.
Hemophilia A
Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
Hemophilia A
Surface-dependent reactions of the vitamin K-dependent enzyme complexes.
Hemophilia A
The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
Hemophilia A
The diagnosis of mild haemophilia by the partial thromboplastin time test. WFH/ICTH study of the Manchester method.
Hemophilia A
The ICTH/WFH study of the partial thromboplastin time in mild haemophilia.
Hemophilia A
The kaolin partial thromboplastin time (PTT) test: the normal value in 150 healthy chinese and the usefulness in the diagnosis and management of coagulopathies especially hemophilia.
Hemophilia A
The mild phenotype in severe hemophilia A with Arg1781His mutation is associated with enhanced binding affinity of factor VIII for factor X.
Hemophilia A
THE PTT TEST: PARTIAL THROMBOPLASTIN TIME. II. ITS USEFULNESS IN THE LABORATORY CONTROL OF PLASMA THERAPY IN HEMOPHILIA.
Hemophilia A
The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C).
Hemophilia A
Thrombelastgram as a hemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII.
Hemophilia A
Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Hemophilia A
Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas.
Hemophilia A
Thromboplastin generation with particular reference to haemophilia.
Hemophilia A
Thromboplastin in hemophilia.
Hemophilia A
Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.
Hemophilia A
Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients.
Hemophilia A
Treatment for abdominal aortic aneurysm in a patient with hemophilia A: a case report and review of the literature.
Hemophilia A
Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review.
Hemophilia A
Unusual Initial Manifestation of Acquired Hemophilia A: A Normal Activated Partial Thromboplastin Time, Intramuscular Hematoma and Cerebral Hemorrhage.
Hemophilia A
Use of purified prothrombin in the study of hemophilia and plasma thromboplastin component (PTC) deficiency.
Hemophilia A
Usefulness of the APTT waveform for the diagnosis of DIC and prediction of the outcome or bleeding risk.
Hemophilia A
Verification of the guidelines for lupus anticoagulant detection: usefulness of index for circulating anticoagulant in APTT mixing test.
Hemophilia A
[A Pediatric Case of Acquired Hemophilia A: The Usefulness of the Activated Partial Thromboplastin Time (APTT) Cross-Mixing Test for Early Diagnosis].
Hemophilia A
[A surgical case of subdural hematoma with hemophilia A]
Hemophilia A
[Acquired hemophilia A associated with chronic myelomonocytic leukemia successfully treated by rituximab and azacitidine].
Hemophilia A
[Acquired hemophilia A complicated by dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid].
Hemophilia A
[Attempted retarded therapy with subcutaneous implantation of thromboplastin in a case of sporadic hemophilia.]
Hemophilia A
[Case of hemophilia caused by deficiency of plasma thromboplastin component, or hemophilia B.]
Hemophilia A
[Case of sporadic hemophilia caused by deficiency of plasma thromboplastin antecedent and plasma thromboplastin component.]
Hemophilia A
[Cerebromeningeal hemorrhages and their sequelae in congenital deficiencies of plasma hemostasis factors. Apropos of a case of Stuart factor deficiency with early cerebromengeal hemorrhage leading to hydrocephalus with considerable psychomotor retardation]
Hemophilia A
[Clinical analysis and laboratory findings in a patient with acquired hemophilia a.]
Hemophilia A
[Clinical efficacy of desmopressin in the treatment of mild hemophilia A in children].
Hemophilia A
[Coagulopathy with autoantibodies to blood-clotting factors: overview and laboratory diagnosis]
Hemophilia A
[Detection of carriers of hemophilia B]
Hemophilia A
[Diagnostic value of the thromboplastin generation test in hemophilia; clinical observations.]
Hemophilia A
[Hemophilia B in a mixed breed male dog: treatment of a hemorrhagic crisis with fresh frozen plasma]
Hemophilia A
[Hemophilia.]
Hemophilia A
[Individualization of a third plasmatic factor of thromboplastin (plasma thromboplastin antecedent) the deficiency of which causes a hemorrhagic disease similar to hemophilia.]
Hemophilia A
[Infective morbidity of replacement therapy in congenital coagulation deficiencies and its effects on demand of coagulation factors]
Hemophilia A
[Ischemic colitis following the treatment of acute hemorrhage in a patient with acquired hemophilia A]
Hemophilia A
[Mixing test for prolonged clotting time: clinical availability and problems]
Hemophilia A
[Newly developed method by the use of factor Y assay for the detection of the lupus anticoagulant]
Hemophilia A
[Partial thromboplastin time in the diagnosis and therapeutic control of hemophilia]
Hemophilia A
[Primary myelofibrosis complicated by acquired hemophilia A and subsequent development of acute myeloid leukemia].
Hemophilia A
[Problem of hemophilia from the standpoint of tissue thrombokinase.]
Hemophilia A
[Radical prostatectomy in a patient with hemophilia B]
Hemophilia A
[Studies on a new hemorrhagic diseases similar to hemophilia; plasma thromboplastin component deficiency.]
Hemophilia A
[The antiphospholipid syndrome during chronic lymphatic leukemia. An association with anti-factor VIII antibodies]
Hemophilia A
[The effect of factor VIII:C activity on the activated partial thromboplastin time (aPTT) in the dog. Adaptation of the aPTT as a screening test for canine hemophilia A?]
Hemophilia A
[Trial therapy of sporadic hemophilia by implant of thromboplastin tablets.]
Hemophilia B
A Candidate Activation Pathway for Coagulation Factor VII.
Hemophilia B
A diagnostic challenge: mild hemophilia B with normal activated partial thromboplastin time.
Hemophilia B
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
Hemophilia B
Advances in gene therapy using factor VIIa in hemophilia.
Hemophilia B
Aminoglycoside suppression of nonsense mutations in severe hemophilia.
Hemophilia B
An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.
Hemophilia B
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
Hemophilia B
Christmas disease: diagnosis and management of a haemorrhagic diathesis following dentofacial trauma.
Hemophilia B
Christmas disease; report of a case of severe bleeding disease showing a failure to form intrinsic thromboplastin.
Hemophilia B
Clinical audit of inherited bleeding disorders in a developing country.
Hemophilia B
Complete and sustained phenotypic correction of hemophilia B in mice following hepatic gene transfer of a high-expressing human factor IX plasmid.
Hemophilia B
Current laboratory practices in the diagnosis and management of haemophilia: a global assessment.
Hemophilia B
Deuterohemophilia: plasma thromboplastin factor B deficiency: plasma thromboplastin component (PTC) deficiency, Christmas disease, hemophilia B.
Hemophilia B
Fatal case of congenital plasma thromboplastin component deficiency: failure of response to therapy in Christmas disease.
Hemophilia B
Five novel point mutations: two causing haemophilia B and three causing factor X deficiency.
Hemophilia B
Gene therapy for hemophilia B mediated by recombinant adeno-associated viral vector with hFIXR338A, a high catalytic activity mutation of human coagulation factor IX.
Hemophilia B
Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
Hemophilia B
Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
Hemophilia B
Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.
Hemophilia B
Mild haemophilia B from a novel missense mutation Ser350Ala of the F9 gene.
Hemophilia B
Missense mutations and evolutionary conservation of amino acids: evidence that many of the amino acids in factor IX function as "spacer" elements.
Hemophilia B
No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
Hemophilia B
Normal activated partial thromboplastin time in Chinese patients with mild hemophilia B.
Hemophilia B
Novel molecules for the correction of factor Xa generation and phenotype in hemophilia.
Hemophilia B
PARTIAL THROMBOPLASTIN TIME TEST WITH KAOLIN. NORMAL RANGE AND MODIFICATIONS FOR THE DIAGNOSIS OF HAEMOPHILIA AND CHRISTMAS DISEASE.
Hemophilia B
Partial thromboplastin time test with kaolin: diagnosis of haemophilia and Christmas disease without natural reference plasmas.
Hemophilia B
Plasma thromboplastin component deficiency --Christmas disease: a report of 3 cases.
Hemophilia B
Plasma thromboplastin component deficiency in the Ehlers-Danlos syndrome.
Hemophilia B
Plasma thromboplastin component deficiency. I. Studies on its inheritance and therapy.
Hemophilia B
Prevalence of HIV infection in a cohort of patients with congenital coagulation defects of the prothrombin complex factors.
Hemophilia B
Prophylaxis Using a Mixture of Plasma-Derived Activated Factor VII and Factor X (pdFVIIa/FX) in a Patient with Hemophilia B Complicated by Inhibitors and Allergy to Factor IX Concentrates: A Case Report.
Hemophilia B
Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
Hemophilia B
Repeated Diffuse Alveolar Hemorrhage in a Patient with Hemophilia B.
Hemophilia B
Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs.
Hemophilia B
Spontaneous thoracolumbar hematomyelia secondary to hemophilia B in a cat.
Hemophilia B
Variable manifestations of plasma thromboplastin component deficiency.
Hemophilia B
[Case of Christmas disease; plasma thromboplastin component deficiency, deuterohemophilia.]
Hemophilia B
[Case of hemophilia caused by deficiency of plasma thromboplastin component, or hemophilia B.]
Hemophilia B
[Detection of carriers of hemophilia B]
Hemophilia B
[Detection of Factor IX gene Mutation in Paitients with Hemophilia B by DNA Sequencing.]
Hemophilia B
[Infective morbidity of replacement therapy in congenital coagulation deficiencies and its effects on demand of coagulation factors]
Hemophilia B
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
Hemophilia B
[Studies on a new hemorrhagic diseases similar to hemophilia; plasma thromboplastin component deficiency.]
Hemophilia B
[Studies on hemorrhagic disease due to plasma thromboplastin component deficiency.]
Hemoptysis
Clinical Phenotype of a First Unprovoked Acute Pulmonary Embolism Associated with Antiphospholipid Antibody Syndrome.
Hemoptysis
Pulmonary hemorrhage after intracoronary stent placement.
Hemoptysis
[Acquired factor V inhibitors in a polytraumatized patient]
Hemorrhagic Disorders
Another patient with a congenital hemorrhagic disorder intermediate between factor X and factor VII deficiency.
Hemorrhagic Disorders
Autoimmune Coagulation Factor X Deficiency as a Rare Acquired Hemorrhagic Disorder: A Literature Review.
Hemorrhagic Disorders
Evaluation of thromboelastography in two factor XII-deficient cats.
Hemorrhagic Disorders
Hemorrhagic diathesis caused by factor X deficiency in a child with thymic cyst.
Hemorrhagic Disorders
Hemorrhagic diathesis due to PTC (plasma thromboplastin component) deficiency.
Hemorrhagic Disorders
Hemorrhagic, Hemostatic, and Thromboelastometric Disorders in 35 Dogs with a Clinical Diagnosis of Leptospirosis: A Prospective Study.
Hemorrhagic Disorders
Prothrombin level and activity in the abnormal factor X (factor X Friuli) hemorrhagic disorder.
Hemorrhagic Disorders
Simultaneous deep venous thrombosis and acquired factor VIII inhibitor.
Hemorrhagic Disorders
[ACQUIRED HEMORRHAGIC DIATHESIS CAUSED BY ISOLATED FACTOR X DEFICIENCY.]
Hemorrhagic Disorders
[Case of hemorrhagic diathesis following prothrombase deficiency.]
Hemorrhagic Disorders
[Clinical studies on platelet function. II. Thromboplastin generation activity of the platelets in various hemorrhagic diathesis and blood disorders.]
Hemorrhagic Disorders
[Coagulation and fibrinolysis associated with contact phase in plasma with high molecular weight kininogen deficiency]
Hemorrhagic Disorders
[Congenital blood coagulation factor X deficiency. Successful result of the use prothrombin concentrated complex in the control of ++cesarean section hemorrhage in 2 pregnancies]
Hemorrhagic Disorders
[Familial hemorrhagic diathesis caused by factor X deficiency]
Hemorrhagic Disorders
[Grave transitory hemorrhagic diathesis in pregnancy; thrombokinase intoxication caused by premature detachment of the placenta in familial purpura simplex.]
Hemorrhagic Disorders
[Hemato-oncological diseases.]
Hemorrhagic Disorders
[Hemorrhagic diathesis due to anticoagulant inhibiting the formation or action of thromboplastin; concerning a personal case observed during chronic evolutive polyarthritis.]
Hemorrhagic Disorders
[Remission of a non-haemophilic patient with acquired factor VIII inhibitor treated with infusion of factor VIII and corticosteroid]
Hemorrhagic Disorders
[The significance of thrombokinase in the pathogenesis, diagnosis and therapy of hemorrhagic diatheses.]
Hemorrhagic Stroke
A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long?term prevention of thromboembolic complications in patients with atrial fibrillation?
Hemorrhagic Stroke
Apolipoprotein E genotype, coagulation, and survival following acute stroke.
Hemorrhagic Stroke
Imaging of Hemorrhagic Stroke.
Hemorrhagic Stroke
Licorice Root Associated With Intracranial Hemorrhagic Stroke and Cerebral Microbleeds.
Hemorrhagic Stroke
Post-stroke seizure-Do the locations, types and managements of stroke matter?
Hemorrhagic Stroke
Rat models of cardiometabolic diseases: baseline clinical chemistries, and rationale for their use in examining air pollution health effects.
Hemostatic Disorders
Designing a point-of-care program for coagulation testing.
Hemostatic Disorders
Factor XI deficiency in an Ashkenazi Jewish child, causing severe postoperative hemorrhage.
Hemostatic Disorders
Indications for plasma in massive transfusion.
Hemostatic Disorders
Peripherally inserted central catheter placement in patients with coagulation disorders: A retrospective analysis.
Hemostatic Disorders
Platelet dysfunction and coagulopathy in intraventricular hemorrhage in the premature infant.
Hemostatic Disorders
Relative value of diagnostic studies for von Willebrand disease.
Hemothorax
An apparent case of brodifacoum toxicosis in a whelping dog.
Hepatic Encephalopathy
Derivation and validation of prognostic models for predicting survival outcomes in Acute-on-chronic liver failure (ACLF) patients.
Hepatic Infarction
In vivo diagnosis of massive hepatic infarction by computed tomography.
Hepatitis
Acquired haemophilia complicated with gastrointestinal bleeding and spontaneous iliopsoas muscle haematoma in a woman with chronic C hepatitis under treatment with pegylated IFN alpha 2a and ribavirin.
Hepatitis
Association of mouse fibrinogen-like protein with murine hepatitis virus-induced prothrombinase activity.
Hepatitis
Circulating anticoagulant associated with chronic active hepatitis.
Hepatitis
Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis.
Hepatitis
Does Hepatitis B Virus Affect the Coagulation Parameters for HBV-Related Decompensated Cirrhosis?
Hepatitis
Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection.
Hepatitis
Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B.
Hepatitis
Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase.
Hepatitis
Induction of prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4 alpha.
Hepatitis
Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity.
Hepatitis
Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis.
Hepatitis
Mouse hepatitis virus-3 induced prothrombinase (Fgl2) maps to proximal chromosome 5.
Hepatitis
Murine hepatitis virus strain 3 induces the macrophage prothrombinase fgl-2 through p38 mitogen-activated protein kinase activation.
Hepatitis
Peliosis hepatis mimicking hepatic malignancy: A case report.
Hepatitis
Reactive oxygen intermediates and serum antioxidative system in patients with chronic C hepatitis treated with IFN-alpha and thymus factor X.
Hepatitis
Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response.
Hepatitis
The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis.
Hepatitis
The nucleocapsid protein of murine hepatitis virus type 3 induces transcription of the novel fgl2 prothrombinase gene.
Hepatitis
Thrombin activatable fibrinolysis inhibitor (TAFI): relationship to hemostatic alteration in patients with beta-thalassemia.
Hepatitis
[Anaesthesia for cesarean section in a patient with acute viral hepatitis (author's transl)]
Hepatitis
[Establishment of pig acute liver failure model and the role of pig fibrinogen-like protein 2.]
Hepatitis
[Hemostatic changes in the course of different chronic hepatopathies]
Hepatitis
[Predictors of massive blood transfusion in liver transplantation for patients with benign end-stage liver disease]
Hepatitis
[The diagnostic value of wedged hepatic vein pressure in chronic hepatitis and liver cirrhosis (author's transl)]
Hepatitis A
Dual interference of novel gene mfgl2 and mTNFR1 ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice.
Hepatitis A
Homogeneous hepatitis A virus particles. Proteolytic release of the assembly signal 2A from procapsids by factor Xa.
Hepatitis A
Novel mfgl2 Antisense Plasmid Inhibits Murine fgl2 Expression and Ameliorates Murine Hepatitis Virus Type 3-Induced Fulminant Hepatitis in BALB/cJ Mice.
Hepatitis A
Novel mfgl2 antisense plasmid inhibits murine fgl2 expression and ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice.
Hepatitis B
A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer.
Hepatitis B
Peliosis hepatis mimicking hepatic malignancy: A case report.
Hepatitis B
Post-Operative Hemorrhage After Liver Transplantation: Risk Factors and Long-Term Outcome.
Hepatitis B
Procoagulant versus anticoagulant factors in cirrhotic patients.
Hepatitis B
Shanghai Score: A Prognostic and Adjuvant Treatment-evaluating System Constructed for Chinese Patients with Hepatocellular Carcinoma after Curative Resection.
Hepatitis B
Treatment with thymic extract TFX for chronic active hepatitis B.
Hepatitis B, Chronic
Thymic factor X treatment of chronic hepatitis B.
Hepatitis C
Impact of sustained virus elimination on natural anticoagulant activity in patients with chronic viral hepatitis C.
Hepatitis C
Procoagulant versus anticoagulant factors in cirrhotic patients.
Hepatitis C
Searching for discrimination rules in protease proteolytic cleavage activity using genetic programming with a min-max scoring function.
Hepatitis C
Use of belatacept as alternative immunosuppression in three renal transplant patients with de novo drug-induced thrombotic microangiopathy.
Hepatitis E
Activities of Thrombin and Factor Xa Are Essential for Replication of Hepatitis E Virus and Are Possibly Implicated in ORF1 Polyprotein Processing.
Hepatitis, Autoimmune
Autoimmune hepatitis associated with the antiphospholipid syndrome.
Hepatitis, Chronic
Circulating anticoagulant associated with chronic active hepatitis.
Hepatitis, Chronic
Coagulation disorders in dogs with hepatic disease.
Hepatitis, Chronic
Treatment with thymic extract TFX for chronic active hepatitis B.
Hepatitis, Chronic
[The diagnostic value of wedged hepatic vein pressure in chronic hepatitis and liver cirrhosis (author's transl)]
Hepatitis, Viral, Human
The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis.
Hepatomegaly
Acquired isolated factor X deficiency associated with systemic amyloidosis. Case report and review of literature.
Hepatomegaly
Non-alcoholic fatty liver disease in the Philippines: comparable with other nations?
Hepatomegaly
Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
Hepatomegaly
The Significance of Prolonged and Saddleback Fever in Hospitalised Adult Dengue.
Hepatomegaly
[Contribution to the aetiology of "reversible hepatic dysfunction" (Stauffer's syndrome) associated with renal tumours]
Hepatomegaly
[Crimean-Congo hemorrhagic fever]
Hernias, Diaphragmatic, Congenital
Development of the Pediatric Extracorporeal Membrane Oxygenation Prediction Model for Risk-Adjusting Mortality.
Herpes Simplex
Effects of viral activation of the vessel wall on inflammation and thrombosis.
Herpes Simplex
Herpes simplex virus type 1-encoded glycoprotein C enhances coagulation factor VIIa activity on the virus.
Herpes Simplex
Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression.
Herpes Simplex
Peptidomimetic design.
Herpes Simplex
Structurally homologous ligand binding of integrin Mac-1 and viral glycoprotein C receptors.
Herpes Zoster
Noncanonical PAR3 activation by factor Xa identifies a novel pathway for Tie2 activation and stabilization of vascular integrity.
Histiocytoma, Benign Fibrous
Multiple eruptive dermatofibromas with CD34+ cells in a patient with hypertriglyceridemia.
HIV Infections
Hemostatic alterations during human immunodeficiency virus infection: a review.
HIV Infections
Identification of two different coagulation phenotypes in people living with HIV with undetectable viral replication.
Hodgkin Disease
A Prolonged Activated Partial Thromboplastin Time in a Child With Hodgkin Lymphoma.
Hodgkin Disease
Protease receptors in Hodgkin's disease: expression of the factor Xa receptor, effector cell protease receptor-1, in Reed-Sternberg cells.
Hydatidiform Mole
Coagulation and fibrinolysis in intact hydatidiform molar pregnancy.
Hydatidiform Mole
Effect of hydatidiform molar vesicular fluid on blood coagulation.
Hydrocephalus
Coronavirus disease 2019 (COVID-19) can predispose young to Intracerebral hemorrhage: a retrospective observational study.
Hydrocephalus
Hunter syndrome complicated by hydrocephalus and an endogenous anticoagulant.
Hydrocephalus
[Cerebromeningeal hemorrhages and their sequelae in congenital deficiencies of plasma hemostasis factors. Apropos of a case of Stuart factor deficiency with early cerebromengeal hemorrhage leading to hydrocephalus with considerable psychomotor retardation]
Hypercholesterolemia
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Hypercholesterolemia
Hemostatic effects of simvastatin in subjects with impaired glucose tolerance.
Hypercholesterolemia
Homozygous factor X deficiency associated with familial hypercholesterolemia, mitral valve prolapse, and hypertrophic cardiomyopathy.
Hypercholesterolemia
Hypercholesteremia and pulmonary arterial lesions produced by thromboplastin.
Hypercholesterolemia
Inhibition of thrombin attenuates stenosis after arterial injury in minipigs.
Hyperemia
Macrophage stimulation and the inflammatory response to asbestos.
Hyperemia
[Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review]
Hypergammaglobulinemia
Reactive plasmacytosis mimicking multiple myeloma associated with SFTS virus infection: a report of two cases and literature review.
Hypergammaglobulinemia
[Abdominal inflammatory pseudotumor (plasma cell granuloma) with anemia and hypergammaglobulinemia]
Hyperglycemia
Assessment of acute moderate hyperglycemia on traditional and thromboelastometry coagulation parameters in healthy adult horses.
Hyperglycemia
Comparison of the hypoglycemic and antithrombotic (anticoagulant) actions of whole bovine and camel milk in streptozotocin-induced diabetes mellitus in rats.
Hyperglycemia
Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma: a pilot study.
Hyperglycemia
Malignant histiocytosis in a cat.
Hyperglycemia
Pyogenic liver abscess. An audit of experience over the past decade.
Hyperglycemia
Why are acute ischemic stroke patients not receiving thrombolysis in a telestroke network?
Hyperhomocysteinemia
[A case report of syphilitic uveitis and deafness.]
Hyperinsulinism
Hyperglycemia-induced hyperinsulinemia decreases maternal and fetal plasma protein C concentration during ovine gestation.
Hyperkalemia
[Heatstroke in dogs in southern Germany. A retrospective study over a 5.5-year period].
Hyperlactatemia
Pulsus alternans in a critically ill dog hospitalized for xylitol toxicity.
Hyperlipidemias
Hyperlipidemia, hypercoagulability, and accelerated thrombosis: studies in congenitally hyperlipidemic rats and in rats and monkeys with induced hyperlipidemia.
Hyperlipidemias
Impaired and exhausted platelets in modified generalized Shwartzman reaction: an analogue of hemolytic uremic syndrome associated with endotoxemia.
Hyperlipidemias
[Clinical characteristics and outcomes of cerebral venous sinus thrombosis during pregnancy and puerperium].
Hyperlipidemias
[Estimation of the correlation between hemostatic parameters and serum lipids in patients with hyperlipidemia type II after simvastatin therapy]
Hyperlipidemias
[Hemostatic changes during pregnancy in reference to hyperlipidemia]
Hyperlipoproteinemia Type II
Homozygous factor X deficiency associated with familial hypercholesterolemia, mitral valve prolapse, and hypertrophic cardiomyopathy.
Hypersensitivity
A risk-benefit assessment of aprotinin in cardiac surgical procedures.
Hypersensitivity
Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases.
Hypersensitivity
Hypersensitivity reaction after administration of rivaroxaban (Xarelto).
Hypersensitivity
Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs.
Hypersensitivity
Prophylaxis Using a Mixture of Plasma-Derived Activated Factor VII and Factor X (pdFVIIa/FX) in a Patient with Hemophilia B Complicated by Inhibitors and Allergy to Factor IX Concentrates: A Case Report.
Hypertension
A role for coagulation factor Xa in experimental pulmonary arterial hypertension.
Hypertension
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Hypertension
Association of Platelets and White Blood Cells Subtypes with Trauma Patients' Mortality Outcome in the Intensive Care Unit.
Hypertension
Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients.
Hypertension
Cardioprotective and antihypertensive effects of Enicostemma littorale Blume extract in fructose-fed rats.
Hypertension
Clinical Characteristics and Abnormal Parameters Evolution in Patients With Novel Coronavirus Infection: A Case Series of 272 Cases in Guangzhou.
Hypertension
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator.
Hypertension
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Hypertension
Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial.
Hypertension
Evaluation of prothrombin time and activated partial thromboplastin time in hypertensive patients attending a tertiary hospital in calabar, Nigeria.
Hypertension
Hematological and Inflammatory Parameters to Predict the Prognosis in COVID-19.
Hypertension
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Hypertension
Increased fibrinogen levels and hemostatic abnormalities in patients with arteriolar nephrosclerosis: association with cardiovascular events.
Hypertension
Intracerebral hemorrhage after liver transplantation.
Hypertension
Maternal serum nitric oxide levels associated with biochemical and clinical parameters in hypertension in pregnancy.
Hypertension
Perioperative Hidden Blood Loss in Elderly Cervical Spondylosis Patients With Anterior Cervical Discectomy Fusion and Influencing Factors.
Hypertension
Peripheral vascular disease in patients with systemic lupus erythematosus.
Hypertension
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
Hypertension
Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study.
Hypertension
Prognosis of spontaneous intracerebral hemorrhage in hemodialysis patients.
Hypertension
Reducing unnecessary coagulation testing in hypertensive disorders of pregnancy.
Hypertension
Risk Factors for Decompression Retinopathy After Glaucoma Surgery.
Hypertension
Risk factors for increased postoperative drainage of calcaneal fractures after open reduction and internal fixation: An observational study.
Hypertension
Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.
Hypertension
Selected Blood Inflammatory and Metabolic Parameters Predicted Successive Bilateral Sudden Sensorineural Hearing Loss.
Hypertension
The FGL2 prothrombinase contributes to the pathological process of experimental pulmonary hypertension.
Hypertension
[Cerebral hemorrhage complicating early anticoagulant treatment of transient ischemic attacks]
Hypertension
[Risk factors of deep venous thrombosis associated with peripherally inserted central venous catheter in upper extremity in ICU].
Hypertension, Portal
Andexanet Alfa Use for Small Bowel Obstruction Patient With History of Sugiura Procedure.
Hypertension, Portal
Disordered hemostasis in extrahepatic portal hypertension.
Hypertension, Portal
Machine Learning for the Prediction of Red Blood Cell Transfusion in Patients During or After Liver Transplantation Surgery.
Hypertension, Portal
Portal hypertension and gastric lesions in the rat.
Hypertension, Pulmonary
A role for coagulation factor Xa in experimental pulmonary arterial hypertension.
Hypertension, Pulmonary
Effect of heparin and warfarin on chronic hypoxic pulmonary hypertension and vascular remodeling in the guinea pig.
Hypertension, Pulmonary
Perioperative anticoagulation management in antiphospholipid syndrome.
Hypertension, Pulmonary
The FGL2 prothrombinase contributes to the pathological process of experimental pulmonary hypertension.
Hyperthyroidism
Acute myocardial infarction and subclinical hyperthyroidism without significant coronary stenoses.
Hyperthyroidism
Atrial fibrillation and acute myocardial infarction without significant coronary stenoses associated with subclinical hyperthyroidism and erythrocytosis.
Hyperthyroidism
Atrial fibrillation associated with exogenous subclinical hyperthyroidism, changing axis deviation, troponin-I positive and without acute coronary syndrome.
Hyperthyroidism
Atrial fibrillation associated with exogenous subclinical hyperthyroidism.
Hyperthyroidism
Atrial fibrillation associated with subclinical hyperthyroidism.
Hyperthyroidism
Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Hyperthyroidism
Changing axis deviation and paroxysmal atrial flutter associated with subclinical hyperthyroidism.
Hyperthyroidism
Coagulation parameters in hyperthyroid cats before and after radioiodine treatment compared with healthy controls.
Hyperthyroidism
Coagulation profiles in hypothyroid and hyperthyroid female patients in Sudan.
Hyperthyroidism
Effects of Thyroid Function on Hemostasis, Coagulation, and Fibrinolysis: A Mendelian Randomization Study.
Hyperthyroidism
Hashitoxicosis with pericardial effusion.
Hyperthyroidism
New Interfaces of Thyroid Hormone Actions With Blood Coagulation and Thrombosis.
Hyperthyroidism
Paroxysmal atrial fibrillation during acute myocardial infarction associated with subclinical hyperthyroidism, severe three vessels coronary artery disease and elevation of prostate-specific antigen after TURP.
Hyperthyroidism
Paroxysmal ventricular tachycardia and paroxysmal atrial fibrillation associated with subclinical hyperthyroidism, chronic renal failure and elevation of prostate-specific antigen during acute myocardial infarction.
Hyperthyroidism
Pericardial effusion associated with subclinical hypothyroidism.
Hyperthyroidism
Prothrombin, activated partial thromboplastin, and proteins induced by vitamin K absence or antagonists clotting times in 20 hyperthyroid cats before and after methimazole treatment.
Hyperthyroidism
Recurrent acute pulmonary embolism and paroxysmal atrial fibrillation associated with subclinical hyperthyroidism.
Hyperthyroidism
["Lupus anticoagulant" in immune hyperthyroidism]
Hypertriglyceridemia
Cardioprotective and antihypertensive effects of Enicostemma littorale Blume extract in fructose-fed rats.
Hypoalbuminemia
Accidental fatal aflatoxicosis due to contaminated commercial diet in 50 dogs.
Hypoalbuminemia
Acute fatty liver of pregnancy: an experience in diagnosis and management of eight cases.
Hypoalbuminemia
Acute fatty liver of pregnancy: diagnosis and management of 8 cases.
Hypoalbuminemia
Celiac disease with diffuse cutaneous vitamin K-deficiency bleeding.
Hypoalbuminemia
Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience.
Hypoalbuminemia
Profile of dengue patients admitted to a tertiary care hospital in Mumbai.
Hypoalbuminemia
Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection.
Hypoalbuminemia
[Acute fatty liver in pregnancy: a clinicopathologic study]
Hypocalcemia
Association between hypocalcemia and rivaroxaban in coagulation disorders: a case report.
Hypocalcemia
Hypocalcemia in trauma patients receiving massive transfusion.
Hypoglycemia
Adrenal insufficiency complicated with antiphospholipid syndrome (APS).
Hypoglycemia
Antithrombin-III treatment limits disseminated intravascular coagulation in endotoxemia.
Hypoglycemia
Heatstroke: clinical signs, diagnosis, treatment, and prognosis.
Hypoglycemia
Hepatocyte-specific glucose-6-phosphatase deficiency disturbs platelet aggregation and decreases blood monocytes upon fasting-induced hypoglycemia.
Hypoglycemia
Mortality rate and prognostic factors for dogs with severe anaphylaxis: 67 cases (2016-2018).
Hypogonadism
Blood coagulation and fibrinolysis in male patients with hypogonadotropic hypogonadism: plasma factor V and factor X activities increase in hypogonadotropic hypogonadism.
Hypokalemia
Evaluation of prognostic factors in the surgical treatment of adrenal gland tumors in dogs: 41 cases (1999-2005).
Hypokalemia
Incidence and risk of adverse perioperative events among surgical patients taking traditional Chinese herbal medicines.
Hypokalemia
Prognostic indicators for canine monocytic ehrlichiosis.
Hypokalemia
[Analysis of clinical characteristics of the 12 cases of neonatal dengue fever in Guangzhou in 2014 and literatures review].
Hyponatremia
Adrenal insufficiency complicated with antiphospholipid syndrome (APS).
Hyponatremia
Analysis of clinical features and early warning indicators of death from severe fever with thrombocytopenia syndrome.
Hyponatremia
Complications and 30-day Outcomes Associated With Venous Thromboembolism in the Pediatric Orthopaedic Surgical Population.
Hyponatremia
Erythema multiforme major and disseminated intravascular coagulation in a dog following application of a d-limonene-based insecticidal dip.
Hyponatremia
Hantavirus pulmonary syndrome due to Andes virus in Temuco, Chile: clinical experience with 16 adults.
Hyponatremia
Profile of dengue patients admitted to a tertiary care hospital in Mumbai.
Hypoproteinemia
Deficiency of the contact phase of intrinsic coagulation in a horse.
Hypoproteinemia
Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma: a pilot study.
Hypoproteinemia
Erythema multiforme major and disseminated intravascular coagulation in a dog following application of a d-limonene-based insecticidal dip.
Hypoprothrombinemias
Autosomal recessive inherited bleeding disorders in Pakistan: a cross-sectional study from selected regions.
Hypoprothrombinemias
Lupus anticoagulant hypoprothrombinemia syndrome associated with bilateral adrenal haemorrhage in a child: early diagnosis and intervention.
Hypoprothrombinemias
Lupus anticoagulant-hypoprothrombinemia syndrome and immunoglobulin-A vasculitis: a report of Japanese sibling cases and review of the literature.
Hypoprothrombinemias
Pulmonary hemorrhage in pediatric lupus anticoagulant hypoprothrombinemia syndrome.
Hypoprothrombinemias
Rare coagulation disorders.
Hypoprothrombinemias
Thrombotic and hemorrhagic complications in children with the lupus anticoagulant.
Hypotension
A new prognostic scoring system for meningococcal septic shock in children. Comparison with three other scoring systems.
Hypotension
Acquired factor VIII deficiency presenting with compartment syndrome.
Hypotension
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Hypotension
Disseminated intravascular coagulation.
Hypotension
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
Hypotension
Factor Xa-evoked relaxation in rat aorta: involvement of PAR-2.
Hypotension
Factors associated with the severity of hypertriglyceridemia induced acute pancreatitis.
Hypotension
Human umbilical cord blood-derived CD34+ cells cause attenuation of multiorgan dysfunction during experimental heatstroke.
Hypotension
Hyperbaric oxygen improves survival in heatstroke rats by reducing multiorgan dysfunction and brain oxidative stress.
Hypotension
Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling.
Hypotension
Microvesicular liver graft steatosis as a risk factor of initial poor function in relation to suboptimal donor parameters.
Hypotension
Predictors of 30-Day Mortality in Traumatic Brain-Injured Patients after Primary Decompressive Craniectomy.
Hypotension
Recombinant tissue factor pathway inhibitor prevents lipopolysaccharide-induced systemic hypotension in rats by inhibiting excessive production of nitric oxide.
Hypotension
Studies of the coagulation system and blood pressure during experimental Bolivian hemorrhagic fever in rhesus monkeys.
Hypotension
Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment.
Hypotension
[Crimean-Congo hemorrhagic fever]
Hypothyroidism
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Hypothyroidism
Coagulation and fibrinolysis in thyroid disease.
Hypothyroidism
Effects of Thyroid Function on Hemostasis, Coagulation, and Fibrinolysis: A Mendelian Randomization Study.
Hypothyroidism
Evaluation of the respective influence of thyroid hormones and TSH on blood coagulation parameters after total thyroidectomy.
Idiopathic Pulmonary Fibrosis
Annexin A2 contributes to lung injury and fibrosis by augmenting factor Xa fibrogenic activity.
Idiopathic Pulmonary Fibrosis
Pirfenidone inhibits p38-mediated generation of procoagulant microparticles by human alveolar epithelial cells.
Ileus
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
Ileus
In vivo diagnosis of massive hepatic infarction by computed tomography.
Immunoglobulin Light-chain Amyloidosis
Acquired combined factor X and XII deficiency with isolated bleeding complications in a patient with AL amyloidosis.
Immunoglobulin Light-chain Amyloidosis
Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome.
Immunoglobulin Light-chain Amyloidosis
Acquired factor X deficiency developed four years after autologous transplantation in a patient with multiple myeloma associated with systemic AL amyloidosis.
Immunoglobulin Light-chain Amyloidosis
Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
Immunoglobulin Light-chain Amyloidosis
Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis.
Immunoglobulin Light-chain Amyloidosis
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.
Immunoglobulin Light-chain Amyloidosis
Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency.
Immunoglobulin Light-chain Amyloidosis
Characterization of amyloid deposits and P component from a patient with factor X deficiency reveals proteins derived from a lambda VI light chain.
Immunoglobulin Light-chain Amyloidosis
Chronic peritoneal dialysis in a patient with primary amyloidosis, renal failure, and factor X deficiency.
Immunoglobulin Light-chain Amyloidosis
Coagulation and fibrinolysis abnormalities in familial amyloid polyneuropathy.
Immunoglobulin Light-chain Amyloidosis
Factor X deficiency in primary amyloidosis.
Immunoglobulin Light-chain Amyloidosis
Factor X deficiency in primary amyloidosis: resolution after splenectomy.
Immunoglobulin Light-chain Amyloidosis
Factor X deficiency: An uncommon presentation of AL amyloidosis.
Immunoglobulin Light-chain Amyloidosis
Heterogeneity of hereditary and acquired factor X deficiencies by combined immunochemical and functional analyses.
Immunoglobulin Light-chain Amyloidosis
Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency.
Immunoglobulin Light-chain Amyloidosis
Importance of pharmacokinetic studies in the management of acquired factor X deficiency.
Immunoglobulin Light-chain Amyloidosis
Primary amyloidosis with severe nephrotic syndrome and acquired factor X deficiency.
Immunoglobulin Light-chain Amyloidosis
Resolution of factor X deficiency in primary amyloidosis following splenectomy.
Immunoglobulin Light-chain Amyloidosis
Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding.
Immunoglobulin Light-chain Amyloidosis
Splenectomy in an uraemic patient with acquired factor X deficiency due to AL amyloidosis.
Immunoglobulin Light-chain Amyloidosis
Splenectomy in plasma cell dyscrasias: a review of the clinical practice.
Immunoglobulin Light-chain Amyloidosis
Spontaneous perinephric hematoma due to acquired factor X deficiency in AL amyloidosis.
Immunoglobulin Light-chain Amyloidosis
Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis.
Immunoglobulin Light-chain Amyloidosis
Spontaneous rupture of the spleen in AL amyloidosis.
Immunoglobulin Light-chain Amyloidosis
Successful perioperative management of factor X deficiency associated with primary amyloidosis.
Immunoglobulin Light-chain Amyloidosis
Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X.
Immunoglobulin Light-chain Amyloidosis
Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients.
Immunoglobulin Light-chain Amyloidosis
The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
Immunoglobulin Light-chain Amyloidosis
Treatment of amyloidosis associated factor X deficiency.
Immunoglobulin Light-chain Amyloidosis
Unusual bleeding manifestations in a case of primary amyloidosis with factor X deficiency but elevations of in vivo markers of thrombin formation and activity.
Immunoglobulin Light-chain Amyloidosis
[A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review]
Immunoglobulin Light-chain Amyloidosis
[ACQUIRED FACTOR X DEFICIENCY IN A PATIENT WITH PRIMARY AMYLOIDOSIS. INJECTION OF A B.S.C. FRACTION.]
Immunoglobulin Light-chain Amyloidosis
[Acquired factor X deficiency in a patient with primary amyloidosis. Injection of a coagulating fraction (C.S.B)]
Immunoglobulin Light-chain Amyloidosis
[Acquired factor X deficiency in primary amyloidosis]
Immunoglobulin Light-chain Amyloidosis
[Extensive subcutaneous hemorrhage complicating primary amyloidosis]
Immunoglobulin Light-chain Amyloidosis
[Hemarthrosis disclosing factor X deficiency in primary amyloidosis]
Immunoglobulin Light-chain Amyloidosis
[Primary amyloidosis associated to severe factor X deficiency]
Immunoglobulin Light-chain Amyloidosis
[Recurrence of Waldenström macroglobulinemia accompanied by factor X deficiency].
Infarction, Middle Cerebral Artery
Early initiation of a factor Xa inhibitor can attenuate tissue repair and neurorestoration after middle cerebral artery occlusion.
Infections
A comparison of two techniques of care for indwelling arterial introducers after coronary angioplasty.
Infections
Abnormal coagulation tests obtained in the emergency department are associated with mortality in patients with suspected infection.
Infections
Acquired, transient factor X (Stuart factor) deficiency in patient with mycoplasma pneumonial infection.
Infections
Adrenal gland infection by serotype 5 adenovirus requires coagulation factors.
Infections
An analysis of potential predictors of tunneled hemodialysis catheter infection or dysfunction.
Infections
Analysis of Bacterial and Fungal Infections after Cytoreduction Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Observational Single-Centre Study.
Infections
Analysis of clinical features and early warning indicators of death from severe fever with thrombocytopenia syndrome.
Infections
Analysis of the relationship between serum amyloid protein A, procalcitonin, C-reactive protein, and peripherally inserted central catheter infection in patients with malignant tumor.
Infections
Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection.
Infections
Association of mouse fibrinogen-like protein with murine hepatitis virus-induced prothrombinase activity.
Infections
Attributable fraction for cardiac malformations.
Infections
Coagulation defect in experimental trypanosomial infection.
Infections
Coagulation factor IX mediates serotype-specific binding of species A adenoviruses to host cells.
Infections
Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components.
Infections
Comparative analysis of clinical features of SARS-CoV-2 and adenovirus infection among children.
Infections
Cutaneous histopathologic findings in 'antiphospholipid syndrome'. Correlation with disease, including human immunodeficiency virus disease.
Infections
Development of cephradine-induced acquired factor v inhibitors: a case report.
Infections
Development of the Pediatric Extracorporeal Membrane Oxygenation Prediction Model for Risk-Adjusting Mortality.
Infections
DIAGNOSING DISSEMINATED INTRAVASCULAR COAGULATION IN ACUTE INFECTION : CAN WE DO WITHOUT FDP & D-DIMER.
Infections
Diagnosis and stage-related treatment of disseminated intravascular coagulation in meningococcal infections.
Infections
Does Hepatitis B Virus Affect the Coagulation Parameters for HBV-Related Decompensated Cirrhosis?
Infections
Effect of a Quality Improvement Program to Improve Guideline Adherence and Attainment of Clinical Standards in Dialysis Care: Report of Outcomes in Year 1.
Infections
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
Infections
Effects of viral activation of the vessel wall on inflammation and thrombosis.
Infections
Enhanced thrombin generation and platelet binding on herpes simplex virus-infected endothelium.
Infections
Evaluating the safety and efficacy of argatroban locking solution in the prevention of the dysfunction of haemodialysis central venous catheters: a study protocol for a randomized controlled trial.
Infections
Expression of factor X and its significance for the determination of paramyxovirus tropism in the chick embryo.
Infections
Factor X and its deficiency states.
Infections
Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase.
Infections
FXa cleaves the SARS-CoV-2 spike protein and blocks cell entry to protect against infection with inferior effects in B.1.1.7 variant.
Infections
Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID-19-A common clinical feature between a rare disorder and a new, common infection.
Infections
Hematological and coagulation profiles in dogs experimentally infected with Angiostrongylus vasorum (Baillet, 1866).
Infections
HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement.
Infections
Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism.
Infections
Hypocoagulation induced by broad-spectrum antibiotics in extensive burn patients.
Infections
Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis.
Infections
Induction of prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4 alpha.
Infections
Inhibition of Herpes Simplex Virus Type 1 Attachment and Infection by Sulfated Polyglycerols with Different Architectures.
Infections
Life-threatening bleeding tendency provoked by an acquired isolated factor X deficiency associated with respiratory infection.
Infections
Longer aPTT values in healthy children than in adults: no single cause.
Infections
Lupus Anticoagulant Positivity in Pediatric Patients With Prolonged Activated Partial Thromboplastin Time: A Single-Center Experience and Review of Literature.
Infections
Masking of retroviral envelope functions by oligomerizing polypeptide adaptors.
Infections
Modification of retroviral tropism by display of IGF-I.
Infections
Monoclonal antibody analysis of a unique macrophage procoagulant activity induced by murine hepatitis virus strain 3 infection.
Infections
Multiple roles of the coagulation protease cascade during virus infection.
Infections
Myocarditis in athletes after COVID-19 infection: The heart is not the only place to screen.
Infections
Oral Route Driven Acute Trypanosoma cruzi Infection Unravels an IL-6 Dependent Hemostatic Derangement.
Infections
PheWAS uncovers a pathological role of coagulation Factor X during Acinetobacter baumannii infection.
Infections
Plasmodium berghei: pulmonary oedema and changes in clotting and fibrinolysis during infection in mice.
Infections
Reduced CD3/TCR complex expression leads to immunosuppression during Plasmodium falciparum malaria.
Infections
Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X.
Infections
Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection.
Infections
Risk factors associated with development of dengue haemorrhagic fever or dengue shock syndrome in adults in Hospital Tengku Ampuan Afzan Kuantan.
Infections
Safety of surgical tracheostomy under continued antithrombotic therapy: a retrospective cohort study.
Infections
Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
Infections
Successful Treatment of Life-threatening Bleeding Caused by Acquired Factor X Deficiency Associated with Respiratory Infection.
Infections
Systemic cancer therapy with engineered adenovirus that evades innate immunity.
Infections
Targeting host cell proteases to prevent SARS-CoV-2 invasion.
Infections
The epidemiology of acute kidney injury in critically ill patients in the Gansu Province: The EACG study.
Infections
The exploration of risk factors of concurrent bacteraemia in patients critically ill with severe dengue.
Infections
The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis.
Infections
The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis.
Infections
The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?
Infections
The phosphoproteomic responses of duck (Cairna moschata) to classical/novel duck reovirus infections in the spleen tissue.
Infections
The procoagulant envelope virus surface: contribution to enhanced infection.
Infections
Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease activated receptor 2 cofactors that enhance infection.
Infections
Trajectories of hepatic and coagulation dysfunctions related to a rapidly fatal outcome among hospitalized patients with dengue fever in Tainan, 2015.
Infections
Transient, selective factor X deficiency and acute liver failure following chest infection treated with erythromycin BP.
Infections
[Analysis of risk factors and prognosis for bleeding in very old male patients with stage 5 chronic kidney disease].
Infections
[Biological diagnosis of postoperative thrombopenia]
Infections
[Clinical significance of detection of thrombus precursor protein in severe sepsis.]
Infections
[Clinical Value Evaluation of Perioperative Prophylactic Anticoagulation Therapy for Lung Cancer Patients].
Infections
[Effect of long-term and short-term mild hypothermia in severe traumatic brain injury: a comparative study].
Infections
[Prospective randomized study comparing the effectiveness and tolerance of various low-molecular-weight heparins in high risk patients]
Infections
[Risk factors analysis of acute respiratory distress syndrome in intensive care unit traumatic patients].
Infections
[Risk factors of deep venous thrombosis associated with peripherally inserted central venous catheter in upper extremity in ICU].
Infectious Mononucleosis
Transient lupus anticoagulant with a prolonged activated partial thromboplastin time secondary to cytomegalovirus-related infectious mononucleosis.
Infertility
An ex vivo evaluation of efficacy of refrigerated canine plasma.
Inflammatory Bowel Diseases
Fibrinogen-like protein 2 prothrombinase may contribute to the progression of inflammatory bowel disease by mediating immune coagulation.
Influenza, Human
A peptide-based approach to evaluate the adaptability of influenza A virus to humans based on its hemagglutinin proteolytic cleavage site.
Influenza, Human
Clinical characteristics and outcome of influenza virus infection among adults hospitalized with severe COVID-19: a retrospective cohort study from Wuhan, China.
Influenza, Human
Expression of Factor X in BHK-21 Cells Promotes Low Pathogenic Influenza Viruses Replication.
Influenza, Human
Human influenza A viruses are proteolytically activated and do not induce apoptosis in CACO-2 cells.
Influenza, Human
Kallikrein-related peptidases in lung diseases.
Influenza, Human
Lack of effect of influenza vaccine on warfarin anticoagulation in the elderly.
Influenza, Human
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases.
Influenza, Human
Replication of influenza B virus in chicken embryos is suppressed by exogenous aprotinin.
Influenza, Human
TGF-? Blood Levels Distinguish Between Influenza A (H1N1)pdm09 Virus Sepsis and Sepsis due to Other Forms of Community-Acquired Pneumonia.
Influenza, Human
Venous Thromboembolism Events Following Venovenous Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Syndrome Coronavirus 2 Based on CT Scans.
Insulin Resistance
Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Insulin Resistance
Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance.
Insulin Resistance
Is There a Tendency for Thrombosis in Gestational Diabetes Mellitus?
Insulin Resistance
Obesity/insulin resistance rather than liver fat increases coagulation factor activities and expression in humans.
Insulin Resistance
Swimming, but not vitamin E, ameliorates prothrombotic state and hypofibrinolysis in a rat model of nonalcoholic fatty liver disease.
Insulinoma
Immunohistochemical localization of factor X-like antigen in pancreatic islets and their tumours.
Intestinal Diseases
[Decrease of antithrombin III and factor Xa inhibitor as the cause of thromboembolism complications in chronic inflammatory intestinal disease]
Intestinal Volvulus
Anticoagulant activity in salivary gland extracts of black flies (Diptera: Simuliidae).
Intracranial Embolism
Hypercoagulability in acute ischemic stroke: analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method.
Intracranial Embolism
Managing the therapeutic dilemma: patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation.
Intracranial Embolism
Preliminary Observations on the Antihypertension Action of Dabigatran Etexilate in Patients With Nonvalvular Atrial Fibrillation: A Prospective Multicenter Single-Arm Interventional Study.
Intracranial Hemorrhage, Traumatic
Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage.
Intracranial Hemorrhage, Traumatic
Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
Intracranial Hemorrhages
A new regimen for heparin use in acute coronary syndromes.
Intracranial Hemorrhages
A rare cause of intracranial hemorrhage: factor X deficiency.
Intracranial Hemorrhages
Acquired hemophilia first manifesting as life-threatening intracranial hemorrhage: case report.
Intracranial Hemorrhages
Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors.
Intracranial Hemorrhages
An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
Intracranial Hemorrhages
Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
Intracranial Hemorrhages
Anticoagulation therapy for atrial fibrillation.
Intracranial Hemorrhages
Comparison of outcomes in patients with intracranial hemorrhage on factor Xa inhibitors versus vitamin K antagonists treated with 4-factor prothrombin complex concentrate.
Intracranial Hemorrhages
Dental management of a patient with factor X deficiency.
Intracranial Hemorrhages
Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.
Intracranial Hemorrhages
Factor Xa Inhibitor-Related Intracranial Hemorrhage: Results From a Multicenter, Observational Cohort Receiving Prothrombin Complex Concentrates.
Intracranial Hemorrhages
Factor Xa inhibitors in patients with continuous-flow left ventricular assist devices.
Intracranial Hemorrhages
Genotype and phenotype correlation in intracranial hemorrhage in neonatal factor VII deficiency among Thai children.
Intracranial Hemorrhages
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage : A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.
Intracranial Hemorrhages
Hemorrhagic Shock after Neonatal Circumcision: Severe Congenital Factor XIII Deficiency.
Intracranial Hemorrhages
Homozygous Factor X gene mutations Gly380Arg and Tyr163delAT are associated with perinatal intracranial hemorrhage.
Intracranial Hemorrhages
Indirect antiplatelet effects of rivaroxaban in a patient with intracranial hemorrhage: An underappreciated coagulopathy of factor Xa inhibitors?
Intracranial Hemorrhages
Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis.
Intracranial Hemorrhages
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
Intracranial Hemorrhages
Intracranial hemorrhage and circulating coagulation inhibitor in beta-thalassemia major.
Intracranial Hemorrhages
Intracranial Hemorrhage as the First Manifestation of Severe Congenital Factor X Deficiency in a 20-Month-Old Male: Case Report and Review of the Literature.
Intracranial Hemorrhages
Low Risk of Traumatic Intracranial Hematoma Expansion with Factor Xa Inhibitors without Andexanet Reversal.
Intracranial Hemorrhages
Low-dose versus standard-dose four-factor prothrombin complex concentrate for factor-Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage.
Intracranial Hemorrhages
Multiple intracranial hemorrhages at the time of a transiently prolonged activated partial thromboplastin time in an infant with congenital factor VII deficiency.
Intracranial Hemorrhages
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Intracranial Hemorrhages
Novel oral anticoagulant management issues for the stroke clinician.
Intracranial Hemorrhages
Prevention of recurrent intracranial hemorrhage in a factor X-deficient infant.
Intracranial Hemorrhages
Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis.
Intracranial Hemorrhages
Prothrombin Complex Concentrates for Intracranial Hemorrhage on Factor Xa Inhibitors.
Intracranial Hemorrhages
Relationship between abnormalities of coagulation and fibrinolysis and postoperative intracranial hemorrhage in head injury.
Intracranial Hemorrhages
Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors.
Intracranial Hemorrhages
Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
Intracranial Hemorrhages
The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes.
Intracranial Hemorrhages
[Difference in examination of coagulation function in heparin anticoagulant therapy between point of care tests and automatic coagulation analyzer]
Intracranial Hemorrhages
[Management of bleeding associated with direct oral anticoagulants: update on reversal strategies].
Intracranial Hypertension
Human umbilical cord blood-derived CD34+ cells cause attenuation of multiorgan dysfunction during experimental heatstroke.
Intracranial Hypertension
Hyperbaric oxygen improves survival in heatstroke rats by reducing multiorgan dysfunction and brain oxidative stress.
Intracranial Thrombosis
A case of cerebral infarction associated with positive antiphospholipid antibody in a systemic lupus patient.
Intracranial Thrombosis
Development of argatroban as an anticoagulant and antithrombin agent in Japan.
Intracranial Thrombosis
Hypercoagulability in acute ischemic stroke: analysis of the extrinsic coagulation reactions in plasma by a highly sensitive automated method.
Ischemic Attack, Transient
Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events.
Ischemic Attack, Transient
Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus.
Ischemic Attack, Transient
Optimal Dosing of Intravenous Unfractionated Heparin Bolus in Transient Ischemic Attack or Stroke.
Ischemic Attack, Transient
Use of rivaroxaban in patients with stroke.
Ischemic Stroke
Activated protein C resistance in ischemic stroke not due to factor V arginine506-->glutamine mutation.
Ischemic Stroke
Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment.
Ischemic Stroke
Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients.
Ischemic Stroke
Antiphospholipid antibody syndrome: an unusual cause of stroke in a 22-year-old female.
Ischemic Stroke
Apixaban decreases brain thrombin activity in a male mouse model of acute ischemic stroke.
Ischemic Stroke
Apixaban Inhibits Cerebral Microembolic Signals Derived from Carotid Arterial Thrombosis in Rabbits.
Ischemic Stroke
Apolipoprotein E genotype, coagulation, and survival following acute stroke.
Ischemic Stroke
Association between Coagulation Function and Cerebral Microbleeds in Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease.
Ischemic Stroke
Direct oral factor Xa inhibitors for the prevention of non-central nervous systemic embolism patients with non-valvular atrial fibrillation - a systematic review and meta-analysis.
Ischemic Stroke
Efficacy and Safety of Direct Factor Xa Inhibitors Versus Warfarin in Prevention of Primary and Secondary Ischemic Strokes in Non-Valvular Atrial Fibrillation: A Literature Review.
Ischemic Stroke
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis.
Ischemic Stroke
Endovascular treatment in acute ischemic stroke patient on factor Xa inhibitor.
Ischemic Stroke
Hemostatic risk factors in ischemic stroke.
Ischemic Stroke
Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study.
Ischemic Stroke
Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation.
Ischemic Stroke
Ischemic stroke as initial manifestation of systemic lupus erythematosus: A case report and review of the literature.
Ischemic Stroke
Linking Endogenous Factor Xa Activity, a Biologically Relevant Pharmacodynamic Marker, to Edoxaban Plasma Concentrations and Clinical Outcomes in the ENGAGE AF-TIMI 48 Trial.
Ischemic Stroke
New thrombin and factor Xa inhibitors for primary and secondary prevention of ischaemic stroke.
Ischemic Stroke
Novel oral anticoagulant management issues for the stroke clinician.
Ischemic Stroke
Novel Oral Anticoagulants as Treatment for Vertebral Artery Dissection: Case Report.
Ischemic Stroke
Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators.
Ischemic Stroke
Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH.
Ischemic Stroke
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
Ischemic Stroke
Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.
Ischemic Stroke
Shortened Activated Partial Thromboplastin Time Is Associated With Acute Ischemic Stroke, Stroke Severity, and Neurological Worsening.
Ischemic Stroke
Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation.
Ischemic Stroke
The effects of heatwaves and cold spells on patients admitted with acute ischemic stroke.
Ischemic Stroke
The frequency of phospholipid antibodies in an unselected stroke population.
Ischemic Stroke
The influence of immunoglobulin class G from blood plasma of patients with stroke on the activity of some parameters of hemostasis system.
Ischemic Stroke
Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism.
Ischemic Stroke
Why are acute ischemic stroke patients not receiving thrombolysis in a telestroke network?
Joint Diseases
[1st studies on the problem of rectal resorption of MPS in the treatment of arthroses]
Kasabach-Merritt Syndrome
Hemangioma of the radius associated with Kasabach-Merritt syndrome: case report and literature review.
Kasabach-Merritt Syndrome
Kasabach-Merritt syndrome complicating treatment of a closed femoral fracture.
Kasabach-Merritt Syndrome
Paravertebral and Retroperitoneal Vascular Tumour Presenting with Kasabach-Merritt Phenomenon in Childhood, Diagnosed with Magnetic Resonance Imaging.
Ketosis
Haemostatic changes in diabetic coma.
Kidney Calculi
[Experience of integrated traditional Chinese and Western medicine in first case of imported Zika virus disease in China].
Kidney Diseases
Edoxaban Exerts Antioxidant Effects Through FXa Inhibition and Direct Radical-Scavenging Activity.
Kidney Failure, Chronic
Association of Platelets and White Blood Cells Subtypes with Trauma Patients' Mortality Outcome in the Intensive Care Unit.
Kidney Failure, Chronic
Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure?
Kidney Failure, Chronic
CD62P and P10 as predictive markers for assessing the efficacy of hemodialysis in treating end-stage renal disease.
Kidney Failure, Chronic
Effect of heparin and prostacyclin-heparin infusion on blood coagulation in haemodialysed patients.
Kidney Failure, Chronic
Reversible Neurological Adverse Reaction to Apixaban.
Kidney Neoplasms
Role of coagulation factors in urological malignancy: A prospective, controlled study on prostate, renal and bladder cancer.
Kidney Neoplasms
[The problem of hepatic dysfunction of the diagnosis of hypernephroid kidney carcinomas (Stauffer syndrome)]
Laryngeal Neoplasms
Risk factors for acute unplanned tracheostomy during panendoscopy in HNSCC patients.
Legg-Calve-Perthes Disease
[Congenital disorders of hemostasis in children with Perthes disease]
Leishmaniasis
Evaluation of secondary haemostasis in canine leishmaniasis.
Leishmaniasis, Visceral
Hemostatic assessment of dogs associated with hepatic parasite load of Leishmania infantum chagasi.
Leprosy
An unusual factor-X inhibitor in leprosy.
Leptospirosis
Activation of the coagulation cascade in patients with leptospirosis.
Leptospirosis
Coagulation studies in leptospirosis.
Leptospirosis
Leptospira Infection Interferes with the Prothrombinase Complex Assembly during Experimental Leptospirosis.
Lethargy
Evaluation of prognostic factors in the surgical treatment of adrenal gland tumors in dogs: 41 cases (1999-2005).
Lethargy
The Significance of Prolonged and Saddleback Fever in Hospitalised Adult Dengue.
Leukemia
Acquired selective factor X deficiency in acute nonlymphocytic leukemia.
Leukemia
Acute Promyelocytic Leukemia-Associated Thrombosis.
Leukemia
Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin.
Leukemia
Asphyxia by Drowning Induces Massive Bleeding Due To Hyperfibrinolytic Disseminated Intravascular Coagulation.
Leukemia
Cancer procoagulant in acute lymphoblastic leukemia.
Leukemia
Evaluation of D-dimer and lactate dehydrogenase plasma levels in patients with relapsed acute leukemia.
Leukemia
Expression of the murine leukemia virus protease in fusion with maltose-binding protein in Escherichia coli.
Leukemia
Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII.
Leukemia
Latest advances from basic and clinical research in hematology.
Leukemia
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Leukemia
Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
Leukemia
The coagulopathy of childhood leukemia. Thrombin activation or primary fibrinolysis?
Leukemia
The use of protein-DNA, chromatin immunoprecipitation, and transcriptome arrays to describe transcriptional circuits in the dehydrated male rat hypothalamus.
Leukemia
[Abnormality of blood coagulation indexes in patients with de novo acute leukemia and its clinical significance].
Leukemia
[Changes in the thromboplastin generation tests in a case of acute leukemia.]
Leukemia
[Isolated factor X deficiency in chronic myelomonocytic leukemia: Report of one case].
Leukemia
[On the presence of thromboplastin inhibitors in the blood in leukemia and their significance.]
Leukemia
[Thromboplastin formation at different periods of acute leukemia in children]
Leukemia
[Unusual pathogenetic aspects of a hemorrhagic syndrome in chronic leukemia myelosis: plasma thromboplastin component (factor IX) defect & increased fibrinolysis; 2 clinical case reports.]
Leukemia, B-Cell
[The antiphospholipid syndrome during chronic lymphatic leukemia. An association with anti-factor VIII antibodies]
Leukemia, Lymphocytic, Chronic, B-Cell
[The antiphospholipid syndrome during chronic lymphatic leukemia. An association with anti-factor VIII antibodies]
Leukemia, Myeloid, Acute
Acquired selective factor X deficiency in acute nonlymphocytic leukemia.
Leukemia, Myeloid, Acute
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Leukemia, Myeloid, Acute
The clinical and biological correlates of coagulopathy in children with acute leukemia.
Leukemia, Myelomonocytic, Chronic
[Isolated factor X deficiency in chronic myelomonocytic leukemia: Report of one case].
Leukemia, Promyelocytic, Acute
Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin.
Leukemia, Promyelocytic, Acute
Asphyxia by Drowning Induces Massive Bleeding Due To Hyperfibrinolytic Disseminated Intravascular Coagulation.
Leukemia, Promyelocytic, Acute
Evaluation of D-dimer and lactate dehydrogenase plasma levels in patients with relapsed acute leukemia.
Leukemia, Promyelocytic, Acute
New onset acute promyelocytic Leukemia during pregnancy: report of 2 cases.
Leukemia, Promyelocytic, Acute
Phosphatidylserine index as a marker of the procoagulant phenotype of acute myelogenous leukemia cells.
Leukocytosis
Brodifacoum-Laced Synthetic Marijuana Toxicity: A Fight Against Time.
Leukocytosis
Clinical manifestations, laboratory findings, treatment and outcome of acute organophosphate or carbamate intoxication in 102 dogs: A retrospective study.
Leukocytosis
Epidemiological and clinical differences of snake bites among children and adults in south western Saudi Arabia.
Leukocytosis
Erythema multiforme major and disseminated intravascular coagulation in a dog following application of a d-limonene-based insecticidal dip.
Leukocytosis
Hantavirus pulmonary syndrome due to Andes virus in Temuco, Chile: clinical experience with 16 adults.
Leukocytosis
Impaired and exhausted platelets in modified generalized Shwartzman reaction: an analogue of hemolytic uremic syndrome associated with endotoxemia.
Leukocytosis
Inhibition of leukocyte-endothelial cell interactions and inflammation by peptides from a bacterial adhesin which mimic coagulation factor X.
Leukocytosis
Investigating the impact of silymarin on liver oxidative injury.
Leukocytosis
Severe adenovirus infection in children.
Leukocytosis
Toxicity with intravenous injection of crude marijuana extract.
Leukocytosis
[Crimean-Congo hemorrhagic fever]
Leukocytosis
[Spontaneous bilateral extradural hematomas: a case report]
Leukopenia
Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation.
Leukopenia
Adenoviral pneumonia in children.
Leukopenia
Clinical features and dynamic ordinary laboratory tests differentiating dengue fever from other febrile illnesses in children.
Leukopenia
Crimean-Congo hemorrhagic fever.
Leukopenia
Evaluation of factors predictive of the prognosis in Crimean-Congo hemorrhagic fever: new suggestions.
Leukopenia
Experimental Sarcocystis suicanis infections: disease in growing pigs.
Leukopenia
Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes.
Leukopenia
Hematologic manifestation of childhood celiac disease.
Leukopenia
Laboratory findings in patients with avian-origin influenza A (H7N9) virus infections.
Leukopenia
Nonresectable hepatocellular carcinoma: long-term toxicity in patients treated with transarterial chemoembolization--single-center experience.
Leukopenia
Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
Leukopenia
The effects of indomethacin on the generalized shwartzman reaction.
Leukopenia
The Significance of Prolonged and Saddleback Fever in Hospitalised Adult Dengue.
limulus clotting factor b deficiency
Deuterohemophilia: plasma thromboplastin factor B deficiency: plasma thromboplastin component (PTC) deficiency, Christmas disease, hemophilia B.
Lipoma
A novel missense mutation Asp506Gly in Exon 13 of the F11 gene in an asymptomatic Korean woman with mild factor XI deficiency.
Lipoma
Posttraumatic lipoma in a patient with congenital factor X deficiency.
Lipoma
[Diagnosis and treatment of posttraumatic pseudolipomas. A retrospective analysis]
Livedoid Vasculopathy
Successful Treatment of Painful Cutaneous Vasculopathy With Rivaroxaban in a Patient With Systemic Lupus Erythematosus.
Liver Cirrhosis
Deciphering the coagulation profile through the dynamics of thrombin activity.
Liver Cirrhosis
Haemostasis unbalance in Pugh-scored liver cirrhosis: characteristic changes of plasma levels of protein C versus protein S.
Liver Cirrhosis
Hyponatremia and Its Correlation With Hepatic Encephalopathy and Severity of Liver Disease.
Liver Cirrhosis
Inhibition of activated factor X; a new pathway in ameliorating carbon tetrachloride-induced liver fibrosis in rats.
Liver Cirrhosis
Multicenter retrospective study of transcatheter arterial embolisation for life-threatening haemorrhage in patients with uncorrected bleeding diathesis.
Liver Cirrhosis
Rotational thromboelastometry can detect factor XIII deficiency and bleeding diathesis in patients with liver cirrhosis.
Liver Cirrhosis
Thrombin and factor Xa link the coagulation system with liver fibrosis.
Liver Cirrhosis
Treatment of posthepatitic cirrhosis by Fuzheng Huayu Tablet for reinforcing qi and resolving stasis.
Liver Cirrhosis
[Biological diagnosis of postoperative thrombopenia]
Liver Cirrhosis
[Effect of intraperitoneal injection of topical thrombin on the coagulation and fibrinolysis of rabbits with experimental liver damages]
Liver Cirrhosis
[Epidural hematoma associated with epidural catheterization in a cirrhotic patient]
Liver Cirrhosis
[Rational hemostatic screening]
Liver Cirrhosis
[Spectrum and bleeding complications of sonographically guided interventions of the liver and pancreas]
Liver Cirrhosis
[The diagnostic value of wedged hepatic vein pressure in chronic hepatitis and liver cirrhosis (author's transl)]
Liver Cirrhosis
[The therapeutic effects of natural vitamin K1, in decreasing the potential of serumsteady thrombokinase factors in cases of obstructive jaundice and of liver cirrhosis.]
Liver Cirrhosis
[Thrombokinase inhibitors and alpha 1-antitrypsin deficiency in liver cirrhosis as a cause for hemorrhage in ascites shunt]
Liver Cirrhosis, Alcoholic
Deceptive prothrombin and activated partial thromboplastin times in alcoholic cirrhosis.
Liver Cirrhosis, Biliary
Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thrombelastography.
Liver Diseases
A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy.
Liver Diseases
A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology.
Liver Diseases
A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation.
Liver Diseases
A Retrospective Cohort Analysis of Pharmacologic VTE Prophylaxis and Padua Prediction Score in Hospitalized Patients With Chronic Liver Disease.
Liver Diseases
Activated partial thromboplastin time abnormality in patients with cholangiocarcinoma.
Liver Diseases
AGA Clinical Practice Update: Coagulation in Cirrhosis.
Liver Diseases
Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time (April).
Liver Diseases
An International Sensitivity Index (ISI) derived from patients with abnormal liver function improves agreement between INRs determined with different reagents.
Liver Diseases
Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place.
Liver Diseases
Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis.
Liver Diseases
Bleeding and clotting disorders in pediatric liver disease.
Liver Diseases
Bloodless living donor liver transplantation: Risk factors, outcomes, and diagnostic predictors.
Liver Diseases
Coagulation abnormalities in 22 cats with naturally occurring liver disease.
Liver Diseases
Coagulation Profile and its Correlation with Severity of Liver Dysfunction and Gastrointestinal Bleed in Alcoholic Liver Disease Patients.
Liver Diseases
Coagulopathy in the nephrotic syndrome.
Liver Diseases
Comparison of a chromogenic prothrombin time with clotting prothrombin time in the assessment of clinical coagulation deficiencies.
Liver Diseases
Comparison of human and rabbit brain thromboplastin in evaluation of haemostatic defect of liver disease.
Liver Diseases
Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis.
Liver Diseases
Comparison of two automated coagulometers and the manual tilt-tube method for the determination of prothrombin time.
Liver Diseases
Cryptococcosis in patients with liver cirrhosis: Death risk factors and predictive value of prognostic models.
Liver Diseases
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Liver Diseases
Diagnosis and therapy of coagulopathies in patients with liver disease.
Liver Diseases
Effect of liver damage on the level of coagulation factor II, X and VII in human and bovine plasma.
Liver Diseases
Effects of DDAVP administrated subcutaneously in dogs with aspirin-induced platelet dysfunction and hemostatic impairment due to chronic liver diseases.
Liver Diseases
Erythrocyte protoporphyrins in hepatitis C viral infection.
Liver Diseases
Factor VII as a marker of hepatocellular synthetic function in liver disease.
Liver Diseases
Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy.
Liver Diseases
Immunoglobulin Light Chain Amyloidosis with Severe Liver Dysfunction Accompanied by Factor X Deficiency.
Liver Diseases
Impact of an Institutional Change in Prothrombin Time Methodology on INR and MELD Scores in Liver Transplant Evaluations.
Liver Diseases
Implications of use of low international sensitivity index thromboplastins in prothrombin time testing.
Liver Diseases
Improved parenchymal liver enhancement with extended delay on Gd-EOB-DTPA-enhanced MRI in patients with parenchymal liver disease: associated clinical and imaging factors.
Liver Diseases
Interpretation of the international normalised ratio in patients with liver disease.
Liver Diseases
Long-term postoperative bleeding after dentoalveolar surgery in the pretransplant liver failure patient.
Liver Diseases
Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis.
Liver Diseases
Platelet Function and Other Indices of Hemostasis in Chronic Liver Disease.
Liver Diseases
Post-Operative Hemorrhage After Liver Transplantation: Risk Factors and Long-Term Outcome.
Liver Diseases
Radioimmunoassays for protein C and factor X. Plasma antigen levels in abnormal hemostatic states.
Liver Diseases
Recombinant human factor VIIa-induced alterations in tissue factor and thrombomodulin in patients with advanced liver cirrhosis.
Liver Diseases
Relation of simple clotting tests to clotting factor levels in liver disease.
Liver Diseases
Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease.
Liver Diseases
S protein/vitronectin in chronic liver diseases: correlations with serum cholinesterase, coagulation factor X and complement component C3.
Liver Diseases
Serum thrombopoietin (c-Mpl ligand) levels in patients with liver cirrhosis.
Liver Diseases
Solvent-detergent plasma: use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies.
Liver Diseases
The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease.
Liver Diseases
The effect of hepatectomy on coagulation: an evaluation by thromboelastography.
Liver Diseases
Thrombin generation measured as thrombin-antithrombin complexes predicts clinical outcomes in patients with cirrhosis.
Liver Diseases
Usefulness and accuracy of the international normalized ratio and activity percent of prothrombin time in patients with liver disease.
Liver Diseases
[A new system of analysis for partial thromboplastin time. Comparison with other blood coagulation tests in liver diseases]
Liver Diseases
[Aspects of blood platelet function in liver diseases; adhesiveness and thromboplastin activity.]
Liver Diseases
[Comparative multicenter study of a rabbit high-sensitivity thromboplastin and a recombinant thromboplastin with synthetic phospholipids]
Liver Diseases
[Platelet function in liver diseases. II. Agglutinability & its plasmatic factor; platelet formula; thromboplastin generation test.]
Liver Diseases
[The diagnostic value of the aminophenazone breath test in chronic liver diseases]
Liver Diseases
[THEORIES CONCERNING FACTOR X (STUART-PROWER) IN LIVER DISEASES AND IN TREATMENT WITH INDIRECT ANTICOAGULANTS.]
Liver Diseases
[Thromboplastin generation test in liver disease.]
Liver Diseases
[Unexpected hemorrhage in surgery]
Liver Failure
Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders.
Liver Failure
Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis.
Liver Failure
Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio?
Liver Failure, Acute
Acute respiratory failure in adult patients with dengue virus infection.
Liver Failure, Acute
Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase.
Liver Failure, Acute
Induction of prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4 alpha.
Liver Failure, Acute
Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio?
Liver Failure, Acute
Transient, selective factor X deficiency and acute liver failure following chest infection treated with erythromycin BP.
Liver Failure, Acute
[Establishment of pig acute liver failure model and the role of pig fibrinogen-like protein 2.]
Lung Diseases
Activated clotting factor X mediates mitochondrial alterations and inflammatory responses via protease-activated receptor signaling in alveolar epithelial cells.
Lung Diseases, Interstitial
Evaluation on blood coagulation and C-reactive protein level among children with mycoplasma pneumoniae pneumonia by different chest imaging findings.
Lung Injury
Annexin A2 contributes to lung injury and fibrosis by augmenting factor Xa fibrogenic activity.
Lung Injury
Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.
Lung Injury
High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan.
Lung Injury
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury.
Lung Injury
Procoagulant, tissue factor-bearing microparticles in bronchoalveolar lavage of interstitial lung disease patients: an observational study.
Lung Injury
The effect of heparin administration in animal models of sepsis: A prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies*
Lung Injury
[Meta-analysis of the impact of continuous anticoagulation therapy with low-dose heparin or low molecular weight heparin on the prognosis of patients with acute respiratory distress syndrome].
Lung Neoplasms
Factor IXi-antithrombin (IXiAT) and thrombin-antithrombin (TAT) complexes in lung cancer patients.
Lung Neoplasms
Haemostatic abnormalities in lung cancer: prognostic implications.
Lung Neoplasms
Perioperative Bypassing Agent Therapy for Pulmonary Pleomorphic Carcinoma with Acquired Hemophilia.
Lung Neoplasms
Prognostic significance of blood coagulation tests in carcinoma of the lung and colon.
Lung Neoplasms
Prognostic significance of blood coagulation tests in lung cancer.
Lung Neoplasms
[Association between hemostasis/coagulation-system parameters and clinicopathological factors in patients with primary lung cancer].
Lung Neoplasms
[Prothrombin time and its standardization]
Lupus Erythematosus, Systemic
A case of Budd-Chiari syndrome with high antiphospholipid antibody in a patient with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
A unique precipitating autoantibody against plasma thromboplastin antecedent associated with multiple apparent plasma clotting factor deficiencies in a patient with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Acquired factor XIII inhibitor: clinical features, treatment, fibrin structure and epitope determination.
Lupus Erythematosus, Systemic
Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Lupus Erythematosus, Systemic
Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays.
Lupus Erythematosus, Systemic
Antibodies to thromboplastin in systemic lupus erythematosus: isotype distribution and clinical significance in a series of 92 patients.
Lupus Erythematosus, Systemic
Antibody to cardiolipin, lupus anticoagulant, and fetal death.
Lupus Erythematosus, Systemic
Assays for lupus anticoagulant: the sensitivity of different assays.
Lupus Erythematosus, Systemic
Association of lupus anticoagulant and anticardiolipin antibodies with thrombosis in patients with systemic lupus erythematosus, primary antiphospholipid syndrome and other disorders.
Lupus Erythematosus, Systemic
Evaluation of four coagulation tests to detect plasma lupus anticoagulants.
Lupus Erythematosus, Systemic
Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome.
Lupus Erythematosus, Systemic
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients.
Lupus Erythematosus, Systemic
Microparticles as biomarkers in autoimmunity: from dust bin to center stage.
Lupus Erythematosus, Systemic
Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies.
Lupus Erythematosus, Systemic
Prolonged Activated Partial Thromboplastin Time in Systemic Lupus Erythematosus Overlap Syndrome: Fatal Bleeding Due to Factor VIII Inhibitor.
Lupus Erythematosus, Systemic
Studies on a circulating anticoagulant in procainamide-induced lupus erythematosus.
Lupus Erythematosus, Systemic
The activated seven lupus anticoagulant assay detects clinically significant antibodies.
Lupus Erythematosus, Systemic
The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level.
Lupus Erythematosus, Systemic
The lupus anticoagulant. High incidence of 'negative' mixing studies in a human immunodeficiency virus-positive population.
Lupus Erythematosus, Systemic
The tissue thromboplastin inhibition test in diabetics without cerebro-cardiovascular diseases.
Lupus Erythematosus, Systemic
[Effectiveness and safety of selective and non - selective factor Xa inhibitors in antiphospholipid syndrome and systemic lupus erythematosus: anti - Xa - activity range].
Lupus Erythematosus, Systemic
[Hemorrhagic syndrome due to a heparin-like anticoagulant in a patient with systemic lupus erythematosus].
Lupus Erythematosus, Systemic
[Interference of factor VIII excess on the detection of lupus anticoagulants by the activated partial thromboplastin time]
Lupus Erythematosus, Systemic
[Presence of lupus-type anticoagulant, in systemic lupus erythematosus and other clinical entities]
Lupus Erythematosus, Systemic
[Regulation of coagulo-fibrinolytic activity and lupus anticoagulants in systemic lupus erythematosus]
Lupus Nephritis
Identification of a unique glomerular factor X activator in murine lupus nephritis.
Lupus Nephritis
Monocyte procoagulant activity in glomerulonephritis associated with systemic lupus erythematosus.
Lymphadenopathy
Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
Lymphatic Metastasis
Coagulation Factor Xa Promotes Solid Tumor Growth, Experimental Metastasis and Endothelial Cell Activation.
Lymphatic Metastasis
Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients.
Lymphedema
A model to assess the risk of peripherally inserted central venous catheter-related thrombosis in patients with breast cancer: a retrospective cohort study.
Lymphocytosis
Lymphoplasmacytic lymphoma exposed by haemoptysis and acquired von Willebrand syndrome.
Lymphoma
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer.
Lymphoma
Alteration in the laboratory profile of a lupus anticoagulant in a patient with non-Hodgkin's lymphoma.
Lymphoma
Approach to the treatment, characterization and diagnosis of an acquired auto-antibody directed against factors prothrombin, factor X and factor IX: a case report and review of the literature.
Lymphoma
Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma.
Lymphoma
Direct Factor X sequestration by systemic amyloid light-chain amyloidosis.
Lymphoma
Factor VIII inhibitors. Laboratory diagnosis of inhibitors.
Lymphoma
Increased activity of cell membrane-associated prothrombinase, fibrinogen-like protein 2, in peripheral blood mononuclear cells of B-cell lymphoma patients.
Lymphoma
Interference from lupus anticoagulant on von Willebrand factor measurement in splenic marginal zone lymphoma: a case report.
Lymphoma
Platelet function in dogs treated for lymphoma and hemangiosarcoma and supplemented with dietary n-3 fatty acids.
Lymphoma
Protease receptors in Hodgkin's disease: expression of the factor Xa receptor, effector cell protease receptor-1, in Reed-Sternberg cells.
Lymphoma
Successful treatment of a noninhibitory antibody-mediated acquired factor X deficiency in a patient with marginal-zone lymphoma.
Lymphoma
The 13-year bleed: Exuberant amyloid angiopathies, angiodysplasias, and acquired coagulopathies of the gut.
Lymphoma
[Relationship between coagulation function and international prognostic index in lymphoma patients].
Lymphoma, B-Cell
Activation of the Endoplasmic Reticulum Stress-Associated Transcription Factor X Box-Binding Protein-1 Occurs in a Subset of Normal Germinal-Center B Cells and in Aggressive B-Cell Lymphomas with Prognostic Implications.
Lymphoma, B-Cell
Increased activity of cell membrane-associated prothrombinase, fibrinogen-like protein 2, in peripheral blood mononuclear cells of B-cell lymphoma patients.
Lymphoma, B-Cell
Prolonged Activated Partial Thromboplastin Time and False-Positive Results for Fibrinogen and Fibrin Degradation Products in a B-Cell Lymphoma Patient.
Lymphoma, Large-Cell, Anaplastic
Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma.
Lymphoma, Non-Hodgkin
Alteration in the laboratory profile of a lupus anticoagulant in a patient with non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Measurement of factor Xa-antithrombin III in plasma: relationship to prothrombin activation in vivo.
Lymphoma, T-Cell
Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity.
Lymphopenia
A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1.
Lymphopenia
COVID-19 versus HIT hypercoagulability.
Lymphopenia
Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis.
Lymphopenia
Laboratory findings in patients with avian-origin influenza A (H7N9) virus infections.
Lymphopenia
Malignant histiocytosis in a cat.
Lymphopenia
Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study.
Lymphopenia
Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection.
Lymphopenia
SARS: clinical features and diagnosis.
Lymphopenia
Severe acute respiratory syndrome in a doctor working at the Prince of Wales Hospital.
Lymphopenia
Severe acute respiratory syndrome in children: experience in a regional hospital in Hong Kong.
Lymphopenia
[Catastrophic antiphospholipid syndrome and rituximab: a new report]
Lymphopenia
[Transverse myelopathy in a patient with systemic lupus erythematosus associated with positive anticardiolipin antibody--a case report]
Macular Degeneration
VEGF: From Discovery to Therapy: The Champalimaud Award Lecture.
Malaria
Activated partial thromboplastin time of owl monkey (Aotus trivirgatus) plasma.
Malaria
Activation of the coagulation cascade in falciparum malaria.
Malaria
Coagulation Status and Platelet Functions in Children with Severe Falciparum Malaria and their Correlation of Outcome.
Malaria
Effects of malaria parasitaemia on some haemostatic parameters among pregnant women of African descent in Specialist Hospital Sokoto, Nigeria.
Malaria
[Treatment of fulminant falciparum malaria with erythrapheresis]
Malaria, Falciparum
Activated partial thromboplastin time of owl monkey (Aotus trivirgatus) plasma.
Malnutrition
Moxalactam in the therapy of serious infections.
Massive Hepatic Necrosis
The nucleocapsid protein of murine hepatitis virus type 3 induces transcription of the novel fgl2 prothrombinase gene.
Mastitis
Alterations in coagulation parameters in dairy cows affected with acute mastitis caused by E. coli and S. aureus pathogens.
Meconium Aspiration Syndrome
Development of the Pediatric Extracorporeal Membrane Oxygenation Prediction Model for Risk-Adjusting Mortality.
Mediastinal Cyst
Hemorrhagic diathesis caused by factor X deficiency in a child with thymic cyst.
Melanoma
Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro.
Melanoma
Assembly and regulation of prothrombinase complex on B16F10 melanoma cells.
Melanoma
Cellular localization of activated factor X by Xa-specific probes.
Melanoma
Coagulation Factor Xa Promotes Solid Tumor Growth, Experimental Metastasis and Endothelial Cell Activation.
Melanoma
Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency.
Melanoma
Effect of MCM09, an active site-directed inhibitor of factor Xa, on B16-BL6 melanoma lung colonies in mice.
Melanoma
Effects of nutritional folate deficiency on the adhesive properties of murine melanoma cells.
Melanoma
Interaction of human tumor cells with human platelets and the coagulation system.
Melanoma
Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ.
Melanoma
Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor.
Melena
Superwarfarin Exposure: An Important Uncommon Cause of Painless Bleeding.
Meniere Disease
Acute peripheral vertigo: involvement of the hemostatic system.
Meningitis, Bacterial
Thromboplastic activity of cerebrospinal fluid in neurological disease.
Meningitis, Viral
Thromboplastic activity of cerebrospinal fluid in neurological disease.
Meningococcal Infections
Diagnosis and stage-related treatment of disseminated intravascular coagulation in meningococcal infections.
Meningococcal Infections
Diagnostic efficacy of activated partial thromboplastin time waveform and procalcitonin analysis in pediatric meningococcal sepsis.
Meningococcal Infections
Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis.
Menorrhagia
Factor X Deficiency: A Rare Cause of Puberty Menorrhagia.
Menorrhagia
Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study.
Menorrhagia
Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
Menorrhagia
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
Menorrhagia
Rare coagulation disorders.
Menorrhagia
Screening and diagnosis of coagulation disorders.
Menorrhagia
von Willebrand factor activity and activated partial thromboplastin time as proxy biomarkers for coagulopathies in women with menorrhagia in Zambia: a case-control study.
Menorrhagia
[Successful long-term management of ovarian bleeding and menorrhagia with prothrombin complex concentrate in a patient with congenital factor X deficiency].
Mesothelioma, Malignant
Abnormal activated partial thromboplastin time and malignancy.
Metabolic Syndrome
Factor xa inhibitor attenuates leukocyte adhesion and thrombus formation in an experimental mouse model of the metabolic syndrome.
Metabolic Syndrome
Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers.
Metrorrhagia
Signal detection for bleeding associated with the use of direct oral anticoagulants.
Migraine Disorders
A Case of Migraine With Aura Resolving on Warfarin But Not on Apixaban.
Migraine Disorders
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Mitral Valve Prolapse
Homozygous factor X deficiency associated with familial hypercholesterolemia, mitral valve prolapse, and hypertrophic cardiomyopathy.
Mitral Valve Prolapse
[Combined 2d-type TAR syndrome, factor X deficiency, immune deficiency and mitral valve prolapse]
Mixed Connective Tissue Disease
Prolonged Activated Partial Thromboplastin Time in Systemic Lupus Erythematosus Overlap Syndrome: Fatal Bleeding Due to Factor VIII Inhibitor.
Monoclonal Gammopathy of Undetermined Significance
Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Monoclonal Gammopathy of Undetermined Significance
The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma.
Mucopolysaccharidosis II
Hunter syndrome complicated by hydrocephalus and an endogenous anticoagulant.
Multiple Myeloma
A Case Report of Acquired Factor X Deficiency in a Patient With Multiple Myeloma.
Multiple Myeloma
A Rare Case of Early Onset Multiple Myeloma in a 20-Year-Old Female With Factor X Inhibitor.
Multiple Myeloma
Acquired factor X deficiency developed four years after autologous transplantation in a patient with multiple myeloma associated with systemic AL amyloidosis.
Multiple Myeloma
Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis.
Multiple Myeloma
Anticoagulant activities of a monoclonal antibody that binds to exosite II of thrombin.
Multiple Myeloma
Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma.
Multiple Myeloma
Factor X Deficiency Caused by Nonsecretory Myeloma Successfully Corrected with Bortezomib: A Case Report and Review of the Literature.
Multiple Myeloma
Light-chain paraproteins with lupus anticoagulant activity.
Multiple Myeloma
Monoclonal antibody light chain with prothrombinase activity.
Multiple Myeloma
The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.
Multiple Myeloma
The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma.
Multiple Myeloma
[A case of retroperitoneal hemorrhage due to multiple myeloma complicated with factor X deficiency and amyloidosis]
Multiple Myeloma
[Factor X deficiency associated with multiple myeloma.]
Multiple Myeloma
[Thromboplastin formation in Waldenström's macroglobulinemia and in multiple myeloma]
Multiple Sclerosis
Influence of human allergic encephalitogenic peptide on platelet aggregation in multiple sclerosis.
Multiple Sclerosis
Prothrombin and factor X are elevated in multiple sclerosis patients.
Myalgia
Alkhumra (Alkhurma) virus outbreak in Najran, Saudi Arabia: Epidemiological, clinical, and Laboratory characteristics.
Myalgia
Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children.
Myalgia
Difference in clinical presentation between the first and second phases of Kyasanur Forest disease: an experience from a teaching hospital in South India.
Myalgia
Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study.
Myalgia
[Crimean-Congo hemorrhagic fever]
Myasthenia Gravis
[High thrombokinase activity in a thymoma during myasthenia gravis]
Mycoplasma Infections
Acquired-transient factor X deficiency in a teenager with extensive burns.
Myeloproliferative Disorders
Phosphatidylserine expression on the platelet membrane of patients with myeloproliferative disorders and its effect on platelet-dependent thrombin formation.
Myocardial Infarction
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Myocardial Infarction
A rare case of fondaparinux-induced major bleeding in postmenopausal woman prescribed for non-ST segment elevation Ml.
Myocardial Infarction
Activated partial thromboplastin time (aPTT) monitoring to achieve therapeutic anticoagulation before and after introducing a nomogram for adjunctive heparin treatment with thrombolytic therapy for acute myocardial infarction.
Myocardial Infarction
Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
Myocardial Infarction
Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial.
Myocardial Infarction
Activated partial thromboplastin time correlates with methoxyhydroxyphenylglycol in acute myocardial infarction patients: therapeutic implications for patients at cardiovascular risk.
Myocardial Infarction
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin.
Myocardial Infarction
Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator.
Myocardial Infarction
Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
Myocardial Infarction
Alteration of plasma antithrombin III levels in ischemic heart disease.
Myocardial Infarction
Alterations in prothrombin time and activated partial thromboplastin time in patients with acute myocardial infarction.
Myocardial Infarction
Association of recurrent myocardial infarction with hemostatic factors: a prospective study.
Myocardial Infarction
Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
Myocardial Infarction
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Myocardial Infarction
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease.
Myocardial Infarction
Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial.
Myocardial Infarction
Coagulation factor Xa stimulates interleukin-8 release in endothelial cells and mononuclear leukocytes: implications in acute myocardial infarction.
Myocardial Infarction
Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review.
Myocardial Infarction
Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease.
Myocardial Infarction
Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
Myocardial Infarction
Conjunctive antithrombotic therapy for thrombolysis in myocardial infarction.
Myocardial Infarction
Correction to: Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction.
Myocardial Infarction
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
Myocardial Infarction
Different clinical presentations of a lupus anticoagulant in the same family.
Myocardial Infarction
Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 Trial.
Myocardial Infarction
Drug evaluation: the directly activated Factor Xa inhibitor otamixaban.
Myocardial Infarction
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis.
Myocardial Infarction
Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial.
Myocardial Infarction
Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
Myocardial Infarction
Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial.
Myocardial Infarction
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Myocardial Infarction
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial.
Myocardial Infarction
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).
Myocardial Infarction
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Myocardial Infarction
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Myocardial Infarction
Exploration of rapid bedside monitoring of coagulation and fibrinolysis parameters during thrombolytic therapy.
Myocardial Infarction
Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction.
Myocardial Infarction
Fluctuation of thrombin-antithrombin III complex in patients with acute myocardial infarction: influence of low-dose heparin administration.
Myocardial Infarction
Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
Myocardial Infarction
Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients.
Myocardial Infarction
Haemostatic function in coronary artery disease (CAD).
Myocardial Infarction
Heparin as an adjuvant to thrombolytic therapy in acute myocardial infarction.
Myocardial Infarction
Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
Myocardial Infarction
Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
Myocardial Infarction
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Myocardial Infarction
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.
Myocardial Infarction
Indications for antithrombotic therapy after myocardial infarction.
Myocardial Infarction
Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin.
Myocardial Infarction
Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
Myocardial Infarction
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial.
Myocardial Infarction
Left atrial structure and function and the risk of death or heart failure in atrial fibrillation.
Myocardial Infarction
Low molecular weight heparin in acute stroke.
Myocardial Infarction
Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage.
Myocardial Infarction
Myocardial infarctions and other acute coronary syndromes in rare congenital bleeding disorders: a critical analysis of all reported cases.
Myocardial Infarction
Natural inhibitors and fibrinogen/fibrin degradation products in patients with myocardial infarction.
Myocardial Infarction
New data in treatment of acute coronary syndromes.
Myocardial Infarction
Non-vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: Differences between factor IIa and factor Xa inhibition?
Myocardial Infarction
Optimisation of oral anticoagulants for patients with atrial fibrillation within 12?months after percutaneous coronary intervention: A meta-analysis and systematic review.
Myocardial Infarction
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Myocardial Infarction
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
Myocardial Infarction
Pre-operative labs: Wasted dollars or predictors of post-operative cardiac and septic events in orthopaedic trauma patients?
Myocardial Infarction
Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
Myocardial Infarction
Prognosis of spontaneous intracerebral hemorrhage in hemodialysis patients.
Myocardial Infarction
Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI.
Myocardial Infarction
Promise of factor Xa inhibition in acute coronary syndromes.
Myocardial Infarction
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.
Myocardial Infarction
Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.
Myocardial Infarction
Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial.
Myocardial Infarction
Reliability of an intravenous intermittent access port (saline lock) for obtaining blood samples for coagulation studies.
Myocardial Infarction
Rivaroxaban in acute coronary syndromes--is it prime time?
Myocardial Infarction
Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1.
Myocardial Infarction
Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction.
Myocardial Infarction
Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)
Myocardial Infarction
Spotlight on fondaparinux sodium in acute coronary syndromes.
Myocardial Infarction
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Myocardial Infarction
Stroke Prevention in Atrial Fibrillation - Outcomes and Future Directions.
Myocardial Infarction
Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time.
Myocardial Infarction
Systemic thrombin generation and activity resistant to low molecular weight heparin administered prior to streptokinase in patients with acute myocardial infarction.
Myocardial Infarction
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48 trial.
Myocardial Infarction
The "Dual-Pathway" Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial.
Myocardial Infarction
The activated partial thromboplastin time in early diagnosis of myocardial infarction.
Myocardial Infarction
The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction.
Myocardial Infarction
The medical management of acute coronary syndromes and potential roles for new antithrombotic agents.
Myocardial Infarction
The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy.
Myocardial Infarction
The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention.
Myocardial Infarction
Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
Myocardial Infarction
Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Myocardial Infarction
[Assessment of hemostasis in patients with myocardial infarction complicated by deep venous thrombosis]
Myocardial Infarction
[Deviation of activated partial thromboplastin time from optimal level after 12 hours of intravenous infusion of unfractionated heparin -- an independent predictor of recurrence and unfavorable 30-day prognosis in patients with myocardial infarction]
Myocardial Infarction
[Difference in examination of coagulation function in heparin anticoagulant therapy between point of care tests and automatic coagulation analyzer]
Myocardial Infarction
[Factor Xa-inhibition in interventional cardiology]
Myocardial Infarction
[Fibrinolysis and hemorrhage after streptokinase in acute myocardial infarct]
Myocardial Infarction
[Fondaparinux: The present and the future.]
Myocardial Infarction
[Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction]
Myocardial Ischemia
Alteration of plasma antithrombin III levels in ischemic heart disease.
Myocardial Ischemia
Aptamer-modified FXa generation assays to investigate hypercoagulability in plasma from patients with ischemic heart disease.
Myocardial Ischemia
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Myocardial Ischemia
Factor VII and haemostasis.
Myocardial Ischemia
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Myocardial Ischemia
Rare variants lowering the levels of coagulation factor X are protective against ischemic heart disease.
Myocardial Ischemia
Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.
Myocardial Ischemia
Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice.
Myocardial Ischemia
[THE TEST OF GENERATION OF THROMBIN IN DYNAMICS IN PATIENTS AFTER TRANSCUTANEOUS CORONARY INTERVENTION].
Myocarditis
Inhibition of coagulation factor Xa improves myocardial function during CVB3-induced myocarditis.
Myocarditis
[EFFECT OF CORCHOROZIDE ON THE THROMBOPLASTIN AND HEPARIN TIME IN RABBITS UNDER NORMAL CONDITIONS AND IN EXPERIMENTAL MYOCARDITIS.]
Myoma
[Changes of coagulation function in patients with adenomyosis and its clinical significance].
Myxoma
Myxoma viral serpin, Serp-1, a unique interceptor of coagulation and innate immune pathways.
Myxoma
Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets.
Nasal Polyps
Thrombin and activated coagulation factor X stimulate the release of cytokines and fibronectin from nasal polyp fibroblasts via protease-activated receptors.
Nasopharyngeal Carcinoma
Routine coagulation molecules predict nasopharyngeal carcinoma and associated metastases.
Nasopharyngeal Carcinoma
[The role of EPR-1 in proliferation and apoptosis in nasopharyngeal carcinoma]
Neoplasm Metastasis
A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors?
Neoplasm Metastasis
Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro.
Neoplasm Metastasis
Cancer and thrombosis in women - molecular mechanisms.
Neoplasm Metastasis
Coagulation Factor Xa Promotes Solid Tumor Growth, Experimental Metastasis and Endothelial Cell Activation.
Neoplasm Metastasis
Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity.
Neoplasm Metastasis
Factor X-activating activity from Guerin epithelioma.
Neoplasm Metastasis
Failure to warfarin to affect the tissue factor activity and the metastatic potential of murine fibrosarcoma cells.
Neoplasm Metastasis
Involvement of the heparanase procoagulant domain in bleeding and wound healing.
Neoplasm Metastasis
Is EPCR a multi-ligand receptor? Pros and cons.
Neoplasm Metastasis
Loss of metastatic and primary tumor factor X activator capabilities by Lewis lung carcinoma cells cultured in vitamin K-dependent protein deficient serum.
Neoplasm Metastasis
Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients.
Neoplasm Metastasis
Mechanisms of cancer-induced thrombosis in cancer.
Neoplasm Metastasis
Risk factors for brain metastases from non-small-cell lung cancer: A protocol for observational study.
Neoplasm Metastasis
The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Neoplasm Metastasis
Thrombin is a selective inducer of heparanase release from platelets and granulocytes via protease-activated receptor-1.
Neoplasm Metastasis
Thromboplastin release, but not content, correlates with spontaneous metastasis of cancer cells.
Neoplasm Metastasis
Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells.
Neoplasm Metastasis
Tumour sublines with different metastatic capacity induce similar blood coagulation changes in the host.
Neoplasm Metastasis
[Contribution to the aetiology of "reversible hepatic dysfunction" (Stauffer's syndrome) associated with renal tumours]
Neoplasms
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
Neoplasms
A discrepancy between prothrombin time and Normotest (Hepaplastintest) results is useful for diagnosis of acquired factor V inhibitors.
Neoplasms
A factor X-activating cysteine protease from malignant tissue.
Neoplasms
A Kunitz-type FXa inhibitor affects tumor progression, hypercoagulable state and triggers apoptosis.
Neoplasms
A Novel Phenotype of Germline Pathogenic Variants in MAX: Concurrence of Pheochromocytoma and Ganglioneuroma in a Chinese Family and Literature Review.
Neoplasms
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer.
Neoplasms
A retrospective analysis of plasma D-dimer dynamic variation in terminal stage cancer patients: implications for disease progression.
Neoplasms
A shortened activated partial thromboplastin time predicts the risk of catheter-associated venous thrombosis in cancer patients.
Neoplasms
A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor induced disseminated intravascular coagulation in rats.
Neoplasms
Abnormal activated partial thromboplastin time and malignancy.
Neoplasms
Acquired factor IX inhibitor in a patient with adenocarcinoma of the colon.
Neoplasms
Activated factor X signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine production from LPS-stimulated myeloid cells.
Neoplasms
Activated protein c can be used as a prophylactic as well as a therapeutic agent for heat stroke in rodents.
Neoplasms
Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation.
Neoplasms
Activated protein C therapy in a rat heat stroke model.
Neoplasms
Activated-protein-C resistance in cancer patients.
Neoplasms
Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients.
Neoplasms
Activation of coagulation after administration of tumor necrosis factor to normal subjects.
Neoplasms
Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.
Neoplasms
Activation of factor X and its regulation by tissue factor pathway inhibitor in small-diameter capillaries lined with human endothelial cells.
Neoplasms
An assessment of monocyte procoagulant activity in patients with solid tumors.
Neoplasms
An ultrastructural and immunohistochemical study of pigmented dermatofibrosarcoma protuberans (Bednar tumor).
Neoplasms
An update on the efficacy and safety of novel anticoagulants for cancer associated thrombosis.
Neoplasms
Ancylostoma caninum anticoagulant peptide blocks metastasis in vivo and inhibits factor Xa binding to melanoma cells in vitro.
Neoplasms
Androgenic adult granulosa cell tumour with prolongation of the activated partial thromboplastin time in a 29 year old woman.
Neoplasms
Antagonism by salvianolic acid B of lipopolysaccharide-induced disseminated intravascular coagulation in rabbits.
Neoplasms
Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
Neoplasms
Antithrombin III and Factor VIII in patients with neoplasms.
Neoplasms
Antithrombotic activities of wogonin and wogonoside via inhibiting platelet aggregation.
Neoplasms
Apixaban for the treatment of cancer-associated venous thromboembolism and left atrial appendage thrombus refractory to optimal anticoagulation with warfarin: a case report.
Neoplasms
Apixaban Suppresses the Release of TF-Positive Microvesicles and Restrains Cancer Cell Proliferation through Directly Inhibiting TF-fVIIa Activity.
Neoplasms
Assembly and regulation of prothrombinase complex on B16F10 melanoma cells.
Neoplasms
Binding of human factors X and Xa to HepG2 and J82 human tumor cell lines. Evidence that factor Xa binds to tumor cells independent of factor Va.
Neoplasms
Blood coagulation in patients with benign and malignant tumours before and after surgery. Special reference to thromboplastin generation in monocytes.
Neoplasms
Brain cooling causes attenuation of cerebral oxidative stress, systemic inflammation, activated coagulation, and tissue ischemia/injury during heatstroke.
Neoplasms
Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis.
Neoplasms
Cancer and thrombosis in women - molecular mechanisms.
Neoplasms
Cancer cell procoagulants and their pharmacological modulation.
Neoplasms
Cancer cells BXPC3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin.
Neoplasms
Cancer procoagulant (CP) analysis in human WM 115 malignant melanoma cells in vitro.
Neoplasms
Cancer procoagulant A: a factor X activating procoagulant from malignant tissue.
Neoplasms
Cancer procoagulant in acute lymphoblastic leukemia.
Neoplasms
Cancer procoagulant in human tumor cells: evidence from melanoma patients.
Neoplasms
Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue.
Neoplasms
Cancer-associated thrombosis: investigating the role of new oral anticoagulants.
Neoplasms
Case Report of a Prolactinoma in a Patient With a Novel
Neoplasms
Cellular localization of activated factor X by Xa-specific probes.
Neoplasms
CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Neoplasms
Characterization of the cell-surface procoagulant activity of T-lymphoblastoid cell lines.
Neoplasms
Characterization of Thrombin Generation Curve Shape in Presence of Platelets from Acute Venous Thromboembolism Patients.
Neoplasms
Circulating endothelial cells in cancer patients do not express tissue factor.
Neoplasms
Clinical conditions and treatment requirements for long-term survival among hepatitis B-related hepatocellular carcinoma initially treated with chemoembolization.
Neoplasms
Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients.
Neoplasms
Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study.
Neoplasms
Clinical significance of increased thromboplastin activity on the monocyte surface--a brief review.
Neoplasms
Clinical studies in patients with solid tumors using a second-generation antisense oligonucleotide (GEM 231) targeted against protein kinase A type I.
Neoplasms
Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function.
Neoplasms
Co-localization of Protein Z, Protein Z-Dependent protease inhibitor and coagulation factor X in human colon cancer tissue: implications for coagulation regulation on tumor cells.
Neoplasms
Coagulant and fibrinolytic activities of a metastasising and non-metastasising tumour line.
Neoplasms
Coagulation and fibrinolysis in chronic venous insufficiency.
Neoplasms
Coagulation and the expression of cell-mediated immunity.
Neoplasms
Coagulation factor Xa drives tumor cells into apoptosis through BH3-only protein Bim up-regulation.
Neoplasms
Coagulation Factor Xa inhibits cancer cell migration via LIMK1-mediated cofilin inactivation.
Neoplasms
Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation.
Neoplasms
Coagulation Factor Xa Promotes Solid Tumor Growth, Experimental Metastasis and Endothelial Cell Activation.
Neoplasms
Coagulation signaling and cancer immunotherapy.
Neoplasms
Combining early coagulation and inflammatory status improves prediction of mortality in burned and nonburned trauma patients.
Neoplasms
Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis.
Neoplasms
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Neoplasms
Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous thromboembolism between patients with and without cancer.
Neoplasms
Correlation of haemostatic abnormalities with tumour stage and characteristics in dogs with mammary carcinoma.
Neoplasms
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism.
Neoplasms
Cutaneous histopathologic findings in 'antiphospholipid syndrome'. Correlation with disease, including human immunodeficiency virus disease.
Neoplasms
Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma.
Neoplasms
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Neoplasms
Development of a novel mouse model for dengue virus infection.
Neoplasms
Development of a Predictive Model of Difficult Hemostasis following Endobronchial Biopsy in Lung Cancer Patients.
Neoplasms
Dexamethasone improves heat stroke-induced multiorgan dysfunction and damage in rats.
Neoplasms
Direct analysis reveals an absence of gamma-carboxyglutamic acid in cancer procoagulant from human tissues.
Neoplasms
Disseminated intravascular coagulopathy.
Neoplasms
Dual functionalized chitosan based composite hydrogel for haemostatic efficacy and adhesive property.
Neoplasms
Dual interference of novel gene mfgl2 and mTNFR1 ameliorates murine hepatitis virus type 3-induced fulminant hepatitis in BALB/cJ mice.
Neoplasms
Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer.
Neoplasms
Early response in septicemia in newborns and their mothers. Effect of Escherichia coli, Streptococcus agalactiae and tumor necrosis factor on lactoferrin release and the generation of tissue thromboplastin.
Neoplasms
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
Neoplasms
Effect of BsaA I genotyped intronic SNP of leptin gene on production and reproduction traits in Indian dairy cattle.
Neoplasms
Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro.
Neoplasms
Effect of FC43se on endotoxin-induced disseminated intravascular coagulation in rats.
Neoplasms
Effect of low molecular weight heparin rectal suppository on experimental ulcerative colitis in mice.
Neoplasms
Effect of Serum Immunoglobulins on Routine Coagulation Tests: A Comparison of Coagulation Analyzers using Mechanical and Optical Clot Detection.
Neoplasms
Effectiveness and safety of oral direct factor Xa inhibitors for the treatment of venous thromboembolism in patients with cancer and/or older age.
Neoplasms
Effects of bacterial translocation on hemodynamic and coagulation parameters during living-donor liver transplant.
Neoplasms
Effects of curcumin on the gene expression profile of L-02 cells.
Neoplasms
Effects of intravenous high doses of ketoprofen on blood clotting, bleeding time and platelet aggregation in man.
Neoplasms
Effects of postoperative parenteral nutrition with different lipid emulsions in patients undergoing major abdominal surgery.
Neoplasms
Efficacy of oral colon-specific delivery capsule of low-molecular-weight heparin on ulcerative colitis.
Neoplasms
Elevated plasma levels of the factor Xa-TFPI complex in cancer patients.
Neoplasms
Emergency Physicians Choose Wisely When Ordering Plain Radiographs for Low Back Pain Patients.
Neoplasms
Endothelial dysfunction in experimental hyperhomocysteinemia.
Neoplasms
Engineering of human coagulation factor x variants activated by prostate-specific antigen.
Neoplasms
Enhanced induction of heme oxygenase-1 suppresses thrombus formation and affects the protein C system in sepsis.
Neoplasms
Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy.
Neoplasms
Evaluation of human recombinant tissue factor-activated thromboelastography in 49 dogs with neoplasia.
Neoplasms
Evaluation of the Activity of Heparin Injected into the Fully Implantable Catheter for Chemotherapy (Portocath) between Two Moments of Use.
Neoplasms
Evidence for a warfarin-sensitive serum factor that participates in factor X activation by Lewis lung tumor cells.
Neoplasms
Evidence that cells from experimental tumours can activate coagulation factor X.
Neoplasms
Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation.
Neoplasms
F10 gene hypomethylation, a putative biomarker for glioma prognosis.
Neoplasms
Factor IXi-antithrombin (IXiAT) and thrombin-antithrombin (TAT) complexes in lung cancer patients.
Neoplasms
Factor VIII inhibitors. Laboratory diagnosis of inhibitors.
Neoplasms
Factor X-activating activity from Guerin epithelioma.
Neoplasms
Factor Xa inhibits HMGB1-induced septic responses in human umbilical vein endothelial cells and in mice.
Neoplasms
Factor Xa: at the crossroads between coagulation and signaling in physiology and disease.
Neoplasms
Fibrinogen deposition without thrombin generation in primary human breast cancer tissue.
Neoplasms
Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-gamma.
Neoplasms
Fibrinolysis, thromboplastin activity and localization of radioiodinated fibrinogen in experimental tumors.
Neoplasms
FVIIa Neutralization by a FXa Inhibitor: How It Could Dampen Tumorigenic Cancer Cell Phenotypes.
Neoplasms
Heme oxygenase 1 modulates thrombomodulin and endothelial protein C receptor levels to attenuate septic kidney injury.
Neoplasms
Hemostasis and cancer: tumor cells induce the expression of tissue factor-like procoagulant activity on endothelial cells.
Neoplasms
Hemostasis and mechanism of action of selective antimetastatic drugs in mice bearing Lewis lung carcinoma.
Neoplasms
Hemostasis following inoculation and during spreading of colon carcinoma in the rat.
Neoplasms
Hemostasis in malignancy.
Neoplasms
Hemostatic abnormalities associated with cancer and its therapy.
Neoplasms
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Neoplasms
Hemostatic function in cancer patients.
Neoplasms
High-dose antithrombin III treatment of severely injured patients: results of a prospective study.
Neoplasms
Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy.
Neoplasms
Improved survival of patients presenting with acute variceal bleeding. Prognostic indicators of short- and long-term mortality.
Neoplasms
In Vitro Screening of Synthetic Fluorogenic Substrates for Detection of Cancer Procoagulant Activity.
Neoplasms
Inactivation of factor Va by activated protein C on selected human tumor cell lines.
Neoplasms
Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.
Neoplasms
Increased activity of cell membrane-associated prothrombinase, fibrinogen-like protein 2, in peripheral blood mononuclear cells of B-cell lymphoma patients.
Neoplasms
Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin.
Neoplasms
Inhibition of tissue factor signaling in breast tumour xenografts induces widespread changes in the microRNA expression profile.
Neoplasms
Inhibitory effect of non-anticoagulant heparin (S-NACH) on pancreatic cancer cell adhesion and metastasis in human umbilical cord vessel segment and in mouse model.
Neoplasms
Interaction between Mouse Adenovirus Type 1 and Cell Surface Heparan Sulfate Proteoglycans.
Neoplasms
INTRACELLULAR LOCATION OF TISSUE THROMBOPLASTIN AND POSSIBLE RELATION TO FIBRIN DEPOSITS IN HUMAN NEOPLASMS.
Neoplasms
Intrinsic versus extrinsic coagulation. Kinetic considerations.
Neoplasms
Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial.
Neoplasms
Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue.
Neoplasms
Lodgement and extravasation of tumour cells in blood-borne metastasis: an electron microscope study.
Neoplasms
Loss of metastatic and primary tumor factor X activator capabilities by Lewis lung carcinoma cells cultured in vitamin K-dependent protein deficient serum.
Neoplasms
Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients.
Neoplasms
Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ.
Neoplasms
Management of postoperative hemorrhage associated with factor VIII inhibitor: report of a case.
Neoplasms
Markers of coagulation activation after hepatic resection for cancer: evidence of sustained upregulation of coagulation.
Neoplasms
Mast cell-derived exosomes activate endothelial cells to secrete plasminogen activator inhibitor type 1.
Neoplasms
Measurement of factor Xa-antithrombin III in plasma: relationship to prothrombin activation in vivo.
Neoplasms
Mechanisms of cancer-induced thrombosis in cancer.
Neoplasms
Myeloid cell-synthesized coagulation factor X dampens antitumor immunity.
Neoplasms
New and old anticoagulants in cancer.
Neoplasms
New antithrombotic drugs: potential for use in oncology.
Neoplasms
New Bisabosquals from Stachybotrys sp. PH30583 Elicited on Solid Media.
Neoplasms
Next Generation Antibody Therapeutics Using Bispecific Antibody Technology.
Neoplasms
Noninvasive evaluation of ovarian endometriosis: a single-center experience.
Neoplasms
Novel factor X deficiency. Normal partial thromboplastin time and associated spindle cell thymoma.
Neoplasms
OC-03 - Modelisation of the procoagulant properties of cancer cells and their capacity to alter the antithrombotic efficiency of LMWHs and specific inhibitors of factor Xa.
Neoplasms
Occurrence of blood coagulation factors in situ in small cell carcinoma of the lung.
Neoplasms
Opposing effects of HIF1? and HIF2? on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Neoplasms
Paravertebral and Retroperitoneal Vascular Tumour Presenting with Kasabach-Merritt Phenomenon in Childhood, Diagnosed with Magnetic Resonance Imaging.
Neoplasms
Partial Thromboplastin Time: Accurate Measurement Through Evidence-Based Practice.
Neoplasms
Pathophysiology of venous thromboembolism.
Neoplasms
Peliosis hepatis mimicking hepatic malignancy: A case report.
Neoplasms
Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues.
Neoplasms
Plasma composition distribution in cancer: Discrimination by thrombin and factor Xa generation.
Neoplasms
Platelets stimulate thromboplastin synthesis in human endothelial cells.
Neoplasms
Platonin, a cyanine photosensitizing dye, causes attenuation of circulatory shock, hypercoagulable state, and tissue ischemia during heat stroke.
Neoplasms
Platonin, a cyanine photosensitizing dye, is effective for attenuation of heatstroke in rats.
Neoplasms
PO-23 - Expression of heparanase in cancer as biomarker of malignancies: overexpression in an aggressive, poor survival gastric cancer "gastric signet ring cell carcinoma" compared with that of other gastric cancers.
Neoplasms
PO-36 - Thrombin Inhibition Preoperatively (TIP) in early breast cancer, the first clinical trial of NOACs as an anti-cancer agent: trial methodology.
Neoplasms
Pre-existing lipopolysaccharide may increase the risk of heatstroke in rats.
Neoplasms
Prediction of gastrointestinal bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational cohort study (STROBE compliant).
Neoplasms
Prediction of Poor Outcomes in Patients with Colorectal Cancer: Elevated Preoperative Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT).
Neoplasms
Preoperative hematological assessment of pediatric patients with cerebral palsy.
Neoplasms
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Neoplasms
Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells.
Neoplasms
Procoagulant activity of mouse and human cultured cells following various types of transformation.
Neoplasms
Procoagulant activity of mouse transformed cells: different expression in freshly isolated or cultured cells.
Neoplasms
Procoagulant properties of human MV3 melanoma cells.
Neoplasms
Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an inner-city population.
Neoplasms
Promotion of metastasis by a specific complex of coagulation factors may be independent of fibrin formation.
Neoplasms
Properties of proteins in cancer procoagulant preparations that are detected by anti-tissue factor antibodies.
Neoplasms
Protease-activated receptor 2 (PAR2) blocking peptide counteracts endotoxin-induced inflammation and coagulation and ameliorates renal fibrin deposition in a rat model of acute renal failure.
Neoplasms
Protective mechanism of Xuebijing injection against heat stroke in rats.
Neoplasms
Protein Z/protein Z-dependent protease inhibitor system in human non-small-cell lung cancer tissue.
Neoplasms
Protein Z/protein Z-dependent protease inhibitor system in loco in human gastric cancer.
Neoplasms
Pulmonary Thromboembolism in COVID-19: Venous Thromboembolism or Arterial Thrombosis?
Neoplasms
Pyogenic liver abscess. An audit of experience over the past decade.
Neoplasms
Rat prostate tumors express cancer procoagulant, an activator of coagulation factor X.
Neoplasms
Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Neoplasms
Recurrent Venous Thromboembolism in Two Patients With Cancer Taking Rivaroxaban.
Neoplasms
Regulatory Factor X 7 and its Potential Link to Lymphoid Cancers.
Neoplasms
Relation between coagulation/fibrinolysis and lactate in the course of human septic shock.
Neoplasms
Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Neoplasms
Rhamnan sulfate extracted from Monostroma nitidum attenuates blood coagulation and inflammation of vascular endothelial cells.
Neoplasms
Risk factors of early death in adult patients with secondary hemophagocytic lymphohistiocytosis: a single-institution study of 171 Chinese patients.
Neoplasms
Rivaroxaban does not affect growth of human pancreatic tumors in mice.
Neoplasms
Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer.
Neoplasms
Rivaroxaban versus enoxaparin for the prevention of recurrent venous thromboembolism in patients with cancer: A meta-analysis.
Neoplasms
Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
Neoplasms
Role of Hypercoagulable State for Predictive Ovarian Malignancy in Women with a Pelvic Mass.
Neoplasms
Role of phosphoinositide 3-kinase in adhesion of platelets to fibrinogen stimulated by cancer procoagulant.
Neoplasms
Role of plasma, platelets, and endothelial cells in tumor metastasis.
Neoplasms
Role of tissue factor in hepatocellular carcinoma genesis, invasion and metastasis.
Neoplasms
Role of tumor thromboplastin in the mode of distribution of metastatic foci in the lung.
Neoplasms
Roles of factor Xa beyond coagulation.
Neoplasms
Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study.
Neoplasms
Several murine metastasizing tumors possess a cysteine proteinase with cancer procoagulant characteristics.
Neoplasms
Shanghai Score: A Prognostic and Adjuvant Treatment-evaluating System Constructed for Chinese Patients with Hepatocellular Carcinoma after Curative Resection.
Neoplasms
Species D Adenoviruses as Oncolytic Viral Vectors.
Neoplasms
Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE.
Neoplasms
Stroke risk factor, pattern and outcome in patients with cancer.
Neoplasms
Substrate optimization and clinical validation of reporter peptides for MS-based protease profiling in serum specimens: a new approach for diagnosis of malignant disease.
Neoplasms
The action of Amblyomma cajennense tick saliva in compounds of the hemostatic system and cytotoxicity in tumor cell lines.
Neoplasms
The C3H/St/Ha mammary tumor. I. Thromboplastin content.
Neoplasms
The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development.
Neoplasms
The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma.
Neoplasms
The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Neoplasms
The features comparison between patients in the ICU and general wards and between patients with different outcomes: a 2020 COVID-19 study.
Neoplasms
The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways.
Neoplasms
The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention.
Neoplasms
The production of tumour necrosis factor, tissue thromboplastin, lactoferrin and cathepsin C during lipopolysaccharide stimulation in whole blood.
Neoplasms
The prophylaxis of venous thrombosis in patients with cancer undergoing major abdominal surgery: emerging options.
Neoplasms
The proteolytic profile of human cancer procoagulant suggests that it promotes cancer metastasis at the level of activation rather than degradation.
Neoplasms
The role of macrophage activation in chronic inflammation.
Neoplasms
The site of activation of factor X by cancer procoagulant.
Neoplasms
Therapy with interleukin-22 alleviates hepatic injury and hemostasis dysregulation in rat model of acute liver failure.
Neoplasms
Thinking outside the box: mechanisms of environmental selective pressures on the outcome of the materno-fetal relationship.
Neoplasms
Three-stage chromogenic assay for the analysis of activation properties of factor X by cancer procoagulant.
Neoplasms
Thrombin stimulates arachidonate metabolism in murine tumor cells.
Neoplasms
Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer.
Neoplasms
Thromboplastic and fibrinolytic activities of cultured human cancer cell lines.
Neoplasms
Thromboplastin release, but not content, correlates with spontaneous metastasis of cancer cells.
Neoplasms
Thrombosis and cancer.
Neoplasms
Thrombosis in brain tumors.
Neoplasms
Tissue Factor Pathway Inhibitor Attenuates the Progression of Malignant Pleural Mesothelioma in Nude Mice.
Neoplasms
Tissue factor-like activity of the human monocytic tumor cell line U937.
Neoplasms
Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.
Neoplasms
Transcription factor RFX7 governs a tumor suppressor network in response to p53 and stress.
Neoplasms
Transduction of liver metastases after intravenous injection of Ad5/35 or Ad35 vectors with and without factor X-binding protein pretreatment.
Neoplasms
Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic options.
Neoplasms
Treatment of cancer with anticoagulants: rationale in the treatment of melanoma.
Neoplasms
Treatment of venous thrombosis in the cancer patient.
Neoplasms
Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives.
Neoplasms
Trousseau's syndrome: cancer-associated thrombosis.
Neoplasms
Tumor cell generation of thrombin via functional prothrombinase assembly.
Neoplasms
Tumor cells augment the factor Xa-catalyzed conversion of prothrombin to thrombin.
Neoplasms
Tumor cells induce platelet aggregation and intraplatelet calcium ion movements.
Neoplasms
Tumor fluid thromboplastin activity.
Neoplasms
Tumor volume estimation by the percentage carcinoma method in uterine cervix carcinoma.
Neoplasms
Update from the laboratory: mechanistic studies of pathways of cancer-associated venous thrombosis using mouse models.
Neoplasms
Use of Viscoelastography in Malignancy-Associated Coagulopathy and Thrombosis: A Review.
Neoplasms
Venous Thromboembolism in Gynecological Malignancy.
Neoplasms
XBP1 silencing decreases glioma cell viability and glycolysis possibly by inhibiting HK2 expression.
Neoplasms
ZFX knockdown inhibits growth and migration of non-small cell lung carcinoma cell line H1299.
Neoplasms
[A Meta-analysis of Qingre Jiedu and Liangxue Sanyu method in the treatment of sepsis].
Neoplasms
[Advances in genes and molecular markers of pheochromocytoma].
Neoplasms
[Anticoagulants: current topics].
Neoplasms
[Assessment of variables relative to prethrombotic state after operation in patients with gynecological malignancies]
Neoplasms
[Changes in the activity of blood thrombokinase in patients with malignant neoplasms under the influence of radiotherapy.]
Neoplasms
[Effect of high-dose medroxyprogesterone acetate on coagulative and fibrinolytic factors in patients with gynecological cancers]
Neoplasms
[Effect of the amount of portal blood stasis removal on endotoxemia and liver function after liver transplantation]
Neoplasms
[Effectiveness of Xuebijing in treatment of multiple organ dysfunction syndrome: a Meta analysis].
Neoplasms
[Establishment of a human lung squamous cell carcinoma cell line LK-17, and characterization of procoagulant, platelet aggregation and metastatic potential]
Neoplasms
[Hemostasis system in lung cancer, benign tumors and chronic nonspecific pneumonias]
Neoplasms
[Influence of thromboplastin on the development of experimental transplantable neoplasms]
Neoplasms
[Meta-analysis of the impact of continuous anticoagulation therapy with low-dose heparin or low molecular weight heparin on the prognosis of patients with acute respiratory distress syndrome].
Neoplasms
[Mixed corticomedullary tumor]
Neoplasms
[On the relation of the tumor process to thrombokinase activity in the tumor tissue.]
Neoplasms
[Paraneoplastic syndrome hematologic abnormalities]
Neoplasms
[Refractory kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: clinical analysis of 10 cases].
Neoplasms
[Studies on thromboplastin activity, fibrinolysis and uptake of radioactive iodine-labeled fibrinogen in various experimental tumors]
Neoplasms
[Study on vascular endothelial injuries and inflammation related cytokines in patients with multiple organ dysfunction syndrome.]
Neoplasms
[The phenomenon of relative resistance to heparin]
Neoplasms
[The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward].
Neoplasms
[Thrombokinase activity of the tissues in various endocrine disorders and tumor growths.]
Neoplasms
[Thrombosis and embolism as paraneoplastic syndrome]
Neoplasms, Plasma Cell
Effect of Serum Immunoglobulins on Routine Coagulation Tests: A Comparison of Coagulation Analyzers using Mechanical and Optical Clot Detection.
Nephritis
Effect of antithrombin III on local hemostasis in the kidneys during experimental nephritis.
Nephritis
Plasma activity of contact coagulation factors in patients with IgA nephritis.
Nephritis
Roles of coagulation pathway and factor Xa in the progression of diabetic nephropathy in db/db mice.
Nephritis, Interstitial
Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis.
Nephrosis
Nonanticoagulant protective effect of heparin in chronic aminonucleoside nephrosis.
Nephrotic Syndrome
Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome.
Nephrotic Syndrome
Acquired von Willebrand Syndrome Complicating Nephrotic Syndrome: A Case of a Patient With Membranous Nephropathy.
Nephrotic Syndrome
Changes of coagulation factors IX, VIII, VII, X, and V in nephrotic syndrome.
Nephrotic Syndrome
Effect of corticosteroids on coagulation factors in children with nephrotic syndrome.
Nephrotic Syndrome
Haemostatic parameters in childhood nephrotic syndrome. (Is there any difference in protein C levels between steroid sensitive and resistant groups?)
Nephrotic Syndrome
Nephrotic syndrome resulting in thromboembolic disease and disseminated intravascular coagulation in a dog.
Nephrotic Syndrome
Primary amyloidosis with severe nephrotic syndrome and acquired factor X deficiency.
Nephrotic Syndrome
Progressive systemic sclerosis with the nephrotic syndrome and acquired factor X deficiency.
Nephrotic Syndrome
Vasculas complications in nephrotic syndrome: relationship to steroid therapy and accelerated thromboplastin generation.
Nephrotic Syndrome
[Nephrotic syndrome and acquired deficiency of Stuart factor revealing the presence of amylosis and myeloma]
Nephrotic Syndrome
[Nephrotic syndrome complicated with intracranial venous thrombosis treated with urokinase: report of 5 cases]
Nephrotic Syndrome
[Primary amyloidosis associated to severe factor X deficiency]
Neurilemmoma
Local Regulation of Thrombin Activity by Factor Xa in Peripheral Nerve Schwann Cells.
Neurofibromatoses
CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Neurofibromatosis 1
CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Neurogenic Inflammation
New mechanistic model for organic diisocyanate-induced respiratory disease.
Neuroinflammatory Diseases
Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis.
Neurologic Manifestations
Factors associated with stroke following the Fontan procedure.
Neuroma, Acoustic
Hypercoagulability in Vestibular Schwannoma Surgery.
Neuromyelitis Optica
Prothrombin and factor X are elevated in multiple sclerosis patients.
Neutropenia
Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.
Neutropenia
Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma.
Neutropenia
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.
Neutropenia
[Clinical and epidemiological characteristic of dengue]
Non-alcoholic Fatty Liver Disease
Hemostatic alterations in fatty liver disease.
Non-ST Elevated Myocardial Infarction
Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
Noonan Syndrome
Hematological findings in Noonan syndrome.
Noonan Syndrome
Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
Obesity
Activated partial thromboplastin time and risk of future venous thromboembolism.
Obesity
Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.
Obesity
Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance.
Obesity
Prevention of venous thromboembolism in obesity.
Obesity
[On various aspects of blood coagulation in obesity. II. Studies on the aggregation ("clumping") of thrombocytes "in vitro" and on the thromboplastin formation]
Obesity, Morbid
Direct oral factor Xa inhibitors in patients with morbid obesity - Author's reply.
Obesity, Morbid
Direct oral factor Xa inhibitors in patients with morbid obesity.
Obesity, Morbid
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Obesity, Morbid
Prevention of venous thromboembolism in obesity.
Obstetric Labor, Premature
Expression of prothrombin and protease activated receptors in human myometrium during pregnancy and labor.
Oliguria
A new prognostic scoring system for meningococcal septic shock in children. Comparison with three other scoring systems.
Opportunistic Infections
Acquired circulating anticoagulants in children with acquired immunodeficiency syndrome.
Opportunistic Infections
Lupus anticoagulant in the acquired immunodeficiency syndrome.
Oral Ulcer
Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions.
Osteoarthritis
Argatroban more effectively inhibits the thrombin activity in synovial fluid than naturally occurring thrombin inhibitors.
Osteoarthritis
Effect of nabumetone on hemostasis during arthroscopic knee surgery.
Osteoarthritis
Effects of intravenous high doses of ketoprofen on blood clotting, bleeding time and platelet aggregation in man.
Osteoarthritis
Effects on leukocyte function by arthroplasty. Thromboplastin activity and oxygen-derived free radicals studied in rheumatoid arthritis and arthrosis.
Osteoarthritis
[Comparison of combined intravenous and topical use of tranexamic acid with different dosage in primary total knee arthroplasty].
Osteomyelitis
Candida vertebra osteomyelitis in a girl with factor X deficiency.
Osteoporosis
Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats.
Osteoporosis
Rivaroxaban significantly inhibits the stimulatory effects of bone-modulating hormones: In vitro study of primary female osteoblasts.
Osteosarcoma
Osteosarcoma cell-calcium signaling through tissue factor-factor VIIa complex and factor Xa.
Otitis
Antiphospholipids antibodies in a 12-month-old presenting with idiopathic thrombocytopenic purpura.
Ovarian Cysts
Two episodes of hemoperitoneum from luteal cysts rupture in a patient with congenital factor X deficiency.
Ovarian Neoplasms
Activated protein C upregulates ovarian cancer cell migration and promotes unclottability of the cancer cell microenvironment.
Overweight
Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
Pancreatic Neoplasms
Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort study.
Pancreatic Neoplasms
The roles of cell surface attachment molecules and coagulation Factor X in adenovirus 5-mediated gene transfer in pancreatic cancer cells.
Pancreatic Neoplasms
[Expression of RAD51 and MAX in pancreatic cancer rats.]
Pancreatic Neoplasms
[Inhibitory effect of anti-platelet prostaglandin on liver metastasis of hamster pancreatic cancer]
Pancreatitis
Gabexate mesylate inhibition of serine proteases: thermodynamic and computer-graphics analysis.
Pancreatitis
Influence of ischemic preconditioning on blood coagulation, fibrinolytic activity and pancreatic repair in the course of caerulein-induced acute pancreatitis in rats.
Pancreatitis
The effects upon blood coagulation in dogs of experimentally induced pancreatitis and the infusion of pancreatic juice.
Pancreatitis
The relationship of coagulation factors to clinical complications of acute pancreatitis.
Pancreatitis
[Biological diagnosis of postoperative thrombopenia]
Pancreatitis
[Hemostatic function and level of autoantibodies to trypsin and factor Xa in rats in experimental pancreatitis]
Pancreatitis, Acute Necrotizing
Factors associated with the severity of hypertriglyceridemia induced acute pancreatitis.
Pancytopenia
A Rare Case of Factor VII Inhibitor in a Patient Presenting with Primary Splenic Marginal Zone Lymphoma.
Pancytopenia
Diagnostic Pitfalls in a Man with Systemic Lupus Erythematous.
Pancytopenia
Pulmonary hemorrhage in pediatric lupus anticoagulant hypoprothrombinemia syndrome.
Pancytopenia
[Chronic hepatic encephalopathy in a patient with primary biliary cirrhosis].
Paraganglioma
A Novel, Likely Pathogenic MAX Germline Variant in a Patient With Unilateral Pheochromocytoma.
Paraganglioma
A patient with a germline SDHB mutation presenting with an isolated pituitary macroprolactinoma.
Paraganglioma
A systematic review on the genetic analysis of paragangliomas: primarily focused on head and neck paragangliomas.
Paraganglioma
CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Paraganglioma
Opposing effects of HIF1? and HIF2? on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Paraganglioma
Somatic and germline mutations in the pathogenesis of pituitary adenomas.
Paraganglioma
Synchronous bilateral pheochromocytomas and paraganglioma with novel germline mutation in MAX: a case report.
Paralysis
Congenital factor X deficiency and incomplete transverse paralysis.
Paralysis
Inhibition of feline collateral vessel development following experimental thrombolic occlusion.
Paralysis
[Suspicious case of epidural hematoma due to coagulopathy caused by vitamin K deficiency associated with antibiotics]
Paraproteinemias
Acquired factor X deficiency in a patient with multiple myeloma: a rare case highlighting the significance of comprehensive evaluation and the need for antimyeloma therapy for bleeding diathesis.
Paraproteinemias
Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
Paraproteinemias
Prolonged Activated Partial Thromboplastin Time and False-Positive Results for Fibrinogen and Fibrin Degradation Products in a B-Cell Lymphoma Patient.
Paraproteinemias
Resolution of acquired factor X deficiency with amyloidosis secondary to plasma cell dyscrasia.
Paraproteinemias
The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma.
Paraproteinemias
Waldenstrom's Macroglobulinemia and Peripheral Neuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes with a Bleeding Diathesis and Rash.
Paraproteinemias
[Acquired factor X deficiency in a case of monoclonal gammopathy]
Parasitemia
Neither heparin nor acetylsalicylic acid influence the clinical course in human Plasmodium falciparum malaria: a prospective randomized study.
Paratuberculosis
Antigenicity of recombinant maltose binding protein-Mycobacterium avium subsp. paratuberculosis fusion proteins with and without factor Xa cleaving.
Paratuberculosis
Cloning and expression in Escherichia coli of DNA encoding a 60 kDa stress protein of Mycobacterium paratuberculosis, the causative agent of Johne's disease.
Paresis
Venous thromboembolism in acute stroke. Prognostic importance of hypercoagulability.
Parkinson Disease
[Electroacupuncture improved locomotor function by regulating expression of tyrosine hydroxylase and ?-synuclein proteins and transcription activating factor 6 and transcription factor X box binding protein 1 mRNAs in substantia nigra of rats with Parkinson's disease].
Pelvic Floor Disorders
The influence on coagulation of transdermal estrogen hormone replacement therapy as a preoperative preparation of the tissue before vaginal hysterectomy.
Pelvic Neoplasms
Establishment of a human renal pelvic cancer cell line producing tissue thromboplastin and plasminogen activator.
Pemphigoid, Bullous
Study on an antibody against F1F2 fragment of human factor V in a patient with Hashimoto's disease and bullous pemphigoid.
Peptic Ulcer
Prediction of gastrointestinal bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational cohort study (STROBE compliant).
Peptic Ulcer
Spontaneous antithrombin in a patient with benign paraprotein.
Pericardial Effusion
Management of Periprocedural and Early Pericardial Effusions with Tamponade Following Ablation of Atrial Fibrillation with Uninterrupted Factor Xa Inhibitors: A Case Series.
Periodontal Diseases
DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa.
Periodontitis
Activation of blood coagulation factor X by arginine-specific cysteine proteinases (gingipain-Rs) from Porphyromonas gingivalis.
Periodontitis
Microvesicles, blood cells, and endothelial cells mediate phosphatidylserine-related prothrombotic state in patients with periodontitis.
Peripheral Arterial Disease
A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.
Peripheral Arterial Disease
Experimental model of lower limb ischemia in rats and the effect of YM466, an oral direct factor Xa inhibitor.
Peripheral Arterial Disease
How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?
Peripheral Arterial Disease
Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease.
Peripheral Arterial Disease
Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
Peripheral Arterial Disease
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Peripheral Vascular Diseases
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Peripheral Vascular Diseases
Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: a single-center experience in 1020 patients.
Peripheral Vascular Diseases
Hypercoagulability in patients with peripheral vascular disease.
Peritoneal Fibrosis
Tissue factor and factor v involvement in rat peritoneal fibrosis.
Peritonitis
Experimental gram-negative peritonitis: decreased thromboplastin activity in organs with a simultaneous rise of thromboplastin in blood monocytes and peritoneal macrophages.
Peritonitis
Macrophage matrix metalloproteinase-12 dampens inflammation and neutrophil influx in arthritis.
Peritonitis
Mononuclear phagocyte thromboplastin and endotoxin in patients with secondary bacterial peritonitis.
Peritonitis
Mononuclear phagocyte thromboplastin, bacterial counts and endotoxin levels in experimental endogenous gram-negative sepsis.
Peritonitis
N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo.
Peritonitis
Variables associated with outcome in dogs undergoing extrahepatic biliary surgery: 60 cases (1988-2002).
Peritonsillar Abscess
[Preoperative markers for risk of post-tonsillectomy bleeding in adults]
Persistent Infection
[Chronic pulmonary heart disease during ventriculo-atrial shunts in children]
Pharyngitis
[Crimean-Congo hemorrhagic fever]
Pheochromocytoma
18F-FDOPA PET/CT imaging of MAX-related pheochromocytoma.
Pheochromocytoma
A Novel Phenotype of Germline Pathogenic Variants in MAX: Concurrence of Pheochromocytoma and Ganglioneuroma in a Chinese Family and Literature Review.
Pheochromocytoma
A Novel, Likely Pathogenic MAX Germline Variant in a Patient With Unilateral Pheochromocytoma.
Pheochromocytoma
CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY.
Pheochromocytoma
Opposing effects of HIF1? and HIF2? on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
Pheochromocytoma
Synchronous bilateral pheochromocytomas and paraganglioma with novel germline mutation in MAX: a case report.
Pheochromocytoma
[Advances in genes and molecular markers of pheochromocytoma].
Pheochromocytoma
[Mixed corticomedullary tumor]
Pituitary Neoplasms
A patient with a germline SDHB mutation presenting with an isolated pituitary macroprolactinoma.
Pituitary Neoplasms
Somatic and germline mutations in the pathogenesis of pituitary adenomas.
Placenta Diseases
The coagulation system in placental insufficiency: a study in the fetal circulation.
Placental Insufficiency
The coagulation system in placental insufficiency: a study in the fetal circulation.
plasma kallikrein deficiency
A Rare Cause of Isolated Prolonged Activated Partial Thromboplastin Time: An Overview of Prekallikrein Deficiency and the Contact System.
plasma kallikrein deficiency
Fletcher factor deficiency, source of variations of the activated partial thromboplastin time test.
plasma kallikrein deficiency
Isolated prolonged activated partial thromboplastin time in an asymptomatic patient: Fletcher factor deficiency.
plasma kallikrein deficiency
Long-term safety outcomes of prekallikrein (Fletcher factor) deficiency: A systematic literature review of case reports.
plasma kallikrein deficiency
Prekallikrein deficiency presenting as recurrent cerebrovascular accident: case report and review of the literature.
plasma kallikrein deficiency
Prolonged Activated Clotting Time Immediately Prior to Open Cardiac Surgery.
plasma kallikrein deficiency
Prolonged activated partial thromboplastin time due to plasma prekallikrein deficiency: a case study and literature review on its clinical significance.
plasma kallikrein deficiency
Prolonged Partial Thromboplastin Time Without Bleeding History; Fletcher Factor Deficiency.
plasma kallikrein deficiency
Severe prekallikrein deficiency due to a homozygous Trp499Stop nonsense mutation.
plasma kallikrein deficiency
The effect of increased contact activation time on the activated partial thromboplastin time.
plasma kallikrein deficiency
[Prekallikrein deficiency: a rare cause of a significant prolongation of the activated partial thromboplastin time. Apropos of a case]
Platelet Storage Pool Deficiency
Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity--a comparison with Scott syndrome.
Pleural Effusion
Heparan sulfate chains contribute to the anticoagulant milieu in malignant pleural effusion.
Pleural Effusion
Procoagulant activity of purified protein derivative-stimulated pleural effusion mononuclear cells in tuberculous pleurisy.
Pneumonia
Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.
Pneumonia
Phlegmasia cerulea dolens superimposed on disseminated intravascular coagulation in COVID-19.
Pneumonia
TGF-? Blood Levels Distinguish Between Influenza A (H1N1)pdm09 Virus Sepsis and Sepsis due to Other Forms of Community-Acquired Pneumonia.
Pneumonia
The role of hypothermia in the management of severe brain injury: a meta-analysis.
Pneumonia
Transient acquired factor X deficiency associated with pneumonia.
Pneumonia
Transient presence of lupus anticoagulant associated with mycoplasma pneumonia.
Pneumonia
Venous Thromboembolism Events Following Venovenous Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Syndrome Coronavirus 2 Based on CT Scans.
Pneumonia
[Coagulopathy correlates with outcomes in patients with community- acquired pneumonia].
Pneumonia
[Comparison of relevant indicators of coagulation and fibrinolysis in patients with varying severity of community-acquired pneumonia].
Pneumonia
[Hemostasis system in lung cancer, benign tumors and chronic nonspecific pneumonias]
Pneumonia
[The predictive value of medical big data for the prognosis of elderly patients with pneumonia: based on the result of clinical database of a Beijing Chaoyang Hospital Consortium Chaoyang Emergency Ward].
Pneumonia, Aspiration
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.
Pneumoperitoneum
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
Pneumoperitoneum
Laparoscopic Sleeve Gastrectomy Affects Coagulation System of Obese Patients.
Pneumothorax
Internal jugular versus subclavian vein catheterization for central venous catheterization in orthotopic liver transplantation.
POEMS Syndrome
The prolonged activated partial thromboplastin time at diagnosis indicates less favorable prognosis in IgA myeloma.
Polycystic Ovary Syndrome
Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation.
Polycythemia
Distal gangrene in a polycythemic recipient fetus in twin-twin transfusion.
Polycythemia
Erythrocytosis as a cause of false increase in prothrombin time and activated partial thromboplastin time.
Posterior Leukoencephalopathy Syndrome
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
Postpartum Hemorrhage
Coagulation parameters during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study.
Postthrombotic Syndrome
Current treatment of acute lower extremity deep venous thrombosis.
Postthrombotic Syndrome
Risk factors of postthrombotic syndrome before and after deep venous thrombosis treatment.
Pre-Eclampsia
Activation of the novel prothrombinase, fg12, as a basis for the pregnancy complications spontaneous abortion and pre-eclampsia.
Pre-Eclampsia
Associations of thrombocytopenia, transaminase elevations, and transfusion with laboratory coagulation tests in women with preeclampsia: a cross-sectional study.
Pre-Eclampsia
Coagulation studies in patients with marked thrombocytopenia due to severe preeclampsia.
Pre-Eclampsia
Disseminated intravascular coagulation.
Pre-Eclampsia
Increased sensitivity to thromboplastin synthesis in blood monocytes from pre-eclamptic patients.
Pre-Eclampsia
Predictive value of 4-Hydroxyglutamate and miR-149-5p on eclampsia.
Pre-Eclampsia
The fgl2 prothrombinase/fibroleukin gene is required for lipopolysaccharide-triggered abortions and for normal mouse reproduction.
Pre-Eclampsia
[Clinical characteristics and outcomes of cerebral venous sinus thrombosis during pregnancy and puerperium].
Pre-Excitation Syndromes
Cardiac Amyloidosis Presenting with Pre-Excitation Syndrome, Heart Failure, and Severe Factor X Deficiency as Part of Systemic Amyloid Light-Chain (AL) Amyloidosis - A Fatal Combination.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A dysfunctional factor X (factor X San Giovanni Rotondo) present at homozygous and double heterozygous level: identification of a novel microdeletion (delC556) and missense mutation (Lys(408)-->Asn) in the factor X gene. A study of an Italian family.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The clinical and biological correlates of coagulopathy in children with acute leukemia.
Pregnancy Complications
Activation of the novel prothrombinase, fg12, as a basis for the pregnancy complications spontaneous abortion and pre-eclampsia.
Pregnancy Complications, Infectious
Diagnostic performance of biomarkers in maternal sepsis: A prospective observational study.
Pregnancy, Prolonged
[Procoagulant properties of the amniotic fluid. II. Thromboplastin acceleration in the amniotic fluid in the diagnosis of prolonged pregnancy]
Primary Ovarian Insufficiency
Relationship between mean platelet volume and low-grade systemic coagulation with vitamin D deficiency in primary ovarian insufficiency.
Prion Diseases
Analysis of the prion protein in primates reveals a new polymorphism in codon 226 (Y226F).
Prostatic Neoplasms
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer.
Prostatic Neoplasms
Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer.
Prostatic Neoplasms
Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants.
Prostatic Neoplasms
Engineering of human coagulation factor x variants activated by prostate-specific antigen.
Protein S Deficiency
Anticoagulant protein C pathway defective in majority of thrombophilic patients.
Protein S Deficiency
Snake Venoms in Diagnostic Hemostasis and Thrombosis.
protein-glutamine gamma-glutamyltransferase deficiency
A longitudinal prospective study of bleeding diathesis in Egyptian pediatric patients: single-center experience.
protein-glutamine gamma-glutamyltransferase deficiency
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
protein-glutamine gamma-glutamyltransferase deficiency
Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and 6-year survival in patients with chronic liver disease.
protein-glutamine gamma-glutamyltransferase deficiency
Clinical audit of inherited bleeding disorders in a developing country.
protein-glutamine gamma-glutamyltransferase deficiency
De Novo Precursor B-Lymphoblastic Leukemia/Lymphoma With Double-Hit Gene Rearrangements (MYC/BCL-2) Presented With Spinal Cord Compression and Acquired Factor XIII Deficiency.
protein-glutamine gamma-glutamyltransferase deficiency
Hemorrhagic Shock after Neonatal Circumcision: Severe Congenital Factor XIII Deficiency.
protein-glutamine gamma-glutamyltransferase deficiency
Inherited bleeding disorders in Indian women with menorrhagia.
protein-glutamine gamma-glutamyltransferase deficiency
Intracranial haemorrhage in patients with congenital haemostatic defects.
protein-glutamine gamma-glutamyltransferase deficiency
Lobar Hemorrhage Induced by Acquired Factor XIII Deficiency in a Patient with Cerebral Amyloid Angiopathy.
protein-glutamine gamma-glutamyltransferase deficiency
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
protein-glutamine gamma-glutamyltransferase deficiency
Rare bleeding disorders in children: identification and primary care management.
protein-glutamine gamma-glutamyltransferase deficiency
Rare inherited coagulation disorders in India.
protein-glutamine gamma-glutamyltransferase deficiency
The rare inherited coagulation disorders.
Proteinuria
A phase II trial of carbetimer for the treatment of colorectal cancer. A trial of the Northern California Oncology Group.
Proteinuria
Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin.
Proteinuria
Acquired isolated factor X deficiency associated with systemic amyloidosis. Case report and review of literature.
Proteinuria
Acute Kidney Injury Induced by Bothrops Venom: Insights into the Pathogenic Mechanisms.
Proteinuria
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.
Proteinuria
Clinical Characteristics and Abnormal Parameters Evolution in Patients With Novel Coronavirus Infection: A Case Series of 272 Cases in Guangzhou.
Proteinuria
Distribution of ABO and Rh blood groups in patients with HELLP syndrome.
Proteinuria
Lupus anticoagulant-like activity observed in a dimeric lambda protein produced by myeloma cells.
Proteinuria
Membranous glomerulonephritis, antiphospholipid syndrome, and persistent low C3 levels associated with meningococcal disease.
Proteinuria
The Long-term Outcomes after VAD plus SCT Therapy in a Patient with AL Amyloidosis and Severe Factor X Deficiency.
Proteinuria
Use of interleukin-2 in patients with acquired immunodeficiency syndrome.
Proteinuria
[Antithrombin III in infantile nephrotic syndrome]
Proteinuria
[Roles of coagulation pathway and factor Xa in chronic kidney disease (CKD)].
Pruritus
Heparin-associated hematomas: possible allergic reaction.
Pulmonary Arterial Hypertension
A role for coagulation factor Xa in experimental pulmonary arterial hypertension.
Pulmonary Disease, Chronic Obstructive
A model to assess the risk of peripherally inserted central venous catheter-related thrombosis in patients with breast cancer: a retrospective cohort study.
Pulmonary Disease, Chronic Obstructive
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
Pulmonary Disease, Chronic Obstructive
Lower Extremity Necrotizing Fasciitis in Diabetic and Nondiabetic Patients: Mortality and Amputation.
Pulmonary Disease, Chronic Obstructive
The FGL2/fibroleukin prothrombinase is involved in alveolar macrophage activation in COPD through the MAPK pathway.
Pulmonary Disease, Chronic Obstructive
Too Cold to Clot? Does Intraoperative Hypothermia Contribute to Bleeding After Aortic Surgery?
Pulmonary Disease, Chronic Obstructive
[Change of coagulation functions and its significance in acute exacerbation of chronic obstructive pulmonary disease].
Pulmonary Embolism
A 78-Year-Old Man with a Pulmonary Embolism Who Developed Skin Necrosis 7 Days After Treatment with the Direct Oral Anticoagulant Factor Xa Inhibitor Apixaban.
Pulmonary Embolism
A comprehensive evaluation of apixaban in the treatment of venous thromboembolism.
Pulmonary Embolism
A cost-analysis model for anticoagulant treatment in the hospital setting.
Pulmonary Embolism
A Novel GNAS Mutation Causing Isolated Infantile Cushing's Syndrome.
Pulmonary Embolism
A patient with pleuritic chest pain and abnormal blood clotting tests.
Pulmonary Embolism
Accidental Rivaroxaban Intoxication in a Boy: Some Lessons in Managing New Oral Anticoagulants in Children.
Pulmonary Embolism
Analysis of Partial Thromboplastin Times in Patients With Pulmonary Embolism During the First 48 Hours of Anticoagulation With Unfractionated Heparin.
Pulmonary Embolism
Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place.
Pulmonary Embolism
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma.
Pulmonary Embolism
Antiphospholipid syndrome presenting as intracardiac thrombus with pulmonary embolism.
Pulmonary Embolism
Apixaban or Rivaroxaban Versus Warfarin for Treatment of Submassive Pulmonary Embolism After Catheter-Directed Thrombolysis.
Pulmonary Embolism
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
Pulmonary Embolism
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Pulmonary Embolism
Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care.
Pulmonary Embolism
Current management of acute symptomatic deep vein thrombosis.
Pulmonary Embolism
Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
Pulmonary Embolism
Direct oral anticoagulants in rare venous thrombosis.
Pulmonary Embolism
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Pulmonary Embolism
Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.
Pulmonary Embolism
Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
Pulmonary Embolism
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial.
Pulmonary Embolism
Erratum to Barco et al. "Home treatment of patients with lowrisk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the Hot-PE Trial" (Thromb Haemost 2016; 116: 191-197).
Pulmonary Embolism
Evaluation of Time to Therapeutic Anticoagulation and Associated Outcomes in Critically Ill, Obese Patients With Pulmonary Embolism Receiving Unfractionated Heparin.
Pulmonary Embolism
Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.
Pulmonary Embolism
Factor X inhibitors.
Pulmonary Embolism
Factor Xa inhibition and sPESI failure in intermediate-high-risk pulmonary embolism.
Pulmonary Embolism
Fondaparinux in heparin-induced thrombocytopenia.
Pulmonary Embolism
Free-floating iliofemoral thrombus. A risk of pulmonary embolism.
Pulmonary Embolism
Heterogeneity of synthetic factor Xa inhibitors.
Pulmonary Embolism
Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial.
Pulmonary Embolism
Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets.
Pulmonary Embolism
Lack of plasminogen activator inhibitor-1 enhances the preventive effect of DX-9065a, a selective factor Xa inhibitor, on venous thrombus and acute pulmonary embolism in mice.
Pulmonary Embolism
Low molecular weight heparin in acute stroke.
Pulmonary Embolism
Myocarditis in athletes after COVID-19 infection: The heart is not the only place to screen.
Pulmonary Embolism
Oral Direct Factor Xa Inhibitors Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in Patients Undergoing Total Hip or Knee Replacement: A Systematic Review and Meta-analysis.
Pulmonary Embolism
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Pulmonary Embolism
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
Pulmonary Embolism
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
Pulmonary Embolism
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism.
Pulmonary Embolism
Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report.
Pulmonary Embolism
Possible Rivaroxaban Failure during the Postpartum Period.
Pulmonary Embolism
Practical Management of Rivaroxaban for the Treatment of Venous Thromboembolism.
Pulmonary Embolism
Probable pulmonary embolism with repeat administration of prothrombin complex concentrate in a factor Xa inhibitor patient.
Pulmonary Embolism
Retrospective evaluation of shortened prothrombin time or activated partial thromboplastin time for the diagnosis of hypercoagulability in dogs: 25 cases (2006-2011).
Pulmonary Embolism
Review of the initiation of anticoagulant therapy.
Pulmonary Embolism
Review: Factor Xa inhibitors reduce DVT more than LMWH in total knee or hip replacement.
Pulmonary Embolism
Rivaroxaban for treatment of venous thromboembolism in older adults.
Pulmonary Embolism
Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
Pulmonary Embolism
Short-Term Subcutaneous Fondaparinux and Oral Edoxaban for Acute Venous Thromboembolism.
Pulmonary Embolism
Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program.
Pulmonary Embolism
SR-90107 (Sanofi-Synthélabo).
Pulmonary Embolism
Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.
Pulmonary Embolism
The 'chest pain kit' study: A 'pill in the pocket' concept to improve the pre-hospital therapy of acute coronary syndrome.
Pulmonary Embolism
The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure.
Pulmonary Embolism
The prophylactic role of tranexamic acid to reduce blood loss during radical surgery: A prospective study.
Pulmonary Embolism
The role of antifibrinolytic agents in gynecologic cancer surgery.
Pulmonary Embolism
The value of inhibitors of factor Xa for the treatment of pulmonary embolism.
Pulmonary Embolism
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice.
Pulmonary Embolism
Thrombin-antithrombin III complexes as an additional diagnostic aid in pulmonary embolism.
Pulmonary Embolism
TLT-1-CONTROLS EARLY THROMBUS FORMATION AND STABILITY BY FACILITATING AIIBB3 OUTSIDE-IN SIGNALING IN MICE.
Pulmonary Embolism
Transitions of care in anticoagulated patients.
Pulmonary Embolism
Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism.
Pulmonary Embolism
Use of rivaroxaban in an elderly patient with intermediate-low early mortality risk due to pulmonary embolism: a case report.
Pulmonary Embolism
Venous thromboembolism prophylaxis guidelines: use by primary care physicians.
Pulmonary Embolism
Warfarin hypersensitivity due to gluten-sensitive enteropathy: a case study.
Pulmonary Embolism
[Clinical Value Evaluation of Perioperative Prophylactic Anticoagulation Therapy for Lung Cancer Patients].
Pulmonary Embolism
[Critical appraisal: Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Prandoni P, Carnovali M, Marchiori A, Galilei investigators. Arch Intern Med 2004; 164: 1077-83]
Pulmonary Embolism
[Determination of factor Xa inhibition doses of low-molecular heparin, nadroparin and reviparin in urological patients]
Pulmonary Embolism
[Disseminated coronary occlusions and massive pulmonary embolism in a 40-year-old woman.]
Pulmonary Embolism
[Effect of tranexamic acid combined flexion position of hip and knee on perioperative bleeding following unilateral total knee arthroplasty].
Pulmonary Embolism
[Fondaparinux: The present and the future.]
Pulmonary Embolism
[Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update].
Pulmonary Embolism
[Recurrent thromboembolisms despite full anticoagulation in a patient with antiphospholipid syndrome].
Pulmonary Fibrosis
Glycogen Synthase Kinase-3? Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis.
Pulmonary Fibrosis
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury.
Pulmonary Fibrosis
Procoagulant, tissue factor-bearing microparticles in bronchoalveolar lavage of interstitial lung disease patients: an observational study.
Purpura
A monoclonal immunoglobulin A (kappa) factor VIII:C inhibitor associated with primary amyloidosis: identification and characterization.
Purpura
Antiphospholipids antibodies in a 12-month-old presenting with idiopathic thrombocytopenic purpura.
Purpura
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
Purpura
Immune Thrombocytopenia Purpura Secondary to COVID-19.
Purpura
Lupus anticoagulant-hypoprothrombinemia syndrome and immunoglobulin-A vasculitis: a report of Japanese sibling cases and review of the literature.
Purpura
Neonatal congenital Factor X deficiency.
Purpura
Prolonged partial thromboplastin times in children with fever and petechiae without bacteremia or sepsis.
Purpura
[Grave transitory hemorrhagic diathesis in pregnancy; thrombokinase intoxication caused by premature detachment of the placenta in familial purpura simplex.]
Purpura
[Transitions of each inhibitor in a patient with lupus anticoagulant and anti-prothrombin antibody]
Purpura, Thrombocytopenic
Diagnostic efficacy of six plasma proteins in evaluating consumptive coagulopathies. Use of receiver operating characteristic curves to compare antithrombin III, plasminogen, alpha 2-plasmin inhibitor, fibronectin, prothrombin, and protein C.
Purpura, Thrombocytopenic
Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies.
Purpura, Thrombocytopenic, Idiopathic
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
Purpura, Thrombocytopenic, Idiopathic
Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients.
Purpura, Thrombocytopenic, Idiopathic
Low-dose rituximab in the treatment of acquired haemophilia.
Purpura, Thrombocytopenic, Idiopathic
Pharmaceutical Approval Update.
Purpura, Thrombocytopenic, Idiopathic
The spectrum of bleeding disorders in women with menorrhagia: a report from Western India.
Purpura, Thrombocytopenic, Idiopathic
[Presence of lupus-type anticoagulant, in systemic lupus erythematosus and other clinical entities]
Purpura, Thrombotic Thrombocytopenic
Clinical factors and biomarkers predicting outcome in patients with immune-mediated thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Virus-inactivated plasma - Plasmasafe: a one-year experience.
Purpura, Thrombotic Thrombocytopenic
[Reasons for fresh frozen plasma transfusion in a general hospital]
Q Fever
Acute Q fever in southern Taiwan: atypical manifestations of hyperbilirubinemia and prolonged fever.
Q Fever
[Activated partial thromboplastin time and Q fever]
Rabies
Rabies virus M protein expressed in Escherichia coli and its regulatory role in virion-associated transcriptase activity.
Rabies
[Vaccination against rabies as a source of thrombokinase.]
Rectal Fistula
[Applicability and indications of colonoscopic screening for Crohn's disease in patients with fistula-in-ano].
Refractive Errors
Risk Factors for Decompression Retinopathy After Glaucoma Surgery.
Renal Insufficiency
A Rare Cause of Coagulopathy in a Patient with Rapidly Progressive Renal Failure.
Renal Insufficiency
Acute respiratory failure in adult patients with dengue virus infection.
Renal Insufficiency
Anticoagulation options for patients with heparin-induced thrombocytopenia requiring renal support in the intensive care unit.
Renal Insufficiency
Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study.
Renal Insufficiency
Argatroban.
Renal Insufficiency
Biomarkers in newborns with hypoxic-ischemic encephalopathy treated with therapeutic hypothermia.
Renal Insufficiency
Bleeding during critical illness: a prospective cohort study using a new measurement tool.
Renal Insufficiency
Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis.
Renal Insufficiency
Chronic peritoneal dialysis in a patient with primary amyloidosis, renal failure, and factor X deficiency.
Renal Insufficiency
Continuous venovenous haemofiltration in cancer patients with renal failure: a single-centre experience.
Renal Insufficiency
Deciphering the coagulation profile through the dynamics of thrombin activity.
Renal Insufficiency
Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin.
Renal Insufficiency
Hemodialysis for removal of dabigatran in a patient with gastric hemorrhage.
Renal Insufficiency
Human umbilical cord blood-derived CD34+ cells cause attenuation of multiorgan dysfunction during experimental heatstroke.
Renal Insufficiency
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection.
Renal Insufficiency
In vivo diagnosis of massive hepatic infarction by computed tomography.
Renal Insufficiency
Incidence and Risk Factors for Cannula-Related Venous Thrombosis After Venovenous Extracorporeal Membrane Oxygenation in Adult Patients With Acute Respiratory Failure.
Renal Insufficiency
Inhibition by anticoagulant drugs of the progressive hypertension and uremia associated with renal infarction in rats.
Renal Insufficiency
Outcomes of patients hospitalized with peptic ulcer disease diagnosed in acute upper endoscopy.
Renal Insufficiency
Polyvinylpyrrolidone induced artefactual prolongation of activated partial thromboplastin times in intravenous drug users with renal failure.
Renal Insufficiency
Prediction of gastrointestinal bleeding events in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An observational cohort study (STROBE compliant).
Renal Insufficiency
Spontaneous resolution of acquired factor X deficiency in amyloidosis.
Renal Insufficiency
The exploration of risk factors of concurrent bacteraemia in patients critically ill with severe dengue.
Renal Insufficiency
[Argatroban: pharmacological properties and anaesthesiological aspects]
Renal Insufficiency
[Renal biopsy: Procedures, contraindications, complications.]
Renal Insufficiency, Chronic
Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function.
Renal Insufficiency, Chronic
Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease.
Renal Insufficiency, Chronic
Polyvinylpyrrolidone induced artefactual prolongation of activated partial thromboplastin times in intravenous drug users with renal failure.
Renal Insufficiency, Chronic
[Apixaban as therapeutic option in nephropathy patients with heparin-induced thrombocytopenia (HIT)].
Renal Insufficiency, Chronic
[Roles of coagulation pathway and factor Xa in chronic kidney disease (CKD)].
Reperfusion Injury
A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver.
Reperfusion Injury
DIANNEXIN DOWN-MODULATES TNF-INDUCED ENDOTHELIAL MICROPARTICLE RELEASE BY BLOCKING MEMBRANE BUDDING PROCESS.
Reperfusion Injury
Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently.
Reperfusion Injury
N-desulfated non-anticoagulant heparin inhibits leukocyte adhesion and transmigration in vitro and attenuates acute peritonitis and ischemia and reperfusion injury in vivo.
Reperfusion Injury
Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice.
Respiratory Distress Syndrome
Efficacy of limited fluid resuscitation in patients with hemorrhagic shock: a meta-analysis.
Respiratory Distress Syndrome
Fresh frozen plasma/red blood cell resuscitation regimen that restores procoagulants without causing adult respiratory distress syndrome.
Respiratory Distress Syndrome
Lower Extremity Necrotizing Fasciitis in Diabetic and Nondiabetic Patients: Mortality and Amputation.
Respiratory Distress Syndrome
[Changes in the blood coagulation potential of premature calves with and without respiratory distress syndrome]
Respiratory Insufficiency
Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation.
Respiratory Insufficiency
Acute respiratory failure and intravascular coagulation.
Respiratory Insufficiency
Association Between Admission Serum Phosphate Level and All-Cause Mortality Among Patients with Spontaneous Intracerebral Hemorrhage.
Respiratory Insufficiency
Clinical trials of deep vein thrombosis prophylaxis in medical patients.
Respiratory Insufficiency
Effects of phospholipase C, a tissue thromboplastin inhibitor, on pulmonary microembolism after missile injury of the limb.
Respiratory Insufficiency
Emergent surgical evacuation of traumatic intracranial hematoma in patients with preoperative thrombocytopenia: surgical risk and early outcome.
Respiratory Insufficiency
Outcome of Dengue Hemorrhagic Fever-Caused Acute Kidney Injury in Thai Children.
Respiratory Insufficiency
Tourniquet ineffectiveness to reduce the severity of envenoming after Crotalus durissus snake bite in Belo Horizonte, Minas Gerais, Brazil.
Respiratory Tract Infections
Factor X and its deficiency states.
Respiratory Tract Infections
Lupus anticoagulant associated with transient severe factor X deficiency: a report of two patients presenting with major bleeding complications.
Retinal Detachment
[Coagulation factors and fibrinolytic system in subretinal liquid in patients with rheumatogenous retinal detachment]
Retinal Perforations
Activated Blood Coagulation Factor X (FXa) Contributes to the Development of Traumatic PVR Through Promoting RPE Epithelial-Mesenchymal Transition.
Retinal Vein Occlusion
The possible role of platelet coagulant activities in the pathogenesis of venous thrombosis.
Retinal Vein Occlusion
VEGF: From Discovery to Therapy: The Champalimaud Award Lecture.
Retinoblastoma
Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Rhabdomyolysis
Acute renal failure after snakebite: a report of four cases.
Rheumatic Diseases
Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays.
Rheumatic Diseases
Effect of immune complex-containing sera from patients with rheumatic diseases on thromboplastin activity of monocytes.
Rheumatic Heart Disease
Association between Coagulation Function and Cerebral Microbleeds in Ischemic Stroke Patients with Atrial Fibrillation and/or Rheumatic Heart Disease.
Sarcoidosis
Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis.
Sarcoma
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
Sarcoma
[On changes in the content of thrombokinase and fibrinogen in the blood during the process of growth of transplantable sarcoma.]
Scleroderma, Diffuse
Progressive systemic sclerosis with the nephrotic syndrome and acquired factor X deficiency.
Scoliosis
Bleeding and coagulation changes during spinal fusion surgery: a comparison of neuromuscular and idiopathic scoliosis patients.
Scoliosis
Clotting parameters and thromboelastography in children with neuromuscular and idiopathic scoliosis undergoing posterior spinal fusion.
Scoliosis
Clotting parameters in patients with adolescent idiopathic scoliosis undergoing posterior spinal fusion and instrumentation.
Scrub Typhus
The clinical differences between dengue and scrub typhus with acute respiratory failure in southern Taiwan.
Seizures
Factor X deficiency in a cat.
Seizures
Phase I-II study of recombinant alpha-2 interferon against advanced leukemia and lymphoma in children.
Seizures
Post-stroke seizure-Do the locations, types and managements of stroke matter?
Seizures
Posterior reversible encephalopathy syndrome following blood transfusion in a patient with factor X deficiency: Is it an unusual systemic manifestation of an adverse transfusion reaction?
Seizures
The FDP/FIB Ratio and Blood FDP Level May Be Related to Seizures After Fever in Young Children.
Seizures
The lupus anticoagulant. High incidence of 'negative' mixing studies in a human immunodeficiency virus-positive population.
Seizures, Febrile
Severe Factor X Deficiency Presenting as Febrile Seizure in an Infant.
Seizures, Febrile
The FDP/FIB Ratio and Blood FDP Level May Be Related to Seizures After Fever in Young Children.
Sepsis
Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B.
Sepsis
Activated partial thromboplastin time waveform analysis as specific sepsis marker in cardiopulmonary bypass surgery.
Sepsis
Activated partial thromboplastin time waveform analysis: a new tool to detect infection?
Sepsis
Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome.
Sepsis
An explainable machine learning algorithm for risk factor analysis of in-hospital mortality in sepsis survivors with ICU readmission.
Sepsis
Antimicrobial and Anticoagulant Activity of N-chlorotaurine (NCT), N,N-dichloro-2,2-dimethyltaurine (NVC-422) and N-monochloro-2,2-dimethyltaurine (NVC-612) in Human Blood.
Sepsis
Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure.
Sepsis
Challenge and rechallenge: drotrecogin alfa (activated)-induced prolongation of activated partial thromboplastin time in a patient with severe sepsis.
Sepsis
Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis.
Sepsis
Clinical, laboratory, and hemostatic findings in cats with naturally occurring sepsis.
Sepsis
Combination of biphasic transmittance waveform with blood procalcitonin levels for diagnosis of sepsis in acutely ill patients.
Sepsis
Continuous heparinization and circulating adhesion molecules in the critically ill.
Sepsis
DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage.
Sepsis
Delta neutrophil index as a prognostic marker in emergent abdominal surgery.
Sepsis
Diagnostic efficacy of activated partial thromboplastin time waveform and procalcitonin analysis in pediatric meningococcal sepsis.
Sepsis
Disseminated intravascular coagulation and coagulation disorders.
Sepsis
Disseminated intravascular coagulation.
Sepsis
Does continuous heparinization influence platelet function in the intensive care patient?
Sepsis
Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis.
Sepsis
Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Implications of lipoprotein-complexed C reactive protein formation.
Sepsis
Early response in septicemia in newborns and their mothers. Effect of Escherichia coli, Streptococcus agalactiae and tumor necrosis factor on lactoferrin release and the generation of tissue thromboplastin.
Sepsis
Ecotin is a potent inhibitor of the contact system proteases factor XIIa and plasma kallikrein.
Sepsis
Effect of cardiopulmonary bypass on activated partial thromboplastin time waveform analysis, serum procalcitonin and C-reactive protein concentrations.
Sepsis
Experimental gram-negative septicemia: thromboplastin generation in mononuclear phagocytes from different anatomical sites.
Sepsis
Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases.
Sepsis
Factor Xa-evoked relaxation in rat aorta: involvement of PAR-2.
Sepsis
FXa Inhibition and Coagulation Changes During DVT Prophylaxis by Enoxaparin Over the Course of a 15-Day Follow-Up in Septic Patients.
Sepsis
Humoral coagulation and early complications after allogeneic bone marrow transplantation.
Sepsis
Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats.
Sepsis
Intracerebral hemorrhage after liver transplantation.
Sepsis
Mononuclear phagocyte thromboplastin, bacterial counts and endotoxin levels in experimental endogenous gram-negative sepsis.
Sepsis
Normalization of Activated Partial Thromboplastin Time Correlates with Low Levels of Dabigatran in a Patient with Severe Sepsis.
Sepsis
Platelet aggregation as a sign of septicemia in thermal injury. A prospective study.
Sepsis
Platelets as a prognostic marker for sepsis: A cohort study from the MIMIC-III database.
Sepsis
Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill patients with suspected sepsis.
Sepsis
Prolonged partial thromboplastin times in children with fever and petechiae without bacteremia or sepsis.
Sepsis
Proteinase inhibitors in severe inflammatory processes (septic shock and experimental endotoxaemia): biochemical, pathophysiological and therapeutic aspects.
Sepsis
Routine coagulation tests on ICU admission are associated with mortality in sepsis: an observational study.
Sepsis
Severe COVID-19 has a distinct phenotype from bacterial sepsis: a retrospective cohort study in deceased patients.
Sepsis
The biphasic transmittance waveform: an early marker of sepsis in patients with neutropenia.
Sepsis
The effect of heparin administration in animal models of sepsis: A prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies*
Sepsis
The production and availability of tissue thromboplastin in cellular populations of whole blood exposed to various concentrations of endotoxin. An assay for detection of endotoxin.
Sepsis
The role of the E2F1 transcription factor in the innate immune response to systemic LPS.
Sepsis
Transmitting and absorbing new information on the early identification of sepsis patients: the partial thromboplastin time biphasic waveform.
Sepsis
Use of rotational thromboelastometry to predict hemostatic complications in pediatric patients undergoing extracorporeal membrane oxygenation: A retrospective cohort study.
Sepsis
Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit.
Sepsis
[A new warning scoring system establishment for prediction of sepsis in patients with trauma in intensive care unit].
Sepsis
[Coagulation tests in septic surgical patients]
Sepsis
[Correlation of coagulation indicators with inflammatory markers for sepsis in the patients with hematological malignancies].
Sepsis
[Heparin and antiheparin in childhood. 3. Heparin level measurements and their importance in heparin monitoring]
Sepsis
[Meningococcal disease: comparison between clinical forms]
Sepsis
[Mononuclear phagocytes, the hemostasis system and the intravascular coagulation syndrome]
Sepsis
[Risk factors and prognosis of acute kidney injury in children with sepsis in pediatric intensive care unit].
Sepsis
[The abnormal activated partial thromboplastin time biphasic waveform: a red flag in the sepsis? Technique and interest as marker of the sepsis]
Severe Acute Respiratory Syndrome
Venous Thromboembolism Events Following Venovenous Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Syndrome Coronavirus 2 Based on CT Scans.
Severe Combined Immunodeficiency
Analysis of the defect in IFN-gamma induction of MHC class II genes in G1B cells: identification of a novel and functionally critical leucine-rich motif (62-LYLYLQL-68) in the regulatory factor X 5 transcription factor.
Severe Combined Immunodeficiency
Identification of regulatory factor X as a novel mismatch repair stimulatory factor.
Severe Combined Immunodeficiency
Mutations in the bare lymphocyte syndrome define critical steps in the assembly of the regulatory factor X complex.
Severe Combined Immunodeficiency
Regulatory factor X, a bare lymphocyte syndrome transcription factor, is a multimeric phosphoprotein complex.
Severe Dengue
Acute kidney injury in dengue virus infection.
Severe Dengue
Coagulation abnormalities in dengue hemorrhagic Fever: serial investigations in 167 Vietnamese children with Dengue shock syndrome.
Severe Dengue
Prothrombin time and partial thromboplastin time as a predictor of bleeding in patients with dengue hemorrhagic fever.
Severe Dengue
The exploration of risk factors of concurrent bacteraemia in patients critically ill with severe dengue.
Severe Fever with Thrombocytopenia Syndrome
Risk factors associated with fatality of severe fever with thrombocytopenia syndrome: a meta-analysis.
Sexually Transmitted Diseases
A study of coagulation and anti-endothelial antibodies in idiopathic livedo reticularis.
Sexually Transmitted Diseases
Case report: the anticardiolipin (antibody) syndrome.
Sexually Transmitted Diseases
Diagnostic Pitfalls in a Man with Systemic Lupus Erythematous.
Sexually Transmitted Diseases
IgG and IgM anticardiolipin antibodies in patients with lupus with anticardiolipin antibody associated clinical syndromes.
Sexually Transmitted Diseases
Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome.
Sexually Transmitted Diseases
The increase of blood anticardiolipin antibody depends on the underlying etiology in cerebral ischemia.
Sexually Transmitted Diseases
[Clinical and analytical manifestations of primary antiphospholipid antibody syndrome]
Sexually Transmitted Diseases
[Transverse myelopathy in a patient with systemic lupus erythematosus associated with positive anticardiolipin antibody--a case report]
Shock, Septic
Antithrombin replacement in patients with sepsis and septic shock.
Shock, Septic
Contact activation in shock caused by invasive group A Streptococcus pyogenes.
Shock, Septic
Effects of dexamethasone on endotoxin shock in the anesthetized pony: hematologic, blood gas, and coagulation changes.
Shock, Septic
Kallikrein-kinin system activation in streptococcal toxic shock syndrome.
Shock, Septic
Lower Extremity Necrotizing Fasciitis in Diabetic and Nondiabetic Patients: Mortality and Amputation.
Shock, Septic
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.
Shock, Septic
Pre-operative labs: Wasted dollars or predictors of post-operative cardiac and septic events in orthopaedic trauma patients?
Shock, Septic
Role of thromboelastography in the evaluation of septic shock patients with normal prothrombin time and activated partial thromboplastin time.
Shock, Septic
Routine coagulation tests on ICU admission are associated with mortality in sepsis: an observational study.
Shock, Septic
[Risk factors and prognosis of acute kidney injury in children with sepsis in pediatric intensive care unit].
Shwartzman Phenomenon
Glomerular coagulation system in renal diseases.
Shwartzman Phenomenon
Thromboplastin content in the vessel walls of different arteries and organs of rabbits.
Sick Sinus Syndrome
Evidence-Based Analysis of the Emergency Temporary Cardiac Pacing (Electrical Stimulation from Metal Wire Electrode).
Sinus Thrombosis, Intracranial
Dural sinus thrombosis in paroxysmal nocturnal hemoglobinuria.
Sinus Thrombosis, Intracranial
Fatal dural sinus thrombosis associated with heterozygous factor V Leiden and a short activated partial thromboplastin time.
Sinus Thrombosis, Intracranial
Novel factor xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients.
Sinus Thrombosis, Intracranial
[Nephrotic syndrome complicated with intracranial venous thrombosis treated with urokinase: report of 5 cases]
Sjogren's Syndrome
Microparticles as biomarkers in autoimmunity: from dust bin to center stage.
Smallpox
[Contribution to the study of vaccination physiopathology. Behavior of certain coagulation factors under smallpox vaccine stimulation (platelets, prothrombin time, partial thromboplastin time)]
Soft Tissue Injuries
Preoperative hematological assessment of pediatric patients with cerebral palsy.
Spinal Cord Diseases
Comparison of cardiovascular parameters between patients with ossification of posterior longitudinal ligament and patients with cervical spondylotic myelopathy.
Spinal Cord Injuries
Gabexate mesilate, a synthetic protease inhibitor, prevents compression-induced spinal cord injury by inhibiting activation of leukocytes in rats.
Splenic Rupture
Atraumatic splenic rupture in a patient treated with apixaban: A case report.
Splenic Rupture
Atraumatic splenic rupture in amyloidosis.
Splenic Rupture
Spontaneous rupture of the spleen as immediate complication in autologous transplantation for primary systemic amyloidosis.
ST Elevation Myocardial Infarction
Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
ST Elevation Myocardial Infarction
Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
ST Elevation Myocardial Infarction
Determination of risk factors affecting the in-hospital prognosis of patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention.
ST Elevation Myocardial Infarction
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
Stomach Neoplasms
Procoagulant activity of human stomach and colon cancers.
Stomach Neoplasms
Protein Z/protein Z-dependent protease inhibitor system in loco in human gastric cancer.
Stomach Ulcer
DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.
Stomatitis
FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Stomatitis
Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
Streptococcal Infections
Host factors in experimental group A streptococcal infections; the role of tissue thromboplastin.
Stroke
A case report of parenchymal hematoma after intravenous thrombolysis in a rivaroxaban-treated patient: Is it a true rivaroxaban hemorrhagic complication?
Stroke
A cost-analysis model for anticoagulant treatment in the hospital setting.
Stroke
A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long?term prevention of thromboembolic complications in patients with atrial fibrillation?
Stroke
A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).
Stroke
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Stroke
A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.
Stroke
Accidental Rivaroxaban Intoxication in a Boy: Some Lessons in Managing New Oral Anticoagulants in Children.
Stroke
Alteplase for Acute Ischemic Stroke after Heparin Reversal with Protamine: A Case Report and Review.
Stroke
Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial.
Stroke
An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation.
Stroke
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation.
Stroke
An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
Stroke
An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.
Stroke
Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
Stroke
Angiotensin II promotes the anticoagulant effects of rivaroxaban via angiotensin type 2 receptor signaling in mice.
Stroke
Anti-Xa Activity and Event Risk in Patients With Direct Factor Xa Inhibitors Initiated Early After Stroke.
Stroke
Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Stroke
Anticoagulation therapy for atrial fibrillation.
Stroke
Anticoagulation therapy: Direct factor Xa inhibition improves stroke prevention in patients with AF.
Stroke
Antiphospholipid antibodies and stroke in the young--a study of three cases.
Stroke
Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions.
Stroke
Antithrombotic medication for cardioembolic stroke prevention.
Stroke
Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda.
Stroke
Antithrombotics in atrial fibrillation and coronary disease.
Stroke
Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial.
Stroke
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
Stroke
Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design.
Stroke
Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study.
Stroke
Apixaban to prevent stroke in patients with atrial fibrillation: a review.
Stroke
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
Stroke
Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model.
Stroke
Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Stroke
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
Stroke
Apixaban: A New Factor Xa Inhibitor for Stroke Prevention in Patients with Atrial Fibrillation.
Stroke
Apolipoprotein E genotype, coagulation, and survival following acute stroke.
Stroke
Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
Stroke
Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants.
Stroke
Association Between Platelet Function and Disc Hemorrhage in Patients With Normal-Tension Glaucoma: A Prospective Cross-Sectional Study.
Stroke
Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: A nested case-control study.
Stroke
Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute.
Stroke
Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants.
Stroke
Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa).
Stroke
Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.
Stroke
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects.
Stroke
Biological effects of distension media in bipolar versus monopolar resectoscopic myomectomy: a randomized trial.
Stroke
Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
Stroke
Blood coagulation and fibrinolysis in acute ischaemic and haemorrhagic (intracerebral and subarachnoid haemorrhage) stroke: does decreased plasmin inhibitor indicate increased fibrinolysis in subarachnoid haemorrhage compared to other types of stroke?
Stroke
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
Stroke
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
Stroke
Characteristics, Management, and Outcomes of Patients with Atrial Fibrillation Experiencing a Major Bleeding Event While on Rivaroxaban.
Stroke
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.
Stroke
Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study.
Stroke
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Stroke
Clinical Pharmacology and Role of Edoxaban in Contemporary Antithrombotic Therapy.
Stroke
Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation.
Stroke
Clopidogrel hydrogen sulphate for atrial fibrillation.
Stroke
Comparative effectiveness of oral anticoagulants in everyday practice.
Stroke
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Stroke
Comparative efficacy and safety of the non-vitamin k antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Stroke
Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism.
Stroke
Comparing Safety and Efficacy of Dabigatran and Factor Xa Inhibitors for Stroke Prevention in Hemophiliacs with Non-Valvular Atrial Fibrillation.
Stroke
Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation.
Stroke
Controversies: Stroke Prevention in Chronic Kidney Disease.
Stroke
Correction to: Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Stroke
Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective.
Stroke
Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Stroke
Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.
Stroke
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Stroke
Current Perspective on Use of NOAC in Clinical Practice in India.
Stroke
Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
Stroke
Design and baseline characteristics of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
Stroke
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
Stroke
Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong.
Stroke
Dexamethasone improves heat stroke-induced multiorgan dysfunction and damage in rats.
Stroke
Diagnosis and Treatment of Atrial Fibrillation.
Stroke
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Stroke
Dilemma of Indication for Thrombolysis in a Patient with Acute Ischemic Stroke Treated with a Novel Oral Anticoagulant.
Stroke
Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Stroke
Direct Factor Xa Inhibitors for Long-term Stroke Prevention in Atrial Fibrillation: Could the Lower Dose Fit All?
Stroke
Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities.
Stroke
Direct Oral Anticoagulants in Nonvalvular Atrial Fibrillation: Practical Considerations on the Choice of Agent and Dosing.
Stroke
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management.
Stroke
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Stroke
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Stroke
Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis.
Stroke
Drug-drug interaction studies of cardiovascular drugs involving p-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor xa inhibitor.
Stroke
Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice?
Stroke
Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
Stroke
Edoxaban tosylate.
Stroke
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
Stroke
EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial.
Stroke
Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Stroke
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation
Stroke
Edoxaban: a new oral direct factor xa inhibitor.
Stroke
Edoxaban: a review in nonvalvular atrial fibrillation.
Stroke
Effect of dual versus mono antiplatelet therapy on recurrent stroke modulated by activated partial thromboplastin time.
Stroke
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.
Stroke
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Stroke
Effect of Heparin on Recanalization in Acute Stroke Patients with Intra-Arterial Thrombi.
Stroke
Effects of dabigatran and rivaroxaban on stroke severity according to the results of routine coagulation tests.
Stroke
Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
Stroke
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48.
Stroke
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Stroke
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Stroke
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
Stroke
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).
Stroke
Efficacy of direct factor Xa inhibitors compared to warfarin in preventing stroke in adults with non-valvular atrial fibrillation: a systematic review protocol.
Stroke
Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events.
Stroke
Embolic Stroke of Undetermined Source: Gateway to a New Stroke Entity?
Stroke
Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.
Stroke
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
Stroke
Factor X inhibitors.
Stroke
Factor Xa inhibition by rivaroxaban regulates fibrogenesis in human atrial fibroblasts with modulation of nitric oxide synthesis and calcium homeostasis.
Stroke
Factor Xa Inhibitor Suppresses the Release of Phosphorylated HSP27 from Collagen-Stimulated Human Platelets: Inhibition of HSP27 Phosphorylation via p44/p42 MAP Kinase.
Stroke
Factor Xa inhibitors differently modulate electrical activities in pulmonary veins and the sinoatrial node.
Stroke
Factor Xa inhibitors in patients with continuous-flow left ventricular assist devices.
Stroke
Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
Stroke
Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation.
Stroke
Factors Associated With Major Bleeding Events: Insights From the ROCKET AF Trial (Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Stroke
Factors That Determine the Prothrombin Time in Patients With Atrial Fibrillation Receiving Rivaroxaban.
Stroke
Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.
Stroke
Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus.
Stroke
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial.
Stroke
Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection.
Stroke
Hemopericardium with subsequent cardiac tamponade secondary to rivaroxaban treatment: a case report.
Stroke
Hemopericardium with tamponade following rivaroxaban administration and its attenuation by CYP3A4 inhibitors.
Stroke
Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment.
Stroke
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
Stroke
Impact of Patent Foramen Ovale on Total Knee Arthroplasty Cerebrovascular Accident Perioperative Management.
Stroke
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial.
Stroke
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.
Stroke
Impact of the approval of intravenous recombinant tissue plasminogen activator therapy on the processes of acute stroke management in Japan: the Stroke Unit Multicenter Observational (SUMO) Study.
Stroke
Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
Stroke
Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation.
Stroke
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Stroke
Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in rats.
Stroke
Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes.
Stroke
Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Stroke
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
Stroke
Intracranial hemorrhage in patient treated with rivaroxaban.
Stroke
Intravenous Thrombolysis for Acute Ischemic Stroke in a Patient Receiving Rivaroxaban.
Stroke
Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study.
Stroke
Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation.
Stroke
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.
Stroke
Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts".
Stroke
Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis.
Stroke
Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation Education Task Force White Paper.
Stroke
Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks.
Stroke
Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation.
Stroke
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
Stroke
Monitoring the anticoagulant effect after a massive rivaroxaban overdose.
Stroke
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban.
Stroke
New anticoagulant treatments to protect against stroke in atrial fibrillation.
Stroke
New insights into the pathogenic mechanisms and treatment of arterial thrombosis in antiphospholipid syndrome.
Stroke
New options for stroke prevention in atrial fibrillation.
Stroke
New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials.
Stroke
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
Stroke
Newer Oral Anticoagulants: Stroke Prevention and Pitfalls.
Stroke
Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.
Stroke
Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Stroke
Novel anticoagulant therapy: principle and practice.
Stroke
Novel anticoagulants for stroke prevention in atrial fibrillation and chronic kidney disease.
Stroke
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Stroke
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Stroke
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Stroke
Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban.
Stroke
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
Stroke
Off-label use of reduced dose direct oral factor Xa-inhibitors in subjects with atrial fibrillation: a review of clinical evidence.
Stroke
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
Stroke
Optimal Dosing of Intravenous Unfractionated Heparin Bolus in Transient Ischemic Attack or Stroke.
Stroke
Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
Stroke
Oral anticoagulants for Asian patients with atrial fibrillation.
Stroke
Oral anticoagulation and vitamin K deficiency.
Stroke
Oral direct factor Xa inhibitors for stroke prevention in atrial fibrillation.
Stroke
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Stroke
Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease.
Stroke
Oral IIa and Xa Inhibitors for Prevention of Stroke in Atrial Fibrillation: Clinical Studies and Regulatory Considerations.
Stroke
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Stroke
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Stroke
Periprocedural management of rivaroxaban-treated patients.
Stroke
Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects.
Stroke
Pharmacokinetics and pharmacodynamics of intravenous and oral apixaban in horses.
Stroke
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Stroke
Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm.
Stroke
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Stroke
Population Pharmacokinetic-Pharmacodynamic Modeling Analysis of Intrinsic FXa and Bleeding From Edoxaban Treatment.
Stroke
Post-stroke seizure-Do the locations, types and managements of stroke matter?
Stroke
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Stroke
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.
Stroke
Practical management of patients on apixaban: a consensus guide.
Stroke
Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.
Stroke
Preclinical and clinical data for factor Xa and "universal" reversal agents.
Stroke
Predicting abnormal coagulation in ischemic stroke: reducing delay in rt-PA use.
Stroke
Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism.
Stroke
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
Stroke
Prevention of Stroke in Patients With Atrial Fibrillation.
Stroke
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
Stroke
Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice.
Stroke
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
Stroke
Prognosis of spontaneous intracerebral hemorrhage in hemodialysis patients.
Stroke
Quantification of apixaban in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry.
Stroke
Quick reference guide to apixaban.
Stroke
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
Stroke
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation.
Stroke
Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation.
Stroke
Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression.
Stroke
Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
Stroke
Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
Stroke
Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry.
Stroke
Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS).
Stroke
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Stroke
Recombinant tissue-type plasminogen activator (rt-PA) therapy in an acute stroke patient taking dabigatran etexilate: a case report and literature review.
Stroke
Rectus Sheath Hematoma Associated with Apixaban.
Stroke
Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
Stroke
Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy.
Stroke
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Stroke
Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts".
Stroke
Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation.
Stroke
Rivaroxaban compared to no treatment in ER-negative stage I-III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial.
Stroke
Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial.
Stroke
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Stroke
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.
Stroke
Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer.
Stroke
Rivaroxaban in atrial fibrillation.
Stroke
Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study.
Stroke
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
Stroke
Rivaroxaban: a review of its use in acute coronary syndromes.
Stroke
Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Stroke
ROCKET AF adds more concerns about Digoxin safety in patients with atrial fibrillation.
Stroke
Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
Stroke
Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice.
Stroke
Safety and effectiveness of oral factor Xa inhibitors versus warfarin in nonvalvular atrial fibrillation patients at high-risk for falls.
Stroke
Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation.
Stroke
Safety and efficacy of apixaban in the treatment of atrial fibrillation.
Stroke
Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.
Stroke
Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation.
Stroke
Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.
Stroke
Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.
Stroke
Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation.
Stroke
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
Stroke
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.
Stroke
Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban.
Stroke
Shortened Activated Partial Thromboplastin Time Is Associated With Acute Ischemic Stroke, Stroke Severity, and Neurological Worsening.
Stroke
Spontaneous cervical artery dissection is accompanied by a hypercoagulable state and simultaneous inflammatory condition.
Stroke
Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials.
Stroke
Stroke and conditions that mimic it: a protocol secures a safe early recognition.
Stroke
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48).
Stroke
Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy.
Stroke
Stroke prevention and treatment.
Stroke
Stroke Prevention in Atrial Fibrillation - Outcomes and Future Directions.
Stroke
Stroke Prevention in Atrial Fibrillation: Impact of Novel Oral Anticoagulants.
Stroke
Stroke prevention with rivaroxaban in higher-risk populations with atrial fibrillation.
Stroke
Successful Peritoneal Dialysis Catheter Placement in a New End-Stage Renal Disease Patient with Combined Antiphospholipid Syndrome and Factor XI Deficiency.
Stroke
Successful thrombolysis without hemorrhage in a patient with cardioembolic stroke under dabigatran treatment-a case report and review of literature.
Stroke
Sudden Loss of Vision: An Insight into Rivaroxaban.
Stroke
Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models.
Stroke
The "Dual-Pathway" Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial.
Stroke
The coagulopathy of heat stroke: alterations in coagulation and fibrinolysis in heat stroke patients during the pilgrimage (Haj) to Makkah.
Stroke
The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor.
Stroke
The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
Stroke
The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis.
Stroke
The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Stroke
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
Stroke
The pharmacology of novel oral anticoagulants.
Stroke
The Potential Role of Edoxaban in Stroke Prevention Guidelines.
Stroke
The potential role of inflammation in cryptogenic stroke.
Stroke
The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy.
Stroke
The role of aspirin for stroke prevention in atrial fibrillation.
Stroke
The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation.
Stroke
The Role of Rivaroxaban in Atrial Fibrillation and Acute Coronary Syndromes.
Stroke
The serial hemostasis-related changes in patients with cerebral infarction: comparison between progressing and non-progressing stroke.
Stroke
Therapeutic Plasma Exchange for Urgent Rivaroxaban Reversal.
Stroke
Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke.
Stroke
Thromboembolic and Hemorrhagic Outcomes in the Direct Oral Anticoagulant Trials Across the Spectrum of Kidney Function.
Stroke
Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
Stroke
Transitions of care in anticoagulated patients.
Stroke
Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.
Stroke
Type 2 Diabetes, Atrial Fibrillation, and Direct Oral Anticoagulation.
Stroke
Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
Stroke
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
Stroke
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial.
Stroke
Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
Stroke
Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
Stroke
Use of rivaroxaban in patients with stroke.
Stroke
Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
Stroke
Vitamin K antagonists. Ready to be replaced?
Stroke
What did we learn from new oral anticoagulant treatment?
Stroke
What's new in stroke? The top 10 studies of 2009-2011: part II.
Stroke
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
Stroke
[Analysis of the Cochrane Review: Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev. 2014,3:CD009893].
Stroke
[Anticoagulant therapy for chronic cardiac diseases. Atrial fibrillation, valvular heart disease, congestive heart failure].
Stroke
[Characteristics and clinical use of rivaroxaban for the treatment of atrial fibrillation and venous thromboembolism].
Stroke
[Characteristics of circulation and microcirculation in healthy people of Han nationality at different altitudes].
Stroke
[Comparison of Novel Oral Anticoagulants and Warfarin in Elderly Patients With Nonvalvular Atrial Fibrillation].
Stroke
[Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)].
Stroke
[Effect of plasma fibrinogen level-based defibrase therapy in patients with acute cerebral infarction.]
Stroke
[Evidence of novel oral anticoagulants (NOAC)].
Stroke
[Interventional left atrial appendage occlusion. A reasonable alternative to oral anticoagulation - even in the era of the new substances?].
Stroke
[New antithrombotics for atrial fibrillation.]
Stroke
[New oral anticoagulants for the prevention of stroke : Open questions in geriatric patients].
Stroke
[New treatments for stroke and thromboembolism prevention in atrial fibrillation].
Stroke
[Novel oral anticoagulants (NOAC)].
Stroke
[Oral factor Xa inhibitors or warfarin for stroke prophylaxis. ROCKET AF and ARISTOTLE studies].
Stroke
[Perioperative management and therapy of bleeding complications].
Stroke
[Pharmacology of the new oral anticoagulants].
Stroke
[Prevention of cardioembolic stroke].
Stroke
[Prevention of stroke in nonvalvular atrial fibrillation. Oral direct factor Xa inhibitor apixaban: positive experiences in general medical practice].
Stroke
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
Stupor
[Acute hepatic insufficiency in guinea pigs. Experimental model caused by the injection of monoethanolamine oleate]
Subarachnoid Hemorrhage, Traumatic
Emergent surgical evacuation of traumatic intracranial hematoma in patients with preoperative thrombocytopenia: surgical risk and early outcome.
Surgical Wound Infection
Effect of different carbon dioxide (CO2) insufflation for laparoscopic colorectal surgery in elderly patients: A randomized controlled trial.
Syphilis
A case of syphilis presenting with prolonged etiology-unrevealed fever, accompanying activated partial thromboplastin time prolongation.
Syphilis
Antiphospholipid antibody syndrome: a case report and review of the literature.
Syphilis
Antiphospholipid antibody syndrome: an unusual cause of stroke in a 22-year-old female.
Syphilis
Chorea and high antiphospholipid antibodies: probable primary antiphospholipid syndrome.
Syphilis
Chorea as a manifestation of the antiphospholipid syndrome in childhood.
Syphilis
Diagnostic Pitfalls in a Man with Systemic Lupus Erythematous.
Syphilis
Non-lupus nephropathy associated with antiphospholipid antibodies.
Syphilis
Perioperative primary thrombosis prophylaxis for colorectal cancer in an asymptomatic antiphospholipid antibody carrier -a case report and literature review-.
Syphilis
Sjögren's syndrome and pregnancy.
Syphilis
The characteristics of beta 2-glycoprotein I-dependent anticardiolipin antibody and blood coagulation status in subjects with classical biological false-positive syphilis reactions.
Syphilis
The tissue thromboplastin inhibition test in diabetics without cerebro-cardiovascular diseases.
Syphilis
[A case of anti-phospholipid antibody syndrome associated with subdural hematoma]
Tachycardia
Acquired factor VIII deficiency presenting with compartment syndrome.
Tachycardia
Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue.
Tachycardia
Outcomes of patients hospitalized with peptic ulcer disease diagnosed in acute upper endoscopy.
Tachycardia
Pediatric Risk of Mortality III Score - Predictor of Mortality and Hospital Stay in Pediatric Intensive Care Unit.
Tachycardia
Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment.
Takayasu Arteritis
Anti-factor IX circulating anticoagulant and immune thrombocytopenia in a case of Takayasu's arteritis.
Telangiectasia, Hereditary Hemorrhagic
Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.
Telangiectasis
Angiodysplasia of upper gastrointestinal tract with coagulopathy.
Telangiectasis
Gross hematuria due to acquired haemophilia in hereditary hemorrhagic telangiectasia.
Telangiectasis
Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.
Tetanus
Hemophilic pseudotumor of the ilium due to plasma thromboplastin component (PTC) deficiency, with post-operative tetanus.
Tetralogy of Fallot
Attributable fraction for cardiac malformations.
Thrombasthenia
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
Thrombasthenia
Glanzmann's thrombasthenia in pregnancy: a case and review of the literature.
Thrombasthenia
Impaired platelet procoagulant mechanisms in patients with bleeding disorders.
Thrombasthenia
Inherited bleeding disorders in the Eastern Province of Saudi Arabia.
Thrombasthenia
Menorrhagia and reproductive health in rare bleeding disorders: a study from the Indian subcontinent.
Thrombasthenia
Platelet prothrombin converting activity in hereditary disorders of platelet function.
Thrombasthenia
Platelet prothrombinase activity and intracellular calcium responses in patients with storage pool deficiency, glycoprotein IIb-IIIa deficiency, or impaired platelet coagulant activity--a comparison with Scott syndrome.
Thrombasthenia
The spectrum of bleeding disorders in women with menorrhagia: a report from Western India.
Thrombasthenia
The use of recombinant factor VIla in a primigravida with Glanzmann's thrombasthenia during delivery.
thrombin deficiency
Apixaban attenuates ischemia-induced myocardial fibrosis by inhibition of Gq/PKC signaling.
Thrombocytopenia
'Lupus' anticoagulant and thrombosis of the hepatic veins (Budd-Chiari syndrome). Report of three patients and review of the literature.
Thrombocytopenia
A 17-Year-Old With Chest Pain.
Thrombocytopenia
A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia.
Thrombocytopenia
A case of Budd-Chiari syndrome with high antiphospholipid antibody in a patient with systemic lupus erythematosus.
Thrombocytopenia
A case of cerebral infarction associated with positive antiphospholipid antibody in a systemic lupus patient.
Thrombocytopenia
A case of immune thrombocytopenic purpura with prolonged aPTT time: A clotter hidden in a bleeder?
Thrombocytopenia
A comparative study of the disease in cattle caused by Theileria parva or T. lawrencei: II. Hematology, clinical chemistry, coagulation studies and complement.
Thrombocytopenia
A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.
Thrombocytopenia
A prospective pilot study of platelet function and its relationship with postoperative bleeding in pediatric cardiac surgery.
Thrombocytopenia
Abnormal peri-operative haemorrhage in asymptomatic patients is not predicted by laboratory testing.
Thrombocytopenia
ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats.
Thrombocytopenia
Accidental fatal aflatoxicosis due to contaminated commercial diet in 50 dogs.
Thrombocytopenia
Acute intrinsic renal failure and blood coagulation disorders after a snakebite in a dog.
Thrombocytopenia
Acute necrotizing encephalopathy associated with hemophagocytic syndrome.
Thrombocytopenia
Acute renal failure after snakebite: a report of four cases.
Thrombocytopenia
Adenoviral pneumonia in children.
Thrombocytopenia
Adverse gastrointestinal complications after cardiopulmonary bypass: can outcome be predicted from preoperative risk factors?
Thrombocytopenia
Albumin dialysis in critically ill patients: use versus omission of intradialytic heparin.
Thrombocytopenia
Alkhumra (Alkhurma) virus outbreak in Najran, Saudi Arabia: Epidemiological, clinical, and Laboratory characteristics.
Thrombocytopenia
Alternative Monitoring of Argatroban Using Plasma-Diluted Thrombin Time (April).
Thrombocytopenia
An increase of blood anti-beta2-glycoprotein I antibody in Japanese encephalitis associated with cerebral ischemia.
Thrombocytopenia
Animal models for antiphospholipid syndrome in pregnancy.
Thrombocytopenia
Anti-factor IX circulating anticoagulant and immune thrombocytopenia in a case of Takayasu's arteritis.
Thrombocytopenia
Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression.
Thrombocytopenia
Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations.
Thrombocytopenia
Antiphospholipid antibody syndrome: an unusual cause of stroke in a 22-year-old female.
Thrombocytopenia
Antiphospholipid syndrome and multiple ischemic strokes in a patient with myasthenia gravis.
Thrombocytopenia
Antiphospholipids antibodies in a 12-month-old presenting with idiopathic thrombocytopenic purpura.
Thrombocytopenia
Antiplatelet and Anticoagulant Drugs in Interventional Radiology.
Thrombocytopenia
Apixaban: a novel agent to treat heparin induced thrombocytopenia and to prevent embolism in patient with atrial fibrillation after multiple valve replacement?
Thrombocytopenia
Apparent argatroban resistance in a patient with elevated factor VIII levels.
Thrombocytopenia
Argatroban and lepirudin requirements in a 6-year-old patient with heparin-induced thrombocytopenia.
Thrombocytopenia
Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients.
Thrombocytopenia
Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.
Thrombocytopenia
Argatroban.
Thrombocytopenia
Assessment of Coagulation by Thromboelastography During Ongoing Postpartum Hemorrhage: A Retrospective Cohort Analysis.
Thrombocytopenia
ATGAM associated coagulopathy in renal transplant patients: a report of two unusual cases.
Thrombocytopenia
Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome.
Thrombocytopenia
Bilateral Orbital Haematomas in an Anticoagulated Patient with Severe H1N1 Influenza.
Thrombocytopenia
Blood coagulation abnormalities associated with envenoming by Trimeresurus albolabris in Hong Kong.
Thrombocytopenia
Bruising associated with the use of fluoxetine.
Thrombocytopenia
Characteristics and pathogenic role of anti-beta2-glycoprotein I single-chain Fv domains: induction of experimental antiphospholipid syndrome.
Thrombocytopenia
Chorea and high antiphospholipid antibodies: probable primary antiphospholipid syndrome.
Thrombocytopenia
Clearance of fibrin from glomeruli. Renal cortical fibrinolytic response after thromboplastin infusion in the rat.
Thrombocytopenia
Clinical and laboratory profile of patients with Kyasanur forest disease: A single-centre study of 192 patients from Karnataka, India.
Thrombocytopenia
Clinical features and dynamic ordinary laboratory tests differentiating dengue fever from other febrile illnesses in children.
Thrombocytopenia
Clinical significance of anticardiolipin and anti-beta2-glycoprotein I antibodies.
Thrombocytopenia
Clinicopathologic findings of naturally occurring Rabbit Hemorrhagic Disease Virus 2 infection in pet rabbits.
Thrombocytopenia
Coagulation abnormalities associated with acute Angiostrongylus vasorum infection in dogs.
Thrombocytopenia
Coagulation and the hypertensive diseases of pregnancy.
Thrombocytopenia
Coagulation defects in rabbits after infusion of dispersed fluorochemicals.
Thrombocytopenia
Coagulation profile, haematological and biochemical changes in kids naturally infected with peste des petits ruminants.
Thrombocytopenia
Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.
Thrombocytopenia
Coagulation studies in patients with marked thrombocytopenia due to severe preeclampsia.
Thrombocytopenia
Coagulopathy After Isolated Severe Traumatic Brain Injury in Children.
Thrombocytopenia
Coagulopathy and its effect on treatment and mortality in patients with traumatic intracranial hemorrhage.
Thrombocytopenia
Coagulopathy associated with hematin treatment for acute intermittent porphyria.
Thrombocytopenia
Coagulopathy in COVID-19.
Thrombocytopenia
Complement in Secondary Thrombotic Microangiopathy.
Thrombocytopenia
Concentration of D-dimers in healthy cats and sick cats with and without disseminated intravascular coagulation (DIC).
Thrombocytopenia
Connective tissue disease associated with sclerodermoid features, early abortion, and circulating anticoagulant.
Thrombocytopenia
Costly coagulation profile tests prior to performing breast biopsies. Do we really need it?
Thrombocytopenia
COVID-19 versus HIT hypercoagulability.
Thrombocytopenia
Crimean-Congo hemorrhagic fever.
Thrombocytopenia
Deficiency of the contact phase of intrinsic coagulation in a horse.
Thrombocytopenia
Detrimental effects of N(omega) nitro-L-arginine methyl ester (L-NAME)in experimental Escherichia coli sepsis in the newborn piglet.
Thrombocytopenia
Development of a novel mouse model for dengue virus infection.
Thrombocytopenia
Difference in clinical presentation between the first and second phases of Kyasanur Forest disease: an experience from a teaching hospital in South India.
Thrombocytopenia
Diffuse hemangiomatosis, coagulopathy and microangiopathic hemolytic anemia.
Thrombocytopenia
Disseminated intravascular coagulation associated with colic in 23 horses (1984-1989).
Thrombocytopenia
Disseminated intravascular coagulation caused by moojenactivase, a procoagulant snake venom metalloprotease.
Thrombocytopenia
Disseminated intravascular coagulation in cats.
Thrombocytopenia
Disseminated intravascular coagulation in endemic hepatosplenic schistosomiasis.
Thrombocytopenia
Disseminated intravascular coagulation in six horses.
Thrombocytopenia
Disseminated intravascular coagulation in the newborn.
Thrombocytopenia
Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids.
Thrombocytopenia
Double filtration plasmapheresis for a case of Crimean-Congo hemorrhagic fever.
Thrombocytopenia
Early Coagulopathy After Isolated Severe Traumatic Brain Injury: Relationship With Hypoperfusion Challenged.
Thrombocytopenia
Effect of a selective PAF antagonist SM-10661 ((+/-)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one HCl) on experimental disseminated intravascular coagulation (DIC).
Thrombocytopenia
Effect of heparin on chronically induced intravascular coagulation in dogs.
Thrombocytopenia
Effects of intravascular clotting on the activation of the complement system: The role of the platelet.
Thrombocytopenia
Emergent surgical evacuation of traumatic intracranial hematoma in patients with preoperative thrombocytopenia: surgical risk and early outcome.
Thrombocytopenia
Erythema multiforme major and disseminated intravascular coagulation in a dog following application of a d-limonene-based insecticidal dip.
Thrombocytopenia
Ethanol intoxication is associated with a lower incidence of admission coagulopathy in severe traumatic brain injury patients.
Thrombocytopenia
Evaluation of a Standardized Protocol Using Lepirudin or Argatroban for Heparin-Induced Thrombocytopenia.
Thrombocytopenia
Evaluation of factors predictive of the prognosis in Crimean-Congo hemorrhagic fever: new suggestions.
Thrombocytopenia
Evaluation of prognostic factors in the surgical treatment of adrenal gland tumors in dogs: 41 cases (1999-2005).
Thrombocytopenia
Evaluation of the potential causes of epistaxis in dogs with natural visceral leishmaniasis.
Thrombocytopenia
Experimental Sarcocystis suicanis infections: disease in growing pigs.
Thrombocytopenia
Fatal diffuse thrombotic microangiopathy after a bite by the "Fer-de-Lance" pit viper (Bothrops lanceolatus) of Martinique.
Thrombocytopenia
Fatal hemorrhage induced by subtilase cytotoxin from Shiga-toxigenic Escherichia coli.
Thrombocytopenia
FcRn augments induction of tissue factor activity by IgG-containing immune complexes.
Thrombocytopenia
Flow cytometric evaluation of disseminated intravascular coagulation in a canine endotoxemia model.
Thrombocytopenia
Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban.
Thrombocytopenia
Fondaparinux in heparin-induced thrombocytopenia.
Thrombocytopenia
Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients.
Thrombocytopenia
Fructose-1,6-bisphosphate inhibits in vitro and ex vivo platelet aggregation induced by ADP and ameliorates coagulation alterations in experimental sepsis in rats.
Thrombocytopenia
Giant hemangioma of the liver (Kasabach-Merritt syndrome): successful suppression of intravascular coagulation permitting surgical removal.
Thrombocytopenia
Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis.
Thrombocytopenia
Haemostatic trends in HIV-infected individuals in Yaoundé, Cameroon: a pilot study.
Thrombocytopenia
Hantavirus pulmonary syndrome due to Andes virus in Temuco, Chile: clinical experience with 16 adults.
Thrombocytopenia
Heat stroke in dogs: A retrospective study of 54 cases (1999-2004) and analysis of risk factors for death.
Thrombocytopenia
Hemangioma of the radius associated with Kasabach-Merritt syndrome: case report and literature review.
Thrombocytopenia
Hematin: unique effects of hemostasis.
Thrombocytopenia
Hematologic and coagulation abnormalities in acute bovine sarcocystosis.
Thrombocytopenia
Hematologic manifestation of childhood celiac disease.
Thrombocytopenia
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Thrombocytopenia
Hemostasis and the complement system in Argentine hemorrhagic fever.
Thrombocytopenia
Hemostatic Abnormalities in COVID-19: An Update.
Thrombocytopenia
Hemostatic abnormalities in dogs with hemangiosarcoma.
Thrombocytopenia
Hemostatic abnormalities in multiple myeloma and related disorders.
Thrombocytopenia
Hemostatic changes in Vietnamese children with mild dengue correlate with the severity of vascular leakage rather than bleeding.
Thrombocytopenia
Hemostatic disorders in cats: a retrospective study and review of the literature.
Thrombocytopenia
Heparin-induced coagulopathy associated with staphylococcal protein A immunoadsorption treatment columns: an in vitro and in vivo analysis.
Thrombocytopenia
Heparin-induced thrombocytopenia and the clinical use of low molecular weight heparins in acute coronary syndromes.
Thrombocytopenia
High-dose argatroban for heparin-induced thrombocytopenia in a child using a ventricular assist device.
Thrombocytopenia
Higher susceptibility of mast-cell-deficient W/WV mutant mice to brain thromboembolism and mortality caused by intravenous injection of India ink.
Thrombocytopenia
Immune Thrombocytopenia Purpura Secondary to COVID-19.
Thrombocytopenia
Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice.
Thrombocytopenia
Importance of platelets in experimental venous thrombosis in the rat.
Thrombocytopenia
Incidence and risk factors of upper gastrointestinal bleeding in mechanically ventilated children.
Thrombocytopenia
Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies.
Thrombocytopenia
Induction of tolerance to experimental anti-phospholipid syndrome (APS) by syngeneic bone marrow cell transplantation.
Thrombocytopenia
Infectious canine hepatitis: animal model for viral-induced disseminated intravascular coagulation.
Thrombocytopenia
Intra-cardiac thrombus in antiphospholipid antibody syndrome: An unusual cause of fever of unknown origin with review of literature.
Thrombocytopenia
Intracardiac thrombosis and acute myocardial infarction as initial presentation of antiphospholipid syndrome.
Thrombocytopenia
Intracerebral hemorrhage after liver transplantation.
Thrombocytopenia
Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator.
Thrombocytopenia
Ischemic stroke as initial manifestation of systemic lupus erythematosus: A case report and review of the literature.
Thrombocytopenia
Kasabach-Merritt syndrome complicating treatment of a closed femoral fracture.
Thrombocytopenia
Laboratory findings in patients with avian-origin influenza A (H7N9) virus infections.
Thrombocytopenia
Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities.
Thrombocytopenia
Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban.
Thrombocytopenia
Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment.
Thrombocytopenia
Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus.
Thrombocytopenia
Malignant histiocytosis in a cat.
Thrombocytopenia
Mammary gland carcinoma in a dog with peripheral blood and bone marrow involvement associated with disseminated intravascular coagulation.
Thrombocytopenia
Meningoencephalitis, myocarditis and disseminated intravascular coagulation in a patient with scrub typhus.
Thrombocytopenia
Modulators of the coagulation cascade: focus and recent advances in inhibitors of tissue factor, factor VIIa and their complex.
Thrombocytopenia
Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry - a prospectively controlled randomized double-blind clinical trial.
Thrombocytopenia
Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?
Thrombocytopenia
Multicenter retrospective study of transcatheter arterial embolisation for life-threatening haemorrhage in patients with uncorrected bleeding diathesis.
Thrombocytopenia
Multifocal lymphangioendotheliomatosis with thrombocytopenia: a newly recognized clinicopathological entity.
Thrombocytopenia
Myocardial infarction as the presenting manifestation of systemic lupus erythematosus with antiphosphatidylserine antibodies.
Thrombocytopenia
Neurotoxic envenoming by South American coral snake (Micrurus lemniscatus helleri): case report from eastern Ecuador and review.
Thrombocytopenia
Oral tolerance to low dose beta 2-glycoprotein I: immunomodulation of experimental antiphospholipid syndrome.
Thrombocytopenia
Orally administered dextran sulfate is absorbed in HIV-positive individuals.
Thrombocytopenia
Paravertebral and Retroperitoneal Vascular Tumour Presenting with Kasabach-Merritt Phenomenon in Childhood, Diagnosed with Magnetic Resonance Imaging.
Thrombocytopenia
Pathogenic natural anti-cardiolipin antibodies: the experience from monoclonal gammopathy.
Thrombocytopenia
Pathogenic serum IgG anticardiolipin antibodies and the idiotypic network.
Thrombocytopenia
Perioperative anticoagulation management in antiphospholipid syndrome.
Thrombocytopenia
Pharmaceutical Approval Update.
Thrombocytopenia
Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Thrombocytopenia
Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer.
Thrombocytopenia
Phase I/II trial of accutane as a potentiator of carboplatin and paclitaxel in squamous cell carcinomas.
Thrombocytopenia
Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults.
Thrombocytopenia
Porcine kidney and heart transplantation in baboons undergoing a tolerance induction regimen and antibody adsorption.
Thrombocytopenia
Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988.
Thrombocytopenia
Predictors of clinical deterioration in non-severe patients with COVID-19: a retrospective cohort study.
Thrombocytopenia
Prevalence of hematologic toxicity from copperhead envenomation: an observational study.
Thrombocytopenia
Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3.
Thrombocytopenia
Primary antiphospholipid syndrome with multiorgan arterial and venous thromboses.
Thrombocytopenia
Primary pulmonary hypertension. Its association with microangiopathic hemolytic anemia and thrombocytopenia.
Thrombocytopenia
Probable intrafamilial transmission of coxsackievirus b3 with vertical transmission, severe early-onset neonatal hepatitis, and prolonged viral RNA shedding.
Thrombocytopenia
Problems of diagnosis of disseminated intravascular coagulation (DIC).
Thrombocytopenia
Profile of dengue patients admitted to a tertiary care hospital in Mumbai.
Thrombocytopenia
Proteins invoked by vitamin K absence and clotting times in clinically ill cats.
Thrombocytopenia
Pulsus alternans in a critically ill dog hospitalized for xylitol toxicity.
Thrombocytopenia
Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage.
Thrombocytopenia
Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits.
Thrombocytopenia
Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome.
Thrombocytopenia
Reduced argatroban doses after coronary artery bypass graft surgery.
Thrombocytopenia
Relationship between tissue perfusion and coagulopathy in traumatic brain injury.
Thrombocytopenia
Review of clinical symptoms and spectrum in humans with influenza A/H5N1 infection.
Thrombocytopenia
Risk factors and impact of portal vein thrombosis in liver transplantation.
Thrombocytopenia
Risk factors associated with fatality of severe fever with thrombocytopenia syndrome: a meta-analysis.
Thrombocytopenia
Risk Factors for Early Fatal Outcomes Among Children with Hemophagocytic Lymphohistiocytosis (HLH): A Single-Institution Case-Series in Vietnam.
Thrombocytopenia
Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study.
Thrombocytopenia
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.
Thrombocytopenia
Rowell's syndrome and associated antiphospholipid syndrome.
Thrombocytopenia
SARS: clinical features and diagnosis.
Thrombocytopenia
Secondary Immune Thrombocytopenic Purpura Triggered by COVID-19.
Thrombocytopenia
Serotonin Syndrome, Disseminated Intravascular Coagulation, and Hepatitis After a Single Ingestion of MDMA in an Asian Woman.
Thrombocytopenia
Severe acute respiratory syndrome in a doctor working at the Prince of Wales Hospital.
Thrombocytopenia
Severe acute respiratory syndrome in children: experience in a regional hospital in Hong Kong.
Thrombocytopenia
Shock in the pediatric emergency service: five years' experience.
Thrombocytopenia
Sjögren's syndrome and pregnancy.
Thrombocytopenia
Sporadic cases of Legionnaires' disease: the expanding clinical spectrum.
Thrombocytopenia
Studies of the coagulation and complement systems during experimental Rocky Mountain spotted fever in rhesus monkeys.
Thrombocytopenia
Studies of the coagulation system and blood pressure during experimental Bolivian hemorrhagic fever in rhesus monkeys.
Thrombocytopenia
Studies on Australian snake venoms, Part II: The haematological effects of brown snake (Pseudonaja) species in the dog.
Thrombocytopenia
Studies on some blood parameters of crossbred calves with experimental Theileria annulata infections.
Thrombocytopenia
Studies on the vascular and hematological changes induced by ellagic acid in rats.
Thrombocytopenia
Sublethal trauma model with systemic endotoxemia for the study of microcirculatory disorders after the second hit.
Thrombocytopenia
Successful delivery in a pregnant woman with lupus anticoagulant positive systemic lupus erythematosus treated with double filtration plasmapheresis.
Thrombocytopenia
Successful treatment of massive gastrointestinal hemorrhage in acute biphenotypic leukemia with recombinant factor VIIa (NovoSeven).
Thrombocytopenia
Suppression of experimental antiphospholipid syndrome and systemic lupus erythematosus in mice by anti-CD4 monoclonal antibodies.
Thrombocytopenia
Systemic disseminated Neospora caninum infection with cutaneous lesions as the initial clinical presentation in a dog.
Thrombocytopenia
Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment.
Thrombocytopenia
Systemic lupus erythematosus presenting with haemorrhagic manifestation.
Thrombocytopenia
The cardiovascular and haematological effects of purified prothrombin activator from the common brown snake (Pseudonaja textilis) and their antagonism with heparin.
Thrombocytopenia
The clinical usefulness of the preoperative bleeding time.
Thrombocytopenia
The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease.
Thrombocytopenia
The effects of indomethacin on the generalized shwartzman reaction.
Thrombocytopenia
The Need for Novel Anticoagulation Therapy in Acute Coronary Syndrome.
Thrombocytopenia
The pathogenesis of leptospirosis I. Hemorrhages in experimental leptospirosis in guinea pigs.
Thrombocytopenia
The pathogenic role of anti-phosphatidylserine antibodies: active immunization with the antibodies leads to the induction of antiphospholipid syndrome.
Thrombocytopenia
The successful treatment of multiple organ dysfunction syndrome and severe hypernatremia, secondary to joint supplement toxicity in a dog.
Thrombocytopenia
The use of ecarin chromogenic assay and prothrombinase induced clotting time in the monitoring of lepirudin for the treatment of heparin-induced thrombocytopenia.
Thrombocytopenia
Thrombocytopenia following heparin flush.
Thrombocytopenia
Thrombocytopenia induced in mice by thromboplastin infusion--essential role of the third complement component.
Thrombocytopenia
Thromboelastography Predicts Thromboembolism in Critically Ill Coagulopathic Patients.
Thrombocytopenia
Thromboelastometry analysis of thrombocytopenic dengue patients: a cross-sectional study.
Thrombocytopenia
Thromboelastometry-guided hemostatic therapy for hemorrhagic shock in the postoperative period of vascular surgery: a case report.
Thrombocytopenia
Thrombotic and hemorrhagic complications in children with the lupus anticoagulant.
Thrombocytopenia
Thrombotic Microangiopathy and Venous Thrombosis in a Patient With Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
Thrombocytopenia
Time course of coagulopathy in isolated severe traumatic brain injury.
Thrombocytopenia
Toxicity with intravenous injection of crude marijuana extract.
Thrombocytopenia
Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation. The importance of the T cell.
Thrombocytopenia
Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia.
Thrombocytopenia
Tufted angioma presenting with subclinical coagulopathy.
Thrombocytopenia
Uneventful administration of plasma products in a recipient with T-activated red cells.
Thrombocytopenia
Unusual Presentation of Diffuse Large B-Cell Lymphoma With Splenic Infarcts.
Thrombocytopenia
Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.
Thrombocytopenia
Vascular disease in the antiphospholipid syndrome: a comparison with the patient population with atherosclerosis.
Thrombocytopenia
Vascular permeability and coagulation during Rickettsia rickettsii infection in dogs.
Thrombocytopenia
Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia.
Thrombocytopenia
Why does activated partial thromboplastin time prolongation occur in severe fever with thrombocytopenia syndrome?
Thrombocytopenia
[A case of antiphospholipid syndrome associated with myasthenia gravis]
Thrombocytopenia
[A disorder in the coagulation mechanism as a possible cause for the development of an antenatal intracranial hemorrhage]
Thrombocytopenia
[Anaesthesia for cesarean section in a patient with acute viral hepatitis (author's transl)]
Thrombocytopenia
[Analysis of clinical characteristics of the 12 cases of neonatal dengue fever in Guangzhou in 2014 and literatures review].
Thrombocytopenia
[Antiphospholipid syndrome with myocardial infarction and aortic valve involvement]
Thrombocytopenia
[Apixaban as therapeutic option in nephropathy patients with heparin-induced thrombocytopenia (HIT)].
Thrombocytopenia
[Biological diagnosis of postoperative thrombopenia]
Thrombocytopenia
[Clinical and epidemiological characteristic of dengue]
Thrombocytopenia
[Crimean-Congo hemorrhagic fever]
Thrombocytopenia
[Factor X decrease in thrombopenias in childhood]
Thrombocytopenia
[Heatstroke in dogs in southern Germany. A retrospective study over a 5.5-year period].
Thrombocytopenia
[Left atrial thrombosis in patients with antiphospholipid antibody syndrome and mesenchymal abnormal septum]
Thrombocytopenia
[Unexpected hemorrhage in surgery]
Thrombocytosis
Cerebral and retinal vascular complications of inflammatory bowel disease.
Thrombocytosis
COVID-19 versus HIT hypercoagulability.
Thrombocytosis
Evaluation of thrombocythemia by the thromboplastin generation test.
Thrombocytosis
Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis.
Thrombocytosis
Haemostatic trends in HIV-infected individuals in Yaoundé, Cameroon: a pilot study.
Thrombocytosis
In vitro thrombotic tendency of reactive thrombocytosis in critically ill patients: a prospective case-control study.
Thrombocytosis
Plasma levels of thrombin-activatable fibrinolysis inhibitor in primary and secondary thrombocytosis.
Thrombocytosis
[Abdominal inflammatory pseudotumor (plasma cell granuloma) with anemia and hypergammaglobulinemia]
Thrombocytosis
[Contribution to the problem of thrombocythemia. Thromboplastin formation in the presence of higher thrombocvte concentrations.]
Thromboembolism
Acute Liver Failure after Initiation of Rivaroxaban: A Case Report and Review of the Literature.
Thromboembolism
Acute management of bleeding in patients on novel oral anticoagulants.
Thromboembolism
An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage.
Thromboembolism
An autoantibody to human plasma prekallikrein blocks activation of the contact system.
Thromboembolism
Angiotensin II promotes the anticoagulant effects of rivaroxaban via angiotensin type 2 receptor signaling in mice.
Thromboembolism
Anticoagulation in Venous Thromboembolism Prophylaxis in Medically Ill Patients: Potential Impact of NOACs.
Thromboembolism
Antithrombotic therapy for stroke prevention in atrial fibrillation.
Thromboembolism
Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study.
Thromboembolism
Betrixaban in the prevention of venous thromboembolism in medically ill patients.
Thromboembolism
Clinical trials of deep vein thrombosis prophylaxis in medical patients.
Thromboembolism
Comparison of outcomes in patients with intracranial hemorrhage on factor Xa inhibitors versus vitamin K antagonists treated with 4-factor prothrombin complex concentrate.
Thromboembolism
Detection of lupus anticoagulant in the era of direct oral anticoagulants.
Thromboembolism
Dilute Russell viper venom time interpretation and clinical correlation: A two-year retrospective institutional review.
Thromboembolism
Dose dependent suppression of mineralocorticoid metabolism by different heparin fractions.
Thromboembolism
Effect of heparin on activated partial thromboplastin time in patients undergoing gynecologic or obstetric surgery.
Thromboembolism
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Thromboembolism
Factor X inhibitors.
Thromboembolism
Factor Xa inhibitors vs warfarin for preventing stroke and thromboembolism in patients with atrial fibrillation.
Thromboembolism
Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment.
Thromboembolism
Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays.
Thromboembolism
Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin.
Thromboembolism
Influence of thromboembolism prophylaxis by low molecular weight heparin CY 216 (Fraxiparine) on several parameters of haemostasis in patients under dialysis and receiving either unfractionated heparin or CY 216.
Thromboembolism
Intravenous Combined with Topical Tranexamic Acid Administration Has No Additional Benefits Compared with Intravenous Administration Alone in High Tibial Osteotomy: A Retrospective Case-Control Study.
Thromboembolism
Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist.
Thromboembolism
Laboratory measurement of the direct oral anticoagulants.
Thromboembolism
Mouse models of focal arterial and venous thrombosis.
Thromboembolism
New Anticoagulants for the Prevention of Thromboembolism.
Thromboembolism
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Thromboembolism
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Thromboembolism
Perioperative Management of Anticoagulation-Review of Latest Evidence.
Thromboembolism
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Thromboembolism
Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism.
Thromboembolism
Reversal of novel oral anticoagulants in patients with major bleeding.
Thromboembolism
Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism.
Thromboembolism
Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors.
Thromboembolism
Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
Thromboembolism
Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism.
Thromboembolism
Should all patients with non-valvular atrial fibrillation be anticoagulated?
Thromboembolism
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.
Thromboembolism
Thromboembolism and resistance to activated protein C in children with underlying cardiac disease.
Thromboembolism
Update on Pharmacologic Approaches To Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
Thromboembolism
Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia.
Thromboembolism
Venous thromboembolism prophylaxis guidelines: use by primary care physicians.
Thromboembolism
[A simple test for the monitoring of plasma anti-XA activity of patients following subcutaneous administration of enoxaparin]
Thromboembolism
[Decrease of antithrombin III and factor Xa inhibitor as the cause of thromboembolism complications in chronic inflammatory intestinal disease]
Thromboembolism
[Focus on managing AF and preventing stroke].
Thromboembolism
[New antithrombotics for atrial fibrillation.]
Thromboembolism
[Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update].
Thromboembolism
[Preventive effect of liquemin depot in thromboembolism; experimental proof with myotoxin thrombokinase test.]
Thromboembolism
[Thromboembolism preventing effect of sublethal intravenous thromboplastin doses.]
Thrombophilia
A chromogenic assay for activated protein C resistance.
Thrombophilia
A rare case of unprovoked venous thromboembolism manifestation in a young patient with antithrombin Type IIB deficiency combined with inferior vena cava anomaly from Lithuania.
Thrombophilia
Activated factor X targeted stored in platelets as an effective gene therapy strategy for both hemophilia A and B.
Thrombophilia
Activated protein C resistance: from phenotype to genotype and clinical practice.
Thrombophilia
APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method.
Thrombophilia
Aptamer-modified FXa generation assays to investigate hypercoagulability in plasma from patients with ischemic heart disease.
Thrombophilia
Assessment of the coagulation profile in hemato-oncological patients receiving ATG-based conditioning treatment for allogeneic stem cell transplantation.
Thrombophilia
Bilateral adrenal gland haemorrhage: an unusual cause.
Thrombophilia
Blood cells diseases and thrombosis.
Thrombophilia
c.259A>C in the fibrinogen gene of alpha chain (FGA) is a fibrinogen with thrombotic phenotype.
Thrombophilia
Changes in blood coagulation markers associated with uterine artery embolization for leiomyomata.
Thrombophilia
Coagulation management in patients undergoing mechanical circulatory support.
Thrombophilia
Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory.
Thrombophilia
Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
Thrombophilia
Dysfibrinogenemia and thrombosis. A case report.
Thrombophilia
Elevated activated partial thromboplastin time-based clot waveform analysis markers have strong positive association with acute venous thromboembolism.
Thrombophilia
Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia.
Thrombophilia
Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis.
Thrombophilia
Factor Xa generation by computational modeling: an additional discriminator to thrombin generation evaluation.
Thrombophilia
Factor Xa or thrombin: is factor Xa a better target?
Thrombophilia
Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-gamma.
Thrombophilia
Heparin monitoring in acute thrombosis associated with antiphospholipid antibody syndrome.
Thrombophilia
Higher morning serum cortisol level predicts increased fibrinogen but not shortened APTT.
Thrombophilia
How I diagnose and manage HIT.
Thrombophilia
HYPERCOAGULABILITY AND THROMBOSIS: EFFECT OF INJECTED THROMBOKINASE AND ADENOSINE DIPHOSPHATE ON ESTABLISHED MICROTHROMBI IN RABBITS.
Thrombophilia
Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment.
Thrombophilia
Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies.
Thrombophilia
Hypercoagulability in patients with peripheral vascular disease.
Thrombophilia
Hypercoagulable states in arterial thromboembolism.
Thrombophilia
Hypocoagulable Tendency on Thromboelastometry Associated With Severity and Anticoagulation Timing in Pediatric Septic Shock: A Prospective Observational Study.
Thrombophilia
Induction of a hypercoagulability state and endothelial cell activation by granulocyte colony-stimulating factor in peripheral blood stem cell donors.
Thrombophilia
Laboratory detection of inherited thrombophilia: a historical perspective.
Thrombophilia
Laboratory diagnosis of antiphospholipid syndrome.
Thrombophilia
Membrane autoantibodies in systemic lupus erythematosus: a case of autoimmune hemolytic anemia, antiphospholipid antibodies, and transient acquired activated protein C resistance.
Thrombophilia
Modulation of severity of clinical bleeding by co-inherited thrombophilia is also true for severe factor X deficiency.
Thrombophilia
Natural inhibitors and fibrinogen/fibrin degradation products in patients with myocardial infarction.
Thrombophilia
Plasma antithrombin III and thrombin generation time: correlation with hemoglobin A1 and fasting serum glucose in young diabetic women.
Thrombophilia
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
Thrombophilia
Point of Care Assessment of Coagulation.
Thrombophilia
Polycations selectively blocking tissue factor-dependent FVII activation: collective in vitro anticoagulation studies.
Thrombophilia
Pregnant patients with thrombophilia and subsequent adverse pregnancy outcomes have a decreased first trimester response to thrombomodulin in an activated partial thromboplastin time (APTT) system.
Thrombophilia
Radioimmunoassays for protein C and factor X. Plasma antigen levels in abnormal hemostatic states.
Thrombophilia
Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis.
Thrombophilia
Retrospective evaluation of shortened prothrombin time or activated partial thromboplastin time for the diagnosis of hypercoagulability in dogs: 25 cases (2006-2011).
Thrombophilia
Screening for thrombophilia: a laboratory perspective.
Thrombophilia
The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.
Thrombophilia
The influence of crystalloid and colloid replacement solutions in acute normovolemic hemodilution: a preliminary survey of hemostatic markers.
Thrombophilia
The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects.
Thrombophilia
The purification and properties of factor X from pig serum and its role in hypercoagulability in vivo.
Thrombophilia
The serial thromboplastin dilution test: a presumptive test for hypercoagulability.
Thrombophilia
Thrombin generation assay and hemostatic profile for elucidating hypercoagulability in endogenous canine hyperadrenocorticism.
Thrombophilia
Whole blood hypercoagulability despite anticoagulation during mechanical cardiac assist.
Thrombophilia
[Haemostatic activation in head injury]
Thrombophilia
[Mechanism of hypercoagulability of the blood following vasopuncture: behavior of the thromboplastin generation test and blood thromboplastin factors.]
Thrombophlebitis
Acute thrombophlebitis; mechanism and treatment with oral thromboplastin.
Thrombophlebitis
Effects of heparin, typhoid vaccine and thrombophlebitis on factor X metabolism in the dog.
Thrombosis
'Lupus' anticoagulant and thrombosis of the hepatic veins (Budd-Chiari syndrome). Report of three patients and review of the literature.
Thrombosis
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.
Thrombosis
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
Thrombosis
A balance between TFPI and thrombin-mediated platelet activation is required for murine embryonic development.
Thrombosis
A Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge.
Thrombosis
A Clinical Study on Low-Molecular Weight Heparin Infusion as Anticoagulation for Nocturnal Home Haemodialysis.
Thrombosis
A comparative study of heparin responses in arterial and venous thromboembolism using molecular markers for thrombosis.
Thrombosis
A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis.
Thrombosis
A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.
Thrombosis
A comparison of heparinised and non-heparinised normal saline solutions for maintaining the patency of arterial pressure measurement cannulae after heart surgery.
Thrombosis
A cost-analysis model for anticoagulant treatment in the hospital setting.
Thrombosis
A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice.
Thrombosis
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.
Thrombosis
A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
Thrombosis
A narrative review of low-dose rivaroxaban in patients with atherothrombotic cardiovascular disease: vascular protection beyond anticoagulation.
Thrombosis
A new animal model of venous thrombosis in rats with low flow conditions in the venous blood stream.
Thrombosis
A new case of high-molecular-weight kininogen inherited deficiency.
Thrombosis
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation.
Thrombosis
A novel model of venous thrombosis in the vena cava of rabbits.
Thrombosis
A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
Thrombosis
A prospective randomized comparative study to determine appropriate edoxaban administration period, to prevent deep vein thromboembolism in patients with total knee arthroplasty.
Thrombosis
A rare case of fondaparinux-induced major bleeding in postmenopausal woman prescribed for non-ST segment elevation Ml.
Thrombosis
A Sardinian Family with Factor XI Deficiency.
Thrombosis
A simple, cost-effective, and rapid separation process for the isolation of anticoagulant active fraction from the fruit extract of Momordica charantia: Characterization of bioactive components and anticoagulant mechanism of active fraction in a mouse model.
Thrombosis
Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.
Thrombosis
Absorption, distribution, metabolism and excretion of YM466, a novel factor Xa inhibitor, in rats.
Thrombosis
Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis.
Thrombosis
Accidental Rivaroxaban Intoxication in a Boy: Some Lessons in Managing New Oral Anticoagulants in Children.
Thrombosis
Activated partial thromboplastin time and risk of future venous thromboembolism.
Thrombosis
Active aneurysm thrombosis after Kawasaki disease in an adult: Insight into anticoagulation therapy.
Thrombosis
Active site-blocked factor Xa prevents thrombus formation in the coronary vasculature in parallel with inhibition of extravascular coagulation in a canine thrombosis model.
Thrombosis
Active site-labeled prothrombin inhibits prothrombinase in vitro and thrombosis in vivo.
Thrombosis
Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis.
Thrombosis
Activity of a synthetic hexadecasaccharide (SanOrg123781A) in a pig model of arterial thrombosis.
Thrombosis
Acute myocardial infarction and antiphospholipid antibody syndrome: a systematic review.
Thrombosis
Acute renal artery and vein thrombosis after renal transplant, associated with a short partial thromboplastin time and factor V Leiden mutation.
Thrombosis
Aeruginosin analogs and other compounds with rigid bicyclic structure as potential antithrombotic agents.
Thrombosis
AGA Clinical Practice Update: Coagulation in Cirrhosis.
Thrombosis
An ethanol extract of Ramulus mori improves blood circulation by inhibiting platelet aggregation.
Thrombosis
Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.
Thrombosis
Andexanet Alfa Use for Small Bowel Obstruction Patient With History of Sugiura Procedure.
Thrombosis
Anti-factor Xa activities of zingerone with anti-platelet aggregation activity.
Thrombosis
Anti-thrombotic activity and chemical characterization of steroidal saponins from Dioscorea zingiberensis C.H. Wright.
Thrombosis
Anti-thrombotic effect of a factor Xa inhibitor TAK-442 in a rabbit model of arteriovenous shunt thrombosis stimulated with tissue factor.
Thrombosis
Anti-thrombotic effect of chronic oral treatment with Orbignya phalerata Mart.
Thrombosis
Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin.
Thrombosis
Anticardiolipin antibodies in patients with pregnancy loss induce factor Xa production in the presence of beta 2-glycoprotein I.
Thrombosis
Anticoagulant and antithrombotic effects of chemically modified heparins and pentosanpolysulfate.
Thrombosis
Anticoagulant drugs: an update.
Thrombosis
Anticoagulant properties of the anti-inflammatory cytokine IL-10 in a factor Xa-activated human monocyte model.
Thrombosis
Anticoagulant therapy after acute myocardial infarction.
Thrombosis
Anticoagulant therapy for recurrent in-stent thrombosis following carotid artery stenting: A case report.
Thrombosis
Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.
Thrombosis
Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place.
Thrombosis
Anticoagulation Management during First Five Days of Infant-Pediatric Extracorporeal Life Support.
Thrombosis
Anticoagulation Practices during Venovenous Extracorporeal Membrane Oxygenation for Respiratory Failure. A Systematic Review.
Thrombosis
Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.
Thrombosis
Antiphospholipid antibodies, haemostatic variables and thrombosis--a survey of 144 patients.
Thrombosis
Antiphospholipid syndrome presenting as intracardiac thrombus with pulmonary embolism.
Thrombosis
Antiplatelet and antithrombotic activities of Korean Red Ginseng.
Thrombosis
Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin.
Thrombosis
Antiplatelet, anticoagulant, and profibrinolytic activities of withaferin A.
Thrombosis
Antithrombin activity of an algal polysaccharide.
Thrombosis
Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
Thrombosis
Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis.
Thrombosis
Antithrombotic activities of ferulic acid via intracellular cyclic nucleotide signaling.
Thrombosis
Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.
Thrombosis
Antithrombotic activity of argatroban in experimental thrombosis in the rabbit.
Thrombosis
Antithrombotic activity of losartan in two kidney, one clip hypertensive rats. A study on the mechanism of action.
Thrombosis
Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis.
Thrombosis
Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis.
Thrombosis
Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
Thrombosis
Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
Thrombosis
Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Thrombosis
Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats.
Thrombosis
Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
Thrombosis
Antithrombotic effect of repeated doses of the ethanolic extract of local olive (Olea europaea L.) leaves in rabbits.
Thrombosis
Antithrombotic effects of (n-3) polyunsaturated fatty acids in rat models of arterial and venous thrombosis.
Thrombosis
Antithrombotic effects of a synthetic inhibitor of activated factor X, JTV-803, in animals.
Thrombosis
Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis.
Thrombosis
Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition.
Thrombosis
Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber.
Thrombosis
Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates.
Thrombosis
Antithrombotic effects of recombinant human soluble thrombomodulin (rhs-TM) on arteriovenous shunt thrombosis in rats.
Thrombosis
Antithrombotic effects of the effective components group of Xiaoshuantongluo formula in vivo and in vitro.
Thrombosis
Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs.
Thrombosis
Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time.
Thrombosis
Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats.
Thrombosis
Antithrombotic efficacy of low-molecular-weight heparin in deep arterial injury.
Thrombosis
Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis.
Thrombosis
Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.
Thrombosis
Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Thrombosis
Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
Thrombosis
Antithrombotic properties of a direct thrombin inhibitor with a prolonged half-life and AT-mediated factor Xa inhibitory activity.
Thrombosis
Apixaban and atrial fibrillation: no clear advantage.
Thrombosis
Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis.
Thrombosis
Apixaban for the treatment of cancer-associated venous thromboembolism and left atrial appendage thrombus refractory to optimal anticoagulation with warfarin: a case report.
Thrombosis
Apixaban in low-weight patients with cancer-associated thrombosis: A cross sectional study of drug levels.
Thrombosis
Apixaban Inhibits Cerebral Microembolic Signals Derived from Carotid Arterial Thrombosis in Rabbits.
Thrombosis
Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.
Thrombosis
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
Thrombosis
Approaches to selective peptidic inhibitors of factor Xa.
Thrombosis
Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits.
Thrombosis
Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome.
Thrombosis
Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review.
Thrombosis
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Thrombosis
Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits.
Thrombosis
Assessment of ex vivo pharmacodynamic markers during inhibition of thrombosis by CI-1031 (ZK-807834), a novel direct factor Xa inhibitor.
Thrombosis
Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis.
Thrombosis
Association Between Hematologic and Inflammatory Markers and 31 Thrombotic and Hemorrhagic Events in Berlin Heart Excor Patients.
Thrombosis
Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin.
Thrombosis
Beneficial effect of sulfamethoxazole and trimethoprim on accelerated coagulation.
Thrombosis
Beta-cyclodextrin tetradecasulfate, a novel cyclic oligosaccharide, inhibits thrombus and neointimal formation after coronary vascular injury.
Thrombosis
Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
Thrombosis
Bioprosthesis leaflet thrombosis following self-expanding valve-in-valve transcatheter aortic valve replacement in patient taking factor Xa inhibitor and warfarin: A case report.
Thrombosis
Bleeding, Thrombosis, and Transfusion With Two Heparin Anticoagulation Protocols in Venoarterial ECMO Patients.
Thrombosis
Blocking of platelets or intrinsic coagulation pathway-driven thrombosis does not prevent cerebral infarctions induced by photothrombosis.
Thrombosis
Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependent thrombosis.
Thrombosis
Blood component utilization in COVID-19 patients in New York City: Transfusions do not follow the curve.
Thrombosis
Cardioprotective Effects of Rivaroxaban on Cardiac Remodeling After Experimental Myocardial Infarction in Mice.
Thrombosis
Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants.
Thrombosis
Cerebral Microembolization in Left Ventricular Assist Device Associated Ischemic Events.
Thrombosis
Changes in blood parameters and coagulation-related gene expression in pregnant rats.
Thrombosis
Characterisation of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation in vivo.
Thrombosis
Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
Thrombosis
Characterization of a tissue factor/factor VIIa-dependent model of thrombosis in hypercholesterolemic rabbits.
Thrombosis
Cholesterol Crystal Embolism Induced by Direct Factor Xa inhibitor: A First Case Report.
Thrombosis
Clinical and experimental experience with factor Xa inhibitors.
Thrombosis
Clinical management of coagulation status and placenta previa in a pregnant woman with Marfan's syndrome after mitral and aortic mechanical heart valve replacement.
Thrombosis
Clinical significance of increased thromboplastin activity on the monocyte surface--a brief review.
Thrombosis
Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients.
Thrombosis
Coagulations Studies Do Not Correlate With Each Other or With Hematologic Complications During Pediatric Extracorporeal Membrane Oxygenation.
Thrombosis
Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance.
Thrombosis
Combined effects of a factor Xa inhibitor YM466 and a GPIIb/IIIa antagonist YM128 on thrombosis and neointima formation in mice.
Thrombosis
Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time.
Thrombosis
Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model.
Thrombosis
Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase.
Thrombosis
Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis.
Thrombosis
Comparative study of the effect of rivaroxaban and fondaparinux on monocyte's coagulant activity and cytokine release.
Thrombosis
Comparison between recombinant and rabbit thromboplastin in the management of patients on oral anticoagulant therapy.
Thrombosis
Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots.
Thrombosis
Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates.
Thrombosis
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
Thrombosis
Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis.
Thrombosis
Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
Thrombosis
Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis.
Thrombosis
Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors.
Thrombosis
Comparison of the antithrombotic effects of low molecular weight heparinoid KB-101 and heparin in a rat experimental model.
Thrombosis
Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Thrombosis
Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis.
Thrombosis
Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding.
Thrombosis
Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study.
Thrombosis
Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria.
Thrombosis
Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
Thrombosis
Considerations for drug dosing post coronary artery bypass graft surgery.
Thrombosis
Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa.
Thrombosis
Contribution of in vivo models of thrombosis to the discovery and development of novel antithrombotic agents.
Thrombosis
Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo.
Thrombosis
Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin times.
Thrombosis
COVID-19 and acute coagulopathy in pregnancy.
Thrombosis
CrataBL, a lectin and Factor Xa inhibitor, plays a role in blood coagulation and impairs thrombus formation.
Thrombosis
Current management of acute symptomatic deep vein thrombosis.
Thrombosis
Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management.
Thrombosis
Deep vein thrombosis following hip surgery. Relation to activated factor X inhibitor activity: effect of heparin and dextran.
Thrombosis
Delayed Vesicular Urticarial Dermatosis Due to Apixaban.
Thrombosis
Delayed-onset heparin-induced thrombocytopenia type-2 during fondiparinux (Arixtra) therapy.
Thrombosis
Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
Thrombosis
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
Thrombosis
Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1.
Thrombosis
Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2.
Thrombosis
Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
Thrombosis
Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors.
Thrombosis
Determinants of plasma factor VIIa levels in humans.
Thrombosis
Determination of prothombinase activation after adding human purified prothrombin to human clot: comparison of hirudin, an activated factor II inhibitor, with DX9065a, an activated factor X inhibitor, on clot-associated thrombin and on prothrombin activation.
Thrombosis
Development of Trypsin-Like Serine Protease Inhibitors as Therapeutic Agents: Opportunities, Challenges, and their Unique Structure-Based Rationales.
Thrombosis
DIC Score: Statistical Relationship with PT, APTT, and Simplified Scoring Systems with Combinations of PT and APTT.
Thrombosis
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Thrombosis
Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently.
Thrombosis
Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Thrombosis
Direct Inhibition Of Factor Viia By Tfpi And Tfpi Constructs.
Thrombosis
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Thrombosis
Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.
Thrombosis
Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).
Thrombosis
Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.
Thrombosis
Disseminated intravascular coagulation in cats.
Thrombosis
Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study.
Thrombosis
Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids.
Thrombosis
Do preoperative laboratory tests predict blood transfusion needs in cardiac operations?
Thrombosis
Dose-dependent antithrombotic effect of warfarin in rabbits.
Thrombosis
Downregulation of Clock in circulatory system leads to an enhancement of fibrinolysis in mice.
Thrombosis
Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X.
Thrombosis
DU-176b, an oral, direct Factor Xa antagonist.
Thrombosis
Dual pathway therapy in acute coronary syndrome.
Thrombosis
DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
Thrombosis
DX-9065a Daiichi.
Thrombosis
DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.
Thrombosis
DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats.
Thrombosis
Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Thrombosis
Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats.
Thrombosis
Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
Thrombosis
Effect of a new inhibitor of factor Xa zifaxaban, on thrombosis in the inferior vena cava in rabbits.
Thrombosis
Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis.
Thrombosis
Effect of combined therapy with catheter-directed thrombolysis and factor Xa inhibitor for inferior vena cava thrombosis: A case report.
Thrombosis
Effect of factor Xa inhibitors on the platelet-derived microparticles procoagulant activity in vitro and in vivo in rats.
Thrombosis
Effect of heparin in nonionic contrast media on blood coagulation and its dose response curve.
Thrombosis
Effect of immune complex-containing sera from patients with rheumatic diseases on thromboplastin activity of monocytes.
Thrombosis
Effect of potato protease inhibitor on the clotting system and fibrinolysis in the dog.
Thrombosis
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
Thrombosis
Effect of selective factor Xa inhibition on arterial thrombus formation triggered by tissue factor/factor VIIa or collagen in an ex vivo model of shear-dependent human thrombogenesis.
Thrombosis
Effect of sepimostat mesilate on experimental venous thrombosis in rats.
Thrombosis
Effect of the Direct Factor Xa Inhibitor Apixaban in Rat Models of Thrombosis and Hemostasis.
Thrombosis
Effect of the Factor Xa Inhibitor Rivaroxaban on Arterial Thrombosis in Wild-Type and Apolipoprotein E-Deficient Mice.
Thrombosis
Effect of vascular injury on inhibition of venous thrombosis with ZK-807834, a direct inhibitor of factor Xa.
Thrombosis
Effectiveness and Tolerability of Fondaparinux vs Enoxaparin in a Population of Indian Patients with Symptomatic Deep Vein Thrombosis: A Retrospective Real-World Study.
Thrombosis
Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats.
Thrombosis
Effects of ethanol on human blood fibrinolysis and coagulation.
Thrombosis
Effects of folic acid combined with vitamin B12 on DVT in patients with homocysteine cerebral infarction.
Thrombosis
Effects of fondaparinux and a direct factor Xa inhibitor TAK-442 on platelet-associated prothrombinase in the balloon-injured artery of rats.
Thrombosis
Effects of hemocoagulase agkistrodon on the coagulation factors and its procoagulant activities.
Thrombosis
Effects of Intravenous Enoxaparin and Intravenous Inogatran in an Electrolytic Injury Model of Venous Thrombosis in the Dog.
Thrombosis
Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
Thrombosis
Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: Murine Ortholog of the Fletcher Trait.
Thrombosis
Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli.
Thrombosis
Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
Thrombosis
Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits.
Thrombosis
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
Thrombosis
Efficacy of local inhibition of procoagulant activity associated with small-diameter prosthetic vascular grafts.
Thrombosis
Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.
Thrombosis
Elevated factor VIII level and stroke in patients without traditional risk factors associated with cardiovascular diseases.
Thrombosis
Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors.
Thrombosis
Engineering a "three-in-one" hirudin prodrug to reduce bleeding risk: A proof-of-concept study.
Thrombosis
Engineering of human coagulation factor x variants activated by prostate-specific antigen.
Thrombosis
Enhanced induction of heme oxygenase-1 suppresses thrombus formation and affects the protein C system in sepsis.
Thrombosis
Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison with heparin and hirudin in a rabbit thrombosis model.
Thrombosis
Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization.
Thrombosis
Epidemiological association between fasting plasma glucose and shortened APTT.
Thrombosis
Evaluating prodrug characteristics of a novel anticoagulant fusion protein neorudin, a prodrug targeting release of hirudin variant 2-Lys47 at the thrombosis site, by means of in vitro pharmacokinetics.
Thrombosis
Evaluating Unfractionated Heparin Fixed Dosing Protocol and Establishing an Institutional Therapeutic Range for UFH in Hospital Setting in Jordan.
Thrombosis
Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.
Thrombosis
Evaluation of Anti-Activated Factor X Activity and Activated Partial Thromboplastin Time Relations and Their Association with Bleeding and Thrombosis during Veno-Arterial ECMO Support: A Retrospective Study.
Thrombosis
Evaluation of argatroban and DUP 714 as anticoagulants for blood gas, electrolyte and ionized calcium analyses.
Thrombosis
Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia.
Thrombosis
Evaluation of nafamostat mesilate as an alternative anticoagulant during intermittent hemodialysis in healthy Beagle dogs.
Thrombosis
Evaluation of the antithrombotic activity of Zhi-Xiong Capsules, a Traditional Chinese Medicinal formula, via the pathway of anti-coagulation, anti-platelet activation and anti-fibrinolysis.
Thrombosis
Evaluation of the Total Thrombus-Formation System (T-TAS): application to human and mouse blood analysis.
Thrombosis
Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor-associated major bleeding.
Thrombosis
Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.
Thrombosis
Expanding the role of coagulation in arterial thrombosis: evidence from animal models using a new factor Xa inhibitor.
Thrombosis
Experimental studies on venous thrombosis: effect of coagulants, procoagulants and vessel contusion.
Thrombosis
Exploring indications for the Use of direct oral anticoagulants and the associated risks of major bleeding.
Thrombosis
Exploring potential anticoagulant drug formulations using thrombin generation test.
Thrombosis
Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries.
Thrombosis
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
Thrombosis
Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels.
Thrombosis
Factor X deficiency.
Thrombosis
Factor X inhibitors.
Thrombosis
Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage.
Thrombosis
Factor xa inhibitor attenuates leukocyte adhesion and thrombus formation in an experimental mouse model of the metabolic syndrome.
Thrombosis
Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation.
Thrombosis
Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Thrombosis
Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: a longitudinal cohort study.
Thrombosis
Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: additional information.
Thrombosis
Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.
Thrombosis
Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit.
Thrombosis
Fibrinolytic and Thrombolytic Effects of an Enzyme Purified from the Fruiting Bodies of Boletus pseudocalopus (Agaricomycetes) from Korea.
Thrombosis
Flow-simulated thrombin generation profiles as a predictor of thrombotic risk among pre-menopausal women.
Thrombosis
Fluorinated Benzyloxyphenyl Piperidine-4-carboxamides with Dual Function against Thrombosis: Inhibitors of Factor Xa and Platelet Aggregation.
Thrombosis
Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban.
Thrombosis
Fondaparinux sodium: a review of its use in the management of acute coronary syndromes.
Thrombosis
Fondaparinux: use in thromboprophylaxis of acute medical patients.
Thrombosis
Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial.
Thrombosis
Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus.
Thrombosis
Functional expression of a novel Kunitz type protease inhibitor from the human blood fluke Schistosoma mansoni.
Thrombosis
Further studies on the presence of functional tissue factor activity on the subendothelium of normal human and rabbit arteries.
Thrombosis
FXa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms.
Thrombosis
FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834.
Thrombosis
Generation of a humanized FXII knock-in mouse-A powerful model system to test novel anti-thrombotic agents.
Thrombosis
Genome-wide association study of peripheral artery disease in the Million Veteran Program.
Thrombosis
Giant deep vein thrombus complicating endovascular cooling therapy after cardiac arrest in a boy with hypertrophic cardiomyopathy.
Thrombosis
Heme oxygenase-1 inducer hemin prevents vascular thrombosis.
Thrombosis
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Thrombosis
Heparin 1986. Indications and effective use.
Thrombosis
Heparin cofactor II inhibits thrombus formation in a rat thrombosis model.
Thrombosis
Heparin improves BMSC cell therapy: Anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal stem cell cytotherapy.
Thrombosis
Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4.
Thrombosis
Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice.
Thrombosis
Heparin-Like Chitosan Hydrogels with Tunable Swelling Behavior, Prolonged Clotting Times, and Prevented Contact Activation and Complement Activation.
Thrombosis
Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis.
Thrombosis
Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis.
Thrombosis
HIT paradigms and paradoxes.
Thrombosis
Homology model of human prothrombinase based on the crystal structure of Pseutarin C.
Thrombosis
How I diagnose and manage HIT.
Thrombosis
Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins.
Thrombosis
HYPERCOAGULABILITY AND THROMBOSIS: EFFECT OF INJECTED THROMBOKINASE AND ADENOSINE DIPHOSPHATE ON ESTABLISHED MICROTHROMBI IN RABBITS.
Thrombosis
Hypercoagulability. Should every patient with venous thrombosis be tested?
Thrombosis
Immobilisation of an anti-platelet adhesion and anti-thrombotic drug (EP224283) on polydopamine coated vascular stent promoting anti-thrombogenic properties.
Thrombosis
Impact of fibrinogen concentration in severely ill patients on mechanical properties of whole blood clots.
Thrombosis
Impact of neutrophil apoptosis on haemostatic activation in chronic liver disease patients.
Thrombosis
Impact of Total Antithrombotic Effect on Bleeding Complications in Patients Receiving Multiple Antithrombotic Agents.
Thrombosis
Importance of platelets in experimental venous thrombosis in the rat.
Thrombosis
Improved efficacy/safety profile of factor XIa inhibitor BMS-724296 versus factor Xa inhibitor apixaban and thrombin inhibitor dabigatran in cynomolgus monkeys.
Thrombosis
In vitro and in vivo studies of AT-1362, a newly synthesized and orally active inhibitor of thrombin.
Thrombosis
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
Thrombosis
In vitro blood compatibility of functional group-grafted and heparin-immobilized polyurethanes prepared by plasma glow discharge.
Thrombosis
In vitro procoagulant and anticoagulant properties of Naja naja naja venom.
Thrombosis
In vivo antithrombotic properties of a heparin from the oocyte test cells of the sea squirt Styela plicata(Chordata-Tunicata).
Thrombosis
Incidence and Risk Factors for Cannula-Related Venous Thrombosis After Venovenous Extracorporeal Membrane Oxygenation in Adult Patients With Acute Respiratory Failure.
Thrombosis
Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy.
Thrombosis
Inferior Vena Cava Agenesis and Deep Vein Thrombosis: A Pharmacological Alternative to Vitamin K Antagonists.
Thrombosis
Inhibition and reversal of platelet-rich arterial thrombus in vivo: direct vs. indirect factor Xa inhibition.
Thrombosis
Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site.
Thrombosis
Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig.
Thrombosis
Inhibition of complement-mediated haemolysis in paroxysmal nocturnal haemoglobinuria by heparin or low-molecular weight heparin.
Thrombosis
Inhibition of Factor Xa : a potential target for the development of new anticoagulants.
Thrombosis
Inhibition of feline collateral vessel development following experimental thrombolic occlusion.
Thrombosis
Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitors.
Thrombosis
Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.
Thrombosis
Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty.
Thrombosis
Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro.
Thrombosis
Inhibitors of serine proteinases from blood coagulation cascade - view on current developments.
Thrombosis
Inhibitory effects of ONO-3307 on various proteases and tissue thromboplastin in vitro and on experimental thrombosis in vivo.
Thrombosis
Innovative Three-Step Microwave-Promoted Synthesis of N-Propargyltetrahydroquinoline and 1,2,3-Triazole Derivatives as a Potential Factor Xa (FXa) Inhibitors: Drug Design, Synthesis, and Biological Evaluation.
Thrombosis
Intracardiac thrombosis and acute myocardial infarction as initial presentation of antiphospholipid syndrome.
Thrombosis
Intravenous recombinant soluble human thrombomodulin prevents venous thrombosis in a rat model.
Thrombosis
Intrinsic pathway of coagulation and arterial thrombosis.
Thrombosis
Investigation of the anticoagulant and antithrombotic effects of chlorogenic acid.
Thrombosis
Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats.
Thrombosis
Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.
Thrombosis
Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
Thrombosis
Isolation and Characterization of Poecistasin, an Anti-Thrombotic Antistasin-Type Serine Protease Inhibitor from Leech Poecilobdella manillensis.
Thrombosis
Lack of plasminogen activator inhibitor-1 enhances the preventive effect of DX-9065a, a selective factor Xa inhibitor, on venous thrombus and acute pulmonary embolism in mice.
Thrombosis
Lactadherin blocks thrombosis and hemostasis in vivo: correlation with platelet phosphatidylserine exposure.
Thrombosis
Left atrial thrombus formation after brief interruption of rivaroxaban.
Thrombosis
Letter by Borst Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation via Protease Activated Receptor-1".
Thrombosis
Locally activity-released bifunctional fusion protein enhances antithrombosis and alleviates bleeding risk.
Thrombosis
Losartan and captopril treatment rescue normal thrombus formation in microfibril associated glycoprotein-1 (MAGP1) deficient mice.
Thrombosis
Low intensity warfarin therapy.
Thrombosis
Low molecular weight heparin in acute stroke.
Thrombosis
Low-dose fibrinolytic therapy. Results and new concepts.
Thrombosis
Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment.
Thrombosis
Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
Thrombosis
Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis.
Thrombosis
Low-molecular-weight heparins and new strategies for the treatment of patients with established venous thrombosis.
Thrombosis
Lufaxin, a Novel Factor Xa Inhibitor From the Salivary Gland of the Sand Fly Lutzomyia longipalpis Blocks Protease-Activated Receptor 2 Activation and Inhibits Inflammation and Thrombosis In Vivo.
Thrombosis
Lupus anticoagulant syndrome: case report.
Thrombosis
Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus.
Thrombosis
Macromolecular complex assembly of prothrombinase is a central process of thrombosis.
Thrombosis
Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.
Thrombosis
Mechanism of protein-z-mediated inhibition of coagulation factor xa by z-protein-dependent inhibitor: a molecular dynamic approach.
Thrombosis
Mechanisms of thromboembolism at arterial plaques.
Thrombosis
Medical management of acute superficial vein thrombosis of the saphenous vein.
Thrombosis
Modified APC-resistance test: variable ratios with respect to source of factor V-deficient plasma.
Thrombosis
Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays.
Thrombosis
Molecular dynamics simulations of the binary complex of human tissue factor (TF(1-242) ) and factor VIIa (TF(1-242) /fVIIa) on a 4:1 POPC/POPS lipid bilayer.
Thrombosis
Moving Up the Coagulation Cascade: Potential Factor X Inhibition for Percutaneous Coronary Intervention.
Thrombosis
Myocarditis in athletes after COVID-19 infection: The heart is not the only place to screen.
Thrombosis
Nanomechanical clinical coagulation diagnostics and monitoring of therapies.
Thrombosis
New anticoagulants.
Thrombosis
New Anticoagulants: Anti IIa vs Anti Xa-Is One Better?
Thrombosis
New antithrombotic strategies for resistant thrombotic processes.
Thrombosis
New developments in antiplatelet and antithrombotic therapy.
Thrombosis
New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy.
Thrombosis
New insights into the pathogenic mechanisms and treatment of arterial thrombosis in antiphospholipid syndrome.
Thrombosis
New targets for antithrombotic drugs.
Thrombosis
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
Thrombosis
No deterioration after 13 years in a stability study of a rabbit brain, plain, thromboplastin, RBT 1010, in rubber-stoppered ampoules.
Thrombosis
No discriminating power in FPA measurements during fibrinaemia in hip replaced patients generating DVT.
Thrombosis
Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis.
Thrombosis
Noncanonical Effects of Oral Thrombin and Factor Xa Inhibitors in Platelet Activation and Arterial Thrombosis.
Thrombosis
Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin.
Thrombosis
Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.
Thrombosis
Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
Thrombosis
Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
Thrombosis
Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin.
Thrombosis
Novel direct factor Xa inhibitory compounds from Tenebrio molitor with anti-platelet aggregation activity.
Thrombosis
Novel inhibitors of factor X for use in cardiovascular diseases.
Thrombosis
Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber.
Thrombosis
Optimal Tests to Minimise Bleeding and Ischaemic Complications in Patients on Extracorporeal Membrane Oxygenation.
Thrombosis
Optimisation of oral anticoagulants for patients with atrial fibrillation within 12?months after percutaneous coronary intervention: A meta-analysis and systematic review.
Thrombosis
Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis.
Thrombosis
Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban.
Thrombosis
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
Thrombosis
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Thrombosis
Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series.
Thrombosis
Overview of Current Evidence on the Impact of the Initial High Dose of the Direct Factor Xa Inhibitor Rivaroxaban on Thrombus Resolution in the Treatment of Venous Thromboembolism.
Thrombosis
Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT.
Thrombosis
Partial thromboplastin time: prediction of adverse events and poor prognosis by low abnormal values.
Thrombosis
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
Thrombosis
Patients with higher body mass index treated with direct / novel oral anticoagulants (DOAC / NOAC) for atrial fibrillation experience worse clinical outcomes.
Thrombosis
Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice.
Thrombosis
Perspectives on factor Xa inhibition.
Thrombosis
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism.
Thrombosis
Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.
Thrombosis
Pharmacokinetics and pharmacodynamics of intravenous and oral apixaban in horses.
Thrombosis
Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
Thrombosis
Pharmacological characterization of the active synthetic factor Xa inhibitors M55551 and M55165.
Thrombosis
Pharmacological interruption of acute thrombus formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: comparison to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model.
Thrombosis
Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis.
Thrombosis
Phosphatidylserine index as a marker of the procoagulant phenotype of acute myelogenous leukemia cells.
Thrombosis
Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models.
Thrombosis
Plasminogen activator inhibitor type 1 in platelets induces thrombogenicity by increasing thrombolysis resistance under shear stress in an in-vitro flow chamber model.
Thrombosis
Platelet aggregation through prothrombinase activation induced by non-aggregant doses of platelet agonists.
Thrombosis
Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus.
Thrombosis
Pleiotropic actions of factor Xa inhibition in cardiovascular prevention - mechanistic insights and implications for anti-thrombotic treatment.
Thrombosis
Possible Rivaroxaban Failure during the Postpartum Period.
Thrombosis
Possible role of rivaroxaban in attenuating pressure-overload-induced atrial fibrosis and fibrillation.
Thrombosis
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients.
Thrombosis
Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.
Thrombosis
Practical Management of Rivaroxaban for the Treatment of Venous Thromboembolism.
Thrombosis
Practical recommendations on incorporating new oral anticoagulants into routine practice.
Thrombosis
Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.
Thrombosis
Predictors of left ventricular thrombus formation in patients with dilated cardiomyopathy: role of activated protein C resistance.
Thrombosis
Preoperative fibrinogen plasma concentration is associated with perioperative bleeding and transfusion requirements in scoliosis surgery.
Thrombosis
Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa.
Thrombosis
Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism.
Thrombosis
Prevalence and Risk Factors for Thrombotic Complications Following Venovenous Extracorporeal Membrane Oxygenation: A CT Scan Study.
Thrombosis
Prevalence and risk factors of deep vein thrombosis in patients undergoing lumbar spine surgery.
Thrombosis
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Thrombosis
Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in rats: monotherapy and in combination with antiplatelet agents.
Thrombosis
Prevention of Stent Thrombosis in Rats by a Direct Oral Factor Xa Inhibitor Edoxaban.
Thrombosis
Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model.
Thrombosis
Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity.
Thrombosis
Procoagulant Adaptation of a Blood Coagulation Prothrombinase-like Enzyme Complex in Australian Elapid Venom.
Thrombosis
Prolonged Activated Partial Thromboplastin Time: Difficulties in Discriminating Coexistent Factor VIII Inhibitor and Lupus Anticoagulant.
Thrombosis
Proof-of-concept Studies for siRNA-mediated Gene Silencing for Coagulation Factors in Rat and Rabbit.
Thrombosis
Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature.
Thrombosis
Pros and cons of new oral anticoagulants.
Thrombosis
Protease-activated receptor 4: a critical participator in inflammatory response.
Thrombosis
Protection of pregnant mice with phospholipase C and with Arvin against foetal death induced by bacterial lipopolysaccharide.
Thrombosis
Protein C and fibrinolysis: a link between coagulation and fibrinolysis.
Thrombosis
Prothrombin fragments in cardiovascular disease.
Thrombosis
Pulmonary Thromboembolism in COVID-19: Venous Thromboembolism or Arterial Thrombosis?
Thrombosis
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
Thrombosis
Rare case of acquired haemophilia and lupus anticoagulant.
Thrombosis
Rare inherited coagulation disorders in India.
Thrombosis
Rate-limiting roles of tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow.
Thrombosis
Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
Thrombosis
Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement.
Thrombosis
Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits.
Thrombosis
Reactions of activated factor X-phosphatide mixtures in vitro and in vivo.
Thrombosis
Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients.
Thrombosis
Recent insights on biochemical and molecular basis for developing antihaemostatic agents: A review.
Thrombosis
Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.
Thrombosis
Recombinant soluble human thrombomodulin: a randomized, blinded assessment of prevention of venous thrombosis and effects on hemostatic parameters in a rat model.
Thrombosis
Recombinant TFPI and variants: potential implications in the treatment of cardiovascular disorders.
Thrombosis
Reduced Smoke-like Echo and Resolved Thrombus in the Left Atrium with Rivaroxaban Therapy in an Acute Cardioembolic Stroke Patient.
Thrombosis
Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity.
Thrombosis
Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats.
Thrombosis
Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
Thrombosis
Research around beta 2-glycoprotein I: a major target for antiphospholipid antibodies.
Thrombosis
Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban.
Thrombosis
Resolution of Internal Carotid Arterial Thrombus by the Thrombolytic Action of Dabigatran: A first case report.
Thrombosis
Resolution of left ventricular thrombus secondary to tachycardia-induced heart failure with rivaroxaban.
Thrombosis
Resolution of massive left atrial appendage thrombi with rivaroxaban before balloon mitral commissurotomy in severe mitral stenosis: A case report and literature review.
Thrombosis
Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding and Death After Factor Xa Inhibitor Reversal in Major Bleeding Patients.
Thrombosis
Reversal of target-specific oral anticoagulants.
Thrombosis
Reversible Neurological Adverse Reaction to Apixaban.
Thrombosis
Risk Factors for Thrombosis, Overshunting and Death in Infants after Modified Blalock-Taussig Shunt.
Thrombosis
Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran.
Thrombosis
Rivaroxaban for treatment of venous thromboembolism in older adults.
Thrombosis
Rivaroxaban in patients with a recent acute coronary syndrome.
Thrombosis
Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1.
Thrombosis
Rivaroxaban therapy resulting in the resolution of right atrial thrombosis resistant to ordinary control with warfarin in a patient with atrial fibrillation.
Thrombosis
Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.
Thrombosis
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions.
Thrombosis
Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
Thrombosis
Rivaroxaban: direct factor Xa inhibition to treat acute deep vein thrombosis.
Thrombosis
Role of factor xa inhibitors in cancer-associated thrombosis: any new data?
Thrombosis
Role of short-term inhibition of factor Xa by FXV673 in arterial passivation: a study in a chronic model of thrombosis in conscious dogs.
Thrombosis
Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots.
Thrombosis
Roles of factor Xa beyond coagulation.
Thrombosis
RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit.
Thrombosis
Rutin-Loaded Silver Nanoparticles With Antithrombotic Function.
Thrombosis
Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
Thrombosis
Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study.
Thrombosis
Scientific and therapeutic insights into the role of the platelet P2Y12 receptor in thrombosis.
Thrombosis
Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.
Thrombosis
Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons.
Thrombosis
Sequential thrombosis and bleeding in a woman with a prolonged activated partial thromboplastin time.
Thrombosis
Sequential treatment of deep leg vein thrombosis with porcine plasmin and low dose streptokinase.
Thrombosis
Serotonin as a factor in depression of collateral blood flow following experimental arterial thrombosis.
Thrombosis
Severe acute respiratory syndrome coronavirus nucleocapsid protein does not modulate transcription of human FGL2 gene.
Thrombosis
Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program.
Thrombosis
Signal detection for bleeding associated with the use of direct oral anticoagulants.
Thrombosis
Simultaneous testing of the heparin effect on the soluble phase and platelet component of hemostasis.
Thrombosis
Small size fullerenol nanoparticles inhibit thrombosis and blood coagulation through inhibiting activities of thrombin and FXa.
Thrombosis
Sodium pentosan polysulfate efficacy as thromboprophylaxis agent in high-risk women following gynecological surgery.
Thrombosis
Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
Thrombosis
Spectrophotometric analysis of thrombolytic activity: SATA assay.
Thrombosis
Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE.
Thrombosis
Spotlight on fondaparinux sodium in acute coronary syndromes.
Thrombosis
SR-90107 (Sanofi-Synthélabo).
Thrombosis
Stroke risk factor, pattern and outcome in patients with cancer.
Thrombosis
Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors.
Thrombosis
Structure-based drug design of pyrrolidine-1, 2-dicarboxamides as a novel series of orally bioavailable factor Xa inhibitors.
Thrombosis
Studies of a microchip flow-chamber system to characterize whole blood thrombogenicity in healthy individuals.
Thrombosis
Studies on coagulation incompatibilities for xenotransplantation.
Thrombosis
Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.
Thrombosis
Successful treatment with rivaroxaban of an extended deep vein thrombosis complicated by pulmonary embolism in a patient with familial antithrombin III deficiency: a case report.
Thrombosis
Sulfonamidopyrrolidinone factor Xa inhibitors: potency and selectivity enhancements via P-1 and P-4 optimization.
Thrombosis
Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis.
Thrombosis
Surface characterization and in vitro blood compatibility of poly(ethylene terephthalate) immobilized with insulin and/or heparin using plasma glow discharge.
Thrombosis
Surgical experience on patients with serum lupus anticoagulants. A report of two cases.
Thrombosis
Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa.
Thrombosis
Swim exercise inhibits hemostatic abnormalities in a rat model of obesity and insulin resistance.
Thrombosis
Synergistic effect of a factor Xa inhibitor, TAK-442, and antiplatelet agents on whole blood coagulation and arterial thrombosis in rats.
Thrombosis
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies.
Thrombosis
Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis.
Thrombosis
Testing strategies for diagnosing lupus anticoagulant: decision analysis.
Thrombosis
The "Dual-Pathway" Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2-TIMI 51 Trial.
Thrombosis
The activated partial thromboplastin time in early diagnosis of myocardial infarction.
Thrombosis
The activated seven lupus anticoagulant assay detects clinically significant antibodies.
Thrombosis
The anaesthetist and the antiphospholipid syndrome.
Thrombosis
The anticoagulant, antithrombotic and haemorrhagic effect of long-term warfarin on experimental venous and arterial thrombosis in the rat.
Thrombosis
The antithrombotic effect of heparin in deep venous thrombosis: relation to four heparin assays.
Thrombosis
The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
Thrombosis
The antithrombotic effects of warfarin and heparin following infusions of tissue thromboplastin in rabbits: clinical implications.
Thrombosis
The Clinical Findings and Prophylactic Treatment in Children with Factor X Deficiency.
Thrombosis
The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.
Thrombosis
The dual FXa/thrombin inhibitor SATI prevents fibrin and platelet deposition in hypercoagulant rats.
Thrombosis
The effect of endothelin-1 on vena jugularis thrombus model in rabbits.
Thrombosis
The effect of heparin administration in animal models of sepsis: A prospective study in Escherichia coli-challenged mice and a systematic review and metaregression analysis of published studies*
Thrombosis
The effect of taurolidine on experimental thrombus formation.
Thrombosis
The efficacy of long-term oral anticoagulant therapy and its laboratory assessment.
Thrombosis
The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis.
Thrombosis
The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis.
Thrombosis
The heparin target organ--the endothelium. Studies in a rat model.
Thrombosis
The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease.
Thrombosis
The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface.
Thrombosis
The influence of Annexin32, a new Ca(2+)-dependent phospholipid-binding protein, on coagulation time and thrombosis.
Thrombosis
The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents.
Thrombosis
The lupus anticoagulant. High incidence of 'negative' mixing studies in a human immunodeficiency virus-positive population.
Thrombosis
The management of heparin-induced thrombocytopenia.
Thrombosis
The pathophysiologic role of fat in dysbaric osteonecrosis.
Thrombosis
The possible role of platelet coagulant activities in the pathogenesis of venous thrombosis.
Thrombosis
The race to an orally active Factor Xa inhibitor: recent advances.
Thrombosis
The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
Thrombosis
The role of cellular cooperation in thromboplastin synthesis.
Thrombosis
The role of intravascular coagulation in pregnancy related acute renal failure.
Thrombosis
The role of new oral anticoagulants in orthopaedics: an update of recent evidence.
Thrombosis
The use of rivaroxaban for the treatment of thrombotic complications in four dogs.
Thrombosis
The value of FDP/FIB and D-dimer/FIB ratios in predicting high-risk APL-related thrombosis.
Thrombosis
The venous antithrombotic profile of naroparcil in the rabbit.
Thrombosis
Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Thrombosis
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.
Thrombosis
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice.
Thrombosis
Thromboelastometry and Thrombelastography Analysis under Normal Physiological Conditions - Systematic Review.
Thrombosis
Thromboembolic risk factors in patients undergoing kidney transplant: implication of abnormally short activated partial thromboplastin time.
Thrombosis
Thromboembolism in cancer patients: pathogenesis and treatment.
Thrombosis
Thrombogenicity of small-diameter prosthetic grafts: relative contributions of graft-associated thrombin and factor Xa.
Thrombosis
Thrombophilia Associated with Anti-DFS70 Autoantibodies.
Thrombosis
Thrombosis and hormone replacement therapy in postmenopausal women.
Thrombosis
Thrombosis in patients with the lupus anticoagulant.
Thrombosis
Thrombosis of a flexible coil coronary stent: frequency, predictors and clinical outcome.
Thrombosis
Thrombosis of Large Aneurysm Induced by Flow-Diverter Stent and Dissolved by Direct Factor Xa Inhibitor.
Thrombosis
Thrombotic and hemorrhagic complications in children with the lupus anticoagulant.
Thrombosis
Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences.
Thrombosis
Thrombus weight as a measure of hypercoagulability induced by drugs.
Thrombosis
Tissue factor and cardiovascular disease: quo vadis?
Thrombosis
Tissue factor pathway inhibitor prevents thrombus formation on procoagulant subendothelial matrix.
Thrombosis
Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications.
Thrombosis
Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis.
Thrombosis
TLT-1-CONTROLS EARLY THROMBUS FORMATION AND STABILITY BY FACILITATING AIIBB3 OUTSIDE-IN SIGNALING IN MICE.
Thrombosis
To bleed or not to bleed? Is that the question for the PTT?
Thrombosis
Toxic characteristics of the synthetic lipid A derivative DT-5461 in rats and monkeys.
Thrombosis
Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons.
Thrombosis
Transitions of care in anticoagulated patients.
Thrombosis
Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators.
Thrombosis
Two characteristics of a recombinant fusion protein composed of staphylokinase and hirudin: high thrombus affinity and thrombus-targeting release ofanticoagulant activity.
Thrombosis
Two new closely related rat models with relevance to arterial thrombosis--efficacies of different antithrombotic drugs.
Thrombosis
Use of an argatroban systemic infusion and purge solution in a patient with a percutaneous ventricular assist device with suspected heparin-induced thrombocytopenia.
Thrombosis
Use of rotational thromboelastometry to predict hemostatic complications in pediatric patients undergoing extracorporeal membrane oxygenation: A retrospective cohort study.
Thrombosis
Use of the subcutaneous heparin pump during pregnancy.
Thrombosis
Vascular biology-the role of tissue factor.
Thrombosis
Venous thromboembolism in acute stroke. Prognostic importance of hypercoagulability.
Thrombosis
Venous thromboembolism prophylaxis guidelines: use by primary care physicians.
Thrombosis
Warfarin-Induced Skin Necrosis in the Presence of Acute Hepatic Injury and May-Thurner Syndrome.
Thrombosis
Which test to measure the anticoagulant effect of rivaroxaban? The anti-xa assay.
Thrombosis
[A case of congenital factor XI (plasma thromboplastin antecedent) deficiency with large organized thrombus in the vena cava inferior]
Thrombosis
[Anti-Xa molecules]
Thrombosis
[Anticoagulant therapy in a pregnant patient with prosthetic mitral valve-emergency for caesarian section and postoperative bleeding].
Thrombosis
[Antithrombotic effect of protein C activator from a snake venom]
Thrombosis
[Cardiac abnormalities in antiphospholipid syndrome]
Thrombosis
[Construction and expression of a fusion protein made of tissue-type plasminogen activator and hirudin in Pichia pastoris]
Thrombosis
[Control of oral anticoagulation. Current concepts]
Thrombosis
[Current biological surveillance of oral anticoagulant treatment]
Thrombosis
[DETERMINATION OF THE POSSIBILITY OF DICOUMARIN PREVENTION OF THROMBUS FORMATION CAUSED BY INTRAVENOUS ADMINISTRATION OF MASSIVE DOSES OF THROMBOPLASTIN.]
Thrombosis
[Direct and indirect effects of epoietin alpha in an experimental model of thrombosis and bleeding in the rabbit]
Thrombosis
[Endothelial microparticles (EMP) in physiology and pathology].
Thrombosis
[Intraoperative coagulation activity--a defined group of trauma surgery patients]
Thrombosis
[Is the activated partial thromboplastin time suitable for monitoring of thrombosis therapy with high-dose standard heparin?]
Thrombosis
[Left atrial thrombosis in patients with antiphospholipid antibody syndrome and mesenchymal abnormal septum]
Thrombosis
[New data on thromboplastin formation in obstetrical and gynecological thromboses. Therapeutic deductions]
Thrombosis
[Novel oral anticoagulants--issues in clinical practice].
Thrombosis
[Paraplegia following removal of an epidural catheter]
Thrombosis
[Pathophysiology and treatment of thrombosis. 1. Hypercoagulable state. (1) Study on the role of tissue thromboplastin in the formation of thrombosis]
Thrombosis
[Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update].
Thrombosis
[Prevention of intravascular blood coagulation in rats by DIP-alpha-thrombin administration]
Thrombosis
[Proceedings: Hypercoagulability and compensated intravascular coagulation in chronic kidney insufficiency and after kidney transplantation]
Thrombosis
[Recurrent thromboembolisms despite full anticoagulation in a patient with antiphospholipid syndrome].
Thrombosis
[Relation of Thromboelastography with Coagulation Function and Plt Count in Different Coagulation States].
Thrombosis
[Relative value of different antiphospholipid antibodies detected in a department of internal medicine: retrospective study of 124 patients]
Thrombosis
[Splenic vein thrombosis with pancytopenia and fever: antiphospholipid antibody syndrome]
Thrombosis
[Study on the safety and effectiveness of low-dose tranexamic acid in operation of multi-level continuous thoracic ossification of ligament flavum].
Thrombosis
[The antithrombotic and thrombolytic activity of a plasminogen activator isolated from a monolayer cell culture]
Thrombosis
[The reactivity of the anticoagulatory system in sympathectomized animals under stress conditions due to acoustic trauma]
Thrombosis
[The thromboplastin formation test in thrombosis and thrombophilic conditions.]
Thrombosis
[THROMBOPLASTIN ("INTRINSIC ACTIVATOR OF PROTHROMBIN") IN OCCLUSIVE VASCULAR DISEASES AND IN THROMBOSES.]
Thrombotic Microangiopathies
Complement in Secondary Thrombotic Microangiopathy.
Thrombotic Microangiopathies
Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target?
Thymoma
Novel factor X deficiency. Normal partial thromboplastin time and associated spindle cell thymoma.
Thymoma
[High thrombokinase activity in a thymoma during myasthenia gravis]
Thyroid Diseases
Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Thyroid Diseases
High prevalence of acquired von Willebrand's syndrome in patients with thyroid diseases undergoing thyroid surgery.
Thyroid Neoplasms
Differential diagnosis and clinical management of isolated prolonged activated partial thromboplastin time in a patient with Hashimoto thyroiditis-associated thyroid cancer: A case report.
Thyroiditis
Haemostatic effects of levothyroxine and selenomethionine in euthyroid patients with Hashimoto's thyroiditis.
Transposition of Great Vessels
Attributable fraction for cardiac malformations.
Trichinellosis
The effect of thymus factor X (TFX Polfa) on the clinical course of human trichinellosis.
Tuberculosis
Analysis of the shotgun expression library of the Mycobacterium tuberculosis genome for immunodominant polypeptides: potential use in serodiagnosis.
Tuberculosis, Pulmonary
[Action of p-aminosalicylic acid on the prothrombin and thromboplastin level in pulmonary tuberculosis.]
Typhoid Fever
Effects of heparin, typhoid vaccine and thrombophlebitis on factor X metabolism in the dog.
Unconsciousness
Evaluation of seroprevalence and clinical and laboratory findings of patients admitted to health institutions in Gümü?hane with suspicion of Crimean-Congo hemorrhagic fever
Unconsciousness
Polytrauma Defined by the New Berlin Definition: A Validation Test Based on Propensity-Score Matching Approach.
Uremia
Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia.
Uremia
Thrombotic Role of Blood and Endothelial Cells in Uremia through Phosphatidylserine Exposure and Microparticle Release.
Ureteral Obstruction
Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis.
Urinary Bladder Neoplasms
Clotting profile in cattle showing chronic enzootic haematuria (CEH) and bladder neoplasms.
Urinary Tract Infections
Attributable fraction for cardiac malformations.
Urinary Tract Infections
Development of cephradine-induced acquired factor v inhibitors: a case report.
Urinary Tract Infections
Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.
Uterine Hemorrhage
Acquired hemophilia A manifesting as plasma transfusion-uncontrolled severe bleeding 2 weeks after chorioamnionitis-induced abortion.
Uterine Hemorrhage
Effect of systematic nursing on patients with dysfunctional uterine bleeding and rehabilitation.
Uterine Hemorrhage
Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism.
Uterine Hemorrhage
Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
Uterine Hemorrhage
Replacement therapy for congenital Factor X deficiency.
Uterine Hemorrhage
Severe factor X deficiency in pregnancy: case report and review of the literature.
Uterine Inertia
New approach to the risk variables for administration of fibrinogen in patients with postpartum hemorrhage by using cluster analysis.
Uterine Prolapse
The influence on coagulation of transdermal estrogen hormone replacement therapy as a preoperative preparation of the tissue before vaginal hysterectomy.
Varicose Veins
Biological findings from the PheWAS catalog: focus on connective tissue-related disorders (pelvic floor dysfunction, abdominal hernia, varicose veins and hemorrhoids).
Varicose Veins
Compression stockings attenuate the expression of proteins associated with vascular damage in human varicose veins.
Varicose Veins
Risk factors and impact of portal vein thrombosis in liver transplantation.
Vascular Diseases
Activated protein C resistance: prevalence and implications in peripheral vascular disease.
Vascular Diseases
Antiplatelet and anticoagulant drugs in coronary vascular disease.
Vascular Diseases
Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants.
Vascular Diseases
Platelet-derived microparticles in alloxan-induced diabetes in rabbits.
Vascular Diseases
Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants.
Vascular Diseases
Safety and Feasibility of Treatment with Rivaroxaban for Non-Canonical Indications: A Case Series Analysis.
Vascular Diseases
[THROMBOPLASTIN ("INTRINSIC ACTIVATOR OF PROTHROMBIN") IN OCCLUSIVE VASCULAR DISEASES AND IN THROMBOSES.]
Vascular Malformations
Surgery in patients with vascular malformations of the head and neck: value of coagulation disorders.
Vascular System Injuries
A direct oral factor Xa inhibitor edoxaban ameliorates neointimal hyperplasia following vascular injury and thrombosis in apolipoprotein E-deficient mice.
Vascular System Injuries
Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats.
Vascular System Injuries
Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production.
Vascular System Injuries
Activation-dependent exposure of the inter-EGF sequence Leu83-Leu88 in factor Xa mediates ligand binding to effector cell protease receptor-1.
Vascular System Injuries
Assessment of an ELISA kit for platelet-derived microparticles by joint research at many institutes in Japan.
Vascular System Injuries
Coagulation factor V: a plethora of anticoagulant molecules.
Vascular System Injuries
Coagulation factor Xa synergistically interacts with serotonin in inducing vascular smooth muscle cell proliferation.
Vascular System Injuries
Cytometric analysis of high shear-induced platelet microparticles and effect of cytokines on microparticle generation.
Vascular System Injuries
Dissimilar interaction of factor VIII with endothelial cells and lipid vesicles during factor X activation.
Vascular System Injuries
Effect of vascular injury on inhibition of venous thrombosis with ZK-807834, a direct inhibitor of factor Xa.
Vascular System Injuries
Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation.
Vascular System Injuries
Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo.
Vascular System Injuries
Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits.
Vascular System Injuries
Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats.
Vascular System Injuries
Experimental model of lower limb ischemia in rats and the effect of YM466, an oral direct factor Xa inhibitor.
Vascular System Injuries
Function and clinical significance of platelet-derived microparticles.
Vascular System Injuries
Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes.
Vascular System Injuries
Gene targeting in hemostasis. tissue factor.
Vascular System Injuries
HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase.
Vascular System Injuries
How do HMG-CoA reductase inhibitors prevent stroke?
Vascular System Injuries
In vivo response to vascular injury in the absence of factor IX: examination in factor IX knockout mice.
Vascular System Injuries
Inhibition of activated factor X by rivaroxaban attenuates neointima formation after wire-mediated vascular injury.
Vascular System Injuries
Inhibition of factor Xa and neointima formation after vascular injury.
Vascular System Injuries
New antithrombotic strategies for resistant thrombotic processes.
Vascular System Injuries
New insights into the spatiotemporal localization of prothrombinase in vivo.
Vascular System Injuries
Platelet tissue factor pathway inhibitor modulates intravascular coagulation.
Vascular System Injuries
Proteolysis of plasma-derived factor V following its endocytosis by megakaryocytes forms the platelet-derived factor V/Va pool.
Vascular System Injuries
Quantitation of coated platelet potential during collection, storage, and transfusion of apheresis platelets.
Vascular System Injuries
Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats.
Vascular System Injuries
Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation.
Vascular System Injuries
Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation.
Vascular System Injuries
Residual factor VIII-like cofactor activity of thioredoxin and related oxidoreductases.
Vascular System Injuries
Slounase, a Batroxobin Containing Activated Factor X Effectively Enhances Hemostatic Clot Formation and Reducing Bleeding in Hypocoagulant Conditions in Mice.
Vascular System Injuries
The procoagulant activity of tissue factor expressed on fibroblasts is increased by tissue factor-negative extracellular vesicles.
Vascular System Injuries
Tissue factor: a key molecule in hemostatic and nonhemostatic systems.
Venous Thromboembolism
A cost analysis of fondaparinux versus enoxaparin in total knee arthroplasty.
Venous Thromboembolism
A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery.
Venous Thromboembolism
A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty.
Venous Thromboembolism
A genetic association study of activated partial thromboplastin time in European Americans and African Americans: the ARIC Study.
Venous Thromboembolism
A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
Venous Thromboembolism
A network meta-analysis of direct factor Xa inhibitors for the treatment of cancer-associated venous thromboembolism.
Venous Thromboembolism
A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement.
Venous Thromboembolism
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
Venous Thromboembolism
A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
Venous Thromboembolism
A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism.
Venous Thromboembolism
A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics.
Venous Thromboembolism
A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
Venous Thromboembolism
Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal.
Venous Thromboembolism
Accidental Rivaroxaban Overdose in a Patient with Pulmonary Embolism: Some Lessons for Managing New Oral Anticoagulants.
Venous Thromboembolism
Activated partial thromboplastin time and risk of future venous thromboembolism.
Venous Thromboembolism
Activated partial thromboplastin time monitoring in patients receiving unfractionated heparin for venous thromboembolism in relation to clinical outcomes.
Venous Thromboembolism
Activated partial thromboplastin time: results of a case-control study evaluating six commercial reagents in assessing the risk of venous thromboembolism.
Venous Thromboembolism
Acute management of bleeding in patients on novel oral anticoagulants.
Venous Thromboembolism
An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults.
Venous Thromboembolism
An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics.
Venous Thromboembolism
Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
Venous Thromboembolism
Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Venous Thromboembolism
Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place.
Venous Thromboembolism
Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Venous Thromboembolism
Antithrombotic drugs in vascular medicine: a historical perspective.
Venous Thromboembolism
Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition.
Venous Thromboembolism
Apixaban for extended treatment of venous thromboembolism.
Venous Thromboembolism
Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation.
Venous Thromboembolism
Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Venous Thromboembolism
Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model.
Venous Thromboembolism
Apixaban: A Review in Venous Thromboembolism.
Venous Thromboembolism
Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery.
Venous Thromboembolism
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Venous Thromboembolism
Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness.
Venous Thromboembolism
Betrixaban: A New Oral Factor Xa Inhibitor for Extended Venous Thromboembolism Prophylaxis in High-Risk Hospitalized Patients.
Venous Thromboembolism
Betrixaban: A Novel Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients.
Venous Thromboembolism
Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide.
Venous Thromboembolism
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects.
Venous Thromboembolism
Challenges in the prevention of venous thromboembolism in the elderly.
Venous Thromboembolism
Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.
Venous Thromboembolism
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists.
Venous Thromboembolism
Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis.
Venous Thromboembolism
Clinical management of rivaroxaban-treated patients.
Venous Thromboembolism
Clinical trials with factor Xa inhibition in the prevention of postoperative venous thromboembolism.
Venous Thromboembolism
Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review.
Venous Thromboembolism
Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism.
Venous Thromboembolism
Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.
Venous Thromboembolism
Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis.
Venous Thromboembolism
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Venous Thromboembolism
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-AF study.
Venous Thromboembolism
Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous thromboembolism between patients with and without cancer.
Venous Thromboembolism
Comparison of the effects of heparin and the direct factor Xa inhibitor, rivaroxaban, on bone microstructure and metabolism in adult rats.
Venous Thromboembolism
Complete response to rivaroxaban in a case of invaginated thrombus thought to have extended through a patent foramen ovale with an accompanying pulmonary embolism.
Venous Thromboembolism
CORR Insights(®): Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?
Venous Thromboembolism
Cost consequence analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery in Belgium.
Venous Thromboembolism
Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism.
Venous Thromboembolism
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.
Venous Thromboembolism
Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.
Venous Thromboembolism
Dabigatran: ready for prime time?
Venous Thromboembolism
Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: Phase III randomized, mechanical prophylaxis-controlled, open-label study.
Venous Thromboembolism
Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
Venous Thromboembolism
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
Venous Thromboembolism
Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Venous Thromboembolism
Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Venous Thromboembolism
Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding.
Venous Thromboembolism
Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan.
Venous Thromboembolism
Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis.
Venous Thromboembolism
Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous Thromboembolism: A Systematic Review and Network Meta-analysis.
Venous Thromboembolism
Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.
Venous Thromboembolism
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Venous Thromboembolism
Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
Venous Thromboembolism
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Venous Thromboembolism
Edoxaban for Venous Thromboembolism Treatment-The New Kid on The Block for Latin America. A Practical Guide.
Venous Thromboembolism
Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels.
Venous Thromboembolism
Edoxaban in patients with atrial fibrillation.
Venous Thromboembolism
Edoxaban tosylate.
Venous Thromboembolism
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism.
Venous Thromboembolism
Edoxaban Was Effective for the Treatment of Deep Vein Thrombosis and Pulmonary Thromboembolism in a Cancer Patient with Antithrombin III Deficiency.
Venous Thromboembolism
Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-Valvular Atrial Fibrillation and Venous Thromboembolism.
Venous Thromboembolism
Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
Venous Thromboembolism
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.
Venous Thromboembolism
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
Venous Thromboembolism
Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing.
Venous Thromboembolism
Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage.
Venous Thromboembolism
Effectiveness and safety of oral direct factor Xa inhibitors for the treatment of venous thromboembolism in patients with cancer and/or older age.
Venous Thromboembolism
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
Venous Thromboembolism
Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency.
Venous Thromboembolism
Elevated activated partial thromboplastin time-based clot waveform analysis markers have strong positive association with acute venous thromboembolism.
Venous Thromboembolism
Enhanced Biopharmaceutical Performance of Rivaroxaban through Polymeric Amorphous Solid Dispersion.
Venous Thromboembolism
Evaluating the efficacy and safety of apixaban, a new oral anticoagulant, using Bayesian meta-analysis.
Venous Thromboembolism
Evaluation of characteristics and dosing regimens in patients with new or recurrent thrombosis on apixaban and rivaroxaban.
Venous Thromboembolism
Evaluation of Factor Xa-Specific Chromogenic Substrate Assays and the Determination of Pharmacokinetics of Fondaparinux.
Venous Thromboembolism
Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.
Venous Thromboembolism
Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.
Venous Thromboembolism
Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.
Venous Thromboembolism
Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban.
Venous Thromboembolism
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).
Venous Thromboembolism
Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
Venous Thromboembolism
Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation.
Venous Thromboembolism
Factor Xa Inhibitors in Acute Coronary Syndromes and Venous Thromboembolism.
Venous Thromboembolism
Factor Xa inhibitors--new anticoagulants for secondary haemostasis.
Venous Thromboembolism
Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.
Venous Thromboembolism
Fondaparinux in the management of patients with ST-elevation acute myocardial infarction.
Venous Thromboembolism
Fondaparinux: a new antithrombotic agent.
Venous Thromboembolism
Future therapeutic directions for factor Xa inhibition in the prophylaxis and treatment of thrombotic disorders.
Venous Thromboembolism
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management.
Venous Thromboembolism
Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants.
Venous Thromboembolism
Hemopericardium with subsequent cardiac tamponade secondary to rivaroxaban treatment: a case report.
Venous Thromboembolism
Heparin and low-molecular-weight heparin in the treatment of venous thromboembolism.
Venous Thromboembolism
Heparin therapy for venous thrombosis and pulmonary embolism.
Venous Thromboembolism
Heterogeneity of synthetic factor Xa inhibitors.
Venous Thromboembolism
Homozygous methylentetrahydrofolate reductase C667T genotype anticipates age at venous thromboembolism by one decade.
Venous Thromboembolism
Identification of UDP-glucuronosyltransferases responsible for the glucuronidation of darexaban, an oral factor Xa inhibitor, in human liver and intestine.
Venous Thromboembolism
Identifying and reducing the incidence of post discharge Venous Thromboembolism (VTE) in orthopaedic patients: a systematic review.
Venous Thromboembolism
Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
Venous Thromboembolism
In vitro assessment of edoxaban anticoagulant effect in pediatric plasma.
Venous Thromboembolism
Inhibition of Factor Xa : a potential target for the development of new anticoagulants.
Venous Thromboembolism
Intravenous Thrombolysis for Acute Ischemic Stroke in a Patient Receiving Rivaroxaban.
Venous Thromboembolism
Is Aspirin as Effective as the Newer Direct Oral Anticoagulants for Venous Thromboembolism Prophylaxis After Total Hip and Knee Arthroplasty? An Analysis From the National Joint Registry for England, Wales, Northern Ireland, and the Isle of Man.
Venous Thromboembolism
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review.
Venous Thromboembolism
Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism.
Venous Thromboembolism
Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis.
Venous Thromboembolism
Management of venous thromboembolism: past, present, and future.
Venous Thromboembolism
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
Venous Thromboembolism
Monitoring and reversal strategies for new oral anticoagulants.
Venous Thromboembolism
Monitoring of hemostatic abnormalities in major orthopedic surgery patients treated with edoxaban by APTT waveform.
Venous Thromboembolism
Monitoring the anticoagulant effect after a massive rivaroxaban overdose.
Venous Thromboembolism
New Anticoagulants - Promising and Failed Developments.
Venous Thromboembolism
New anticoagulants and their potential impact on the treatment of thromboembolic disease.
Venous Thromboembolism
New Oral Anticoagulants for Venous Thromboembolism: Focus on Factor Xa and Thrombin Inhibitors.
Venous Thromboembolism
New oral anticoagulants: not quite there yet.
Venous Thromboembolism
New oral anticoagulants: prevention of VTE in phase III studies in total joint replacement surgery and the hospitalized medically-ill patients.
Venous Thromboembolism
Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors.
Venous Thromboembolism
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Venous Thromboembolism
Old and new anticoagulant drugs: a minireview.
Venous Thromboembolism
Oral anticoagulation with edoxaban.
Venous Thromboembolism
Oral anticoagulation with edoxaban. Focus on current phase III clinical development.
Venous Thromboembolism
Oral apixaban for the treatment of acute venous thromboembolism.
Venous Thromboembolism
Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
Venous Thromboembolism
Oral Direct Factor Xa Inhibitors Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in Patients Undergoing Total Hip or Knee Replacement: A Systematic Review and Meta-analysis.
Venous Thromboembolism
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Venous Thromboembolism
Oral factor Xa inhibitors for venous thromboembolism prevention in major orthopedic surgery: a review.
Venous Thromboembolism
Oral Factor Xa Inhibitors versus Warfarin for the Treatment of Venous Thromboembolism in Advanced Chronic Kidney Disease.
Venous Thromboembolism
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
Venous Thromboembolism
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
Venous Thromboembolism
Overview of Current Evidence on the Impact of the Initial High Dose of the Direct Factor Xa Inhibitor Rivaroxaban on Thrombus Resolution in the Treatment of Venous Thromboembolism.
Venous Thromboembolism
Pentasaccharides in the prophylaxis and treatment of venous thromboembolism: a systematic review.
Venous Thromboembolism
Periprocedural management of rivaroxaban-treated patients.
Venous Thromboembolism
Phamacokinetics of rivaroxaban in adolescents.
Venous Thromboembolism
Pharmacokinetics of fondaparinux 1.5 mg once daily in a real-world cohort of patients with renal impairment undergoing major orthopaedic surgery.
Venous Thromboembolism
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
Venous Thromboembolism
Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
Venous Thromboembolism
Physician-guided treatment compared with a heparin protocol for deep vein thrombosis.
Venous Thromboembolism
PK evaluation of fondaparinux sodium for the treatment of thrombosis.
Venous Thromboembolism
Plasma accumulation of fondaparinux 2.5 mg in patients after total hip arthroplasty.
Venous Thromboembolism
Population Pharmacokinetic-Pharmacodynamic Modeling Analysis of Intrinsic FXa and Bleeding From Edoxaban Treatment.
Venous Thromboembolism
Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery.
Venous Thromboembolism
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.
Venous Thromboembolism
Preclinical and Clinical Data for Factor Xa and "Universal" Reversal Agents.
Venous Thromboembolism
Preclinical and clinical data for factor Xa and "universal" reversal agents.
Venous Thromboembolism
Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time.
Venous Thromboembolism
Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
Venous Thromboembolism
Principles for diagnosis and treatment of pulmonary embolism.
Venous Thromboembolism
ProC Global: the first functional screening assay for the complete protein C pathway.
Venous Thromboembolism
Pulmonary Venous Thromboembolism in an Acutely Ill Medical Patient Receiving Rivaroxaban.
Venous Thromboembolism
Quality improvement: Adherence to nurse-driven heparin protocols.
Venous Thromboembolism
Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.
Venous Thromboembolism
Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.
Venous Thromboembolism
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.
Venous Thromboembolism
Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood.
Venous Thromboembolism
Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
Venous Thromboembolism
Recurrent Venous Thromboembolism in Two Patients With Cancer Taking Rivaroxaban.
Venous Thromboembolism
Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times.
Venous Thromboembolism
Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.
Venous Thromboembolism
Report of the Subcommittee on Control of Anticoagulation on the determination of the anticoagulant effects of apixaban: communication from the SSC of the ISTH.
Venous Thromboembolism
Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
Venous Thromboembolism
Reversal Agents for the Direct Factor Xa Inhibitors: Biochemical Mechanisms of Current and Newly Emerging Therapies.
Venous Thromboembolism
Review of the Pharmacology of the Emerging Possibilities of the Direct Oral Anticoagulants' Reversal.
Venous Thromboembolism
Review: Factor Xa inhibitors reduce DVT more than LMWH in total knee or hip replacement.
Venous Thromboembolism
Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
Venous Thromboembolism
Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism.
Venous Thromboembolism
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Venous Thromboembolism
Rivaroxaban limits complement activation compared to warfarin in antiphospholipid syndrome patients with venous thromboembolism.
Venous Thromboembolism
Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty.
Venous Thromboembolism
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Venous Thromboembolism
Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice.
Venous Thromboembolism
Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
Venous Thromboembolism
Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
Venous Thromboembolism
Rivaroxaban: a review of its use in acute coronary syndromes.
Venous Thromboembolism
Role of Orally Available Antagonists of Factor Xa in the Treatment and Prevention of Thromboembolic Disease: Focus on Rivaroxaban.
Venous Thromboembolism
Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date.
Venous Thromboembolism
SAfety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: A pilot study.
Venous Thromboembolism
Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery.
Venous Thromboembolism
Short-Term Subcutaneous Fondaparinux and Oral Edoxaban for Acute Venous Thromboembolism.
Venous Thromboembolism
Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition.
Venous Thromboembolism
Subcutaneous unfractionated heparin compared with low-molecular-weight heparin for the initial treatment of venous thromboembolism.
Venous Thromboembolism
Subcutaneous unfractionated heparin for the treatment of venous thromboembolism.
Venous Thromboembolism
Successful use of fondaparinux in a patient with a mechanical heart valve replacement and a history of heparin-induced thrombocytopenia.
Venous Thromboembolism
The Cost-Effectiveness of Oral Direct Factor Xa Inhibitors Compared with Low-Molecular-Weight Heparin for the Prevention of Venous Thromboembolism Prophylaxis in Total Hip or Knee Replacement Surgery.
Venous Thromboembolism
The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice.
Venous Thromboembolism
The discovery and development of rivaroxaban.
Venous Thromboembolism
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
Venous Thromboembolism
The in vitro anticoagulant effect of rivaroxaban in children.
Venous Thromboembolism
The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
Venous Thromboembolism
The relative contributions of antithrombin III during heparin treatment, and of clinically recognisable risk factors, to early recurrence of venous thromboembolism.
Venous Thromboembolism
The role of factor Xa inhibitors in venous thromboembolism treatment.
Venous Thromboembolism
The use of factor Xa inhibitors following opening-wedge high tibial osteotomy for venous thromboembolism prophylaxis.
Venous Thromboembolism
Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism.
Venous Thromboembolism
Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
Venous Thromboembolism
Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis.
Venous Thromboembolism
Treatment of venous thromboembolism with new oral anticoagulants according to patient risk.
Venous Thromboembolism
Treatment of venous thrombosis in the cancer patient.
Venous Thromboembolism
Trousseau's syndrome: cancer-associated thrombosis.
Venous Thromboembolism
Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping.
Venous Thromboembolism
Unsuitability of evacuated tubes for monitoring heparin therapy by activated partial thromboplastin time.
Venous Thromboembolism
Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review.
Venous Thromboembolism
Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism.
Venous Thromboembolism
Use of newer anticoagulants in patients with chronic kidney disease.
Venous Thromboembolism
Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
Venous Thromboembolism
Venous thromboembolism prevention through the use of novel Factor Xa inhibitors.
Venous Thromboembolism
Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?
Venous Thromboembolism
Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
Venous Thromboembolism
Vitamin K antagonists. Ready to be replaced?
Venous Thromboembolism
YM-150, a Factor Xa inhibitor for the prevention of venous thromboembolism and coronary artery disease.
Venous Thromboembolism
[Characteristics and clinical use of rivaroxaban for the treatment of atrial fibrillation and venous thromboembolism].
Venous Thromboembolism
[Determination of factor Xa inhibition doses of low-molecular heparin, nadroparin and reviparin in urological patients]
Venous Thromboembolism
[Lengthened activated thromboplastin time in the course of tinzaparin therapy of accidental venous thromboembolism. Pilot study]
Venous Thromboembolism
[New oral anticoagulants from the perspective of trauma surgery].
Venous Thromboembolism
[Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update].
Venous Thromboembolism
[Prevention of venous thromboembolism after major orthopedic surgery: update and contribution of a specific synthetic inhibitor of factor Xa]
Venous Thromboembolism
[Prevention of venous thromboembolism in surgical patients].
Venous Thromboembolism
[Safety and economics of fondaparinux administration in the laparoscopic surgery].
Venous Thromboembolism
[Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
Venous Thrombosis
'Lupus' anticoagulant and thrombosis of the hepatic veins (Budd-Chiari syndrome). Report of three patients and review of the literature.
Venous Thrombosis
A Case of a Reversible Neurologic Adverse Reaction to Apixaban Confirmed by Re-Challenge.
Venous Thrombosis
A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis.
Venous Thrombosis
A comprehensive evaluation of apixaban in the treatment of venous thromboembolism.
Venous Thrombosis
A cost-analysis model for anticoagulant treatment in the hospital setting.
Venous Thrombosis
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.
Venous Thrombosis
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation.
Venous Thrombosis
A prospective randomized comparative study to determine appropriate edoxaban administration period, to prevent deep vein thromboembolism in patients with total knee arthroplasty.
Venous Thrombosis
A shortened activated partial thromboplastin time predicts the risk of catheter-associated venous thrombosis in cancer patients.
Venous Thrombosis
A Single-Center Retrospective Evaluation of the Use of Oral Factor Xa Inhibitors in Patients With Cerebral Venous Thrombosis.
Venous Thrombosis
Accidental Rivaroxaban Intoxication in a Boy: Some Lessons in Managing New Oral Anticoagulants in Children.
Venous Thrombosis
Activation of the factor VII-tissue factor pathway.
Venous Thrombosis
Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data.
Venous Thrombosis
Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement.
Venous Thrombosis
AGA Clinical Practice Update: Coagulation in Cirrhosis.
Venous Thrombosis
An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Venous Thrombosis
Anti-thrombosis effect of diosgenin extract from Dioscorea zingiberensis C.H. Wright in vitro and in vivo.
Venous Thrombosis
Anticoagulant efficacy and immunogenicity of the selective factor Xa inhibitor antistasin following subcutaneous administration in the rhesus monkey.
Venous Thrombosis
Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place.
Venous Thrombosis
Anticoagulation-related intracranial hemorrhages.
Venous Thrombosis
Antiphospholipid antibodies, haemostatic variables and thrombosis--a survey of 144 patients.
Venous Thrombosis
Antiphospholipid syndrome and factor V Leiden. Three cases with recurrent venous thrombosis.
Venous Thrombosis
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma.
Venous Thrombosis
Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
Venous Thrombosis
Antithrombotic activity of recombinant tick anticoagulant peptide and heparin in a rabbit model of venous thrombosis.
Venous Thrombosis
Antithrombotic activity of SR 46349, a novel, potent and selective 5-HT2 receptor antagonist.
Venous Thrombosis
Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis.
Venous Thrombosis
Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
Venous Thrombosis
Antithrombotic and bleeding effects of a low molecular weight heparin fraction.
Venous Thrombosis
Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Venous Thrombosis
Antithrombotic effects of (n-3) polyunsaturated fatty acids in rat models of arterial and venous thrombosis.
Venous Thrombosis
Antithrombotic efficacy of a recombinant nematode anticoagulant peptide (rNAP5) in canine models of thrombosis after single subcutaneous administration.
Venous Thrombosis
Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis.
Venous Thrombosis
Apixaban Enhances Vasodilatation Mediated by Protease-Activated Receptor 2 in Isolated Rat Arteries.
Venous Thrombosis
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.
Venous Thrombosis
Apparent heparin resistance form elevated factor VIII in a patient with postoperative deep venous thrombosis. A case report.
Venous Thrombosis
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Venous Thrombosis
Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin.
Venous Thrombosis
Characterization of an immunologic polymorphism (D79H) in the heavy chain of factor V.
Venous Thrombosis
Cholesterol Crystal Embolism Induced by Direct Factor Xa inhibitor: A First Case Report.
Venous Thrombosis
Clinical and experimental experience with factor Xa inhibitors.
Venous Thrombosis
Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus.
Venous Thrombosis
Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase.
Venous Thrombosis
Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.
Venous Thrombosis
Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis.
Venous Thrombosis
Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Venous Thrombosis
Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis.
Venous Thrombosis
Comparison of three activated protein C resistance tests in the risk assessment of venous thrombosis in non-carriers of the factor V Leiden mutation.
Venous Thrombosis
Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
Venous Thrombosis
Current management of acute symptomatic deep vein thrombosis.
Venous Thrombosis
Deep vein thrombosis following hip surgery. Relation to activated factor X inhibitor activity: effect of heparin and dextran.
Venous Thrombosis
Deep Venous Thrombosis with Decreased Cerebral Blood Flow to the Thalamus was Completely Restored by Factor Xa Inhibitor.
Venous Thrombosis
Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
Venous Thrombosis
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
Venous Thrombosis
Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Venous Thrombosis
Design, synthesis, and structure-activity relationship of novel and effective apixaban derivatives as FXa inhibitors containing 1,2,4-triazole/pyrrole derivatives as P2 binding element.
Venous Thrombosis
Development of an experimental model of pre-thrombosis in rats based on Wessler's principle using a calibrated venous stasis.
Venous Thrombosis
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Venous Thrombosis
Different clinical presentations of a lupus anticoagulant in the same family.
Venous Thrombosis
Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
Venous Thrombosis
Direct oral anticoagulants in rare venous thrombosis.
Venous Thrombosis
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Venous Thrombosis
DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
Venous Thrombosis
Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
Venous Thrombosis
Effect of vascular injury on inhibition of venous thrombosis with ZK-807834, a direct inhibitor of factor Xa.
Venous Thrombosis
Effectiveness and Tolerability of Fondaparinux vs Enoxaparin in a Population of Indian Patients with Symptomatic Deep Vein Thrombosis: A Retrospective Real-World Study.
Venous Thrombosis
Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis.
Venous Thrombosis
Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits.
Venous Thrombosis
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study.
Venous Thrombosis
Efficacy of an intravenous low-molecular-weight dermatan sulphate (Desmin) in patients with acute proximal deep venous thrombosis and silent pulmonary embolism. A pilot study.
Venous Thrombosis
Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism.
Venous Thrombosis
Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events.
Venous Thrombosis
Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.
Venous Thrombosis
Exploiting the antithrombotic effect of the (pro)thrombin inhibitor bothrojaracin.
Venous Thrombosis
Factor X inhibitors.
Venous Thrombosis
Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis.
Venous Thrombosis
Factor Xa Inhibitor Suppresses the Release of Phosphorylated HSP27 from Collagen-Stimulated Human Platelets: Inhibition of HSP27 Phosphorylation via p44/p42 MAP Kinase.
Venous Thrombosis
Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Venous Thrombosis
Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
Venous Thrombosis
Giant deep vein thrombus complicating endovascular cooling therapy after cardiac arrest in a boy with hypertrophic cardiomyopathy.
Venous Thrombosis
Hemostatic properties of the lymph: relationships with occlusion and thrombosis.
Venous Thrombosis
Heparin and warfarin: use of anticoagulants in the prevention and treatment of venous thrombosis and pulmonary embolism.
Venous Thrombosis
Heparin dosage adjustment in patients with deep-vein thrombosis using heparin concentrations rather than activated partial thromboplastin time.
Venous Thrombosis
HIT paradigms and paradoxes.
Venous Thrombosis
Importance of platelets in experimental venous thrombosis in the rat.
Venous Thrombosis
Improved anticoagulant effect of fucosylated chondroitin sulfate orally administered as gastro-resistant tablets.
Venous Thrombosis
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
Venous Thrombosis
Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy.
Venous Thrombosis
Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance.
Venous Thrombosis
Inhibition of purified factor Xa amidolytic activity may not be predictive of inhibition of in vivo thrombosis: implications for identification of therapeutically active inhibitors.
Venous Thrombosis
Intravenous recombinant soluble human thrombomodulin prevents venous thrombosis in a rat model.
Venous Thrombosis
Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers.
Venous Thrombosis
Low molecular weight heparin in acute stroke.
Venous Thrombosis
Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment.
Venous Thrombosis
Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis.
Venous Thrombosis
Lupus anticoagulant syndrome: case report.
Venous Thrombosis
Measurement of a newly developed thrombomodulin addition activated partial thromboplastin time assay in patients with deep venous thrombosis.
Venous Thrombosis
Minor Plasma Lipids Modulate Clotting Factor Activities and May Affect Thrombosis Risk.
Venous Thrombosis
Myocarditis in athletes after COVID-19 infection: The heart is not the only place to screen.
Venous Thrombosis
Newer Anticoagulants in Cardiovascular Disease: A Systematic Review of The Literature.
Venous Thrombosis
Nonbenzamidine isoxazoline derivatives as factor Xa inhibitors.
Venous Thrombosis
Nonbenzamidine tetrazole derivatives as factor Xa inhibitors.
Venous Thrombosis
Novel factor xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients.
Venous Thrombosis
Novel therapeutic agents in the management of hemorrhage and thrombosis.
Venous Thrombosis
Oral anticoagulants controlled by the British comparative thromboplastin versus low-dose heparin in prophylaxis of deep vein thrombosis.
Venous Thrombosis
Oral Direct Factor Xa Inhibitors Versus Low-Molecular-Weight Heparin to Prevent Venous Thromboembolism in Patients Undergoing Total Hip or Knee Replacement: A Systematic Review and Meta-analysis.
Venous Thrombosis
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis.
Venous Thrombosis
Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism.
Venous Thrombosis
Oral rivaroxaban for symptomatic venous thromboembolism.
Venous Thrombosis
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Venous Thrombosis
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
Venous Thrombosis
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
Venous Thrombosis
Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice.
Venous Thrombosis
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism.
Venous Thrombosis
Pharmacokinetics and pharmacodynamics of intravenous and oral apixaban in horses.
Venous Thrombosis
Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
Venous Thrombosis
Possible Rivaroxaban Failure during the Postpartum Period.
Venous Thrombosis
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients.
Venous Thrombosis
Practical Management of Rivaroxaban for the Treatment of Venous Thromboembolism.
Venous Thrombosis
Pre-clinical pharmacodynamic study of a novel oral factor Xa inhibitor zifaxaban.
Venous Thrombosis
Prevalence and Risk Factors for Thrombotic Complications Following Venovenous Extracorporeal Membrane Oxygenation: A CT Scan Study.
Venous Thrombosis
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Venous Thrombosis
Preventive and therapeutic approach to venous thromboembolic disease and pulmonary embolism--can death from pulmonary embolism be prevented?
Venous Thrombosis
Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity.
Venous Thrombosis
Primary sclerosing cholangitis in the presence of a lupus anticoagulant.
Venous Thrombosis
Pulmonary Thromboembolism in COVID-19: Venous Thromboembolism or Arterial Thrombosis?
Venous Thrombosis
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
Venous Thrombosis
Rapid profiling of cantharidin analogues in Mylabris phalerata Pallas by ultra-performance liquid chromatography-quadrupole time-of-flight-tandem mass spectrometry.
Venous Thrombosis
Rare inherited coagulation disorders in India.
Venous Thrombosis
Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients.
Venous Thrombosis
Rectus Sheath Hematoma Associated with Apixaban.
Venous Thrombosis
Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times.
Venous Thrombosis
Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arterio-venous thrombosis.
Venous Thrombosis
Reversible Neurological Adverse Reaction to Apixaban.
Venous Thrombosis
Review of the initiation of anticoagulant therapy.
Venous Thrombosis
Review: Factor Xa inhibitors reduce DVT more than LMWH in total knee or hip replacement.
Venous Thrombosis
Risk factors of postthrombotic syndrome before and after deep venous thrombosis treatment.
Venous Thrombosis
Rivaroxaban for treatment of venous thromboembolism in older adults.
Venous Thrombosis
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Venous Thrombosis
Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.
Venous Thrombosis
Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
Venous Thrombosis
Rivaroxaban: direct factor Xa inhibition to treat acute deep vein thrombosis.
Venous Thrombosis
Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.
Venous Thrombosis
RPR120844, a novel, specific inhibitor of coagulation factor Xa inhibits venous thrombosis in the rabbit.
Venous Thrombosis
Safety and efficacy of tranexamic acid in spinal canal tumors: a retrospective cohort study.
Venous Thrombosis
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.
Venous Thrombosis
Sequential thrombosis and bleeding in a woman with a prolonged activated partial thromboplastin time.
Venous Thrombosis
Short-Term Subcutaneous Fondaparinux and Oral Edoxaban for Acute Venous Thromboembolism.
Venous Thrombosis
Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program.
Venous Thrombosis
Spontaneous rectus sheath hematoma during rivaroxaban therapy.
Venous Thrombosis
SR-90107 (Sanofi-Synthélabo).
Venous Thrombosis
Stroke risk factor, pattern and outcome in patients with cancer.
Venous Thrombosis
Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: a Polish multicenter trial.
Venous Thrombosis
Successful treatment with rivaroxaban of an extended deep vein thrombosis complicated by pulmonary embolism in a patient with familial antithrombin III deficiency: a case report.
Venous Thrombosis
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies.
Venous Thrombosis
The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.
Venous Thrombosis
The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure.
Venous Thrombosis
The efficacy of long-term oral anticoagulant therapy and its laboratory assessment.
Venous Thrombosis
The lupus anticoagulant. High incidence of 'negative' mixing studies in a human immunodeficiency virus-positive population.
Venous Thrombosis
The possible role of platelet coagulant activities in the pathogenesis of venous thrombosis.
Venous Thrombosis
The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
Venous Thrombosis
The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
Venous Thrombosis
The use of rivaroxaban for the treatment of thrombotic complications in four dogs.
Venous Thrombosis
The venous antithrombotic profile of naroparcil in the rabbit.
Venous Thrombosis
Thrombosis of Large Aneurysm Induced by Flow-Diverter Stent and Dissolved by Direct Factor Xa Inhibitor.
Venous Thrombosis
Transitions of care in anticoagulated patients.
Venous Thrombosis
Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators.
Venous Thrombosis
Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Venous Thrombosis
Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
Venous Thrombosis
Two new closely related rat models with relevance to arterial thrombosis--efficacies of different antithrombotic drugs.
Venous Thrombosis
Venous thromboembolism in acute stroke. Prognostic importance of hypercoagulability.
Venous Thrombosis
Venous thromboembolism prophylaxis guidelines: use by primary care physicians.
Venous Thrombosis
Warfarin-Induced Skin Necrosis in the Presence of Acute Hepatic Injury and May-Thurner Syndrome.
Venous Thrombosis
[A case of anti-phospholipid antibody syndrome associated with subdural hematoma]
Venous Thrombosis
[Change of coagulation functions and its significance in acute exacerbation of chronic obstructive pulmonary disease].
Venous Thrombosis
[Effect of tranexamic acid combined flexion position of hip and knee on perioperative bleeding following unilateral total knee arthroplasty].
Venous Thrombosis
[Factor Xa Inhibitor for the Treatment of Cerebral Venous Thrombosis with Intracerebral Hemorrhage during Anticoagulation Therapy:A Case Report].
Venous Thrombosis
[Fondaparinux: The present and the future.]
Venous Thrombosis
[Nephrotic syndrome complicated with intracranial venous thrombosis treated with urokinase: report of 5 cases]
Venous Thrombosis
[New oral anticoagulants : Better than vitamin K antagonists?]
Venous Thrombosis
[Pharmacology of the new oral anticoagulants].
Venous Thrombosis
[Polish guidelines for the prevention and treatment of venous thromboembolism. 2012 update].
Venous Thrombosis
[Recurrent thromboembolisms despite full anticoagulation in a patient with antiphospholipid syndrome].
Venous Thrombosis
[Risk factors of deep venous thrombosis associated with peripherally inserted central venous catheter in upper extremity in ICU].
Venous Thrombosis
[Study on the safety and effectiveness of low-dose tranexamic acid in operation of multi-level continuous thoracic ossification of ligament flavum].
Ventricular Dysfunction, Left
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial.
Vertebral Artery Dissection
Novel Oral Anticoagulants as Treatment for Vertebral Artery Dissection: Case Report.
Virus Diseases
Assessment of aPTT-based clot waveform analysis for the detection of haemostatic changes in different types of infections.
Virus Diseases
Cutaneous histopathologic findings in 'antiphospholipid syndrome'. Correlation with disease, including human immunodeficiency virus disease.
Virus Diseases
Xanthine oxidoreductase activity in human liver disease.
Vitamin E Deficiency
Studies on vitamin E and selenium deficiency in young pigs. IV. Effect on coagulation system.
Vitamin K Deficiency
Coagulopathy in the nephrotic syndrome.
Vitamin K Deficiency
Evidence for a warfarin-sensitive serum factor that participates in factor X activation by Lewis lung tumor cells.
Vitamin K Deficiency
Macroscopic hematuria as presenting symptom of celiac disease.
Vitamin K Deficiency
Vitamin K deficiency in newborns: a case report in alpha-1-antitrypsin deficiency and a review of factors predisposing to hemorrhage.
Vitamin K Deficiency
[Effects of cefotaxime on the coagulation system, especially their dependence on vitamin K-related factors]
Vitamin K Deficiency Bleeding
Spontaneous Retrobulbar Hemorrhage in a Previously Healthy Infant.
von Willebrand Disease, Type 3
Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
von Willebrand Diseases
A two-center retrospective review of the hematologic evaluation and laboratory abnormalities in suspected victims of non-accidental injury.
von Willebrand Diseases
Absence of a bleeding tendency in severe acquired von Willebrand's disease. The role of platelet von Willebrand factor in maintaining normal hemostasis.
von Willebrand Diseases
Acquired type 3-like von Willebrand syndrome preceded full-blown systemic lupus erythematosus.
von Willebrand Diseases
An investigation of the spectrum of common and rare inherited coagulation disorders in North-Eastern Iran.
von Willebrand Diseases
Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
von Willebrand Diseases
Combined hereditary factor XI (plasma thromboplastin antecedent) deficiency, von Willebrand's disease, and xeroderma pigmentosum in a Japanese family.
von Willebrand Diseases
Dextran 40-induced coagulopathy confused with von Willebrand disease.
von Willebrand Diseases
Effect of intravenous adrenalin infusion and corticosteroid treatment in patients with von Willebrand's disease.
von Willebrand Diseases
Evaluation of laboratory methods to improve characterization of dogs with von Willebrand disease.
von Willebrand Diseases
Evaluation of the Hemostatic Disorders in Adolescent Girls with Menorrhagia: Experiences from a Tertiary Referral Hospital.
von Willebrand Diseases
Frequency of inherited bleeding disorders in women with menorrhagia.
von Willebrand Diseases
Gastrointestinal angiodysplasia: a possible component of von Willebrand's disease.
von Willebrand Diseases
Intracranial haemorrhage in patients with congenital haemostatic defects.
von Willebrand Diseases
Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification.
von Willebrand Diseases
Mild Bleeders: Diagnosis is Elusive in Large Number of Patients.
von Willebrand Diseases
Multicenter retrospective study of transcatheter arterial embolisation for life-threatening haemorrhage in patients with uncorrected bleeding diathesis.
von Willebrand Diseases
Obstetric analgesia and anaesthesia in women with inherited bleeding disorders.
von Willebrand Diseases
Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT.
von Willebrand Diseases
Preoperative screening for coagulopathy using prothrombin time and partial thromboplastin time in patients requiring primary cranial vault remodeling.
von Willebrand Diseases
Resolving Differential Diagnostic Problems in von Willebrand Disease, in Fibrinogen Disorders, in Prekallikrein Deficiency and in Hereditary Hemorrhagic Telangiectasia by Next-Generation Sequencing.
von Willebrand Diseases
Screening and diagnosis of coagulation disorders.
von Willebrand Diseases
The spectrum of bleeding disorders in women with menorrhagia: a report from Western India.
von Willebrand Diseases
Use of a questionnaire to predict von Willebrand disease status and characterize hemorrhagic signs in a population of dogs and evaluation of a diagnostic profile to predict risk of bleeding.
von Willebrand Diseases
Vascular type Ehlers-Danlos syndrome is associated with platelet dysfunction and low vitamin D serum concentration.
von Willebrand Diseases
von Willebrand factor as a regulator of intrinsic factor X activation.
von Willebrand Diseases
[Infective morbidity of replacement therapy in congenital coagulation deficiencies and its effects on demand of coagulation factors]
von Willebrand Diseases
[Successes and failures of the activated partial thromboplastin time in the preoperative evaluation]
Waldenstrom Macroglobulinemia
Antibody studies of factor VIII inhibitor in a case with Waldenström's macroglobulinemia.
Waldenstrom Macroglobulinemia
[Recurrence of Waldenström macroglobulinemia accompanied by factor X deficiency].
Waldenstrom Macroglobulinemia
[Thromboplastin formation in Waldenström's macroglobulinemia and in multiple myeloma]
Whipple Disease
Monocyte procoagulant activity in Whipple's disease.
Whooping Cough
Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation.
Wilms Tumor
Acquired factor VII deficiency associated with Wilms tumor.
Wound Infection
Coagulation Laboratory Testing Is Predictive of Wound Complications Following Microdiscectomy.
Wound Infection
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
Xanthomatosis
Evaluation of plaque stability of advanced atherosclerotic lesions in apo e-deficient mice after treatment with the oral factor xa inhibitor rivaroxaban.
Xeroderma Pigmentosum
Combined hereditary factor XI (plasma thromboplastin antecedent) deficiency, von Willebrand's disease, and xeroderma pigmentosum in a Japanese family.
Yellow Fever
Alboserpin, a factor xa inhibitor from the mosquito vector of yellow Fever, binds heparin and membrane phospholipids and exhibits antithrombotic activity.
Yellow Fever
Isolation and characterization of the gene encoding a novel factor Xa-directed anticoagulant from the yellow fever mosquito, Aedes aegypti.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
show
top
